<?xml version="1.0" encoding="UTF-8"?><search-results xmlns="http://www.w3.org/2005/Atom" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:opensearch="http://a9.com/-/spec/opensearch/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/"><opensearch:totalResults>2992343</opensearch:totalResults><opensearch:startIndex>2000</opensearch:startIndex><opensearch:itemsPerPage>100</opensearch:itemsPerPage><opensearch:Query role="request" searchTerms="heart" startPage="2000"/><link ref="self" href="http://api.elsevier.com:80/content/search/index:scopus?start=2000&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="first" href="http://api.elsevier.com:80/content/search/index:scopus?start=0&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="prev" href="http://api.elsevier.com:80/content/search/index:scopus?start=1900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="next" href="http://api.elsevier.com:80/content/search/index:scopus?start=2100&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="last" href="http://api.elsevier.com:80/content/search/index:scopus?start=4900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930211101"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930211101?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930211101&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930211101&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930211101</prism:url><dc:identifier>SCOPUS_ID:84930211101</dc:identifier><eid>2-s2.0-84930211101</eid><dc:title>Relationship between health-related quality of life, comorbidities and acute health care utilisation, in adults with chronic conditions</dc:title><dc:creator>Hutchinson A.</dc:creator><prism:publicationName>Health and Quality of Life Outcomes</prism:publicationName><prism:eIssn>14777525</prism:eIssn><prism:volume>13</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>May 29, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12955-015-0260-2</prism:doi><dc:description>Â© 2015 Hutchinson et al. Background: There is increased interest in developing multidisciplinary ambulatory care models of service delivery to manage patients with complex chronic diseases. These programs are expensive and given limited resources it is important that care is targeted effectively. One potential screening strategy is to identify individuals who report the greatest decrement in health related quality of life (HRQoL) and thus greater need. The aim of this study was to explore the relationship between HRQoL, comorbid conditions and acute health care utilisation. Methods: A prospective, longitudinal cohort design was used to evaluate the impact of HRQoL on acute care utilisation rates over three-years of follow-up. Participants were enrolled in chronic disease management programs run by a metropolitan health service in Australia. Baseline data was collected from 2007-2009 and follow-up data until 2012. Administrative data was used to classify patients' primary reasons for enrolment, number of comorbidities (Charlson Score) and presentations to acute care. At enrolment, HRQoL was measured using the Assessment of Quality of Life (AQoL) instrument, for analysis AQoL scores were dichotomised at two standard deviations below the population norm. Results: There were 1999 participants (54% male) with a mean age of 63years (range 18-101), enrolled in the study. Participants' primary health conditions at enrolment were: diabetes 915 (46%), chronic respiratory disease 463 (23%), cardiac disease 260 (13%), peripheral vascular disease, and 181 (9%) and aged care 180 (9%). At 1-year multivariate logistic regression models demonstrated that AQOL utility score was not predictive of acute care presentations after adjusting for comorbidities. Over 3-years an AQoL utility score in the lowest quartile was predictive of both ED presentation (OR 1.58, 95% CI, 1.16-2.13, p=0.003) and admissions (OR 1.67, 95% CI.1.21 to 2.30, p=0.002) after adjusting for differences in age and comorbidities. Conclusion: This study found that both HRQoL and comorbidities were predictive of subsequent acute care attendance over 3-years of follow-up. At 1-year, comorbidities was a better predictor of acute care representation than HRQoL. To maximise benefits, programs should initially focus on medical disease management, but subsequently switch to strategies that enhance health independence and raise HRQoL.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113214158</affiliation-url><afid>113214158</afid><affilname>Northern Clinical Research Centre</affilname><name-variant>Northern Clinical Research Centre</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018805</affiliation-url><afid>60018805</afid><affilname>Deakin University</affilname><name-variant>Deakin University</name-variant><affiliation-city>Geelong</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005087</affiliation-url><afid>60005087</afid><affilname>Austin Health</affilname><name-variant>Austin Health</name-variant><affiliation-city>Heidelberg</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026553</affiliation-url><afid>60026553</afid><affilname>University of Melbourne</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Parkville</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7101660152</author-url><authid>7101660152</authid><authname>Hutchinson A.</authname><surname>Hutchinson</surname><given-name>Anastasia F.</given-name><initials>A.F.</initials><afid>113214158</afid><afid>60018805</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7101660152</author-url><authid>7101660152</authid><authname>Hutchinson A.</authname><surname>Hutchinson</surname><given-name>Anastasia F.</given-name><initials>A.F.</initials><afid>113214158</afid><afid>60018805</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:25928350800</author-url><authid>25928350800</authid><authname>Graco M.</authname><surname>Graco</surname><given-name>Marnie</given-name><initials>M.</initials><afid>113214158</afid><afid>60005087</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:25928350800</author-url><authid>25928350800</authid><authname>Graco M.</authname><surname>Graco</surname><given-name>Marnie</given-name><initials>M.</initials><afid>113214158</afid><afid>60005087</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35088838900</author-url><authid>35088838900</authid><authname>Rasekaba T.</authname><surname>Rasekaba</surname><given-name>Tshepo Mokuedi</given-name><initials>T.M.</initials><afid>113214158</afid><afid>60026553</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35088838900</author-url><authid>35088838900</authid><authname>Rasekaba T.</authname><surname>Rasekaba</surname><given-name>Tshepo Mokuedi</given-name><initials>T.M.</initials><afid>113214158</afid><afid>60026553</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56346172200</author-url><authid>56346172200</authid><authname>Parikh S.</authname><surname>Parikh</surname><given-name>Sumit</given-name><initials>S.</initials><afid>113214158</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005049388</author-url><authid>7005049388</authid><authname>Berlowitz D.</authname><surname>Berlowitz</surname><given-name>David John</given-name><initials>D.J.</initials><afid>60005087</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:9246702800</author-url><authid>9246702800</authid><authname>Lim W.</authname><surname>Lim</surname><given-name>Wen Kwang</given-name><initials>W.K.</initials><afid>113214158</afid><afid>60026553</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:9246702800</author-url><authid>9246702800</authid><authname>Lim W.</authname><surname>Lim</surname><given-name>Wen Kwang</given-name><initials>W.K.</initials><afid>113214158</afid><afid>60026553</afid></author><authkeywords>Acute healthcare utilisation | Aged care | Ambulatory care sensitive conditions | Chronic disease management | Chronic heart failure | Chronic obstructive pulmonary disease | Diabetes | Health-related quality of life</authkeywords><intid>536087690</intid><article-number>69</article-number><source-id>20846</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930155270"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930155270?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930155270&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930155270&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930155270</prism:url><dc:identifier>SCOPUS_ID:84930155270</dc:identifier><eid>2-s2.0-84930155270</eid><dc:title>Reporting for Double Duty: A Dyadic Perspective on the Biopsychosocial Health of Dual Military Air Force Couples</dc:title><dc:creator>Lacks M.</dc:creator><prism:publicationName>Contemporary Family Therapy</prism:publicationName><prism:issn>08922764</prism:issn><prism:eIssn>15733335</prism:eIssn><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10591-015-9341-y</prism:doi><dc:description>Â© 2015 Springer Science+Business Media New York There are approximately 1.5 million active duty service members in today's military and approximately 726,000 (56.1 %) of these individuals are married. Therefore, healthy couple functioning is important for the military community. Although there is current literature on couple functioning in non-dual military couples, there is limited research on the marital health of dual military couples. This study explored the marital health (marital satisfaction, adjustment, and quality) and stress among dual Air Force couples in relation to length of time in service, rank, deployments, and level of physiological stress. Results indicated that husbands' deployments, rank, and time in service were related to his physiological distress, wives' rank was negatively related to her marital adjustment and marital quality, and husbands' marital satisfaction was negatively related to wives' rank. Future research recommendations and implications for using a biopsychosocial approach for assessing dual military couples are provided.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016280</affiliation-url><afid>60016280</afid><affilname>East Carolina University</affilname><name-variant>East Carolina University</name-variant><affiliation-city>Greenville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005745</affiliation-url><afid>60005745</afid><affilname>University of Minnesota System</affilname><name-variant>University of Minnesota</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109913454</affiliation-url><afid>109913454</afid><affilname>Northcentral University</affilname><name-variant>Northcentral University</name-variant><affiliation-city>Prescott</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662122200</author-url><authid>56662122200</authid><authname>Lacks M.</authname><surname>Lacks</surname><given-name>Meghan H.</given-name><initials>M.H.</initials><afid>60016280</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56589768600</author-url><authid>56589768600</authid><authname>Lamson A.</authname><surname>Lamson</surname><given-name>Angela L.</given-name><initials>A.L.</initials><afid>60016280</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55472866100</author-url><authid>55472866100</authid><authname>Lewis M.</authname><surname>Lewis</surname><given-name>Melissa E.</given-name><initials>M.E.</initials><afid>60005745</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55472874200</author-url><authid>55472874200</authid><authname>White M.</authname><surname>White</surname><given-name>Mark B.</given-name><initials>M.B.</initials><afid>109913454</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6506240677</author-url><authid>6506240677</authid><authname>Russoniello C.</authname><surname>Russoniello</surname><given-name>Carmen</given-name><initials>C.</initials><afid>60016280</afid></author><authkeywords>Couples | Dual military | Heart rate variability | Marital health | Rank | Stress</authkeywords><intid>1536076934</intid><source-id>13414</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930174245"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930174245?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930174245&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930174245&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930174245</prism:url><dc:identifier>SCOPUS_ID:84930174245</dc:identifier><eid>2-s2.0-84930174245</eid><dc:title>Influence of non-cardiac comorbidities on outcome after percutaneous mitral valve repair: results from the German transcatheter mitral valve interventions (TRAMI) registry</dc:title><dc:creator>Zuern C.</dc:creator><prism:publicationName>Clinical Research in Cardiology</prism:publicationName><prism:issn>18610684</prism:issn><prism:eIssn>18610692</prism:eIssn><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00392-015-0872-x</prism:doi><dc:description>Â© 2015 Springer-Verlag Berlin Heidelberg Aims: To investigate the influence of non-cardiac comorbidities on outcomes of patients enrolled in the German transcatheter mitral valve interventions (TRAMI) registry. Methods and results: Intrahospital and 30-day MACCE rates (death of all causes, stroke and myocardial infarction) of 828 patients from the TRAMI registry were stratified by the number of non-cardiac comorbidities. The following non-cardiac comorbidities were prospectively recorded in the registry: diabetes, renal insufficiency, extracardiac arteriopathy, chronic lung disease, neurological disease or malignancy on palliative care. The 375 (45.3 %) patients with multiple (â¥2) non-cardiac comorbidities presented with higher NYHA classes, higher logistic Euroscores, higher levels of NT-proBNP and a shorter 6-min walk distance. Rates of intraprocedural death (0.3 vs. 0.0 %, p = 0.41) and intrahospital MACCE (3.6 vs. 1.9 %, p = 0.16) were not significantly higher in patients with multiple non-cardiac comorbidities, but 30-day MACCE rate was significantly enhanced (6.4 vs. 3.6 %, p = 0.049). However, both patient groups showed a similar clinical improvement after 30 days. Renal insufficiency was the only non-cardiac comorbidity which was independently associated with the 30-day MACCE rate. Conclusions: MitraClip device placement is feasible and safe in patients with multiple non-cardiac comorbidities resulting in a significant clinical improvement and acceptable intrahospital and 30-day event rates. Renal failure is an independent predictor of outcome.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022653</affiliation-url><afid>60022653</afid><affilname>Universitatsklinikum Tubingen Medizinische Fakultat</affilname><affiliation-city>Tubingen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113041492</affiliation-url><afid>113041492</afid><affilname>UniversitÃ¤res Herzzentrum</affilname><name-variant>UniversitÃ¤res Herzzentrum GmbH</name-variant><affiliation-city>Hamburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115289145</affiliation-url><afid>115289145</afid><affilname>Klinikum Siegburg (Kardiologie und Angiologie)</affilname><name-variant>Klinikum Siegburg (Kardiologie und Angiologie)</name-variant><affiliation-city/><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031514</affiliation-url><afid>60031514</afid><affilname>Universitat Gottingen</affilname><name-variant>UniversitÃ¤t GÃ¶ttingen</name-variant><affiliation-city>Gottingen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022135</affiliation-url><afid>60022135</afid><affilname>Klinikum der Johannes-Gutenberg-Universitat und Fachbereich Medizin</affilname><affiliation-city>Mainz</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100527874</affiliation-url><afid>100527874</afid><affilname>Stiftung Institut fÃ¼r Herzinfarktforschung</affilname><name-variant>Stiftung Institut fÃ¼r Herzinfarktforschung</name-variant><affiliation-city>Ludwigshafen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101538805</affiliation-url><afid>101538805</afid><affilname>Herzzentrum Brandenburg</affilname><name-variant>Herzzentrum Brandenburg</name-variant><affiliation-city>Bernau</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60084797</affiliation-url><afid>60084797</afid><affilname>CCB Cardioangiologisches Centrum Bethanien</affilname><name-variant>Cardioangiologisches Ctr. Bethanien</name-variant><affiliation-city>Frankfurt am Main</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030465</affiliation-url><afid>60030465</afid><affilname>Universitats-Klinikum Bonn und Medizinische Fakultat</affilname><affiliation-city>Bonn</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100566706</affiliation-url><afid>100566706</afid><affilname>Herzzentrum</affilname><name-variant>Herzzentrum</name-variant><affiliation-city>Ludwigshafen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24082118200</author-url><authid>24082118200</authid><authname>Zuern C.</authname><surname>Zuern</surname><given-name>Christine S.</given-name><initials>C.S.</initials><afid>60022653</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35274645300</author-url><authid>35274645300</authid><authname>Bauer A.</authname><surname>Bauer</surname><given-name>Axel</given-name><initials>A.</initials><afid>60022653</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8365789700</author-url><authid>8365789700</authid><authname>Lubos E.</authname><surname>Lubos</surname><given-name>Edith</given-name><initials>E.</initials><afid>113041492</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005955507</author-url><authid>7005955507</authid><authname>Boekstegers P.</authname><surname>Boekstegers</surname><given-name>Peter</given-name><initials>P.</initials><afid>115289145</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:14011827400</author-url><authid>14011827400</authid><authname>Puls M.</authname><surname>Puls</surname><given-name>Miriam</given-name><initials>M.</initials><afid>60031514</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662252300</author-url><authid>56662252300</authid><authname>Bardeleben R.</authname><surname>Bardeleben</surname><given-name>Ralph Stephan V</given-name><initials>R.S.V.</initials><afid>60022135</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55346014700</author-url><authid>55346014700</authid><authname>Ouarrak T.</authname><surname>Ouarrak</surname><given-name>Taoufik</given-name><initials>T.</initials><afid>100527874</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55866666600</author-url><authid>55866666600</authid><authname>Butter C.</authname><surname>Butter</surname><given-name>Christian</given-name><initials>C.</initials><afid>101538805</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55861822400</author-url><authid>55861822400</authid><authname>Eggebrecht H.</authname><surname>Eggebrecht</surname><given-name>Holger</given-name><initials>H.</initials><afid>60084797</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55618199500</author-url><authid>55618199500</authid><authname>Nickenig G.</authname><surname>Nickenig</surname><given-name>Georg</given-name><initials>G.</initials><afid>60030465</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56661816800</author-url><authid>56661816800</authid><authname>Zahn R.</authname><surname>Zahn</surname><given-name>Ralph</given-name><initials>R.</initials><afid>100566706</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7103265432</author-url><authid>7103265432</authid><authname>Senges J.</authname><surname>Senges</surname><given-name>Jochen</given-name><initials>J.</initials><afid>100527874</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56442055700</author-url><authid>56442055700</authid><authname>May A.</authname><surname>May</surname><given-name>Andreas E.</given-name><initials>A.E.</initials><afid>60022653</afid></author><authkeywords>Heart failure | MitraClip | Mitral valve regurgitation | Non-cardiac comorbidities | Percutaneous mitral valve repair</authkeywords><intid>1786077119</intid><source-id>3100147501</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225809"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225809?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225809&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225809&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0925838815012529"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225809</prism:url><dc:identifier>SCOPUS_ID:84930225809</dc:identifier><eid>2-s2.0-84930225809</eid><dc:title>Lattice-constant prediction and effect of vacancies in aliovalently doped perovskites</dc:title><dc:creator>Ubic R.</dc:creator><prism:publicationName>Journal of Alloys and Compounds</prism:publicationName><prism:issn>09258388</prism:issn><prism:volume>644</prism:volume><prism:pageRange>982-995</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jallcom.2015.04.213</prism:doi><pii>S0925838815012529</pii><dc:description>Â© 2015 Elsevier B.V. All rights reserved. Processing-structure relationships are at the heart of materials science, and predictive tools are essential for modern technological industries insofar as structure dictates properties. Point defects can have a profound effect on structure and consequently properties, but their effect on crystal chemistry is still not generally known or understood. None of the very few theoretical models which exist for perovskites are suited to the doped and defective ceramics most commonly used in commercial devices; therefore, a new empirical approach is presented here. A predictive model for the effective size of anions as well as cation vacancies and ultimately the pseudocubic lattice constant of such perovskites, based solely on published ionic radii data, has been developed here. The model can also be used to derive ionic radii of cations in twelvefold coordination. Vacancies have an effective size due to both bond relaxation and mutual repulsion of coordinating anions, and as expected this size scales with the host cation radius, but not in a straightforward way. The model is able to predict pseudocubic lattice constants, calculate the effective size of anions and cation vacancies, and identify the effects of both cation ordering and second-order Jahn Teller distortions. A lower limit on the tolerance factor of stable oxide perovskites is proposed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001456</affiliation-url><afid>60001456</afid><affilname>Boise State University</affilname><name-variant>Boise State University</name-variant><affiliation-city>Boise</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007774</affiliation-url><afid>60007774</afid><affilname>Forschungszentrum JÃ¼lich (FZJ)</affilname><name-variant>Forschungszentrum JÃ¼lich</name-variant><affiliation-city>Julich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603517104</author-url><authid>6603517104</authid><authname>Ubic R.</authname><surname>Ubic</surname><given-name>R.</given-name><initials>R.</initials><afid>60001456</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55694722900</author-url><authid>55694722900</authid><authname>Tolman K.</authname><surname>Tolman</surname><given-name>K.</given-name><initials>K.</initials><afid>60001456</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56114759900</author-url><authid>56114759900</authid><authname>Talley K.</authname><surname>Talley</surname><given-name>K.</given-name><initials>K.</initials><afid>60001456</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35076189400</author-url><authid>35076189400</authid><authname>Joshi B.</authname><surname>Joshi</surname><given-name>B.</given-name><initials>B.</initials><afid>60001456</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8053708300</author-url><authid>8053708300</authid><authname>Schmidt J.</authname><surname>Schmidt</surname><given-name>J.</given-name><initials>J.</initials><afid>60001456</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662893600</author-url><authid>56662893600</authid><authname>Faulkner E.</authname><surname>Faulkner</surname><given-name>E.</given-name><initials>E.</initials><afid>60001456</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56312696900</author-url><authid>56312696900</authid><authname>Owens J.</authname><surname>Owens</surname><given-name>J.</given-name><initials>J.</initials><afid>60001456</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56507222200</author-url><authid>56507222200</authid><authname>Papac M.</authname><surname>Papac</surname><given-name>M.</given-name><initials>M.</initials><afid>60001456</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56662839100</author-url><authid>56662839100</authid><authname>Garland A.</authname><surname>Garland</surname><given-name>A.</given-name><initials>A.</initials><afid>60001456</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56663235500</author-url><authid>56663235500</authid><authname>Rumrill C.</authname><surname>Rumrill</surname><given-name>C.</given-name><initials>C.</initials><afid>60001456</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:55695068300</author-url><authid>55695068300</authid><authname>Chan K.</authname><surname>Chan</surname><given-name>K.</given-name><initials>K.</initials><afid>60001456</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:54889733300</author-url><authid>54889733300</authid><authname>Lundy N.</authname><surname>Lundy</surname><given-name>N.</given-name><initials>N.</initials><afid>60001456</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:6508240739</author-url><authid>6508240739</authid><authname>Kungl H.</authname><surname>Kungl</surname><given-name>H.</given-name><initials>H.</initials><afid>60007774</afid></author><authkeywords>Oxide materials | Point defects | Solid state reactions | X-ray diffraction</authkeywords><intid>1536087792</intid><source-id>12325</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930144733"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930144733?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930144733&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930144733&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930144733</prism:url><dc:identifier>SCOPUS_ID:84930144733</dc:identifier><eid>2-s2.0-84930144733</eid><dc:title>TURNING MOURNING: TROLLOPE'S AMBIVALENT WIDOWS</dc:title><dc:creator>Alexander K.</dc:creator><prism:publicationName>Victorian Literature and Culture</prism:publicationName><prism:issn>10601503</prism:issn><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1017/S1060150315000108</prism:doi><pii>S1060150315000108</pii><dc:description>Copyright Â© Cambridge University Press 2015 Near the end of Anthony Trollope's The Small House at Allington (1864), the protagonist Lily Dale disagrees with her mother about the prospect of marrying Johnny Eames, an earnest, but perhaps too ardent graduate of hobbledehoyhood whom Lily finds herself both unwilling and unable to love. Having been jilted by Adolphus Crosbie, a social climber as naÃ¯ve as he is disingenuous, Lily protests that marrying Johnny Eames would constitute a form of adultery. âIn my heart I am married to that other man,â Lily contends, âI gave myself to him, and loved him, and rejoiced in his loveâ (630; ch. 57). Noting that the situation may have changed â Crosbie has since married a noble's daughter and run through her fortune â Lily nevertheless maintains that there âare things that will not have themselves buried and put out of sight, as though they had never beenâ (631; ch. 57).</dc:description><citedby-count>0</citedby-count><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56661775200</author-url><authid>56661775200</authid><authname>Alexander K.</authname><surname>Alexander</surname><given-name>Kaelin B C</given-name><initials>K.B.C.</initials></author><intid>1786077815</intid><source-id>16500154712</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930145019"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930145019?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930145019&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930145019&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930145019</prism:url><dc:identifier>SCOPUS_ID:84930145019</dc:identifier><eid>2-s2.0-84930145019</eid><dc:title>Potential cardiovascular adverse events when phenylephrine is combined with paracetamol: simulation and narrative review</dc:title><dc:creator>Atkinson H.</dc:creator><prism:publicationName>European Journal of Clinical Pharmacology</prism:publicationName><prism:issn>00316970</prism:issn><prism:eIssn>14321041</prism:eIssn><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00228-015-1876-1</prism:doi><dc:description>Â© 2015 The Author(s) Background: Increased bioavailability of phenylephrine is reported when combined with paracetamol in over-the-counter formulations for the symptomatic treatment of the common cold and influenza. Such formulations could increase phenylephrine-related cardiovascular adverse events particularly in susceptible individuals. Quantification of the effect of phenylephrine concentration on blood pressure allows simulation of potential adverse combination therapy effects. Methods: MEDLINE and EMBASE databases were searched for papers discussing or describing any adverse effect, hypersensitivity or safety concerns related to phenylephrine alone or in combination with other drugs. The pharmacodynamic relationship between plasma phenylephrine concentration and mean arterial blood pressure was characterized using published observations of blood pressure changes after ophthalmic eye drops. The resulting pharmacokinetic and pharmacodynamic parameters were then used to predict mean arterial blood pressure (MAP) changes in that population if given an oral combination of phenylephrine and paracetamol. Results: There were 1172 papers identified for examination. Forty-seven reports fulfilled the inclusion criteria. Increases in blood pressure and decreases in heart rate have been reported with doses over 15 mg. It has been estimated that a 20-mmHg increase in systolic blood pressure would occur with an oral dose of 45 mg phenylephrine in normotensive healthy people. Those taking monoamine oxidase inhibitors report increased systolic blood pressure of greater than 60 mmHg. Blood pressure and heart rate changes are potentiated in patients with underlying hypertension. Simulation showed a modest increase in MAP when phenylephrine 10 mg was co-administered with paracetamol 1 g (4.2 vs 12.3 mmHg). Conclusions: Combination paracetamol phenylephrine oral therapy has potential to increase blood pressure more than phenylephrine alone in those with cardiovascular compromise.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114805605</affiliation-url><afid>114805605</afid><affilname>AFT Pharmaceuticals Ltd</affilname><name-variant>AFT Pharmaceuticals Ltd</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Clinical Solutions NZ Ltd</affilname><affiliation-city>Hamilton</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005686</affiliation-url><afid>60005686</afid><affilname>University of Auckland</affilname><name-variant>University of Auckland</name-variant><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56073547500</author-url><authid>56073547500</authid><authname>Atkinson H.</authname><surname>Atkinson</surname><given-name>Hartley C.</given-name><initials>H.C.</initials><afid>114805605</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:14322290400</author-url><authid>14322290400</authid><authname>Potts A.</authname><surname>Potts</surname><given-name>Amanda L.</given-name><initials>A.L.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7404263321</author-url><authid>7404263321</authid><authname>Anderson B.</authname><surname>Anderson</surname><given-name>Brian J.</given-name><initials>B.J.</initials><afid>60005686</afid></author><authkeywords>Blood pressure | Interaction | Paracetamol | Pharmacodynamics | Phenylephrine</authkeywords><intid>1786077796</intid><source-id>21326</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930154939"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930154939?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930154939&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930154939&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930154939</prism:url><dc:identifier>SCOPUS_ID:84930154939</dc:identifier><eid>2-s2.0-84930154939</eid><dc:title>Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution</dc:title><dc:creator>Tagaya M.</dc:creator><prism:publicationName>Heart and Vessels</prism:publicationName><prism:issn>09108327</prism:issn><prism:eIssn>16152573</prism:eIssn><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00380-015-0694-9</prism:doi><dc:description>Â© 2015 Springer Japan New oral anticoagulants (NOACs) are now clinically available. However, few studies have demonstrated which patients with non-valvular atrial fibrillation (NVAF) actually receive NOACs in a clinical setting. We analyzed 182 NVAF patients who received oral anticoagulants. Clinical backgrounds and the risk of stroke, systemic embolism, and bleeding associated with oral anticoagulants were investigated. Seventy-three (40 %) patients were treated with NOACs and 109 (60 %) patients were treated with warfarin. A significantly lower mean number of bleeding risk factors was observed among the patients treated with NOACs than among those treated with warfarin (P = 0.010). Of the bleeding risk factors, NOACs were significantly less frequently prescribed in patients with a bleeding history and elderly subjects (&gt;65 years) than in those who received warfarin (P &lt; 0.001 and P = 0.029). A multivariate logistic regression analysis revealed that CHF and bleeding history were independently and significantly associated with the administration of NOACs (P = 0.047 and P = 0.003). The rate of a history of intracranial hemorrhage was comparable between the patients treated with NOACs and those treated with warfarin (P = 1.000). Significantly lower rates of a history of gastrointestinal and other minor bleeding were observed in the patients who received NOACs versus those who received warfarin (P = 0.001 and P = 0.026). NOACs were less frequently prescribed in patients with a history of bleeding, especially those with a history of gastrointestinal bleeding in a clinical setting.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026940</affiliation-url><afid>60026940</afid><affilname>Fujita Health University</affilname><name-variant>Fujita Health University</name-variant><affiliation-city>Toyoake</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020492</affiliation-url><afid>60020492</afid><affilname>Nagoya University School of Medicine</affilname><name-variant>Nagoya University School of Medicine</name-variant><affiliation-city>Nagoya</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026940</affiliation-url><afid>60026940</afid><affilname>Fujita Health University</affilname><name-variant>Fujita Health University</name-variant><affiliation-city>Toyoake</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026940</affiliation-url><afid>60026940</afid><affilname>Fujita Health University</affilname><name-variant>Fujita Health University</name-variant><affiliation-city>Toyoake</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">17</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56661911800</author-url><authid>56661911800</authid><authname>Tagaya M.</authname><surname>Tagaya</surname><given-name>Manaka</given-name><initials>M.</initials><afid>60026940</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:32467599500</author-url><authid>32467599500</authid><authname>Yoshikawa D.</authname><surname>Yoshikawa</surname><given-name>Daiji</given-name><initials>D.</initials><afid>60026940</afid><afid>60020492</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:32467599500</author-url><authid>32467599500</authid><authname>Yoshikawa D.</authname><surname>Yoshikawa</surname><given-name>Daiji</given-name><initials>D.</initials><afid>60026940</afid><afid>60020492</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55628777700</author-url><authid>55628777700</authid><authname>Sugishita Y.</authname><surname>Sugishita</surname><given-name>Yoshinori</given-name><initials>Y.</initials><afid>60026940</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56661958400</author-url><authid>56661958400</authid><authname>Yamauchi F.</authname><surname>Yamauchi</surname><given-name>Fumi</given-name><initials>F.</initials><afid>60026940</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56465238800</author-url><authid>56465238800</authid><authname>Ito T.</authname><surname>Ito</surname><given-name>Takehiro</given-name><initials>T.</initials><afid>60026940</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55630934400</author-url><authid>55630934400</authid><authname>Kamada T.</authname><surname>Kamada</surname><given-name>Tomohito</given-name><initials>T.</initials><afid>60026940</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102077474</author-url><authid>7102077474</authid><authname>Yoshinaga M.</authname><surname>Yoshinaga</surname><given-name>Masataka</given-name><initials>M.</initials><afid>60026940</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55123221100</author-url><authid>55123221100</authid><authname>Mukaide D.</authname><surname>Mukaide</surname><given-name>Daisuke</given-name><initials>D.</initials><afid>60026940</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6506038667</author-url><authid>6506038667</authid><authname>Fujiwara W.</authname><surname>Fujiwara</surname><given-name>Wakaya</given-name><initials>W.</initials><afid>60026940</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55124573200</author-url><authid>55124573200</authid><authname>Yokoi H.</authname><surname>Yokoi</surname><given-name>Hiroatsu</given-name><initials>H.</initials><afid>60026940</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56447789400</author-url><authid>56447789400</authid><authname>Hayashi M.</authname><surname>Hayashi</surname><given-name>Mutsuharu</given-name><initials>M.</initials><afid>60026940</afid><afid>60020492</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56447789400</author-url><authid>56447789400</authid><authname>Hayashi M.</authname><surname>Hayashi</surname><given-name>Mutsuharu</given-name><initials>M.</initials><afid>60026940</afid><afid>60020492</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56661787000</author-url><authid>56661787000</authid><authname>Watanabe E.</authname><surname>Watanabe</surname><given-name>Eiichi</given-name><initials>E.</initials><afid>60026940</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56661845800</author-url><authid>56661845800</authid><authname>Ishii J.</authname><surname>Ishii</surname><given-name>Junichi</given-name><initials>J.</initials><afid>60026940</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:56463482100</author-url><authid>56463482100</authid><authname>Ozaki Y.</authname><surname>Ozaki</surname><given-name>Yukio</given-name><initials>Y.</initials><afid>60026940</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:56602460100</author-url><authid>56602460100</authid><authname>Izawa H.</authname><surname>Izawa</surname><given-name>Hideo</given-name><initials>H.</initials><afid>60026940</afid></author><authkeywords>Anticoagulants | Arrhythmia | Atrial fibrillation | Drugs | Warfarin</authkeywords><intid>536077866</intid><source-id>23221</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225562"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225562?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225562&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225562&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225562</prism:url><dc:identifier>SCOPUS_ID:84930225562</dc:identifier><eid>2-s2.0-84930225562</eid><dc:title>The biosynthesis of capuramycin-type antibiotics: Identification of the A-102395 biosynthetic gene cluster, mechanism of self-resistance, and formation of uridine-5â²-carboxamide</dc:title><dc:creator>Cai W.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>22</prism:issueIdentifier><prism:pageRange>13710-13724</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M115.646414</prism:doi><dc:description>Â© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. A-500359s, A-503083s, and A-102395 are capuramycin-type nucleoside antibiotics that were discovered using a screen to identify inhibitors of bacterial translocase I, an essential enzyme in peptidoglycan cell wall biosynthesis. Like the parent capuramycin, A-500359s and A-503083s consist of three structural components: a uridine-5â²-carboxamide (CarU), a rare unsaturated hexuronic acid, and an aminocaprolactam, the last of which is substituted by an unusual arylamine-containing polyamide in A-102395. The biosynthetic gene clusters for A-500359s and A-503083s have been reported, and two genes encoding a putative non-heme Fe(II)-dependent Î±-ketoglutarate:UMP dioxygenase and an L-Thr:uridine-5â²-aldehyde transaldolase were uncovered, suggesting that C-C bond formation during assembly of the high carbon (C6) sugar backbone of CarU proceeds from the precursors UMP and L-Thr to form 5â²-C-glycyluridine (C7) as a biosynthetic intermediate. Here, isotopic enrichment studies with the producer of A-503083s were used to indeed establish L-Thr as the direct source of the carboxamide of CarU. With this knowledge, the A-102395 gene cluster was subsequently cloned and characterized. A genetic system in the A-102395-producing strain was developed, permitting the inactivation of several genes, including those encoding the dioxygenase (cpr19) and transaldolase (cpr25), which abolished the production of A-102395, thus confirming their role in biosynthesis. Heterologous production of recombinant Cpr19 and CapK, the transaldolase homolog involved in A-503083 biosynthesis, confirmed their expected function. Finally, a phosphotransferase (Cpr17) conferring self-resistance was functionally characterized. The results provide the opportunity to use comparative genomics along with in vivo and in vitro approaches to probe the biosynthetic mechanism of these intriguing structures.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015941</affiliation-url><afid>60015941</afid><affilname>University of Kentucky</affilname><name-variant>University of Kentucky</name-variant><affiliation-city>Lexington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60057894</affiliation-url><afid>60057894</afid><affilname>Chinese Academy of Medical Sciences</affilname><name-variant>Chinese Academy of Medical Sciences</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021456</affiliation-url><afid>60021456</afid><affilname>Daiichi Sankyo Kabushiki-gaisha</affilname><affiliation-city>Chuo-ku</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113369604</affiliation-url><afid>113369604</afid><affilname>Daiichi Sankyo RD Novare Co., Ltd.</affilname><name-variant>Daiichi-Sankyo RD Novare Co., Ltd</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021456</affiliation-url><afid>60021456</afid><affilname>Daiichi Sankyo Kabushiki-gaisha</affilname><affiliation-city>Chuo-ku</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027155</affiliation-url><afid>60027155</afid><affilname>University of Kentucky HealthCare</affilname><name-variant>University of Kentucky HealthCare ^</name-variant><affiliation-city>Lexington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033241</affiliation-url><afid>60033241</afid><affilname>Universitat des Saarlandes</affilname><name-variant>Saarland University</name-variant><affiliation-city>Saarbrucken</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662653500</author-url><authid>56662653500</authid><authname>Cai W.</authname><surname>Cai</surname><given-name>Wenlong</given-name><initials>W.</initials><afid>60015941</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55489867000</author-url><authid>55489867000</authid><authname>Goswami A.</authname><surname>Goswami</surname><given-name>Anwesha</given-name><initials>A.</initials><afid>60015941</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55605770757</author-url><authid>55605770757</authid><authname>Yang Z.</authname><surname>Yang</surname><given-name>Zhaoyong</given-name><initials>Z.</initials><afid>60057894</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662605500</author-url><authid>56662605500</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xiaodong</given-name><initials>X.</initials><afid>60015941</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:15759702300</author-url><authid>15759702300</authid><authname>Green K.</authname><surname>Green</surname><given-name>Keith D.</given-name><initials>K.D.</initials><afid>60015941</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55489936900</author-url><authid>55489936900</authid><authname>Barnard-Britson S.</authname><surname>Barnard-Britson</surname><given-name>Sandra</given-name><initials>S.</initials><afid>60015941</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:26038924300</author-url><authid>26038924300</authid><authname>Baba S.</authname><surname>Baba</surname><given-name>Satoshi</given-name><initials>S.</initials><afid>60021456</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35169141300</author-url><authid>35169141300</authid><authname>Funabashi M.</authname><surname>Funabashi</surname><given-name>Masanori</given-name><initials>M.</initials><afid>113369604</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:8790001200</author-url><authid>8790001200</authid><authname>Nonaka K.</authname><surname>Nonaka</surname><given-name>Koichi</given-name><initials>K.</initials><afid>60021456</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:35760638800</author-url><authid>35760638800</authid><authname>Sunkara M.</authname><surname>Sunkara</surname><given-name>Manjula</given-name><initials>M.</initials><afid>60027155</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:35449710300</author-url><authid>35449710300</authid><authname>Morris A.</authname><surname>Morris</surname><given-name>Andrew J.</given-name><initials>A.J.</initials><afid>60027155</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:35146785100</author-url><authid>35146785100</authid><authname>Spork A.</authname><surname>Spork</surname><given-name>Anatol P.</given-name><initials>A.P.</initials><afid>60033241</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:6603903461</author-url><authid>6603903461</authid><authname>Ducho C.</authname><surname>Ducho</surname><given-name>Christian</given-name><initials>C.</initials><afid>60033241</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:8979930700</author-url><authid>8979930700</authid><authname>Garneau-Tsodikova S.</authname><surname>Garneau-Tsodikova</surname><given-name>Sylvie</given-name><initials>S.</initials><afid>60015941</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7102301453</author-url><authid>7102301453</authid><authname>Thorson J.</authname><surname>Thorson</surname><given-name>Jon S.</given-name><initials>J.S.</initials><afid>60015941</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:8671229300</author-url><authid>8671229300</authid><authname>Van Lanen S.</authname><surname>Van Lanen</surname><given-name>Steven G.</given-name><initials>S.G.</initials><afid>60015941</afid></author><intid>1036082904</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930199080"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930199080?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930199080&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930199080&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115002925"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930199080</prism:url><dc:identifier>SCOPUS_ID:84930199080</dc:identifier><eid>2-s2.0-84930199080</eid><dc:title>Medicinal effect and its JP2/RyR2-based mechanism of Smilax glabra flavonoids on angiotensin II-induced hypertrophy model of cardiomyocytes</dc:title><dc:creator>Cai Y.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>169</prism:volume><prism:pageRange>435-440</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.04.026</prism:doi><pii>S0378874115002925</pii><dc:description>Â© 2015 Elsevier Ireland Ltd. All rights reserved. Ethnopharmacological relevance Rhizome and root of Smilax glabra Roxb (Liliaceae family) is a widely used traditional Chinese medicine (TCM) named Tu-fu-ling (TFL) for cardiac disease therapy. The TFL flavonoids (TFLF) has been extracted and proven to possess the anti-cardiac hypertrophy effect in our previous reports. Such effect could be mediated by the modulation of intracellular Ca&lt;sup&gt;2+&lt;/sup&gt; flux in myocardial cells, in which junctophilin-2 (JP2) and ryanodine receptor 2 (RyR2) play an important role. However, its mechanism of the anti-cardiac hypertrophy effect remains unclarified. Materials and methods 2 Î¼mol/L Ang II was applied to induce hypertrophy model of rat primary cardiomyocytes. After treatment of TFLF at 0.25, 0.5 and 1.0 mg/ml, the cell size was microscopic measured, and the protein and mRNA expressions of JP2 and RyR2 in cardiomyocytes were estimated by immunofluorescence imaging, ELISA and real-time PCR assay. Results Obvious hypertrophy of cardiomyocytes was induced by Ang II but reversed by TFLF from 0.5 to 1.0 mg/ml. The protein and mRNA expressions of JP2 and RyR2 in cardiomyocytes were also inhibited by Ang II but restored by TFLF at its dose range. Such effect of TFLF was exerted at a dose dependent manner, which was even better than that of verapamil. Conclusions Our findings may evidence the correlation between JP2/RyR2 and myocardiac hypertrophy, and indicate the JP2/RyR2-mediated anti-hypertrophy mechanism of TFLF for the first time. It deserves to be developed as a promising TCM candidate of new drug for myocardial hypertrophy treatment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082198</affiliation-url><afid>60082198</afid><affilname>Zhejiang Chinese Medical University</affilname><name-variant>Zhejiang Chinese Medical University</name-variant><affiliation-city>Hangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069727</affiliation-url><afid>60069727</afid><affilname>Zhejiang Academy of Medical Sciences</affilname><name-variant>Zhejiang Academy of Medical Sciences</name-variant><affiliation-city>Hangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56326957900</author-url><authid>56326957900</authid><authname>Cai Y.</authname><surname>Cai</surname><given-name>Yueqin</given-name><initials>Y.</initials><afid>60082198</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56643195700</author-url><authid>56643195700</authid><authname>Tu J.</authname><surname>Tu</surname><given-name>Jue</given-name><initials>J.</initials><afid>60082198</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55855561000</author-url><authid>55855561000</authid><authname>Pan S.</authname><surname>Pan</surname><given-name>Shuizhen</given-name><initials>S.</initials><afid>60069727</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55856014900</author-url><authid>55856014900</authid><authname>Jiang J.</authname><surname>Jiang</surname><given-name>Jianping</given-name><initials>J.</initials><afid>60082198</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36443045600</author-url><authid>36443045600</authid><authname>Shou Q.</authname><surname>Shou</surname><given-name>Qiyang</given-name><initials>Q.</initials><afid>60082198</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55780672700</author-url><authid>55780672700</authid><authname>Ling Y.</authname><surname>Ling</surname><given-name>Yun</given-name><initials>Y.</initials><afid>60082198</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56662740700</author-url><authid>56662740700</authid><authname>Chen Y.</authname><surname>Chen</surname><given-name>Yunxiang</given-name><initials>Y.</initials><afid>60069727</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55713266800</author-url><authid>55713266800</authid><authname>Wang D.</authname><surname>Wang</surname><given-name>Dejun</given-name><initials>D.</initials><afid>60082198</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56662559200</author-url><authid>56662559200</authid><authname>Yang W.</authname><surname>Yang</surname><given-name>Weiji</given-name><initials>W.</initials><afid>60082198</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:42062394700</author-url><authid>42062394700</authid><authname>Shan L.</authname><surname>Shan</surname><given-name>Letian</given-name><initials>L.</initials><afid>60082198</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56333915400</author-url><authid>56333915400</authid><authname>Chen M.</authname><surname>Chen</surname><given-name>Minli</given-name><initials>M.</initials><afid>60082198</afid></author><authkeywords>Cardiac hypertrophy | Flavonoids | JP2 | RyR2 | Smilax glabra</authkeywords><intid>36086536</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226899"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226899?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226899&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226899&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226899</prism:url><dc:identifier>SCOPUS_ID:84930226899</dc:identifier><eid>2-s2.0-84930226899</eid><dc:title>Mutating the conserved Q-loop glutamine 1291 selectively disrupts adenylate kinase-dependent channel gating of the ATP-binding cassette (ABC) adenylate kinase cystic fibrosis transmembrane conductance regulator (CFTR) and reduces channel function in primary human airway epithelia</dc:title><dc:creator>Dong Q.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>22</prism:issueIdentifier><prism:pageRange>14140-14153</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M114.611616</prism:doi><dc:description>Â© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. The ATP-binding cassette (ABC) transporter cystic fibrosis transmembrane conductance regulator (CFTR) and two other non-membrane-bound ABC proteins, Rad50 and a structural maintenance of chromosome (SMC) protein, exhibit adenylate kinase activity in the presence of physiologic concentrations of ATP and AMP or ADP (ATP + AMP &amp;lrarr2; 2 ADP). The crystal structure of the nucleotide-binding domain of an SMC protein in complex with the adenylate kinase bisubstrate inhibitor P&lt;sup&gt;1&lt;/sup&gt;,P&lt;sup&gt;5&lt;/sup&gt;-di(adenosine-5â²) pentaphosphate (Ap&lt;inf&gt;5&lt;/inf&gt;A) suggests that AMP binds to the conserved Q-loop glutamine during the adenylate kinase reaction. Therefore, we hypothesized that mutating the corresponding residue in CFTR, Gln-1291, selectively disrupts adenylate kinase-dependent channel gating at physiologic nucleotide concentrations. We found that substituting Gln-1291 with bulky side-chain amino acids abolished the effects of Ap&lt;inf&gt;5&lt;/inf&gt;A, AMP, and adenosine 5â²-monophosphoramidate on CFTR channel function. 8-Azidoadenosine 5â²-monophosphate photolabeling of the AMP-binding site and adenylate kinase activity were disrupted in Q1291F CFTR. The Gln-1291 mutations did not alter the potency of ATP at stimulating current or ATP-dependent gating when ATP was the only nucleotide present. However, when physiologic concentrations of ADP and AMP were added, adenylate kinase-deficient Q1291F channels opened significantly less than wild type. Consistent with this result, we found that Q1291F CFTR displayed significantly reduced Cl&lt;sup&gt;-&lt;/sup&gt; channel function in well differentiated primary human airway epithelia. These results indicate that a highly conserved residue of an ABC transporter plays an important role in adenylate kinase-dependent CFTR gating. Furthermore, the results suggest that adenylate kinase activity is important for normal CFTR channel function in airway epithelia.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024324</affiliation-url><afid>60024324</afid><affilname>University of Iowa</affilname><name-variant>University of Iowa</name-variant><affiliation-city>Iowa City</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024324</affiliation-url><afid>60024324</afid><affilname>University of Iowa</affilname><name-variant>University of Iowa</name-variant><affiliation-city>Iowa City</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024324</affiliation-url><afid>60024324</afid><affilname>University of Iowa</affilname><name-variant>University of Iowa</name-variant><affiliation-city>Iowa City</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024324</affiliation-url><afid>60024324</afid><affilname>University of Iowa</affilname><name-variant>University of Iowa</name-variant><affiliation-city>Iowa City</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009470</affiliation-url><afid>60009470</afid><affilname>Howard Hughes Medical Institute</affilname><name-variant>Howard Hughes Medical Institute</name-variant><affiliation-city>Chevy Chase</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35233146800</author-url><authid>35233146800</authid><authname>Dong Q.</authname><surname>Dong</surname><given-name>Qian</given-name><initials>Q.</initials><afid>60024324</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36706048700</author-url><authid>36706048700</authid><authname>Ernst S.</authname><surname>Ernst</surname><given-name>Sarah E.</given-name><initials>S.E.</initials><afid>60024324</afid><afid>60009470</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36706048700</author-url><authid>36706048700</authid><authname>Ernst S.</authname><surname>Ernst</surname><given-name>Sarah E.</given-name><initials>S.E.</initials><afid>60024324</afid><afid>60009470</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6701764343</author-url><authid>6701764343</authid><authname>Ostedgaard L.</authname><surname>Ostedgaard</surname><given-name>Lynda S.</given-name><initials>L.S.</initials><afid>60024324</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56438742800</author-url><authid>56438742800</authid><authname>Shah V.</authname><surname>Shah</surname><given-name>Viral S.</given-name><initials>V.S.</initials><afid>60024324</afid><afid>60024324</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56438742800</author-url><authid>56438742800</authid><authname>Shah V.</authname><surname>Shah</surname><given-name>Viral S.</given-name><initials>V.S.</initials><afid>60024324</afid><afid>60024324</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55427379700</author-url><authid>55427379700</authid><authname>Ver Heul A.</authname><surname>Ver Heul</surname><given-name>Amanda R.</given-name><initials>A.R.</initials><afid>60024324</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35447946600</author-url><authid>35447946600</authid><authname>Welsh M.</authname><surname>Welsh</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>60024324</afid><afid>60024324</afid><afid>60009470</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35447946600</author-url><authid>35447946600</authid><authname>Welsh M.</authname><surname>Welsh</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>60024324</afid><afid>60024324</afid><afid>60009470</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35447946600</author-url><authid>35447946600</authid><authname>Welsh M.</authname><surname>Welsh</surname><given-name>Michael J.</given-name><initials>M.J.</initials><afid>60024324</afid><afid>60024324</afid><afid>60009470</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602189052</author-url><authid>6602189052</authid><authname>Randak C.</authname><surname>Randak</surname><given-name>Christoph O.</given-name><initials>C.O.</initials><afid>60024324</afid></author><intid>1536087466</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226879"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226879?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226879&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226879&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226879</prism:url><dc:identifier>SCOPUS_ID:84930226879</dc:identifier><eid>2-s2.0-84930226879</eid><dc:title>The N terminus of sarcolipin plays an important role in uncoupling sarco-endoplasmic reticulum Ca&lt;sup&gt;2+&lt;/sup&gt;-ATPase (SERCA) ATP hydrolysis from Ca&lt;sup&gt;2+&lt;/sup&gt; transport</dc:title><dc:creator>Sahoo S.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>22</prism:issueIdentifier><prism:pageRange>14057-14067</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M115.636738</prism:doi><dc:description>Â© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. The sarcoendoplasmic reticulum Ca&lt;sup&gt;2+&lt;/sup&gt;-ATPase (SERCA) is responsible for intracellular Ca&lt;sup&gt;2+&lt;/sup&gt; homeostasis. SERCA activity in muscle can be regulated by phospholamban (PLB), an affinity modulator, and sarcolipin (SLN), an uncoupler. Although PLB gets dislodged from Ca&lt;sup&gt;2+&lt;/sup&gt;-bound SERCA, SLN continues to bind SERCA throughout its kinetic cycle and promotes uncoupling of Ca&lt;sup&gt;2+&lt;/sup&gt; transport from ATP hydrolysis. To determine the structural regions of SLN that mediate uncoupling of SERCA, we employed mutagenesis and generated chimeras of PLB and SLN. In this study we demonstrate that deletion of SLN N-terminal residues &lt;sup&gt;2&lt;/sup&gt;ERSTQ leads to loss of the uncoupling function even though the truncated peptide can target and constitutively bind SERCA. Furthermore, molecular dynamics simulations of SLN and SERCA interaction showed a rearrangement of SERCA residues that is altered when the SLN N terminus is deleted. Interestingly, transfer of the PLB cytosolic domain to the SLN transmembrane (TM) and luminal tail causes the chimeric protein to lose SLN-like function. Further introduction of the PLB TM region into this chimera resulted in conversion to full PLB-like function. We also found that swapping PLB N and C termini with those from SLN caused the resulting chimera to acquire SLN-like function. Swapping the C terminus alone was not sufficient for this conversion. These results suggest that domains can be switched between SLN and PLB without losing the ability to regulate SERCA activity; however, the resulting chimeras acquire functions different from the parent molecules. Importantly, our studies highlight that the N termini of SLN and PLB influence their respective unique functions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019160</affiliation-url><afid>60019160</afid><affilname>Syddansk Universitet</affilname><name-variant>University of Southern Denmark</name-variant><affiliation-city>Odense</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112584896</affiliation-url><afid>112584896</afid><affilname>Sanford-Burnham Medical Research Institute at Lake Nona</affilname><name-variant>Sanford Burnham Medical Research Institute at Lake Nona</name-variant><affiliation-city>Orlando</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25633004600</author-url><authid>25633004600</authid><authname>Sahoo S.</authname><surname>Sahoo</surname><given-name>Sanjaya K.</given-name><initials>S.K.</initials><afid>112584896</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36464152300</author-url><authid>36464152300</authid><authname>Shaikh S.</authname><surname>Shaikh</surname><given-name>Sana A.</given-name><initials>S.A.</initials><afid>60003500</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37062127000</author-url><authid>37062127000</authid><authname>Sopariwala D.</authname><surname>Sopariwala</surname><given-name>Danesh H.</given-name><initials>D.H.</initials><afid>60003500</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36883500900</author-url><authid>36883500900</authid><authname>Bal N.</authname><surname>Bal</surname><given-name>Naresh C.</given-name><initials>N.C.</initials><afid>60003500</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662882500</author-url><authid>56662882500</authid><authname>Bruhn D.</authname><surname>Bruhn</surname><given-name>Dennis SkjÃ¸th</given-name><initials>D.S.</initials><afid>60019160</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55673668400</author-url><authid>55673668400</authid><authname>Kopec W.</authname><surname>Kopec</surname><given-name>Wojciech</given-name><initials>W.</initials><afid>60019160</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:9244251900</author-url><authid>9244251900</authid><authname>Khandelia H.</authname><surname>Khandelia</surname><given-name>Himanshu</given-name><initials>H.</initials><afid>60019160</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7102360615</author-url><authid>7102360615</authid><authname>Periasamy M.</authname><surname>Periasamy</surname><given-name>Muthu</given-name><initials>M.</initials><afid>60003500</afid><afid>112584896</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7102360615</author-url><authid>7102360615</authid><authname>Periasamy M.</authname><surname>Periasamy</surname><given-name>Muthu</given-name><initials>M.</initials><afid>60003500</afid><afid>112584896</afid></author><intid>36085944</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930205123"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930205123?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930205123&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930205123&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930205123</prism:url><dc:identifier>SCOPUS_ID:84930205123</dc:identifier><eid>2-s2.0-84930205123</eid><dc:title>Emergency department and inpatient health care utilization among patients who require interpreter services Utilization, expenditure, economics and financing systems</dc:title><dc:creator>Njeru J.</dc:creator><prism:publicationName>BMC Health Services Research</prism:publicationName><prism:eIssn>14726963</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12913-015-0874-4</prism:doi><dc:description>Â© 2015 Njeru et al.; licensee BioMed Central. Background: Limited English proficiency is associated with health disparities and suboptimal health outcomes. Although Limited English proficiency is a barrier to effective health care, its association with inpatient health care utilization is unclear. The aim of this study was to examine the association between patients with limited English proficiency, and emergency department visits and hospital admissions. Methods: We compared emergency department visits and hospitalizations in 2012 between patients requiring interpreter services and age-matched English-proficient patients (who did not require interpreters), in a retrospective cohort study of adult patients actively empanelled to a large primary health care network in a medium-sized United States city (n = 3,784). Results: Patients who required interpreter services had significantly more Emergency Department visits (841 vs 620; P.001) and hospitalizations (408 vs 343; P; .001) than patients who did not require interpreter services. On regression analysis the risk of a first Emergency Department visit was 60 % higher for patients requiring interpreter services than those who did not (unadjusted hazard ratio [HR], 1.6; 95 % confidence interval (CI), 1.4-1.9; P &lt; .05), while that of a first hospitalization was 50 % higher (unadjusted HR, 1.5; 95 % CI, 1.2-1.8; P &lt; .05). These findings remained significant after adjusting for age, sex, medical complexity, residency and outpatient health care utilization. Conclusions: Patients who required interpreter services had higher rates of inpatient health care utilization compared with patients who did not require an interpreter. Further research is required to understand factors associated with this utilization and to develop sociolinguistically tailored interventions to facilitate appropriate health care provision for this population.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663150100</author-url><authid>56663150100</authid><authname>Njeru J.</authname><surname>Njeru</surname><given-name>Jane W.</given-name><initials>J.W.</initials><afid>60005558</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56603272100</author-url><authid>56603272100</authid><authname>St. Sauver J.</authname><surname>St. Sauver</surname><given-name>Jennifer L.</given-name><initials>J.L.</initials><afid>60005558</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7201872580</author-url><authid>7201872580</authid><authname>Jacobson D.</authname><surname>Jacobson</surname><given-name>Debra J.</given-name><initials>D.J.</initials><afid>60005558</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003696512</author-url><authid>7003696512</authid><authname>Ebbert J.</authname><surname>Ebbert</surname><given-name>Jon O.</given-name><initials>J.O.</initials><afid>60005558</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004295080</author-url><authid>7004295080</authid><authname>Takahashi P.</authname><surname>Takahashi</surname><given-name>Paul Y.</given-name><initials>P.Y.</initials><afid>60005558</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56413753000</author-url><authid>56413753000</authid><authname>Fan C.</authname><surname>Fan</surname><given-name>Chun</given-name><initials>C.</initials><afid>60005558</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36171946400</author-url><authid>36171946400</authid><authname>Wieland M.</authname><surname>Wieland</surname><given-name>Mark L.</given-name><initials>M.L.</initials><afid>60005558</afid></author><authkeywords>Health disparities | Health services research | Limited English proficiency</authkeywords><intid>36086238</intid><article-number>214</article-number><source-id>28098</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930205629"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930205629?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930205629&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930205629&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930205629</prism:url><dc:identifier>SCOPUS_ID:84930205629</dc:identifier><eid>2-s2.0-84930205629</eid><dc:title>The role of HSP70 and its co-chaperones in protein misfolding, aggregation and disease</dc:title><dc:creator>Duncan E.</dc:creator><prism:publicationName>Sub-Cellular Biochemistry</prism:publicationName><prism:issn>03060225</prism:issn><prism:volume>78</prism:volume><prism:pageRange>1-31</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1007/978-3-319-11731-7_12</prism:doi><dc:description>Â© Springer International Publishing Switzerland 2015. Molecular chaperones and their associated co-chaperones are essential in health and disease as they are key facilitators of protein folding, quality control and function. In particular, the HSP70 molecular chaperone networks have been associated with neurodegenerative diseases caused by aberrant protein folding. The pathogenesis of these disorders usually includes the formation of deposits of misfolded, aggregated protein. HSP70 and its co-chaperones have been recognised as potent modulators of inclusion formation and cell survival in cellular and animal models of neurodegenerative disease. In has become evident that the HSP70 chaperone machine functions not only in folding, but also in proteasome mediated degradation of neurodegenerative disease proteins. Thus, there has been a great deal of interest in the potential manipulation of molecular chaperones as a therapeutic approach for many neurodegenerations. Furthermore, mutations in several HSP70 co-chaperones and putative co-chaperones have been identified as causing inherited neurodegenerative and cardiac disorders, directly linking the HSP70 chaperone system to human disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021435</affiliation-url><afid>60021435</afid><affilname>Barts and The London Queen Mary's School of Medicine and Dentistry</affilname><name-variant>Queen Mary University of London</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013148</affiliation-url><afid>60013148</afid><affilname>UCL Institute of Ophthalmology</affilname><name-variant>University College London</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56610585400</author-url><authid>56610585400</authid><authname>Duncan E.</authname><surname>Duncan</surname><given-name>Emma J.</given-name><initials>E.J.</initials><afid>60021435</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004465799</author-url><authid>7004465799</authid><authname>Cheetham M.</authname><surname>Cheetham</surname><given-name>Michael E.</given-name><initials>M.E.</initials><afid>60013148</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003353456</author-url><authid>7003353456</authid><authname>Chapple J.</authname><surname>Chapple</surname><given-name>J. Paul</given-name><initials>J.P.</initials><afid>60021435</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701844271</author-url><authid>6701844271</authid><authname>Van Der Spuy J.</authname><surname>Van Der Spuy</surname><given-name>Jacqueline</given-name><initials>J.</initials><afid>60013148</afid></author><authkeywords>Co-chaperone | HSP70 | Protein misfolding and aggregation Â·Neurodegeneration</authkeywords><intid>1036082673</intid><source-id>38020</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930207049"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930207049?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930207049&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930207049&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930207049</prism:url><dc:identifier>SCOPUS_ID:84930207049</dc:identifier><eid>2-s2.0-84930207049</eid><dc:title>Bisphenol-A plasma levels are related to inflammatory markers, visceral obesity and insulin-resistance: A cross-sectional study on adult male population</dc:title><dc:creator>Savastano S.</dc:creator><prism:publicationName>Journal of Translational Medicine</prism:publicationName><prism:eIssn>14795876</prism:eIssn><prism:volume>13</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>May 29, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12967-015-0532-y</prism:doi><dc:description>Â© 2015 Savastano et al. Background: The current increase of obesity and metabolic syndrome (MS) focuses attention on bisphenol-A (BPA), "obesogen" endocrine disruptor, main plastic component. Aim was to verify the role of BPA in metabolic alterations, insulin resistance, low grade inflammation and visceral obesity. Methods: A cross-sectional study was performed in 76 out of 139 environmentally exposed adult males, unselected Caucasian subjects, enrolled by routine health survey at the "Federico II" University of Naples outpatient facilities. BPA plasma levels (ELISA), metabolic risk factors, homeostasis model assessment of insulin resistance index, plasma monocyte chemoattractant protein 1, interleukin-6 (IL-6) and tumor necrosis factor-alpha were performed. Clinical and biochemical parameters have been compared with BPA and pro-inflammatory cytokines levels. Results: In total 24 subjects out of 76 (32%) presented with waist circumference (WC) &gt;102 cm, 36 (47%) had impaired fasting glucose and 24 (32%) subjects had insulin resistance [11 out 52 (21%) with WC â¤102 cm and 13 out of 24 with WC &gt;102 cm (54%), Î§&lt;sup&gt;2&lt;/sup&gt; 6.825, p = 0.009]. BPA and pro-inflammatory cytokine levels were significantly higher in subjects with visceral adiposity (WC &gt; 102 cm). BPA correlated with WC, triglycerides, glucose homeostasis and inflammatory markers. At the multivariate analysis WC and IL-6 remained the main predictors of BPA. Conclusions: Detectable BPA plasma levels have been found also in our population. The strictly association between BPA and WC, components of MS, and inflammatory markers, further supports the BPA role in visceral obesity-related low grade chronic inflammation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017293</affiliation-url><afid>60017293</afid><affilname>Universita degli Studi di Napoli Federico II</affilname><name-variant>University of Naples Federico II</name-variant><affiliation-city>Naples</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113676867</affiliation-url><afid>113676867</afid><affilname>Cancer Research Center of Mercogliano</affilname><name-variant>Cancer Research Center of Mercogliano</name-variant><affiliation-city/><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017293</affiliation-url><afid>60017293</afid><affilname>Universita degli Studi di Napoli Federico II</affilname><name-variant>University of Naples Federico II</name-variant><affiliation-city>Naples</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017293</affiliation-url><afid>60017293</afid><affilname>Universita degli Studi di Napoli Federico II</affilname><name-variant>University of Naples Federico II</name-variant><affiliation-city>Naples</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113084428</affiliation-url><afid>113084428</afid><affilname>Stella Maris Mediterraneum Foundation</affilname><name-variant>Stella Maris Mediterraneum Foundation</name-variant><affiliation-city>Potenza</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006355654</author-url><authid>7006355654</authid><authname>Savastano S.</authname><surname>Savastano</surname><given-name>Silvia</given-name><initials>S.</initials><afid>60017293</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004428832</author-url><authid>7004428832</authid><authname>Tarantino G.</authname><surname>Tarantino</surname><given-name>Giovanni</given-name><initials>G.</initials><afid>60017293</afid><afid>113676867</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004428832</author-url><authid>7004428832</authid><authname>Tarantino G.</authname><surname>Tarantino</surname><given-name>Giovanni</given-name><initials>G.</initials><afid>60017293</afid><afid>113676867</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:25824881500</author-url><authid>25824881500</authid><authname>D'Esposito V.</authname><surname>D'Esposito</surname><given-name>Vittoria</given-name><initials>V.</initials><afid>60017293</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36646479500</author-url><authid>36646479500</authid><authname>Passaretti F.</authname><surname>Passaretti</surname><given-name>Federica</given-name><initials>F.</initials><afid>60017293</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36809059100</author-url><authid>36809059100</authid><authname>Cabaro S.</authname><surname>Cabaro</surname><given-name>Serena</given-name><initials>S.</initials><afid>60017293</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55933477700</author-url><authid>55933477700</authid><authname>Liotti A.</authname><surname>Liotti</surname><given-name>Antonietta</given-name><initials>A.</initials><afid>60017293</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6603762228</author-url><authid>6603762228</authid><authname>Liguoro D.</authname><surname>Liguoro</surname><given-name>Domenico</given-name><initials>D.</initials><afid>60017293</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:23493290400</author-url><authid>23493290400</authid><authname>Perruolo G.</authname><surname>Perruolo</surname><given-name>Giuseppe</given-name><initials>G.</initials><afid>60017293</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56663281700</author-url><authid>56663281700</authid><authname>Ariemma F.</authname><surname>Ariemma</surname><given-name>Fabiana</given-name><initials>F.</initials><afid>60017293</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7006629033</author-url><authid>7006629033</authid><authname>Finelli C.</authname><surname>Finelli</surname><given-name>Carmine</given-name><initials>C.</initials><afid>113084428</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7006833765</author-url><authid>7006833765</authid><authname>Beguinot F.</authname><surname>Beguinot</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60017293</afid><afid>60017293</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7006833765</author-url><authid>7006833765</authid><authname>Beguinot F.</authname><surname>Beguinot</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60017293</afid><afid>60017293</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004341423</author-url><authid>7004341423</authid><authname>Formisano P.</authname><surname>Formisano</surname><given-name>Pietro</given-name><initials>P.</initials><afid>60017293</afid><afid>60017293</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004341423</author-url><authid>7004341423</authid><authname>Formisano P.</authname><surname>Formisano</surname><given-name>Pietro</given-name><initials>P.</initials><afid>60017293</afid><afid>60017293</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7006618490</author-url><authid>7006618490</authid><authname>Valentino R.</authname><surname>Valentino</surname><given-name>Rossella</given-name><initials>R.</initials><afid>60017293</afid></author><authkeywords>Bisphenol-A | Endocrine-disruptors | Metabolic Syndrome | Obesity | Visceral adiposity</authkeywords><intid>2036082511</intid><article-number>169</article-number><source-id>16440</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930200415"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930200415?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930200415&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930200415&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930200415</prism:url><dc:identifier>SCOPUS_ID:84930200415</dc:identifier><eid>2-s2.0-84930200415</eid><dc:title>UCS proteins: Chaperones for myosin and co-chaperones for Hsp90</dc:title><dc:creator>Ni W.</dc:creator><prism:publicationName>Sub-Cellular Biochemistry</prism:publicationName><prism:issn>03060225</prism:issn><prism:volume>78</prism:volume><prism:pageRange>1-20</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1007/978-3-319-11731-7_7</prism:doi><dc:description>Â© Springer International Publishing Switzerland 2015 The UCS (UNC-45/CRO1/She4p) family of proteins has emerged as chaperones that are specific for the folding, assembly and function of myosin. These proteins participate in various important myosin-dependent cellular processes that include myofibril organization and muscle functions, cell differentiation, cardiac and skeletal muscle development, cytokinesis and endocytosis. Mutations in the genes that code for UCS proteins cause serious defects in these actomyosin-based processes. Homologs of UCS proteins can be broadly divided into (1) animal UCS proteins, generally known as UNC-45 proteins, which contain an N-terminal tetratricopeptide repeat (TPR) domain in addition to the canonical UCS domain, and (2) fungal UCS proteins, which lack the TPR domain. Structurally, except for TPR domain, both sub-classes of UCS proteins comprise of several irregular armadillo (ARM) repeats that are divided into two-domain architecture: a combined centralneck domain and a C-terminal UCS domain. Structural analyses suggest that UNC-45 proteins form elongated oligomers that serve as scaffolds to recruit Hsp90 and/or Hsp70 to form a multi-protein chaperoning complex that assists myosin heads to fold and simultaneously organize them into myofibrils. Similarly, fungal UCS proteins may dimerize to promote folding of non-muscle myosins as well as determine their step size along actin filaments. These findings confirm UCS proteins as a new class of myosin-specific chaperones and co-chaperones for Hsp90. This chapter reviews the implications of the outcome of studies on these proteins in cellular processes such as muscle formation, and disease states such as myopathies and cancer.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017691</affiliation-url><afid>60017691</afid><affilname>Stephen F. Austin State University</affilname><name-variant>Stephen F. Austin State University</name-variant><affiliation-city>Nacogdoches</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009470</affiliation-url><afid>60009470</afid><affilname>Howard Hughes Medical Institute</affilname><name-variant>Howard Hughes Medical Institute</name-variant><affiliation-city>Chevy Chase</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55642105000</author-url><authid>55642105000</authid><authname>Ni W.</authname><surname>Ni</surname><given-name>Weiming</given-name><initials>W.</initials><afid>60009470</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602645678</author-url><authid>6602645678</authid><authname>Odunuga O.</authname><surname>Odunuga</surname><given-name>Odutayo O.</given-name><initials>O.O.</initials><afid>60017691</afid></author><authkeywords>Chaperones | Co-chaperones | Myosin | TPR | UCS</authkeywords><intid>1786087962</intid><source-id>38020</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930205463"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930205463?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930205463&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930205463&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930205463</prism:url><dc:identifier>SCOPUS_ID:84930205463</dc:identifier><eid>2-s2.0-84930205463</eid><dc:title>Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis</dc:title><dc:creator>Ally M.</dc:creator><prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName><prism:eIssn>14712474</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12891-015-0587-1</prism:doi><dc:description>Â© 2015 Ally et al.; licensee BioMed Central. Background: To measure circulating anti-citrullinated peptide antibodies (ACPA) and cytokines pre- and 6 months post-therapy as a strategy to predict and optimize responses to traditional disease-modifying antirheumatic drugs (DMARDs) in early RA, which is an unmet need in developing countries. Patients and methods: A cohort of 140 predominantly (88.5 %) black female South African patients with early RA was treated with synthetic DMARDs, mostly methotrexate (MTX) alone, or in combination with low-dose oral corticosteroids (CS). Circulating ACPA and a panel of circulating cytokines/chemokines/growth factors were measured at baseline and after 6 months of therapy in relation to disease activity and Shared Epitope (SE). Results: Following 6 months of therapy, the median simplified disease activity index (SDAI) declined from a baseline of 41.4 to 16.0 (pâ=â0.0001) for the entire cohort, which was paralleled by significant falls in median serum ACPA levels (516.6 vs. 255.7 units/ml, pâ=â&lt;0.0001) and several of the circulating cytokines (IL-4, IL-7, IL-8, G-CSF, VEGF; pâ&lt;â0.0010 - pâ&lt;â0.0001) which were most evident in the subgroup of patients treated with a combination of MTX and CS. Although biomarker concentrations decreased most notably in the low-disease activity group post-therapy, no significant correlations between these biomarkers and disease activity were observed, Baseline ACPA levels, but not SDAI or cytokines, were significantly higher in the subgroup of risk allele-positive patients (561.1 vs. 331.9 units/ml, pâ&lt;â0.05), while no associations with ACPA and a smoking history were evident. Conclusions: The use of DMARDs in RA is associated with significant decreases in ACPA and cytokines which did not correlate with changes in SDAI, precluding the utility of serial measurement of these biomarkers to monitor early responses to therapy, but may have prognostic value.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021902</affiliation-url><afid>60021902</afid><affilname>Universiteit van Pretoria</affilname><name-variant>University of Pretoria</name-variant><affiliation-city>Pretoria</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021902</affiliation-url><afid>60021902</afid><affilname>Universiteit van Pretoria</affilname><name-variant>University of Pretoria</name-variant><affiliation-city>Pretoria</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016218</affiliation-url><afid>60016218</afid><affilname>University of Witwatersrand</affilname><name-variant>University of the Witwatersrand</name-variant><affiliation-city>Johannesburg</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024308</affiliation-url><afid>60024308</afid><affilname>National Health Laboratory Services</affilname><name-variant>National Health Laboratory Services</name-variant><affiliation-city>Johannesburg</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016218</affiliation-url><afid>60016218</afid><affilname>University of Witwatersrand</affilname><name-variant>University of the Witwatersrand</name-variant><affiliation-city>Johannesburg</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36243029200</author-url><authid>36243029200</authid><authname>Ally M.</authname><surname>Ally</surname><given-name>Mahmood M T M</given-name><initials>M.M.T.M.</initials><afid>60021902</afid><afid>60021902</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36243029200</author-url><authid>36243029200</authid><authname>Ally M.</authname><surname>Ally</surname><given-name>Mahmood M T M</given-name><initials>M.M.T.M.</initials><afid>60021902</afid><afid>60021902</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24343664000</author-url><authid>24343664000</authid><authname>Hodkinson B.</authname><surname>Hodkinson</surname><given-name>Bridget</given-name><initials>B.</initials><afid>60016218</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55430825400</author-url><authid>55430825400</authid><authname>Meyer P.</authname><surname>Meyer</surname><given-name>Pieter W A</given-name><initials>P.W.A.</initials><afid>60021902</afid><afid>60024308</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55430825400</author-url><authid>55430825400</authid><authname>Meyer P.</authname><surname>Meyer</surname><given-name>Pieter W A</given-name><initials>P.W.A.</initials><afid>60021902</afid><afid>60024308</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:25924528100</author-url><authid>25924528100</authid><authname>Musenge E.</authname><surname>Musenge</surname><given-name>Eustasius</given-name><initials>E.</initials><afid>60016218</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602444863</author-url><authid>6602444863</authid><authname>Tintinger G.</authname><surname>Tintinger</surname><given-name>Gregory R.</given-name><initials>G.R.</initials><afid>60021902</afid><afid>60021902</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602444863</author-url><authid>6602444863</authid><authname>Tintinger G.</authname><surname>Tintinger</surname><given-name>Gregory R.</given-name><initials>G.R.</initials><afid>60021902</afid><afid>60021902</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004118459</author-url><authid>7004118459</authid><authname>Tikly M.</authname><surname>Tikly</surname><given-name>Mohammed</given-name><initials>M.</initials><afid>60016218</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7406489754</author-url><authid>7406489754</authid><authname>Anderson R.</authname><surname>Anderson</surname><given-name>Ronald</given-name><initials>R.</initials><afid>60021902</afid></author><authkeywords>Anticyclic citrullinated peptide antibodies | Cytokines | Disease modifying antirheumatic drugs | Rheumatoid arthritis | Shared epitope</authkeywords><intid>536087451</intid><article-number>130</article-number><source-id>29541</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930227334"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930227334?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930227334&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930227334&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930227334</prism:url><dc:identifier>SCOPUS_ID:84930227334</dc:identifier><eid>2-s2.0-84930227334</eid><dc:title>The human mitochondrial DNA depletion syndrome gene MPV17 encodes a non-selective channel that modulates membrane potential</dc:title><dc:creator>Antonenkov V.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>22</prism:issueIdentifier><prism:pageRange>13840-13861</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M114.608083</prism:doi><dc:description>Â© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. The human MPV17-related mitochondrial DNA depletion syndrome is an inherited autosomal recessive disease caused by mutations in the inner mitochondrial membrane protein MPV17. Although more than 30 MPV17 gene mutations were shown to be associated with mitochondrial DNA depletion syndrome, the function of MPV17 is still unknown. Mice deficient in Mpv17 show signs of premature aging. In the present study, we used electrophysiological measurements with recombinant MPV17 to reveal that this protein forms a non-selective channel with a pore diameter of 1.8 nm and located the channel's selectivity filter. The channel was weakly cation-selective and showed several subconductance states. Voltage-dependent gating of the channel was regulated by redox conditions and pH and was affected also in mutants mimicking a phosphorylated state. Likewise, the mitochondrial membrane potential (ÎÏ&lt;inf&gt;m&lt;/inf&gt;) and the cellular production of reactive oxygen species were higher in embryonic fibroblasts from Mpv17&lt;sup&gt;-/-&lt;/sup&gt; mice. However, despite the elevated ÎÏ&lt;inf&gt;m&lt;/inf&gt;, the Mpv17-deficient mitochondria showed signs of accelerated fission. Together, these observations uncover the role of MPV17 as a ÎÏ&lt;inf&gt;m&lt;/inf&gt;-modulating channel that apparently contributes to mitochondrial homeostasis under different conditions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012954</affiliation-url><afid>60012954</afid><affilname>Oulun Yliopisto</affilname><name-variant>University of Oulu</name-variant><affiliation-city>Oulu</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072360</affiliation-url><afid>60072360</afid><affilname>Heinrich-Pette-Institut</affilname><name-variant>Heinrich-Pette-Institute for Experimental Virology and Immunology</name-variant><affiliation-city>Hamburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006154600</author-url><authid>7006154600</authid><authname>Antonenkov V.</authname><surname>Antonenkov</surname><given-name>Vasily D.</given-name><initials>V.D.</initials><afid>60012954</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56663270900</author-url><authid>56663270900</authid><authname>Isomursu A.</authname><surname>Isomursu</surname><given-name>Antti</given-name><initials>A.</initials><afid>60012954</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55967910600</author-url><authid>55967910600</authid><authname>Mennerich D.</authname><surname>Mennerich</surname><given-name>Daniela</given-name><initials>D.</initials><afid>60012954</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:12786683700</author-url><authid>12786683700</authid><authname>Vapola M.</authname><surname>Vapola</surname><given-name>Miia H.</given-name><initials>M.H.</initials><afid>60012954</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003933582</author-url><authid>7003933582</authid><authname>Weiher H.</authname><surname>Weiher</surname><given-name>Hans</given-name><initials>H.</initials><afid>60072360</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004214502</author-url><authid>7004214502</authid><authname>Kietzmann T.</authname><surname>Kietzmann</surname><given-name>Thomas</given-name><initials>T.</initials><afid>60012954</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35263979500</author-url><authid>35263979500</authid><authname>Hiltunen J.</authname><surname>Hiltunen</surname><given-name>J. Kalervo</given-name><initials>J.K.</initials><afid>60012954</afid></author><intid>1786087309</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930199437"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930199437?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930199437&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930199437&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930199437</prism:url><dc:identifier>SCOPUS_ID:84930199437</dc:identifier><eid>2-s2.0-84930199437</eid><dc:title>Genetically encoded fluorescent sensors for redox processes</dc:title><dc:creator>Bilan D.</dc:creator><prism:publicationName>Russian Journal of Bioorganic Chemistry</prism:publicationName><prism:issn>10681620</prism:issn><prism:volume>41</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>231-244</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1134/S106816201502003X</prism:doi><dc:description>Â© 2015 Pleiades Publishing, Ltd. Redox processes play a key role in the cells of any organism. These processes imply directed flows of electrons transferred via the so-called redox pairs - compounds present in cells simultaneously in both oxidized and reduced states such as NAD&lt;sup&gt;+&lt;/sup&gt;/NADH, NADP&lt;sup&gt;+&lt;/sup&gt;/NADPH, GSSG/GSH. Up to now, investigation of redox processes in live cells has been hampered by the lack of suitable methods. Genetically encoded fluorescent biosensors represent a new tool for investigation of biological processes including redox ones. Biosensors allow real-time monitoring of messengers, metabolites, and enzyme activities in live systems of different levels of complexity from cultivated cells to transgenic animals. Major types of the known redox-biosensors and examples of their application are presented in this review.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60085212</affiliation-url><afid>60085212</afid><affilname>Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences</affilname><name-variant>Russian Academy of Sciences</name-variant><affiliation-city>Moscow</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112362885</affiliation-url><afid>112362885</afid><affilname>Ministry of Healthcare of the</affilname><name-variant>Ministry of Healthcare of the</name-variant><affiliation-city>Moscow</affiliation-city><affiliation-country>Russian Federation</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:49860926900</author-url><authid>49860926900</authid><authname>Bilan D.</authname><surname>Bilan</surname><given-name>D. S.</given-name><initials>D.S.</initials><afid>60085212</afid><afid>112362885</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:49860926900</author-url><authid>49860926900</authid><authname>Bilan D.</authname><surname>Bilan</surname><given-name>D. S.</given-name><initials>D.S.</initials><afid>60085212</afid><afid>112362885</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004533175</author-url><authid>7004533175</authid><authname>Lukyanov S.</authname><surname>Lukyanov</surname><given-name>S. A.</given-name><initials>S.A.</initials><afid>60085212</afid><afid>112362885</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004533175</author-url><authid>7004533175</authid><authname>Lukyanov S.</authname><surname>Lukyanov</surname><given-name>S. A.</given-name><initials>S.A.</initials><afid>60085212</afid><afid>112362885</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102704965</author-url><authid>7102704965</authid><authname>Belousov V.</authname><surname>Belousov</surname><given-name>V. V.</given-name><initials>V.V.</initials><afid>60085212</afid><afid>112362885</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102704965</author-url><authid>7102704965</authid><authname>Belousov V.</authname><surname>Belousov</surname><given-name>V. V.</given-name><initials>V.V.</initials><afid>60085212</afid><afid>112362885</afid></author><authkeywords>2GSH/GSSG | genetically encoded fluorescent redox-biosensors | NAD&lt;sup&gt;+&lt;/sup&gt;/NADH | reactive oxygen species</authkeywords><intid>1036082910</intid><source-id>26483</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225536"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225536?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225536&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225536&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225536</prism:url><dc:identifier>SCOPUS_ID:84930225536</dc:identifier><eid>2-s2.0-84930225536</eid><dc:title>LLY-507, a cell-active, potent, and selective inhibitor of protein-lysine methyltransferase SMYD2</dc:title><dc:creator>Nguyen H.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>22</prism:issueIdentifier><prism:pageRange>13641-13653</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M114.626861</prism:doi><dc:description>Â© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. SMYD2 is a lysine methyltransferase that catalyzes the monomethylation of several protein substrates including p53. SMYD2 is overexpressed in a significant percentage of esophageal squamous primary carcinomas, and that overexpression correlates with poor patient survival. However, the mechanism(s) by which SMYD2 promotes oncogenesis is not understood. A small molecule probe for SMYD2 would allow for the pharmacological dissection of this biology. In this report, we disclose LLY-507, a cell-active, potent small molecule inhibitor of SMYD2. LLY-507 is &gt;100-fold selective for SMYD2 over a broad range of methyltransferase and non-methyltransferase targets. A 1.63-Ã resolution crystal structure of SMYD2 in complex with LLY-507 shows the inhibitor binding in the substrate peptide binding pocket. LLY-507 is active in cells as measured by reduction of SMYD2-induced monomethylation of p53 Lys&lt;sup&gt;370&lt;/sup&gt; at submicromolar concentrations. We used LLY-507 to further test other potential roles of SMYD2. Mass spectrometry-based proteomics showed that cellular global histone methylation levels were not significantly affected by SMYD2 inhibition with LLY-507, and subcellular fractionation studies indicate that SMYD2 is primarily cytoplasmic, suggesting that SMYD2 targets a very small subset of histones at specific chromatin loci and/or non-histone substrates. Breast and liver cancers were identified through in silico data mining as tumor types that display amplification and/or overexpression of SMYD2. LLY-507 inhibited the proliferation of several esophageal, liver, and breast cancer cell lines in a dose-dependent manner. These findings suggest that LLY-507 serves as a valuable chemical probe to aid in the dissection of SMYD2 function in cancer and other biological processes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025685</affiliation-url><afid>60025685</afid><affilname>Eli Lilly and Company</affilname><name-variant>Lilly Corporate Center</name-variant><affiliation-city>Indianapolis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006297</affiliation-url><afid>60006297</afid><affilname>University of Pennsylvania</affilname><name-variant>University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">26</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662637200</author-url><authid>56662637200</authid><authname>Nguyen H.</authname><surname>Nguyen</surname><given-name>Hannah</given-name><initials>H.</initials><afid>60025685</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602214677</author-url><authid>6602214677</authid><authname>Allali-Hassani A.</authname><surname>Allali-Hassani</surname><given-name>Abdellah</given-name><initials>A.</initials><afid>60016849</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37053469800</author-url><authid>37053469800</authid><authname>Antonysamy S.</authname><surname>Antonysamy</surname><given-name>Stephen</given-name><initials>S.</initials><afid>60025685</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662574300</author-url><authid>56662574300</authid><authname>Chang S.</authname><surname>Chang</surname><given-name>Shawn</given-name><initials>S.</initials><afid>60025685</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662557000</author-url><authid>56662557000</authid><authname>Chen L.</authname><surname>Chen</surname><given-name>Lisa Hong</given-name><initials>L.H.</initials><afid>60025685</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662741000</author-url><authid>56662741000</authid><authname>Curtis C.</authname><surname>Curtis</surname><given-name>Carmen</given-name><initials>C.</initials><afid>60025685</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602423430</author-url><authid>6602423430</authid><authname>Emtage S.</authname><surname>Emtage</surname><given-name>Spencer</given-name><initials>S.</initials><afid>60025685</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7402512883</author-url><authid>7402512883</authid><authname>Fan L.</authname><surname>Fan</surname><given-name>Li</given-name><initials>L.</initials><afid>60025685</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6507020506</author-url><authid>6507020506</authid><authname>Gheyi T.</authname><surname>Gheyi</surname><given-name>Tarun</given-name><initials>T.</initials><afid>60025685</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:17135234800</author-url><authid>17135234800</authid><authname>Li F.</authname><surname>Li</surname><given-name>Fengling</given-name><initials>F.</initials><afid>60016849</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56235922500</author-url><authid>56235922500</authid><authname>Liu S.</authname><surname>Liu</surname><given-name>Shichong</given-name><initials>S.</initials><afid>60006297</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56662567000</author-url><authid>56662567000</authid><authname>Martin J.</authname><surname>Martin</surname><given-name>Joseph R.</given-name><initials>J.R.</initials><afid>60025685</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7005194735</author-url><authid>7005194735</authid><authname>Mendel D.</authname><surname>Mendel</surname><given-name>David</given-name><initials>D.</initials><afid>60025685</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:55312556300</author-url><authid>55312556300</authid><authname>Olsen J.</authname><surname>Olsen</surname><given-name>Jonathan B.</given-name><initials>J.B.</initials><afid>60025685</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:56662806200</author-url><authid>56662806200</authid><authname>Pelletier L.</authname><surname>Pelletier</surname><given-name>Laura</given-name><initials>L.</initials><afid>60025685</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:6506203897</author-url><authid>6506203897</authid><authname>Shatseva T.</authname><surname>Shatseva</surname><given-name>Tatiana</given-name><initials>T.</initials><afid>60016849</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:56210784700</author-url><authid>56210784700</authid><authname>Wu S.</authname><surname>Wu</surname><given-name>Song</given-name><initials>S.</initials><afid>60025685</afid></author><author seq="18"><author-url>http://api.elsevier.com/content/author/author_id:36462055200</author-url><authid>36462055200</authid><authname>Zhang F.</authname><surname>Zhang</surname><given-name>Feiyu Fred</given-name><initials>F.F.</initials><afid>60025685</afid></author><author seq="19"><author-url>http://api.elsevier.com/content/author/author_id:7006642154</author-url><authid>7006642154</authid><authname>Arrowsmith C.</authname><surname>Arrowsmith</surname><given-name>Cheryl H.</given-name><initials>C.H.</initials><afid>60016849</afid><afid>60016849</afid></author><author seq="19"><author-url>http://api.elsevier.com/content/author/author_id:7006642154</author-url><authid>7006642154</authid><authname>Arrowsmith C.</authname><surname>Arrowsmith</surname><given-name>Cheryl H.</given-name><initials>C.H.</initials><afid>60016849</afid><afid>60016849</afid></author><author seq="20"><author-url>http://api.elsevier.com/content/author/author_id:36989023100</author-url><authid>36989023100</authid><authname>Brown P.</authname><surname>Brown</surname><given-name>Peter J.</given-name><initials>P.J.</initials><afid>60016849</afid></author><author seq="21"><author-url>http://api.elsevier.com/content/author/author_id:19633619500</author-url><authid>19633619500</authid><authname>Campbell R.</authname><surname>Campbell</surname><given-name>Robert M.</given-name><initials>R.M.</initials><afid>60025685</afid></author><author seq="22"><author-url>http://api.elsevier.com/content/author/author_id:10043205600</author-url><authid>10043205600</authid><authname>Garcia B.</authname><surname>Garcia</surname><given-name>Benjamin A.</given-name><initials>B.A.</initials><afid>60006297</afid></author><author seq="23"><author-url>http://api.elsevier.com/content/author/author_id:6602873877</author-url><authid>6602873877</authid><authname>Barsyte-Lovejoy D.</authname><surname>Barsyte-Lovejoy</surname><given-name>Dalia</given-name><initials>D.</initials><afid>60016849</afid></author><author seq="24"><author-url>http://api.elsevier.com/content/author/author_id:7007013997</author-url><authid>7007013997</authid><authname>Mader M.</authname><surname>Mader</surname><given-name>Mary</given-name><initials>M.</initials><afid>60025685</afid></author><author seq="25"><author-url>http://api.elsevier.com/content/author/author_id:6602942792</author-url><authid>6602942792</authid><authname>Vedadi M.</authname><surname>Vedadi</surname><given-name>Masoud</given-name><initials>M.</initials><afid>60016849</afid></author><intid>536087487</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930216540"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930216540?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930216540&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930216540&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930216540</prism:url><dc:identifier>SCOPUS_ID:84930216540</dc:identifier><eid>2-s2.0-84930216540</eid><dc:title>Negative regulation of leptin-induced reactive oxygen species (ROS) formation by cannabinoid CB&lt;inf&gt;1&lt;/inf&gt; receptor activation in hypothalamic neurons</dc:title><dc:creator>Palomba L.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>22</prism:issueIdentifier><prism:pageRange>13669-13677</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M115.646885</prism:doi><dc:description>Â© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. The adipocyte-derived, anorectic hormone leptin was recently shown to owe part of its regulatory effects on appetite-regulating hypothalamic neuropeptides to the elevation of reactive oxygen species (ROS) levels in arcuate nucleus (ARC) neurons. Leptin is also known to exert a negative regulation on hypothalamic endocannabinoid levels and hence on cannabinoid CB&lt;inf&gt;1&lt;/inf&gt; receptor activity. Here we investigated the possibility of a negative regulation by CB&lt;inf&gt;1&lt;/inf&gt; receptors of leptin-mediated ROS formation in the ARC. Through pharmacological and molecular biology experiments we report data showing that leptin-induced ROS accumulation is 1) blunted by arachidonyl-2â²-chloroethylamide (ACEA) in a CB&lt;inf&gt;1&lt;/inf&gt;-dependent manner in both the mouse hypothalamic cell line mHypoE-N41 and ARC neuron primary cultures, 2) likewise blocked by a peroxisome proliferator-activated receptor-Î³ (PPAR-Î³) agonist, troglitazone, in a manner inhibited by T0070907, a PPAR-Î³ antagonist that also inhibited the ACEA effect on leptin, 3) blunted under conditions of increased endocannabinoid tone due to either pharmacological or genetic inhibition of endocannabinoid degradation in mHypoE-N41 and primary ARC neuronal cultures from MAGL&lt;sup&gt;-/-&lt;/sup&gt; mice, respectively, and 4) associated with reduction of both PPAR-Î³ and catalase activity, which are reversed by both ACEA and troglitazone. We conclude that CB&lt;inf&gt;1&lt;/inf&gt; activation reverses leptin-induced ROS formation and hence possibly some of the ROS-mediated effects of the hormone by preventing PPAR-Î³ inhibition by leptin, with subsequent increase of catalase activity. This mechanism might underlie in part CB1 orexigenic actions under physiopathological conditions accompanied by elevated hypothalamic endocannabinoid levels.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032111</affiliation-url><afid>60032111</afid><affilname>Universita degli Studi di Urbino</affilname><name-variant>UniversitÃ  di Urbino</name-variant><affiliation-city>Urbino</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021199</affiliation-url><afid>60021199</afid><affilname>Consiglio Nazionale delle Ricerche</affilname><name-variant>CNR</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021199</affiliation-url><afid>60021199</afid><affilname>Consiglio Nazionale delle Ricerche</affilname><name-variant>CNR</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015150</affiliation-url><afid>60015150</afid><affilname>Imperial College London</affilname><name-variant>Imperial College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">17</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603577624</author-url><authid>6603577624</authid><authname>Palomba L.</authname><surname>Palomba</surname><given-name>Letizia</given-name><initials>L.</initials><afid>60032111</afid><afid>60021199</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603577624</author-url><authid>6603577624</authid><authname>Palomba L.</authname><surname>Palomba</surname><given-name>Letizia</given-name><initials>L.</initials><afid>60032111</afid><afid>60021199</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54387429500</author-url><authid>54387429500</authid><authname>Silvestri C.</authname><surname>Silvestri</surname><given-name>Cristoforo</given-name><initials>C.</initials><afid>60021199</afid><afid>60021199</afid><afid>60015150</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54387429500</author-url><authid>54387429500</authid><authname>Silvestri C.</authname><surname>Silvestri</surname><given-name>Cristoforo</given-name><initials>C.</initials><afid>60021199</afid><afid>60021199</afid><afid>60015150</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54387429500</author-url><authid>54387429500</authid><authname>Silvestri C.</authname><surname>Silvestri</surname><given-name>Cristoforo</given-name><initials>C.</initials><afid>60021199</afid><afid>60021199</afid><afid>60015150</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55315985500</author-url><authid>55315985500</authid><authname>Imperatore R.</authname><surname>Imperatore</surname><given-name>Roberta</given-name><initials>R.</initials><afid>60021199</afid><afid>60021199</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55315985500</author-url><authid>55315985500</authid><authname>Imperatore R.</authname><surname>Imperatore</surname><given-name>Roberta</given-name><initials>R.</initials><afid>60021199</afid><afid>60021199</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662828900</author-url><authid>56662828900</authid><authname>Morello G.</authname><surname>Morello</surname><given-name>Giovanna</given-name><initials>G.</initials><afid>60021199</afid><afid>60021199</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662828900</author-url><authid>56662828900</authid><authname>Morello G.</authname><surname>Morello</surname><given-name>Giovanna</given-name><initials>G.</initials><afid>60021199</afid><afid>60021199</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56342932700</author-url><authid>56342932700</authid><authname>Piscitelli F.</authname><surname>Piscitelli</surname><given-name>Fabiana</given-name><initials>F.</initials><afid>60021199</afid><afid>60021199</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56342932700</author-url><authid>56342932700</authid><authname>Piscitelli F.</authname><surname>Piscitelli</surname><given-name>Fabiana</given-name><initials>F.</initials><afid>60021199</afid><afid>60021199</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:37117336500</author-url><authid>37117336500</authid><authname>Martella A.</authname><surname>Martella</surname><given-name>Andrea</given-name><initials>A.</initials><afid>60021199</afid><afid>60021199</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:37117336500</author-url><authid>37117336500</authid><authname>Martella A.</authname><surname>Martella</surname><given-name>Andrea</given-name><initials>A.</initials><afid>60021199</afid><afid>60021199</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6506988838</author-url><authid>6506988838</authid><authname>Cristino L.</authname><surname>Cristino</surname><given-name>Luigia</given-name><initials>L.</initials><afid>60021199</afid><afid>60021199</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6506988838</author-url><authid>6506988838</authid><authname>Cristino L.</authname><surname>Cristino</surname><given-name>Luigia</given-name><initials>L.</initials><afid>60021199</afid><afid>60021199</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7101602863</author-url><authid>7101602863</authid><authname>Di Marzo V.</authname><surname>Di Marzo</surname><given-name>Vincenzo</given-name><initials>V.</initials><afid>60021199</afid><afid>60021199</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7101602863</author-url><authid>7101602863</authid><authname>Di Marzo V.</authname><surname>Di Marzo</surname><given-name>Vincenzo</given-name><initials>V.</initials><afid>60021199</afid><afid>60021199</afid></author><intid>36085738</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930204604"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930204604?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930204604&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930204604&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930204604</prism:url><dc:identifier>SCOPUS_ID:84930204604</dc:identifier><eid>2-s2.0-84930204604</eid><dc:title>CHIP: A co-chaperone for degradation by the proteasome</dc:title><dc:creator>Edkins A.</dc:creator><prism:publicationName>Sub-Cellular Biochemistry</prism:publicationName><prism:issn>03060225</prism:issn><prism:volume>78</prism:volume><prism:pageRange>1-24</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1007/978-3-319-11731-7_11</prism:doi><dc:description>Â© Springer International Publishing Switzerland 2015 Protein homeostasis relies on a balance between protein folding and protein degradation. Molecular chaperones like Hsp70 and Hsp90 fulfil well-defined roles in protein folding and conformational stability via ATP dependent reaction cycles. These folding cycles are controlled by associations with a cohort of non-client protein co-chaperones, such as Hop, p23 and Aha1. Pro-folding co-chaperones facilitate the transit of the client protein through the chaperone mediated folding process. However, chaperones are also involved in ubiquitin-mediated proteasomal degradation of client proteins. Similar to folding complexes, the ability of chaperones to mediate protein degradation is regulated by co-chaperones, such as the C terminal Hsp70 binding protein (CHIP). CHIP binds to Hsp70 and Hsp90 chaperones through its tetratricopeptide repeat (TPR) domain and functions as an E3 ubiquitin ligase using a modified RING finger domain (U-box). This unique combination of domains effectively allows CHIP to network chaperone complexes to the ubiquitin-proteasome system. This chapter reviews the current understanding of CHIP as a co-chaperone that switches Hsp70/Hsp90 chaperone complexes from protein folding to protein degradation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026548</affiliation-url><afid>60026548</afid><affilname>Rhodes University</affilname><name-variant>Rhodes University</name-variant><affiliation-city>Grahamstown</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:22134279300</author-url><authid>22134279300</authid><authname>Edkins A.</authname><surname>Edkins</surname><given-name>Adrienne L.</given-name><initials>A.L.</initials><afid>60026548</afid></author><authkeywords>CHIP | Proteasome | STUB1 | Ubiquitin</authkeywords><intid>2036082716</intid><source-id>38020</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930158469"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930158469?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930158469&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930158469&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930158469</prism:url><dc:identifier>SCOPUS_ID:84930158469</dc:identifier><eid>2-s2.0-84930158469</eid><dc:title>Heart rate recovery and parasympathetic modulation in boys and girls following maximal and submaximal exercise</dc:title><dc:creator>Guilkey J.</dc:creator><prism:publicationName>European Journal of Applied Physiology</prism:publicationName><prism:issn>14396319</prism:issn><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00421-015-3192-y</prism:doi><dc:description>Â© 2015 Springer-Verlag Berlin Heidelberg Purpose: This study examined heart rate recovery (HRR) and heart rate variability (HRV) following submaximal and maximal exercise in boys (n = 13; 10.1 Â± 0.8 years) and girls (n = 12; 10.1 Â± 0.7 years). Methods: Participants completed 10 min of supine rest followed by a graded exercise test to maximal effort. On a separate day, participants performed submaximal exercise at ventilatory threshold. Immediately following both exercise bouts, 1-min HRR was assessed in the supine position. HRV variables were analyzed under controlled breathing in the time and frequency domains over the final 5 min of rest and recovery. Results: There were no significant differences in HRR following maximal and submaximal exercise between boys (58 Â± 8 and 59 Â± 8 beats min&lt;sup&gt;â1&lt;/sup&gt;, respectively) and girls (54 Â± 6 and 52 Â± 19 beats min&lt;sup&gt;â1&lt;/sup&gt;, respectively). There also were no significant interactions between groups from rest to recovery from maximal exercise for any HRV variables. However, there was a difference in the response between sexes from rest to recovery from submaximal exercise for log transformed standard deviation of NN intervals (lnSDNN) and log transformed total power (lnTP). No differences were observed for lnSDNN at rest (boys = 4.61 Â± 0.28 vs. girls = 4.28 Â± 0.52 ms) or during recovery (lnSDNN: boys 3.78 Â± 0.46 vs. girls 3.87 Â± 0.64 ms and lnTP: boys 7.33 Â± 1.09 vs. girls; 7.44 Â± 1.24 ms&lt;sup&gt;2&lt;/sup&gt;). Post hoc pairwise comparisons showed a significant difference between boys and girls for lnTP at rest (boys = 9.14 Â± 0.42 vs. girls = 8.30 Â± 1.05 ms&lt;sup&gt;2&lt;/sup&gt;). Conclusion: Parasympathetic modulation was similar between boys and girls at rest and during recovery from exercise, which could explain similarities observed in HRR.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028244</affiliation-url><afid>60028244</afid><affilname>Ball State University</affilname><name-variant>Ball State University</name-variant><affiliation-city>Muncie</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55358262400</author-url><authid>55358262400</authid><authname>Guilkey J.</authname><surname>Guilkey</surname><given-name>J. P.</given-name><initials>J.P.</initials><afid>60028244</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56301306400</author-url><authid>56301306400</authid><authname>Overstreet M.</authname><surname>Overstreet</surname><given-name>M.</given-name><initials>M.</initials><afid>60028244</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005242998</author-url><authid>7005242998</authid><authname>Mahon A.</authname><surname>Mahon</surname><given-name>A. D.</given-name><initials>A.D.</initials><afid>60028244</afid></author><authkeywords>Cardiovascular regulation | Heart rate variability | Pediatrics | Sex differences</authkeywords><intid>1536077124</intid><source-id>23402</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930172898"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930172898?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930172898&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930172898&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930172898</prism:url><dc:identifier>SCOPUS_ID:84930172898</dc:identifier><eid>2-s2.0-84930172898</eid><dc:title>Increased cardiac remodeling in cardiac-specific Flt-1 receptor knockout mice with pressure overload</dc:title><dc:creator>Mei L.</dc:creator><prism:publicationName>Cell and Tissue Research</prism:publicationName><prism:issn>0302766X</prism:issn><prism:eIssn>14320878</prism:eIssn><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00441-015-2209-5</prism:doi><dc:description>Â© 2015 Springer-Verlag Berlin Heidelberg Vascular endothelial growth factor (VEGF) inhibition has previously been shown to have damaging effects on the heart. Because the role of Flt-1 (a phosphotyrosine kinase receptor for VEGF) in cardiac function and hypertrophy is unclear, we generated mice lacking Flt-1 only in their cardiomyocytes (Flt-1 KO). The hearts from 8- to 10-weekâold mice were measured by using echocardiography and histology. No significant differences were seen in fraction shortening, cross-sectional area of cardiomyocytes, and interstitial collagen fraction between littermate controls and KO mice at baseline. To test the hypothesis that Flt-1 is involved in cardiac remodeling, we performed transverse aorta constriction (TAC) by ligating the transverse ascending aorta. Four weeks after TAC, echocardiography of the mice was performed, and the hearts were excised for pathological analysis and Western blotting. No difference in mortality was found between Flt-1 KO mice and controls; however, KO mice showed a greater cardiomyocyte cross-sectional area and interstitial collagen fraction than controls. Western blotting indicated that AKT was activated less in Flt-1 KO hearts after TAC compared with that in control hearts. Thus, Flt-1 deletion in cardiomyocytes increased hypertrophy, fibrosis, and regression of AKT phosphorylation. Our study suggests that Flt-1 plays a critical role in cardiac hypertrophy induced by pressure overload via the activation of AKT, which seems to be cardioprotective.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101475601</affiliation-url><afid>101475601</afid><affilname>Wenzhou Medical University</affilname><name-variant>Wenzhou Medical University</name-variant><affiliation-city>Hangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113751624</affiliation-url><afid>113751624</afid><affilname>The Second Affiliated Hospital of Wenzhou Medical University</affilname><name-variant>The Second Affiliated Hospital of Wenzhou Medical University</name-variant><affiliation-city>WenZhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073652</affiliation-url><afid>60073652</afid><affilname>Tongji University</affilname><name-variant>Tongji University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025761</affiliation-url><afid>60025761</afid><affilname>Huazhong University of Science and Technology</affilname><name-variant>Huazhong Univ. of Sci. and Technol.</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56661753300</author-url><authid>56661753300</authid><authname>Mei L.</authname><surname>Mei</surname><given-name>Liqin</given-name><initials>L.</initials><afid>101475601</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56661477900</author-url><authid>56661477900</authid><authname>Huang Y.</authname><surname>Huang</surname><given-name>Yinqing</given-name><initials>Y.</initials><afid>113751624</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56661381200</author-url><authid>56661381200</authid><authname>Lin J.</authname><surname>Lin</surname><given-name>Jiafeng</given-name><initials>J.</initials><afid>113751624</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56661703600</author-url><authid>56661703600</authid><authname>Chu M.</authname><surname>Chu</surname><given-name>Maoping</given-name><initials>M.</initials><afid>113751624</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55774957400</author-url><authid>55774957400</authid><authname>Hu C.</authname><surname>Hu</surname><given-name>Chaohui</given-name><initials>C.</initials><afid>60073652</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56661705000</author-url><authid>56661705000</authid><authname>Zhou N.</authname><surname>Zhou</surname><given-name>Ning</given-name><initials>N.</initials><afid>60025761</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55775072300</author-url><authid>55775072300</authid><authname>Wu L.</authname><surname>Wu</surname><given-name>Lianpin</given-name><initials>L.</initials><afid>113751624</afid></author><authkeywords>AKT | Cardiac remodeling | Flt-1 | Mouse | Pressure overload</authkeywords><intid>1786077615</intid><source-id>18446</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930160071"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930160071?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930160071&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930160071&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930160071</prism:url><dc:identifier>SCOPUS_ID:84930160071</dc:identifier><eid>2-s2.0-84930160071</eid><dc:title>Application of 3D imaging in the real-time USâCT fusion navigation for minimal invasive tumor therapy</dc:title><dc:creator>Wu W.</dc:creator><prism:publicationName>International Journal of Computer Assisted Radiology and Surgery</prism:publicationName><prism:issn>18616410</prism:issn><prism:eIssn>18616429</prism:eIssn><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11548-015-1224-z</prism:doi><dc:description>Â© 2015 CARS Purpose: Image-guided minimally invasive treatment (IG-MIT) has been widely used for local therapy of both benign and malignant tumors. However, precise needle targeting is a very important step in the minimally invasive treatment. Nowadays, minimally invasive treatment is usually performed with the guidance of the two-dimensional (2D) image. The tip of the puncture needle is difficult to place with precise positioning into the three-dimensional (3D) space of the tumor. This study was an experimental ex vivo study in porcine liver and heart samples with internal targets, focusing on the accuracy with the guidance of the real-time 3D imaging using a self-developed real-time ultrasonography and preoperative computed tomography (CT) fusion navigation system for minimal invasive tumor (liver tumor and uterine fibroid) therapy. Methods: There are thirty porcine liver samples and thirty porcine heart samples used in the experiments. The average weight of the porcine liver samples was 2216.8 g, and the average weight of the porcine heart samples was 510.5 g. We conducted statistical analysis of the experimental results obtained by five medical students and five interventional radiologists. Results: The puncture precision of the needle placement under the guidance of 3D imaging was significantly higher than that of the other groups, and the assistant function is more obvious for medical students than that for interventional radiologists (Formula presented.). Assistant function of the USâCT fusion imaging is higher than that of the first group too (Formula presented.). The precision of the puncture with guidance of the 3D imaging was very satisfied in the fact that it was found that there was a mean discrepancy of (Formula presented.) (medical students) and (Formula presented.) (interventional radiologists) in porcine livers and there was a mean discrepancy of (Formula presented.) (medical students) and (Formula presented.) (interventional radiologists) in porcine hearts. Conclusions: Experimental results showed that the accuracy of needle targeting can be improved with the guidance of the real-time 3D imaging than that with the guidance of both 2D US images and USâCT fusion images in IG-MIT. Assistant function of 3D imaging is obviously for medical students.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069744</affiliation-url><afid>60069744</afid><affilname>General Hospital of People's Liberation Army</affilname><name-variant>General Hospital of Chinese PLA</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114745227</affiliation-url><afid>114745227</afid><affilname>Zoucheng People's Hospital</affilname><name-variant>Zoucheng Peopleâs Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114745227</affiliation-url><afid>114745227</afid><affilname>Zoucheng People's Hospital</affilname><name-variant>Zoucheng Peopleâs Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114745227</affiliation-url><afid>114745227</afid><affilname>Zoucheng People's Hospital</affilname><name-variant>Zoucheng Peopleâs Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114745227</affiliation-url><afid>114745227</afid><affilname>Zoucheng People's Hospital</affilname><name-variant>Zoucheng Peopleâs Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55906749800</author-url><authid>55906749800</authid><authname>Wu W.</authname><surname>Wu</surname><given-name>Wenbo</given-name><initials>W.</initials><afid>60069744</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56413673500</author-url><authid>56413673500</authid><authname>Xue Y.</authname><surname>Xue</surname><given-name>Yingfeng</given-name><initials>Y.</initials><afid>114745227</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56413295300</author-url><authid>56413295300</authid><authname>Wang D.</authname><surname>Wang</surname><given-name>Dong</given-name><initials>D.</initials><afid>114745227</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662286600</author-url><authid>56662286600</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xiaoguang</given-name><initials>X.</initials><afid>114745227</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55192380400</author-url><authid>55192380400</authid><authname>Xue J.</authname><surname>Xue</surname><given-name>Jin</given-name><initials>J.</initials><afid>60069744</afid><afid>114745227</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55192380400</author-url><authid>55192380400</authid><authname>Xue J.</authname><surname>Xue</surname><given-name>Jin</given-name><initials>J.</initials><afid>60069744</afid><afid>114745227</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56661752900</author-url><authid>56661752900</authid><authname>Duan S.</authname><surname>Duan</surname><given-name>Shaobo</given-name><initials>S.</initials><afid>60069744</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56661485700</author-url><authid>56661485700</authid><authname>Wang F.</authname><surname>Wang</surname><given-name>Fang</given-name><initials>F.</initials><afid>114745227</afid></author><authkeywords>3D image guidance | Minimally invasive treatment | Precise needle targeting | Ultrasound guidance | USâCT fusion navigation</authkeywords><intid>1036071685</intid><source-id>4700152490</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930150589"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930150589?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930150589&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930150589&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930150589</prism:url><dc:identifier>SCOPUS_ID:84930150589</dc:identifier><eid>2-s2.0-84930150589</eid><dc:title>FAIR CHANCE AND MODAL CONSEQUENTIALISM</dc:title><dc:creator>StefÃ¡nsson H.</dc:creator><prism:publicationName>Economics and Philosophy</prism:publicationName><prism:issn>02662671</prism:issn><prism:eIssn>14740028</prism:eIssn><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1017/S0266267115000152</prism:doi><pii>S0266267115000152</pii><dc:description>Copyright Â© Cambridge University Press This paper develops a Multidimensional Decision Theory and argues that it better captures ordinary intuitions about fair distribution of chances than classical decision theory. The theory is an extension of Richard Jeffreyâs decision theory to counterfactual prospect and is a form of Modal Consequentialism, according to which the value of actual outcomes often depends on what could have been. Unlike existing versions of modal consequentialism, the multidimensional decision theory allows us to explicitly model the desirabilistic dependencies between actual and counterfactual outcomes that, I contend, are at the heart of common intuitions about fair distribution of chances.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city/><affiliation-country/></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56661964500</author-url><authid>56661964500</authid><authname>StefÃ¡nsson H.</authname><surname>StefÃ¡nsson</surname><given-name>H. Orri</given-name><initials>H.O.</initials><afid/></author><authkeywords>consequentialism | counterfactuals | decision theory | fairness</authkeywords><intid>536077089</intid><source-id>24888</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930172551"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930172551?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930172551&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930172551&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930172551</prism:url><dc:identifier>SCOPUS_ID:84930172551</dc:identifier><eid>2-s2.0-84930172551</eid><dc:title>Flow and oscillations in collapsible tubes: Physiological applications and low-dimensional models</dc:title><dc:creator>PEDLEY T.</dc:creator><prism:publicationName>Sadhana - Academy Proceedings in Engineering Sciences</prism:publicationName><prism:issn>02562499</prism:issn><prism:eIssn>09737677</prism:eIssn><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12046-015-0363-9</prism:doi><dc:description>Â© 2015 Indian Academy of Sciences The motivation for this subject comes from physiology: Air-flow in the lungs, where flow limitation during forced expiration is a consequence of large-airway collapse, and wheezing, which is a manifestation of self-excited mechanical oscillations; Blood flow in veins, such as those of giraffes, in which the return of blood to the heart from the head must be accompanied by partial venous collapse, and in arteries, which exhibit self-excited oscillations (Korotkov sounds) when compressed by a blood-pressure cuff. Laboratory experiments are frequently conducted in a Starling resistor, a finite length of flexible tube, mounted between two rigid tubes and contained in a pressurised chamber. Steady conditions upstream and downstream give rise not only to steady flows, but also to a rich variety of self-excited oscillations, which theoreticians have been seeking to understand for at least five decades. Some of the observations have been reproduced in full NavierâStokes computations for a two-dimensional model, but these do not provide physical understanding. We seek a self-consistent mathematical model for the oscillations. We concentrate first on 1D models, in which the key dependent variables are the cross-sectional area A and the cross-sectionally averaged velocity u and pressure p, all taken to be functions of longitudinal coordinate x and time t. The governing equations are those of conservation of mass and momentum and a tube law representing the elastic properties of the vessel. In the momentum equation, the viscous resistance term is conventionally modelled either as a linear function of fluid velocity, accurate at low Reynolds number, or with an ad hoc representation of the energy loss at flow separation. Even with such crude approximations, the predictions of 1D models agree quite well both with observations in the giraffe and with some of the 2D computations and 3D experiments. For a more rational model, we examine a 2D model problem, in which part of one wall of a parallel sided channel is replaced by a membrane under tension. One approach, for large Reynolds-number flow, and a long membrane, is to consider small deflections of the membrane and use interactive boundary-layer theory. This leads to interesting predictions, such as the impossibility of simultaneously prescribing the flow rate and the upstream pressure, but not to oscillations, except in cases where wall inertia is important (flutter). Another approach is to assume a parabolic velocity profile everywhere, leading to a rational choice for the inertia and viscous terms in the 1D momentum equation. If, further, the undisturbed membrane is taken to be flat, by a suitable choice of external pressure distribution, the system leads to an oscillatory instability even without wall inertia. Whether these oscillations have the same physics as those computed numerically at lower Reynolds number remains to be seen.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031101</affiliation-url><afid>60031101</afid><affilname>University of Cambridge</affilname><name-variant>University of Cambridge</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003771</affiliation-url><afid>60003771</afid><affilname>University of Manchester</affilname><name-variant>University of Manchester</name-variant><affiliation-city>Manchester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7101811293</author-url><authid>7101811293</authid><authname>PEDLEY T.</authname><surname>PEDLEY</surname><given-name>T. J.</given-name><initials>T.J.</initials><afid>60031101</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55014560700</author-url><authid>55014560700</authid><authname>PIHLER-PUZOVIÄ D.</authname><surname>PIHLER-PUZOVIÄ</surname><given-name>D.</given-name><initials>D.</initials><afid>60003771</afid></author><authkeywords>1D models | 2D models. | Collapsible tubes | flow-structure interactions</authkeywords><intid>2036072609</intid><source-id>23531</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930175642"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930175642?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930175642&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930175642&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930175642</prism:url><dc:identifier>SCOPUS_ID:84930175642</dc:identifier><eid>2-s2.0-84930175642</eid><dc:title>Novel Targets of Drug Treatment for Pulmonary Hypertension</dc:title><dc:creator>Hu J.</dc:creator><prism:publicationName>American Journal of Cardiovascular Drugs</prism:publicationName><prism:issn>11753277</prism:issn><prism:eIssn>1179187X</prism:eIssn><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s40256-015-0125-4</prism:doi><dc:description>Â© 2015 Springer International Publishing Switzerland Biomedical advances over the last decade have identified the central role of proliferative pulmonary arterial smooth muscle cells (PASMCs) in the development of pulmonary hypertension (PH). Furthermore, promoters of proliferation and apoptosis resistance in PASMCs and endothelial cells, such as aberrant signal pathways involving growth factors, G protein-coupled receptors, kinases, and microRNAs, have also been described. As a result of these discoveries, PH is currently divided into subgroups based on the underlying pathology, which allows focused and targeted treatment of the condition. The defining features of PH, which subsequently lead to vascular wall remodeling, are dysregulated proliferation of PASMCs, local inflammation, and apoptosis-resistant endothelial cells. Efforts to assess the relative contributions of these factors have generated several promising targets. This review discusses recent novel targets of therapies for PH that have been developed as a result of these advances, which are now in pre-clinical and clinical trials (e.g., imatinib [phase III]; nilotinib, AT-877ER, rituximab, tacrolimus, paroxetine, sertraline, fluoxetine, bardoxolone methyl [phase II]; and sorafenib, FK506, aviptadil, endothelial progenitor cells (EPCs) [phase I]). While substantial progress has been made in recent years in targeting key molecular pathways, PH still remains without a cure, and these novel therapies provide an important conceptual framework of categorizing patients on the basis of molecular phenotype(s) for effective treatment of the disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015543</affiliation-url><afid>60015543</afid><affilname>University of Pittsburgh</affilname><name-variant>University of Pittsburgh</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015543</affiliation-url><afid>60015543</afid><affilname>University of Pittsburgh</affilname><name-variant>University of Pittsburgh</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56661446800</author-url><authid>56661446800</authid><authname>Hu J.</authname><surname>Hu</surname><given-name>Jian</given-name><initials>J.</initials><afid>60015543</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56661511300</author-url><authid>56661511300</authid><authname>Xu Q.</authname><surname>Xu</surname><given-name>Qinzi</given-name><initials>Q.</initials><afid>60015543</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003444749</author-url><authid>7003444749</authid><authname>McTiernan C.</authname><surname>McTiernan</surname><given-name>Charles</given-name><initials>C.</initials><afid>60015543</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:53871487500</author-url><authid>53871487500</authid><authname>Lai Y.</authname><surname>Lai</surname><given-name>Yen Chun</given-name><initials>Y.C.</initials><afid>60015543</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36775000300</author-url><authid>36775000300</authid><authname>Osei-Hwedieh D.</authname><surname>Osei-Hwedieh</surname><given-name>David</given-name><initials>D.</initials><afid>60015543</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56661902900</author-url><authid>56661902900</authid><authname>Gladwin M.</authname><surname>Gladwin</surname><given-name>Mark</given-name><initials>M.</initials><afid>60015543</afid><afid>60015543</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56661902900</author-url><authid>56661902900</authid><authname>Gladwin M.</authname><surname>Gladwin</surname><given-name>Mark</given-name><initials>M.</initials><afid>60015543</afid><afid>60015543</afid></author><intid>536077040</intid><source-id>22416</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930176114"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930176114?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930176114&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930176114&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930176114</prism:url><dc:identifier>SCOPUS_ID:84930176114</dc:identifier><eid>2-s2.0-84930176114</eid><dc:title>In Vivo Evaluation of 5-ASA Colon-Specific Tablets Using Experimental-Induced Colitis Rat Animal Model</dc:title><dc:creator>Sawarkar S.</dc:creator><prism:publicationName>AAPS PharmSciTech</prism:publicationName><prism:eIssn>15309932</prism:eIssn><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1208/s12249-015-0331-z</prism:doi><dc:description>Â© 2015 American Association of Pharmaceutical Scientists Colonic drug delivery is intended not only for local treatment in inflammatory bowel disease (IBD) but also for systemic delivery of therapeutics. Intestinal myeloperoxidase (MPO) determination could be used to estimate the average level of inflammation in colon as well as to determine the efficacy of drugs to be used in the treatment of inflammatory bowel diseases or study the specificity of dosage forms to be used for colonic targeting of anti-inflammatory drugs. Colonic prodrug sulfasalazine (SASP) gets metabolized to give 5-aminosalicylic acid (5-ASA), which is the active portion of SASP. However, when given orally, 5-ASA is absorbed in upper part of gastrointestinal tract (GIT) and not made available in colon. In the present study, colon-targeted delivery of 5-ASA was achieved by formulating tablets with two natural polymers namely guar gum and pectin using compression coating method. Colonic specificity of 5-ASA tablets (prepared using guar gum and pectin as polymers) was evaluated in vitro using simulated fluids mimicking in vivo environment as well as in vivo method using chemically (2,4,6-trinitrobenzenesulfonic acid and acetic acid)-induced colitis rat model. Both colon-specific formulations of 5-ASA (guar gum and pectin) were observed to be more effective in reducing inflammation in chemically induced colitis rat models when compared to colon-specific prodrug sulfasalazine as well as conventional 5-ASA administered orally.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070267</affiliation-url><afid>60070267</afid><affilname>Principal K.M. Kundnani College of Pharmacy</affilname><name-variant>Prin. K. M. Kundnani College of Pharmacy</name-variant><affiliation-city>Mumbai</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070267</affiliation-url><afid>60070267</afid><affilname>Principal K.M. Kundnani College of Pharmacy</affilname><name-variant>Prin. K. M. Kundnani College of Pharmacy</name-variant><affiliation-city>Mumbai</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106561738</affiliation-url><afid>106561738</afid><affilname>Max-Planck-Inst. for Heart/Lung Res.</affilname><name-variant>Max Planck Research Institute for Heart and Lung Research</name-variant><affiliation-city>Bad Nauheim</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662046100</author-url><authid>56662046100</authid><authname>Sawarkar S.</authname><surname>Sawarkar</surname><given-name>Sujata P.</given-name><initials>S.P.</initials><afid>60070267</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56661761300</author-url><authid>56661761300</authid><authname>Deshpande S.</authname><surname>Deshpande</surname><given-name>S. G.</given-name><initials>S.G.</initials><afid>60070267</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56661867400</author-url><authid>56661867400</authid><authname>Bajaj A.</authname><surname>Bajaj</surname><given-name>A. N.</given-name><initials>A.N.</initials><afid>60070267</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:37085507000</author-url><authid>37085507000</authid><authname>Nikam V.</authname><surname>Nikam</surname><given-name>V. S.</given-name><initials>V.S.</initials><afid>106561738</afid></author><intid>36076144</intid><source-id>19374</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930077260"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930077260?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930077260&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930077260&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930077260</prism:url><dc:identifier>SCOPUS_ID:84930077260</dc:identifier><eid>2-s2.0-84930077260</eid><dc:title>Inhibition of NADPH oxidase activation reduces EAE-induced white matter damage in mice</dc:title><dc:creator>Choi B.</dc:creator><prism:publicationName>Journal of Neuroinflammation</prism:publicationName><prism:eIssn>17422094</prism:eIssn><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>May 28, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12974-015-0325-5</prism:doi><dc:description>Â© 2015 Choi et al.; licensee BioMed Central. Background: To evaluate the role of NADPH oxidase-mediated reactive oxygen species (ROS) production in multiple sclerosis pathogenesis, we examined the effects of apocynin, an NADPH oxidase assembly inhibitor, on experimental autoimmune encephalomyelitis (EAE). Methods: EAE was induced by immunization with myelin oligodendrocyte glycoprotein (MOG (35-55)) in C57BL/6 female mice. Three weeks after initial immunization, the mice were analyzed for demyelination, immune cell infiltration, and ROS production. Apocynin (30 mg/kg) was given orally once daily for the entire experimental course or after the typical onset of clinical symptom (15 days after first MOG injection). Results: Clinical signs of EAE first appeared on day 11 and reached a peak level on day 19 after the initial immunization. The daily clinical symptoms of EAE mice were profoundly reduced by apocynin. The apocynin-mediated inhibition of the clinical course of EAE was accompanied by suppression of demyelination, reduced infiltration by encephalitogenic immune cells including CD4, CD8, CD20, and F4/80-positive cells. Apocynin reduced MOG-induced pro-inflammatory cytokines in cultured microglia. Apocynin also remarkably inhibited EAE-associated ROS production and blood-brain barrier (BBB) disruption. Furthermore, the present study found that post-treatment with apocynin also reduced the clinical course of EAE and spinal cord demyelination. Conclusions: These results demonstrate that apocynin inhibits the clinical features and neuropathological changes associated with EAE. Therefore, the present study suggests that inhibition of NADPH oxidase activation by apocynin may have a high therapeutic potential for treatment of multiple sclerosis pathogenesis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018986</affiliation-url><afid>60018986</afid><affilname>Hallym University</affilname><name-variant>Hallym University</name-variant><affiliation-city>Chuncheon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018986</affiliation-url><afid>60018986</afid><affilname>Hallym University</affilname><name-variant>Hallym University</name-variant><affiliation-city>Chuncheon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028876</affiliation-url><afid>60028876</afid><affilname>Inha University, Incheon</affilname><name-variant>Inha University</name-variant><affiliation-city>Incheon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108610616</affiliation-url><afid>108610616</afid><affilname>CHA University</affilname><name-variant>CHA University</name-variant><affiliation-city>Pocheon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009697</affiliation-url><afid>60009697</afid><affilname>University of Manitoba</affilname><name-variant>University of Manitoba</name-variant><affiliation-city>Winnipeg</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55133742800</author-url><authid>55133742800</authid><authname>Choi B.</authname><surname>Choi</surname><given-name>Bo Young</given-name><initials>B.Y.</initials><afid>60018986</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56660362400</author-url><authid>56660362400</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Jin Hee</given-name><initials>J.H.</initials><afid>60018986</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56660461600</author-url><authid>56660461600</authid><authname>Kho A.</authname><surname>Kho</surname><given-name>A. Ra</given-name><initials>A.R.</initials><afid>60018986</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56660141300</author-url><authid>56660141300</authid><authname>Kim I.</authname><surname>Kim</surname><given-name>In Yeol</given-name><initials>I.Y.</initials><afid>60018986</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56462183100</author-url><authid>56462183100</authid><authname>Lee S.</authname><surname>Lee</surname><given-name>Song Hee</given-name><initials>S.H.</initials><afid>60018986</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56660082800</author-url><authid>56660082800</authid><authname>Lee B.</authname><surname>Lee</surname><given-name>Bo Eun</given-name><initials>B.E.</initials><afid>60018986</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56660226900</author-url><authid>56660226900</authid><authname>Choi E.</authname><surname>Choi</surname><given-name>Eunhi</given-name><initials>E.</initials><afid>60018986</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36142200000</author-url><authid>36142200000</authid><authname>Sohn M.</authname><surname>Sohn</surname><given-name>Min</given-name><initials>M.</initials><afid>60028876</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56660307200</author-url><authid>56660307200</authid><authname>Stevenson M.</authname><surname>Stevenson</surname><given-name>Mackenzie</given-name><initials>M.</initials><afid>60009697</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56493906500</author-url><authid>56493906500</authid><authname>Chung T.</authname><surname>Chung</surname><given-name>Tae Nyoung</given-name><initials>T.N.</initials><afid>108610616</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7006801240</author-url><authid>7006801240</authid><authname>Kauppinen T.</authname><surname>Kauppinen</surname><given-name>Tiina M.</given-name><initials>T.M.</initials><afid>60009697</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7201479669</author-url><authid>7201479669</authid><authname>Suh S.</authname><surname>Suh</surname><given-name>Sang Won</given-name><initials>S.W.</initials><afid>60018986</afid></author><authkeywords>Apocynin | Experimental autoimmune encephalomyelitis | Microglia | Multiple sclerosis | NADPH oxidase | Reactive oxygen species</authkeywords><intid>36060114</intid><source-id>50032</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930153164"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930153164?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930153164&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930153164&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930153164</prism:url><dc:identifier>SCOPUS_ID:84930153164</dc:identifier><eid>2-s2.0-84930153164</eid><dc:title>Left atrial enlargement increases the risk of major adverse cardiac events independent of coronary vasodilator capacity</dc:title><dc:creator>Koh A.</dc:creator><prism:publicationName>European Journal of Nuclear Medicine and Molecular Imaging</prism:publicationName><prism:issn>16197070</prism:issn><prism:eIssn>16197089</prism:eIssn><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00259-015-3086-6</prism:doi><dc:description>Â© 2015 Springer-Verlag Berlin Heidelberg Purpose: Longstanding uncontrolled atherogenic risk factors may contribute to left atrial (LA) hypertension, LA enlargement (LAE) and coronary vascular dysfunction. Together they may better identify risk of major adverse cardiac events (MACE). The aim of this study was to test the hypothesis that chronic LA hypertension as assessed by LAE modifies the relationship between coronary vascular function and MACE. Methods: In 508 unselected subjects with a normal clinical &lt;sup&gt;82&lt;/sup&gt;Rb PET/CT, ejection fraction â¥40 %, no prior coronary artery disease, valve disease or atrial fibrillation, LAE was determined based on LA volumes estimated from the hybrid perfusion and CT transmission scan images and indexed to body surface area. Absolute myocardial blood flow and global coronary flow reserve (CFR) were calculated. Subjects were systematically followed-up for the primary end-point â MACE â a composite of all-cause death, myocardial infarction, hospitalization for heart failure, stroke, coronary artery disease progression or revascularization. Results: During a median follow-up of 862 days, 65 of the subjects experienced a composite event. Compared with subjects with normal LA size, subjects with LAE showed significantly lower CFR (2.25 Â± 0.83 vs. 1.95 Â± 0.80, p = 0.01). LAE independently and incrementally predicted MACE even after accounting for clinical risk factors, medication use, stress left ventricular ejection fraction, stress left ventricular end-diastolic volume index and CFR (chi-squared statistic increased from 30.9 to 48.3; p = 0.001). Among subjects with normal CFR, those with LAE had significantly worse event-free survival (risk adjusted HR 5.4, 95 % CI 2.3 â 12.8, p &lt; 0.0001). Conclusion: LAE and reduced CFR are related but distinct cardiovascular adaptations to atherogenic risk factors. LAE is a risk marker for MACE independent of clinical factors and left ventricular volumes; individuals with LAE may be at risk of MACE despite normal coronary vascular function.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004409</affiliation-url><afid>60004409</afid><affilname>National Heart Centre, Singapore</affilname><name-variant>National Heart Centre Singapore</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56661873200</author-url><authid>56661873200</authid><authname>Koh A.</authname><surname>Koh</surname><given-name>Angela S.</given-name><initials>A.S.</initials><afid>60016782</afid><afid>60004409</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56661873200</author-url><authid>56661873200</authid><authname>Koh A.</authname><surname>Koh</surname><given-name>Angela S.</given-name><initials>A.S.</initials><afid>60016782</afid><afid>60004409</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:52264419100</author-url><authid>52264419100</authid><authname>Murthy V.</authname><surname>Murthy</surname><given-name>Venkatesh L.</given-name><initials>V.L.</initials><afid>60016782</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003622340</author-url><authid>7003622340</authid><authname>Sitek A.</authname><surname>Sitek</surname><given-name>Arkadiusz</given-name><initials>A.</initials><afid>60016782</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662098300</author-url><authid>56662098300</authid><authname>Gayed P.</authname><surname>Gayed</surname><given-name>Peter</given-name><initials>P.</initials><afid>60016782</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55988119700</author-url><authid>55988119700</authid><authname>Bruyere J.</authname><surname>Bruyere</surname><given-name>John</given-name><initials>J.</initials><afid>60016782</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56661386500</author-url><authid>56661386500</authid><authname>Wu J.</authname><surname>Wu</surname><given-name>Justina</given-name><initials>J.</initials><afid>60016782</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003752090</author-url><authid>7003752090</authid><authname>Di Carli M.</authname><surname>Di Carli</surname><given-name>Marcelo F.</given-name><initials>M.F.</initials><afid>60016782</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603292133</author-url><authid>6603292133</authid><authname>Dorbala S.</authname><surname>Dorbala</surname><given-name>Sharmila</given-name><initials>S.</initials><afid>60016782</afid><afid>60016782</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603292133</author-url><authid>6603292133</authid><authname>Dorbala S.</authname><surname>Dorbala</surname><given-name>Sharmila</given-name><initials>S.</initials><afid>60016782</afid><afid>60016782</afid></author><authkeywords>Coronary flow reserve | Diastole | Left atrium | Microcirculation | Prognosis</authkeywords><intid>36076372</intid><source-id>40526</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930224977"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930224977?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930224977&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930224977&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0263224115002304"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930224977</prism:url><dc:identifier>SCOPUS_ID:84930224977</dc:identifier><eid>2-s2.0-84930224977</eid><dc:title>Health parameters monitoring by smartphone for quality of life improvement</dc:title><dc:creator>Lamonaca F.</dc:creator><prism:publicationName>Measurement: Journal of the International Measurement Confederation</prism:publicationName><prism:issn>02632241</prism:issn><prism:volume>73</prism:volume><prism:pageRange>82-94</prism:pageRange><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.measurement.2015.04.017</prism:doi><pii>S0263224115002304</pii><dc:description>Â© 2015 Elsevier Ltd. All rights reserved. The large diffusion of smartphones equipped with new built-in sensors has stimulated researchers to develop applications in different fields. The aim of this work is to provide an overview of the most significant health-care applications. Interest is focused on the use of (i) 3D accelerometer for actimetric, body posture and falls monitoring, (ii) camera for evaluating cardiovascular system parameters, blood oxygen saturation, and eye pathologies, and (iii) microphone for recognizing diseases of the respiratory system. A comparison of these applications to traditional medical devices is discussed, in order to highlight strong and weak points. Limits and possible future research directions are argued.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020261</affiliation-url><afid>60020261</afid><affilname>Universita della Calabria</affilname><name-variant>UniversitÃ  della Calabria</name-variant><affiliation-city>Cosenza</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026810</affiliation-url><afid>60026810</afid><affilname>Vrije Universiteit Brussel</affilname><name-variant>Vrije Universiteit Brussel</name-variant><affiliation-city>Elsene</affiliation-city><affiliation-country>Belgium</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:21933997900</author-url><authid>21933997900</authid><authname>Lamonaca F.</authname><surname>Lamonaca</surname><given-name>F.</given-name><initials>F.</initials><afid>60020261</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56348947500</author-url><authid>56348947500</authid><authname>Polimeni G.</authname><surname>Polimeni</surname><given-name>G.</given-name><initials>G.</initials><afid>60020261</afid><afid>60026810</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56348947500</author-url><authid>56348947500</authid><authname>Polimeni G.</authname><surname>Polimeni</surname><given-name>G.</given-name><initials>G.</initials><afid>60020261</afid><afid>60026810</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:21933906300</author-url><authid>21933906300</authid><authname>BarbÃ© K.</authname><surname>BarbÃ©</surname><given-name>K.</given-name><initials>K.</initials><afid>60026810</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35598994900</author-url><authid>35598994900</authid><authname>Grimaldi D.</authname><surname>Grimaldi</surname><given-name>D.</given-name><initials>D.</initials><afid>60020261</afid></author><authkeywords>Health-care | Home health monitoring | Mobile system | Smartphone | Smartphone based health parameters monitoring</authkeywords><intid>536087439</intid><source-id>15424</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930212231"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930212231?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930212231&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930212231&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930212231</prism:url><dc:identifier>SCOPUS_ID:84930212231</dc:identifier><eid>2-s2.0-84930212231</eid><dc:title>Correspondence</dc:title><dc:creator>Korgaonkar S.</dc:creator><prism:publicationName>Indian Pediatrics</prism:publicationName><prism:issn>00196061</prism:issn><prism:eIssn>09747559</prism:eIssn><prism:volume>52</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>439-444</prism:pageRange><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s13312-015-0653-7</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002815</affiliation-url><afid>60002815</afid><affilname>King Edward Memorial Hospital India</affilname><name-variant>K.E.M. Hospital</name-variant><affiliation-city>Mumbai</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000137</affiliation-url><afid>60000137</afid><affilname>Postgraduate Institute of Medical Education and Research</affilname><name-variant>PGIMER</name-variant><affiliation-city>Chandigarh</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026716</affiliation-url><afid>60026716</afid><affilname>Gulhane Military Medical Academy</affilname><name-variant>GÃ¼lhane Military Medical Academy</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029253</affiliation-url><afid>60029253</afid><affilname>Banaras Hindu University Institute of Medical Sciences</affilname><name-variant>Banaras Hindu University</name-variant><affiliation-city>Varanasi</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106688714</affiliation-url><afid>106688714</afid><affilname>Mahatma Gandhi Mission Medical College</affilname><name-variant>Mahatma Gandhi Memorial Medical College</name-variant><affiliation-city>Navi Mumbai</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113675609</affiliation-url><afid>113675609</afid><affilname>Dr RK Nursing Home</affilname><name-variant>Dr RK Nursing Home</name-variant><affiliation-city>Thanjavur</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Peoples campus</affilname><name-variant>Department of Pediatrics</name-variant><affiliation-city>Bhanpur</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115293939</affiliation-url><afid>115293939</afid><affilname>Motherhood hospital Bangalore</affilname><name-variant>Motherhood hospital Bangalore</name-variant><affiliation-city/><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24923459100</author-url><authid>24923459100</authid><authname>Korgaonkar S.</authname><surname>Korgaonkar</surname><given-name>Seema</given-name><initials>S.</initials><afid>60002815</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507787716</author-url><authid>6507787716</authid><authname>Vundinti B.</authname><surname>Vundinti</surname><given-name>Babu Rao</given-name><initials>B.R.</initials><afid>60002815</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56653844900</author-url><authid>56653844900</authid><authname>Srikanth K.</authname><surname>Srikanth</surname><given-name>K. P.</given-name><initials>K.P.</initials><afid>60000137</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005935931</author-url><authid>7005935931</authid><authname>Thapa B.</authname><surname>Thapa</surname><given-name>B. R.</given-name><initials>B.R.</initials><afid>60000137</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:13204671000</author-url><authid>13204671000</authid><authname>Atas E.</authname><surname>Atas</surname><given-name>Erman</given-name><initials>E.</initials><afid>60026716</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:24401187100</author-url><authid>24401187100</authid><authname>Kesik V.</authname><surname>Kesik</surname><given-name>Vural</given-name><initials>V.</initials><afid>60026716</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:54937188600</author-url><authid>54937188600</authid><authname>Bagri N.</authname><surname>Bagri</surname><given-name>N. K.</given-name><initials>N.K.</initials><afid>60029253</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55574185806</author-url><authid>55574185806</authid><authname>Kumar A.</authname><surname>Kumar</surname><given-name>A.</given-name><initials>A.</initials><afid>60029253</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56482952900</author-url><authid>56482952900</authid><authname>Shamim A.</authname><surname>Shamim</surname><given-name>Ahmar</given-name><initials>A.</initials><afid>106688714</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55204018100</author-url><authid>55204018100</authid><authname>Krishna M.</authname><surname>Krishna</surname><given-name>Mani Ram</given-name><initials>M.R.</initials><afid>113675609</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56537767300</author-url><authid>56537767300</authid><authname>Verma P.</authname><surname>Verma</surname><given-name>Pramila</given-name><initials>P.</initials><afid/></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56165933200</author-url><authid>56165933200</authid><authname>Razak A.</authname><surname>Razak</surname><given-name>Abdul</given-name><initials>A.</initials><afid>115293939</afid></author><intid>1786087926</intid><source-id>15030</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929179760"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929179760?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929179760&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929179760&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929179760</prism:url><dc:identifier>SCOPUS_ID:84929179760</dc:identifier><eid>2-s2.0-84929179760</eid><dc:title>Design of magnetic nanoparticles for hepatocellular carcinoma treatment using the control mechanisms of the cell internal nucleus and external membrane</dc:title><dc:creator>Zhan X.</dc:creator><prism:publicationName>Journal of Materials Chemistry B</prism:publicationName><prism:issn>20507518</prism:issn><prism:eIssn>2050750X</prism:eIssn><prism:volume>3</prism:volume><prism:issueIdentifier>20</prism:issueIdentifier><prism:pageRange>4191-4204</prism:pageRange><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1039/c5tb00514k</prism:doi><dc:description>Â© The Royal Society of Chemistry 2015. Nanoparticle drugs and relevant treatment technologies have achieved widespread attention in recent years. Hepatocellular carcinoma (HCC) remains a challenging malignancy of worldwide importance since it is one of the worst malignant tumors. In this study, magnetic Fe&lt;inf&gt;3&lt;/inf&gt;O&lt;inf&gt;4&lt;/inf&gt; nanoparticles are prepared via a co-precipitation reaction with self-assembled surface monolayers of oleic acid molecules. For synthesizing the nanoparticle anti-tumor drug used against HCC, the liquid photo-immobilization method is used to bond the photoactive N-isopropylacrylamide derivative (NIPAm-AA) onto the oleic acid monolayer for subsequently embedding doxorubicin, photoactive tumor necrosis factor-Î± (TNF-Î±)/interferon-Î³ (IFN-Î³), and folic acid (FOL). We investigate how the nanoparticle drug inhibits the growth of human hepatocellular carcinoma HepG2 cells in vitro and in vivo. Remarkably, our characterizations show that the nanoparticle drug demonstrates much higher anticancer efficacy (94.7%) in vitro than previously reported drugs. It is revealed that the programmed cell death induced by the drug is mainly oncosis, a new programmed cell death pathway, different from earlier proposed mechanisms. This oncosis mechanism is also confirmed in the other two hepatocellular carcinoma cells (BEL-7402 and Huh-7). This study may be helpful for developing a new type of nanoparticle drug capable of assuring molecular control of both the cell inner nucleus and outer membrane as a means to enormously increase the drug efficacy in human hepatocellular carcinoma.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005816</affiliation-url><afid>60005816</afid><affilname>South China Normal University</affilname><name-variant>South China Normal University</name-variant><affiliation-city>Guangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005816</affiliation-url><afid>60005816</afid><affilname>South China Normal University</affilname><name-variant>South China Normal University</name-variant><affiliation-city>Guangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56640586800</author-url><authid>56640586800</authid><authname>Zhan X.</authname><surname>Zhan</surname><given-name>Xiuyu</given-name><initials>X.</initials><afid>60005816</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7202923902</author-url><authid>7202923902</authid><authname>Guan Y.</authname><surname>Guan</surname><given-name>Yan Qing</given-name><initials>Y.Q.</initials><afid>60005816</afid><afid>60005816</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7202923902</author-url><authid>7202923902</authid><authname>Guan Y.</authname><surname>Guan</surname><given-name>Yan Qing</given-name><initials>Y.Q.</initials><afid>60005816</afid><afid>60005816</afid></author><intid>1535917713</intid><source-id>21100229202</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930197068"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930197068?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930197068&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930197068&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0263224115002808"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930197068</prism:url><dc:identifier>SCOPUS_ID:84930197068</dc:identifier><eid>2-s2.0-84930197068</eid><dc:title>Sensitivity analysis of the discharge coefficient of a modified triangular side weir by adaptive neuro-fuzzy methodology</dc:title><dc:creator>Bonakdari H.</dc:creator><prism:publicationName>Measurement: Journal of the International Measurement Confederation</prism:publicationName><prism:issn>02632241</prism:issn><prism:volume>73</prism:volume><prism:pageRange>74-81</prism:pageRange><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.measurement.2015.05.021</prism:doi><pii>S0263224115002808</pii><dc:description>Â© 2015 Elsevier Ltd. All rights reserved. The discharge coefficient of a modified triangular side weir is analyzed regarding various non-dimensional input sets. It is desirable to select and analyze factors or parameters that are truly relevant or the most influential to triangular side weir discharge coefficient estimation and prediction. The Adaptive Neuro-Fuzzy Inference System (ANFIS) is applied for the selection of the most prominent triangular side weir discharge coefficient parameters based on ten input parameters. The input variables were searched using the ANFIS network to specify the input parameters' effects on the discharge coefficients. According to the obtained results, the side weir included angle has the most effect on modeling the discharge coefficient. Then by using the selected input variables, the discharge coefficient was modeled with ANFIS, artificial neural network, support vector machine and multi non linear regression methods. The results show that ANFIS could predict the discharge coefficient significantly better than the other investigated models.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021967</affiliation-url><afid>60021967</afid><affilname>Razi University</affilname><name-variant>Razi University</name-variant><affiliation-city>Kermanshah</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029157</affiliation-url><afid>60029157</afid><affilname>University of Malaya</affilname><name-variant>University of Malaya</name-variant><affiliation-city>Kuala Lumpur</affiliation-city><affiliation-country>Malaysia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029157</affiliation-url><afid>60029157</afid><affilname>University of Malaya</affilname><name-variant>University of Malaya</name-variant><affiliation-city>Kuala Lumpur</affiliation-city><affiliation-country>Malaysia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068806</affiliation-url><afid>60068806</afid><affilname>Univerzitet u Niu</affilname><name-variant>University of NiÅ¡</name-variant><affiliation-city>Nis</affiliation-city><affiliation-country>Serbia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23388736200</author-url><authid>23388736200</authid><authname>Bonakdari H.</authname><surname>Bonakdari</surname><given-name>Hossein</given-name><initials>H.</initials><afid>60021967</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56404648500</author-url><authid>56404648500</authid><authname>Zaji A.</authname><surname>Zaji</surname><given-name>Amir Hossein</given-name><initials>A.H.</initials><afid>60021967</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36643049500</author-url><authid>36643049500</authid><authname>Shamshirband S.</authname><surname>Shamshirband</surname><given-name>Shahaboddin</given-name><initials>S.</initials><afid>60029157</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8640798800</author-url><authid>8640798800</authid><authname>Hashim R.</authname><surname>Hashim</surname><given-name>Roslan</given-name><initials>R.</initials><afid>60029157</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:37461848600</author-url><authid>37461848600</authid><authname>Petkovic D.</authname><surname>Petkovic</surname><given-name>Dalibor</given-name><initials>D.</initials><afid>60068806</afid></author><authkeywords>ANFIS | Discharge coefficient | Modified triangular side weir | Variable selection</authkeywords><intid>1536087831</intid><source-id>15424</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929379566"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929379566?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929379566&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929379566&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929379566</prism:url><dc:identifier>SCOPUS_ID:84929379566</dc:identifier><eid>2-s2.0-84929379566</eid><dc:title>Resveratrol-based benzoselenophenes with an enhanced antioxidant and chain breaking capacity</dc:title><dc:creator>Tanini D.</dc:creator><prism:publicationName>Organic and Biomolecular Chemistry</prism:publicationName><prism:issn>14770520</prism:issn><prism:volume>13</prism:volume><prism:issueIdentifier>20</prism:issueIdentifier><prism:pageRange>5757-5764</prism:pageRange><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1039/c5ob00193e</prism:doi><dc:description>Â© The Royal Society of Chemistry 2015. The structural modification of the resveratrol scaffold is currently an active issue in the quest for more potent and versatile antioxidant derivatives for biomedical applications. Disclosed herein is an expedient and efficient entry to a novel class of resveratrol derivatives featuring an unprecedented 2-phenylbenzoselenophene skeleton. The new compounds were obtained in good yields by direct selenenylation of resveratrol with Se(0) and SO&lt;inf&gt;2&lt;/inf&gt;Cl&lt;inf&gt;2&lt;/inf&gt; in dry THF. Varying the [Se:SO&lt;inf&gt;2&lt;/inf&gt;Cl&lt;inf&gt;2&lt;/inf&gt;:resveratrol] ratio resulted in the formation of the parent benzoselenophene (1) and/or mono (2) and/or dichloro (3) benzoselenophene derivatives. All the benzoselenophene derivatives proved to be more efficient than resveratrol in the 2,2-diphenyl-1-picrylhydrazyl (DPPH) and ferric reducing/antioxidant power (FRAP) assays, with 1 showing an activity nearly comparable to that of Trolox. 1-3 also proved to be more efficient inhibitors than the parent resveratrol in kinetic experiments of styrene autoxidation. DFT calculations of the O-H bond dissociation enthalpy (BDE) revealed that the introduction of the Se-atom causes a significant decrease of the BDE of 3-OH and 5-OH, with just a small increase of the 4â²-OH BDE. Compounds 1-3 showed no cytotoxicity at 5 Î¼M concentrations on human keratinocyte (HaCaT) and intestinal (CaCo-2) cell lines.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021859</affiliation-url><afid>60021859</afid><affilname>Universita degli Studi di Firenze</affilname><name-variant>UniversitÃ  di Firenze</name-variant><affiliation-city>Florence</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017293</affiliation-url><afid>60017293</afid><affilname>Universita degli Studi di Napoli Federico II</affilname><name-variant>University of Naples Federico II</name-variant><affiliation-city>Naples</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028218</affiliation-url><afid>60028218</afid><affilname>Alma Mater Studiorum Universita di Bologna</affilname><name-variant>University of Bologna</name-variant><affiliation-city>Bologna</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017293</affiliation-url><afid>60017293</afid><affilname>Universita degli Studi di Napoli Federico II</affilname><name-variant>University of Naples Federico II</name-variant><affiliation-city>Naples</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55767692700</author-url><authid>55767692700</authid><authname>Tanini D.</authname><surname>Tanini</surname><given-name>Damiano</given-name><initials>D.</initials><afid>60021859</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506494711</author-url><authid>6506494711</authid><authname>Panzella L.</authname><surname>Panzella</surname><given-name>Lucia</given-name><initials>L.</initials><afid>60017293</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602226598</author-url><authid>6602226598</authid><authname>Amorati R.</authname><surname>Amorati</surname><given-name>Riccardo</given-name><initials>R.</initials><afid>60028218</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603868667</author-url><authid>6603868667</authid><authname>Capperucci A.</authname><surname>Capperucci</surname><given-name>Antonella</given-name><initials>A.</initials><afid>60021859</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23098141900</author-url><authid>23098141900</authid><authname>Pizzo E.</authname><surname>Pizzo</surname><given-name>Elio</given-name><initials>E.</initials><afid>60017293</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7102403188</author-url><authid>7102403188</authid><authname>Napolitano A.</authname><surname>Napolitano</surname><given-name>Alessandra</given-name><initials>A.</initials><afid>60017293</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003979767</author-url><authid>7003979767</authid><authname>Menichetti S.</authname><surname>Menichetti</surname><given-name>Stefano</given-name><initials>S.</initials><afid>60021859</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7005131059</author-url><authid>7005131059</authid><authname>D'Ischia M.</authname><surname>D'Ischia</surname><given-name>Marco</given-name><initials>M.</initials><afid>60017293</afid></author><intid>2035940605</intid><source-id>26388</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929224419"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929224419?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929224419&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929224419&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929224419</prism:url><dc:identifier>SCOPUS_ID:84929224419</dc:identifier><eid>2-s2.0-84929224419</eid><dc:title>Thermo/redox/pH-triple sensitive poly(N-isopropylacrylamide-co-acrylic acid) nanogels for anticancer drug delivery</dc:title><dc:creator>Zhan Y.</dc:creator><prism:publicationName>Journal of Materials Chemistry B</prism:publicationName><prism:issn>20507518</prism:issn><prism:eIssn>2050750X</prism:eIssn><prism:volume>3</prism:volume><prism:issueIdentifier>20</prism:issueIdentifier><prism:pageRange>4221-4230</prism:pageRange><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1039/c5tb00468c</prism:doi><dc:description>Â© The Royal Society of Chemistry 2015. The clinical application of doxorubicin (DOX), like other anticancer drugs, is limited by insufficient cellular uptake and the numerous drug resistance mechanisms existing in cells. The development of smart nanomaterials capable of carrying the drugs into the cells and of releasing them under the control of the microenvironment is an interesting approach that may increase the success of the anticancer drugs currently in use. Herein, we report an easy process to prepare biocompatible nanogels (NGs) with thermo/redox/pH-triple sensitivity, which are highly effective in the intracellular delivery of DOX. Redox-sensitive/degradable NGs (PNA-BAC) and nondegradable NGs (PNA-MBA) were prepared through in situ polymerization of N-isopropylacrylamide (NIPAM) and acrylic acid (AA) in the presence of sodium dodecyl sulfate (SDS) as a surfactant, using N,Nâ²-bis(acryloyl)cystamine (BAC) as a biodegradable crosslinker or N,Nâ²-methylene bisacrylamide (MBA) as a nondegradable crosslinker, respectively. After that, the cationic DOX drug was loaded into the NGs through electrostatic interactions, by simply mixing them in aqueous solution. Compared to nondegradable PNA-MBA NGs, PNA-BAC NGs not only presented a higher DOX drug loading capacity, but also allowed a more sustainable drug release behavior under physiological conditions. More importantly, PNA-BAC NGs displayed thermo-induced drug release properties and an in vitro accelerated release of DOX under conditions that mimic intracellular reductive conditions and acidic tumor microenvironments. The thermo/redox/pH multi-sensitive NGs can quickly be taken up by CAL-72 cells (an osteosarcoma cell line), resulting in a high DOX intracellular accumulation and an improved cytotoxicity when compared with free DOX and DOX-loaded nondegradable PNA-MBA NGs. The developed NGs can be possibly used as an effective platform for the delivery of cationic therapeutic agents for biomedical applications.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029386</affiliation-url><afid>60029386</afid><affilname>Hubei University</affilname><name-variant>Hubei University</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112930279</affiliation-url><afid>112930279</afid><affilname>MMRG</affilname><name-variant>MMRG</name-variant><affiliation-city>Funchal</affiliation-city><affiliation-country>Portugal</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011069</affiliation-url><afid>60011069</afid><affilname>East China University of Science and Technology</affilname><name-variant>East China University of Science and Technology</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56199011600</author-url><authid>56199011600</authid><authname>Zhan Y.</authname><surname>Zhan</surname><given-name>Yuan</given-name><initials>Y.</initials><afid>60029386</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55682654856</author-url><authid>55682654856</authid><authname>GonÃ§alves M.</authname><surname>GonÃ§alves</surname><given-name>Mara</given-name><initials>M.</initials><afid>112930279</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56640728700</author-url><authid>56640728700</authid><authname>Yi P.</authname><surname>Yi</surname><given-name>Panpan</given-name><initials>P.</initials><afid>60029386</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56080987800</author-url><authid>56080987800</authid><authname>Capelo D.</authname><surname>Capelo</surname><given-name>DÃ©bora</given-name><initials>D.</initials><afid>112930279</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56025105800</author-url><authid>56025105800</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yuhong</given-name><initials>Y.</initials><afid>60029386</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:9233278800</author-url><authid>9233278800</authid><authname>Rodrigues J.</authname><surname>Rodrigues</surname><given-name>JoÃ£o</given-name><initials>J.</initials><afid>112930279</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56640320500</author-url><authid>56640320500</authid><authname>Liu C.</authname><surname>Liu</surname><given-name>Changsheng</given-name><initials>C.</initials><afid>60011069</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56003353100</author-url><authid>56003353100</authid><authname>TomÃ¡s H.</authname><surname>TomÃ¡s</surname><given-name>Helena</given-name><initials>H.</initials><afid>112930279</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55989027700</author-url><authid>55989027700</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yulin</given-name><initials>Y.</initials><afid>112930279</afid><afid>60011069</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55989027700</author-url><authid>55989027700</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yulin</given-name><initials>Y.</initials><afid>112930279</afid><afid>60011069</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7202088784</author-url><authid>7202088784</authid><authname>He P.</authname><surname>He</surname><given-name>Peixin</given-name><initials>P.</initials><afid>60029386</afid></author><intid>1535916632</intid><source-id>21100229202</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930193020"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930193020?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930193020&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930193020&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930193020</prism:url><dc:identifier>SCOPUS_ID:84930193020</dc:identifier><eid>2-s2.0-84930193020</eid><dc:title>Students' perspectives on promoting healthful food choices from campus vending machines: A qualitative interview study Health behavior, health promotion and society</dc:title><dc:creator>Ali H.</dc:creator><prism:publicationName>BMC Public Health</prism:publicationName><prism:eIssn>14712458</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12889-015-1859-2</prism:doi><dc:description>Â© 2015 Ali et al.; licensee BioMed Central. Background: Increasing the healthfulness of campus food environments is an important step in promoting healthful food choices among college students. This study explored university students' suggestions on promoting healthful food choices from campus vending machines. It also examined factors influencing students' food choices from vending machines. Methods: Peer-led semi-structured individual interviews were conducted with 43 undergraduate students (33 females and 10 males) recruited from students enrolled in an introductory nutrition course in a large national university in the United Arab Emirates. Interviews were audiotaped, transcribed, and coded to generate themes using N-Vivo software. Results: Accessibility, peer influence, and busy schedules were the main factors influencing students' food choices from campus vending machines. Participants expressed the need to improve the nutritional quality of the food items sold in the campus vending machines. Recommendations for students' nutrition educational activities included placing nutrition tips on or beside the vending machines and using active learning methods, such as competitions on nutrition knowledge. Conclusions: The results of this study have useful applications in improving the campus food environment and nutrition education opportunities at the university to assist students in making healthful food choices.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008665</affiliation-url><afid>60008665</afid><affilname>United Arab Emirates University</affilname><name-variant>United Arab Emirates University</name-variant><affiliation-city>Al Ain</affiliation-city><affiliation-country>United Arab Emirates</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033041</affiliation-url><afid>60033041</afid><affilname>Alexandria University</affilname><name-variant>Alexandria University</name-variant><affiliation-city>Alexandria</affiliation-city><affiliation-country>Egypt</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35068967100</author-url><authid>35068967100</authid><authname>Ali H.</authname><surname>Ali</surname><given-name>Habiba I.</given-name><initials>H.I.</initials><afid>60008665</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26660492400</author-url><authid>26660492400</authid><authname>Jarrar A.</authname><surname>Jarrar</surname><given-name>Amjad H.</given-name><initials>A.H.</initials><afid>60008665</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663205100</author-url><authid>56663205100</authid><authname>Abo-El-Enen M.</authname><surname>Abo-El-Enen</surname><given-name>Mostafa</given-name><initials>M.</initials><afid>60008665</afid><afid>60033041</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663205100</author-url><authid>56663205100</authid><authname>Abo-El-Enen M.</authname><surname>Abo-El-Enen</surname><given-name>Mostafa</given-name><initials>M.</initials><afid>60008665</afid><afid>60033041</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56214818000</author-url><authid>56214818000</authid><authname>Al Shamsi M.</authname><surname>Al Shamsi</surname><given-name>Mariam</given-name><initials>M.</initials><afid>60008665</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56663255500</author-url><authid>56663255500</authid><authname>Al Ashqar H.</authname><surname>Al Ashqar</surname><given-name>Huda</given-name><initials>H.</initials><afid>60008665</afid></author><authkeywords>Nutrition education | Qualitative interviews | United Arab Emirates | University students | Vending machines</authkeywords><intid>2036082211</intid><article-number>512</article-number><source-id>19621</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929148462"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929148462?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929148462&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929148462&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929148462</prism:url><dc:identifier>SCOPUS_ID:84929148462</dc:identifier><eid>2-s2.0-84929148462</eid><dc:title>One-pot cross-linked copolymerization for the construction of robust antifouling and antibacterial composite membranes</dc:title><dc:creator>Cheng C.</dc:creator><prism:publicationName>Journal of Materials Chemistry B</prism:publicationName><prism:issn>20507518</prism:issn><prism:eIssn>2050750X</prism:eIssn><prism:volume>3</prism:volume><prism:issueIdentifier>20</prism:issueIdentifier><prism:pageRange>4170-4180</prism:pageRange><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1039/c5tb00136f</prism:doi><dc:description>Â© The Royal Society of Chemistry.2015. This study reports a highly efficient, convenient and universal protocol for the fabrication of robust antifouling and antibacterial polymeric membranes via one-pot cross-linked copolymerization of methyl acryloyloxygen ethyl trimethyl ammonium chloride (DMC) and poly(ethylene glycol) methyl ether methacrylate (PEGMA). The infrared testing and X-ray photoelectron spectroscopy gave obvious evidence that abundant DMC and PEGMA chains had enriched on the membrane surface. The surface and cross-sectional SEM images indicated that the addition of DMC and PEGMA had a little effect on the membrane roughness and inner structure. Meanwhile, the systematic investigations into the water contact angle, protein adsorption, ultrafiltration and bacterial inhibition indicated that the composite membranes showed improved hydrophilicity, decreased protein adsorption, increased water flux and antifouling property, as well as greatly enhanced antibacterial ability. Furthermore, it was found that the cross-linked copolymerization could further endow the composite membrane with multi-chemical properties, for instance the charged interface. As a model system, Ag nanoparticle-PDMC multilayers were coated onto the positively charged PES-DMC6 membranes via layer by layer assembly, and the successful surface coating confirmed their versatile ability and also provided a more effective and durable antibacterial coating to the composite membranes. All these results suggest that the robust antifouling and antibacterial composite membranes can be prepared via the proposed one-pot cross-linked copolymerization, and it is believed that this approach has great potential to be applied in various biomedical or industrial fields where antifouling and antibacterial properties are highly demanded.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016521</affiliation-url><afid>60016521</afid><affilname>Sichuan University</affilname><name-variant>Sichuan University</name-variant><affiliation-city>Chengdu</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025778</affiliation-url><afid>60025778</afid><affilname>University Michigan Ann Arbor</affilname><name-variant>University of Michigan</name-variant><affiliation-city>Ann Arbor</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016521</affiliation-url><afid>60016521</afid><affilname>Sichuan University</affilname><name-variant>Sichuan University</name-variant><affiliation-city>Chengdu</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55505228000</author-url><authid>55505228000</authid><authname>Cheng C.</authname><surname>Cheng</surname><given-name>Chong</given-name><initials>C.</initials><afid>60016521</afid><afid>60025778</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55505228000</author-url><authid>55505228000</authid><authname>Cheng C.</authname><surname>Cheng</surname><given-name>Chong</given-name><initials>C.</initials><afid>60016521</afid><afid>60025778</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55902836100</author-url><authid>55902836100</authid><authname>He A.</authname><surname>He</surname><given-name>Ai</given-name><initials>A.</initials><afid>60016521</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55929505800</author-url><authid>55929505800</authid><authname>Nie C.</authname><surname>Nie</surname><given-name>Chuanxiong</given-name><initials>C.</initials><afid>60016521</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55972041700</author-url><authid>55972041700</authid><authname>Xia Y.</authname><surname>Xia</surname><given-name>Yi</given-name><initials>Y.</initials><afid>60016521</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36006285700</author-url><authid>36006285700</authid><authname>He C.</authname><surname>He</surname><given-name>Chao</given-name><initials>C.</initials><afid>60016521</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56419083600</author-url><authid>56419083600</authid><authname>Ma L.</authname><surname>Ma</surname><given-name>Lang</given-name><initials>L.</initials><afid>60016521</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7403563969</author-url><authid>7403563969</authid><authname>Zhao C.</authname><surname>Zhao</surname><given-name>Changsheng</given-name><initials>C.</initials><afid>60016521</afid><afid>60016521</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7403563969</author-url><authid>7403563969</authid><authname>Zhao C.</authname><surname>Zhao</surname><given-name>Changsheng</given-name><initials>C.</initials><afid>60016521</afid><afid>60016521</afid></author><intid>2035910404</intid><source-id>21100229202</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929327605"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929327605?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929327605&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929327605&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929327605</prism:url><dc:identifier>SCOPUS_ID:84929327605</dc:identifier><eid>2-s2.0-84929327605</eid><dc:title>Differential dependencies on [Ca&lt;sup&gt;2+&lt;/sup&gt;] and temperature of the monolayer spontaneous curvatures of DOPE, DOPA and cardiolipin: Effects of modulating the strength of the inter-headgroup repulsion</dc:title><dc:creator>Chen Y.</dc:creator><prism:publicationName>Soft Matter</prism:publicationName><prism:issn>1744683X</prism:issn><prism:eIssn>17446848</prism:eIssn><prism:volume>11</prism:volume><prism:issueIdentifier>20</prism:issueIdentifier><prism:pageRange>4041-4053</prism:pageRange><prism:coverDate>2015-05-28</prism:coverDate><prism:coverDisplayDate>28 May 2015</prism:coverDisplayDate><prism:doi>10.1039/c5sm00577a</prism:doi><dc:description>Â© The Royal Society of Chemistry. Biomembranes assume nonlamellar structures in many cellular events, with the tendency of forming a nonlamellar structure quantified by the monolayer spontaneous curvature, C&lt;inf&gt;0&lt;/inf&gt;, and with many of these events involving the acts of Ca&lt;sup&gt;2+&lt;/sup&gt;. Despite this biologically important intimacy, how C&lt;inf&gt;0&lt;/inf&gt; is affected by [Ca&lt;sup&gt;2+&lt;/sup&gt;] is unknown. In this study, we use the X-ray diffraction technique and the reconstruction of electron density profiles to measure the C&lt;inf&gt;0&lt;/inf&gt;s of a zwitterionic phospholipid, DOPE, and two anionic phospholipids, DOPA and 18:1 (9Z) cardiolipin, at temperatures from 20 Â°C to 40 Â°C and [Ca&lt;sup&gt;2+&lt;/sup&gt;]s from 0 mM to 100 mM; these phospholipids are chosen to examine the contributions of the electric charge density per molecule. While showing a strong dependence on temperature, C&lt;inf&gt;0,DOPE&lt;/inf&gt; is nearly independent of [Ca&lt;sup&gt;2+&lt;/sup&gt;]. In contrast, C&lt;inf&gt;0,DOPA&lt;/inf&gt; and C&lt;inf&gt;0,cardiolipin&lt;/inf&gt; are almost unresponsive to the temperature change but affected by the [Ca&lt;sup&gt;2+&lt;/sup&gt;] variation; and C&lt;inf&gt;0,DOPA&lt;/inf&gt; varies with [Ca&lt;sup&gt;2+&lt;/sup&gt;] â¼1.5 times more strongly than C&lt;inf&gt;0,cardiolipin&lt;/inf&gt;, with the phase preferences of DOPA and cardiolipin shifting to the H&lt;inf&gt;II&lt;/inf&gt; phase and remaining on the L&lt;inf&gt;Î±&lt;/inf&gt; phase, respectively, at [Ca&lt;sup&gt;2+&lt;/sup&gt;] = 100 mM. From these observations, we reveal the effects of modulating the strength of the inter-headgroup repulsion and discuss the mechanisms underlying the phase behaviour and cellular functions of the investigated phospholipids. Most importantly, this study recognizes that the headgroup charge density is dominant in dictating the phase behaviour of the anionic phospholipids, and that the unique molecular characteristics of cardiolipin are critically needed both for maintaining the structural integrity of cardiolipin-rich biomembranes and for fulfilling the biological roles of the phospholipid. This journal is</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024666</affiliation-url><afid>60024666</afid><affilname>National Central University Taiwan</affilname><name-variant>National Central University</name-variant><affiliation-city>Chung-Li</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56644489400</author-url><authid>56644489400</authid><authname>Chen Y.</authname><surname>Chen</surname><given-name>Y. F.</given-name><initials>Y.F.</initials><afid>60024666</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56644067700</author-url><authid>56644067700</authid><authname>Tsang K.</authname><surname>Tsang</surname><given-name>K. Y.</given-name><initials>K.Y.</initials><afid>60024666</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56643628600</author-url><authid>56643628600</authid><authname>Chang W.</authname><surname>Chang</surname><given-name>W. F.</given-name><initials>W.F.</initials><afid>60024666</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56643643300</author-url><authid>56643643300</authid><authname>Fan Z.</authname><surname>Fan</surname><given-name>Z. A.</given-name><initials>Z.A.</initials><afid>60024666</afid></author><intid>1785945717</intid><source-id>145691</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930160639"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930160639?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930160639&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930160639&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930160639</prism:url><dc:identifier>SCOPUS_ID:84930160639</dc:identifier><eid>2-s2.0-84930160639</eid><dc:title>Anesthesia in children and adolescents with congenital heart defects | AnÃ¤sthesie bei Kindern und Jugendlichen nach angeborenen Herzfehlern</dc:title><dc:creator>Baehner T.</dc:creator><prism:publicationName>Anaesthesist</prism:publicationName><prism:issn>00032417</prism:issn><prism:eIssn>1432055X</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00101-015-0028-4</prism:doi><dc:description>Â© 2015 Springer-Verlag Berlin Heidelberg The incidence of congenital heart defects (CHD) has remained constant over many years; however, due to improved therapeutic options an increasing number of children and adolescents even with complex heart defects now reach adulthood. The increasing prevalence of adults with persisting or surgically corrected CHD as well as age-dependent non-cardiac comorbidities will increase the need for medical and non-cardiac surgical treatment in this population. Although elective medical care for these patients should be reserved for highly specialized centers, emergency treatment might become necessary in a non-specialized hospital setting as well. Due to the variety and complexity of CHD it is difficult to provide standardized guidelines for the anesthetic management. The treatment of patients with complex CHD requires a profound understanding of the underlying CHD and the current state of the hemodynamics by the anesthesiologist. Furthermore, typical comorbidities, such as chronic heart failure, altered coagulation and arrhythmia also have to be taken into account to ensure successful perioperative treatment. Especially in patients with shunt lesions or passive pulmonary blood flow the anesthetic management often substantially affects the hemodynamics and may be the starting point of severe decompensation. Awareness of anesthesia-induced changes of pulmonary and/or systemic vascular resistance as well as of preload alterations are the basis for successful anesthetic management. Finally, a multidisciplinary approach including cardiologists and radiologists in the planning is absolutely essential to achieve an optimal postoperative result for the patient.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030465</affiliation-url><afid>60030465</afid><affilname>Universitats-Klinikum Bonn und Medizinische Fakultat</affilname><affiliation-city>Bonn</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115289216</affiliation-url><afid>115289216</afid><affilname>Abteilung fÃ¼r Kardiologie</affilname><name-variant>Abteilung fÃ¼r Kardiologie</name-variant><affiliation-city>Sankt Augustin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030465</affiliation-url><afid>60030465</afid><affilname>Universitats-Klinikum Bonn und Medizinische Fakultat</affilname><affiliation-city>Bonn</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115289510</affiliation-url><afid>115289510</afid><affilname>Klinik fÃ¼r AnÃ¤sthesie, Intensivmedizin und Schmerztherapie</affilname><name-variant>Klinik fÃ¼r AnÃ¤sthesie, Intensivmedizin und Schmerztherapie</name-variant><affiliation-city>Bonn</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55088279500</author-url><authid>55088279500</authid><authname>Baehner T.</authname><surname>Baehner</surname><given-name>T.</given-name><initials>T.</initials><afid>60030465</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:16644840800</author-url><authid>16644840800</authid><authname>Boehm O.</authname><surname>Boehm</surname><given-name>O.</given-name><initials>O.</initials><afid>60030465</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662120000</author-url><authid>56662120000</authid><authname>Kliemann M.</authname><surname>Kliemann</surname><given-name>M.</given-name><initials>M.</initials><afid>115289216</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55567790200</author-url><authid>55567790200</authid><authname>Heinze I.</authname><surname>Heinze</surname><given-name>I.</given-name><initials>I.</initials><afid>60030465</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56661863100</author-url><authid>56661863100</authid><authname>Breuer J.</authname><surname>Breuer</surname><given-name>J.</given-name><initials>J.</initials><afid>60030465</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005674456</author-url><authid>7005674456</authid><authname>Hoeft A.</authname><surname>Hoeft</surname><given-name>A.</given-name><initials>A.</initials><afid>60030465</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:24066640800</author-url><authid>24066640800</authid><authname>Baumgarten G.</authname><surname>Baumgarten</surname><given-name>G.</given-name><initials>G.</initials><afid>60030465</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603593896</author-url><authid>6603593896</authid><authname>Knuefermann P.</authname><surname>Knuefermann</surname><given-name>P.</given-name><initials>P.</initials><afid>115289510</afid></author><authkeywords>Arrhythmia | Coagulation | Emergencies | Heart failure | Hemodynamics</authkeywords><intid>2036071372</intid><source-id>50004</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930147264"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930147264?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930147264&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930147264&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930147264</prism:url><dc:identifier>SCOPUS_ID:84930147264</dc:identifier><eid>2-s2.0-84930147264</eid><dc:title>Utility of a High-Resolution 3D MRI Sequence (3D-SPACE) for Evaluation of Congenital Heart Disease</dc:title><dc:creator>Malayeri A.</dc:creator><prism:publicationName>Pediatric Cardiology</prism:publicationName><prism:issn>01720643</prism:issn><prism:eIssn>14321971</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00246-015-1194-5</prism:doi><dc:description>Â© 2015 Springer Science+Business Media New York The purpose of this study was to evaluate the role of a high-resolution 3D dark-blood turbo spin echo sequence with variable flip angles (3D-SPACE) in evaluation of congenital heart disease. SPACE sequence was performed in 20 patients (mean age, 17.6 Â± 12.6 years, range 9 monthsâ57 years, M: 13) with either unrepaired (N = 3) or post-repair (n = 17) congenital heart disease. All scans were performed on 1.5 T Aera scanners (Siemens). Two separate observers with expertise in cardiovascular imaging scored the quality of the images for blood suppression and definition of key anatomical structures in a blinded fashion using a 5 grade scoring system. Mean of average overall quality scores for two observers was 4 Â± 0.62. All overall quality scores were greater than 3. None of the studies were deemed nondiagnostic. Mean length of the SPACE acquisition time was 12.7 min (4â21 min). There was no significant correlation between image quality and duration of scans. Lack of blood suppression was the limiting factor in image quality with the most common place being ascending aorta in nine patients. However, overall blood suppression score was very good with score of 3.9 Â± 0.43. There was very good overall agreement between observers in rating the image quality (85.6 % agreement, kappa 0.5, standard error 0.04, p &lt; 0.0001). The 3D-SPACE dark-blood sequence with near-isotropic spatial resolution coupled with respiratory and cardiac gating can be feasibly performed in all age groups with diagnostic image quality in all cases in this study.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001555</affiliation-url><afid>60001555</afid><affilname>Johns Hopkins Hospital</affilname><name-variant>Johns Hopkins Hospital</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006577</affiliation-url><afid>60006577</afid><affilname>National Institutes of Health, Bethesda</affilname><name-variant>National Institute of Health</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6504019356</author-url><authid>6504019356</authid><authname>Malayeri A.</authname><surname>Malayeri</surname><given-name>Ashkan A.</given-name><initials>A.A.</initials><afid>60001555</afid><afid>60006577</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6504019356</author-url><authid>6504019356</authid><authname>Malayeri A.</authname><surname>Malayeri</surname><given-name>Ashkan A.</given-name><initials>A.A.</initials><afid>60001555</afid><afid>60006577</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56664719500</author-url><authid>56664719500</authid><authname>Spevak P.</authname><surname>Spevak</surname><given-name>Philip J.</given-name><initials>P.J.</initials><afid>60001555</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56661798200</author-url><authid>56661798200</authid><authname>Zimmerman S.</authname><surname>Zimmerman</surname><given-name>Stefan L.</given-name><initials>S.L.</initials><afid>60001555</afid></author><authkeywords>Cardiac | Congenital | High-resolution imaging | MRI | SPACE</authkeywords><intid>1536077270</intid><source-id>20526</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930169072"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930169072?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930169072&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930169072&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930169072</prism:url><dc:identifier>SCOPUS_ID:84930169072</dc:identifier><eid>2-s2.0-84930169072</eid><dc:title>A systematic variant screening in familial cases of congenital heart defects demonstrates the usefulness of molecular genetics in this field</dc:title><dc:creator>El Malti R.</dc:creator><prism:publicationName>European Journal of Human Genetics</prism:publicationName><prism:issn>10184813</prism:issn><prism:eIssn>14765438</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1038/ejhg.2015.105</prism:doi><pii>ejhg2015105</pii><dc:description>Â© 2015 Macmillan Publishers Limited The etiology of congenital heart defect (CHD) combines environmental and genetic factors. So far, there were studies reporting on the screening of a single gene on unselected CHD or on familial cases selected for specific CHD types. Our goal was to systematically screen a proband of familial cases of CHD on a set of genetic tests to evaluate the prevalence of disease-causing variant identification. A systematic screening of GATA4, NKX2-5, ZIC3 and Multiplex ligation-dependent probe amplification (MLPA) P311 Kit was setup on the proband of 154 families with at least two cases of non-syndromic CHD. Additionally, ELN screening was performed on families with supravalvular arterial stenosis. Twenty-two variants were found, but segregation analysis confirmed unambiguously the causality of 16 variants: GATA4 (1 Ã ), NKX2-5 (6 Ã ), ZIC3 (3 Ã ), MLPA (2 Ã ) and ELN (4 Ã ). Therefore, this approach was able to identify the causal variant in 10.4% of familial CHD cases. This study demonstrated the existence of a de novo variant even in familial CHD cases and the impact of CHD variants on adult cardiac condition even in the absence of CHD. This study showed that the systematic screening of genetic factors is useful in familial CHD cases with up to 10.4% elucidated cases. When successful, it drastically improved genetic counseling by discovering unaffected variant carriers who are at risk of transmitting their variant and are also exposed to develop cardiac complications during adulthood thus prompting long-term cardiac follow-up. This study provides an important baseline at dawning of the next-generation sequencing era.European Journal of Human Genetics advance online publication, 27 May 2015; doi:10.1038/ejhg.2015.105.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105616454</affiliation-url><afid>105616454</afid><affilname>Laboratoire CardiogÃ©nÃ©tique</affilname><name-variant>Laboratoire CardiogÃ©nÃ©tique</name-variant><affiliation-city>Lyon</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">24</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54986323500</author-url><authid>54986323500</authid><authname>El Malti R.</authname><surname>El Malti</surname><given-name>Rajae</given-name><initials>R.</initials><afid>105616454</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56661401900</author-url><authid>56661401900</authid><authname>Liu H.</authname><surname>Liu</surname><given-name>Hui</given-name><initials>H.</initials></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56661974700</author-url><authid>56661974700</authid><authname>Doray B.</authname><surname>Doray</surname><given-name>BÃ©rÃ©nice</given-name><initials>B.</initials></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55064917700</author-url><authid>55064917700</authid><authname>Thauvin C.</authname><surname>Thauvin</surname><given-name>Christel</given-name><initials>C.</initials></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:15841861500</author-url><authid>15841861500</authid><authname>Maltret A.</authname><surname>Maltret</surname><given-name>Alice</given-name><initials>A.</initials></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56661966600</author-url><authid>56661966600</authid><authname>Dauphin C.</authname><surname>Dauphin</surname><given-name>Claire</given-name><initials>C.</initials></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:37024384200</author-url><authid>37024384200</authid><authname>GonÃ§alves-Rocha M.</authname><surname>GonÃ§alves-Rocha</surname><given-name>Miguel</given-name><initials>M.</initials></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56661987200</author-url><authid>56661987200</authid><authname>Teboul M.</authname><surname>Teboul</surname><given-name>Michel</given-name><initials>M.</initials></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56661879700</author-url><authid>56661879700</authid><authname>Blanchet P.</authname><surname>Blanchet</surname><given-name>Patricia</given-name><initials>P.</initials></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6701722662</author-url><authid>6701722662</authid><authname>Roume J.</authname><surname>Roume</surname><given-name>JoÃ«lle</given-name><initials>J.</initials></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:55320346200</author-url><authid>55320346200</authid><authname>Gronier C.</authname><surname>Gronier</surname><given-name>CÃ©line</given-name><initials>C.</initials></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56662035600</author-url><authid>56662035600</authid><authname>Ducreux C.</authname><surname>Ducreux</surname><given-name>Corinne</given-name><initials>C.</initials></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:37038918300</author-url><authid>37038918300</authid><authname>Veyrier M.</authname><surname>Veyrier</surname><given-name>Magali</given-name><initials>M.</initials></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:56661953300</author-url><authid>56661953300</authid><authname>MarÃ§on F.</authname><surname>MarÃ§on</surname><given-name>FranÃ§ois</given-name><initials>F.</initials></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:56661937100</author-url><authid>56661937100</authid><authname>Acar P.</authname><surname>Acar</surname><given-name>Philippe</given-name><initials>P.</initials></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:7006237840</author-url><authid>7006237840</authid><authname>Lusson J.</authname><surname>Lusson</surname><given-name>Jean RenÃ©</given-name><initials>J.R.</initials></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:56661651000</author-url><authid>56661651000</authid><authname>Levy M.</authname><surname>Levy</surname><given-name>Marilyne</given-name><initials>M.</initials></author><author seq="18"><author-url>http://api.elsevier.com/content/author/author_id:56662004500</author-url><authid>56662004500</authid><authname>Beyler C.</authname><surname>Beyler</surname><given-name>Constance</given-name><initials>C.</initials></author><author seq="19"><author-url>http://api.elsevier.com/content/author/author_id:56661876100</author-url><authid>56661876100</authid><authname>Vigneron J.</authname><surname>Vigneron</surname><given-name>Jacqueline</given-name><initials>J.</initials></author><author seq="20"><author-url>http://api.elsevier.com/content/author/author_id:6506268190</author-url><authid>6506268190</authid><authname>Cordier-Alex M.</authname><surname>Cordier-Alex</surname><given-name>Marie Pierre</given-name><initials>M.P.</initials></author><author seq="21"><author-url>http://api.elsevier.com/content/author/author_id:56661884800</author-url><authid>56661884800</authid><authname>Heitz F.</authname><surname>Heitz</surname><given-name>FranÃ§ois</given-name><initials>F.</initials></author><author seq="22"><author-url>http://api.elsevier.com/content/author/author_id:6602184728</author-url><authid>6602184728</authid><authname>Sanlaville D.</authname><surname>Sanlaville</surname><given-name>Damien</given-name><initials>D.</initials></author><author seq="23"><author-url>http://api.elsevier.com/content/author/author_id:56661830800</author-url><authid>56661830800</authid><authname>Bonnet D.</authname><surname>Bonnet</surname><given-name>Damien</given-name><initials>D.</initials></author><author seq="24"><author-url>http://api.elsevier.com/content/author/author_id:7004377709</author-url><authid>7004377709</authid><authname>Bouvagnet P.</authname><surname>Bouvagnet</surname><given-name>Patrice</given-name><initials>P.</initials></author><intid>1036071757</intid><source-id>22101</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929885303"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929885303?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929885303&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929885303&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929885303</prism:url><dc:identifier>SCOPUS_ID:84929885303</dc:identifier><eid>2-s2.0-84929885303</eid><dc:title>Comparing Retesting Rates Between Different Screening Methods for Critical Congenital Heart Disease: A Case from Northeast Brazil</dc:title><dc:creator>de Freitas C.</dc:creator><prism:publicationName>Pediatric Cardiology</prism:publicationName><prism:issn>01720643</prism:issn><prism:eIssn>14321971</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00246-015-1183-8</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070422</affiliation-url><afid>60070422</afid><affilname>Real Hospital Portugues</affilname><name-variant>Real Hospital Portugues</name-variant><affiliation-city>Recife</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56656189000</author-url><authid>56656189000</authid><authname>de Freitas C.</authname><surname>de Freitas</surname><given-name>Carolina Paim Gomes</given-name><initials>C.P.G.</initials><afid>60070422</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55385750600</author-url><authid>55385750600</authid><authname>Mourato F.</authname><surname>Mourato</surname><given-name>Felipe Alves</given-name><initials>F.A.</initials><afid>60070422</afid></author><intid>36036261</intid><source-id>20526</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930260365"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930260365?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930260365&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930260365&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930260365</prism:url><dc:identifier>SCOPUS_ID:84930260365</dc:identifier><eid>2-s2.0-84930260365</eid><dc:title>Database and Informatic Challenges in Representing Both Diploid and Tetraploid Xenopus Species in Xenbase</dc:title><dc:creator>Vize P.</dc:creator><prism:publicationName>Cytogenetic and Genome Research</prism:publicationName><prism:issn>14248581</prism:issn><prism:eIssn>1424859X</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1159/000430427</prism:doi><pii>000430427</pii><dc:description>Copyright Â© 2015, S. Karger AG. All rights reserved. At the heart of databases is a data model referred to as a schema. Relational databases store information in tables, and the schema defines the tables and provides a map of relationships that show how the different table/data types relate to one another. In Xenbase, we were tasked to represent genomic, molecular, and biological data of both a diploid and tetraploid Xenopus species. When the database model was built over a decade ago, we had very little information on the nature of the X.laevis tetraploidization, but a Chado-based data model was proposed that could deal with the various forms of data in both species. Once the X.laevis genome was sequenced and annotated, it became clear that the data schema is very like the evolutionary schema that resulted in the X.laevis genome. Â© 2015 S. Karger AG, Basel</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city/><affiliation-country/></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003648875</author-url><authid>7003648875</authid><authname>Vize P.</authname><surname>Vize</surname><given-name>Peter D.</given-name><initials>P.D.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56664536200</author-url><authid>56664536200</authid><authname>Liu Y.</authname><surname>Liu</surname><given-name>Y.</given-name><initials>Y.</initials></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56511480700</author-url><authid>56511480700</authid><authname>Karimi K.</authname><surname>Karimi</surname><given-name>Kamran</given-name><initials>K.</initials></author><intid>536093159</intid><source-id>22081</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929891674"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929891674?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929891674&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929891674&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929891674</prism:url><dc:identifier>SCOPUS_ID:84929891674</dc:identifier><eid>2-s2.0-84929891674</eid><dc:title>Ectoine alleviates behavioural, physiological and biochemical changes in Daphnia magna subjected to formaldehyde</dc:title><dc:creator>Bownik A.</dc:creator><prism:publicationName>Environmental Science and Pollution Research</prism:publicationName><prism:issn>09441344</prism:issn><prism:eIssn>16147499</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11356-015-4747-5</prism:doi><dc:description>Â© 2015 Springer-Verlag Berlin Heidelberg Ectoine (ECT) is produced by halophilic microorganisms in response to various stressful factors. Its protective properties in bacteria and some populations of isolated cells are known; however, no data are available on its protective influence on aquatic invertebrates subjected to a common pollutant, formaldehyde (FA). The purpose of this study was to determine the effects of FA alone (at 20 and 60 mg/L) and in the combination with various concentrations of ECT (5, 10 and 25 mg/L) at various times of exposure on behavioural, physiological and biochemical parameters of Daphnia magna. Specifically, mortality, heart rate, thoracic limb movement, reduced glutathione (GSH)/oxidised glutathione (GSSG) ratio, catalase (CAT) activity and nitric oxide (NO&lt;inf&gt;x&lt;/inf&gt;) levels were determined. The results showed that both concentrations of FA when administered alone induced significant alterations of the determined parameters. On the other hand, animals treated with the combinations of FA + ECT showed decreased mortalities, attenuated inhibition of heart rates and thoracic limb activities, less decreased GSH/GSSG ratios, lower stimulation of CAT activities and NOx levels when compared to the crustaceans subjected to FA alone. The most distinct attenuation of toxic effects was observed in the combinations in which the highest concentrations of ECT were used. The results suggest that oxidative stress induced by FA in daphnids is likely to be alleviated by the antioxidative action of ECT.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027229</affiliation-url><afid>60027229</afid><affilname>John Paul II Catholic University of Lublin</affilname><name-variant>John Paul II Catholic University of Lublin</name-variant><affiliation-city>Lublin</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027229</affiliation-url><afid>60027229</afid><affilname>John Paul II Catholic University of Lublin</affilname><name-variant>John Paul II Catholic University of Lublin</name-variant><affiliation-city>Lublin</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507268408</author-url><authid>6507268408</authid><authname>Bownik A.</authname><surname>Bownik</surname><given-name>Adam</given-name><initials>A.</initials><afid>60027229</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55936991000</author-url><authid>55936991000</authid><authname>StÄpniewska Z.</authname><surname>StÄpniewska</surname><given-name>Zofia</given-name><initials>Z.</initials><afid>60027229</afid></author><authkeywords>Catalase | Daphnia | Ectoine | Formaldehyde | Glutathione | Nitric oxide | Oxidative stress</authkeywords><intid>1786038273</intid><source-id>23918</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929848689"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929848689?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929848689&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929848689&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929848689</prism:url><dc:identifier>SCOPUS_ID:84929848689</dc:identifier><eid>2-s2.0-84929848689</eid><dc:title>Fetal Ventricular Hypertrabeculation/Noncompaction: Clinical Presentation, Genetics, Associated Cardiac and Extracardiac Abnormalities and Outcome</dc:title><dc:creator>StÃ¶llberger C.</dc:creator><prism:publicationName>Pediatric Cardiology</prism:publicationName><prism:issn>01720643</prism:issn><prism:eIssn>14321971</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00246-015-1200-y</prism:doi><dc:description>Â© 2015 Springer Science+Business Media New York Left ventricular hypertrabeculation/noncompaction (LVHT) is a cardiac abnormality of unknown etiology. Aim of the review was to summarize the current knowledge about fetal LVHT, including clinical presentation, associated cardiac and extracardiac abnormalities and outcome. In 88 cases, LVHT was diagnosed by fetal echocardiography. In 36 %, no additional cardiac abnormalities were reported; in the remaining 64 %, one or more cardiac abnormalities were reported. Eight cases died prenatally, 17 were electively terminated, and 24 patients died after birth. Six patients were lost to follow-up, and 33 patients are alive at a mean age of 26 months. Surviving cases presented less frequently with fetal hydrops (13 vs. 62 %, p = 0.0004), complete heart block (27 vs. 78 %, p = 0.0076), more than three associated cardiac abnormalities (9 vs. 47 %, p = 0.0008) and more frequently with isolated LVHT (52 vs. 19 %, p = 0.009) than cases who died. Of the surviving patients, 16 received pharmacotherapy, three received pacemakers, eight underwent surgical procedures and four underwent heart transplantation. Postnatal regression of left ventricular hypertrophy and development of LVHT was found in four cases, improvement in cardiac function in two, and regression of right VHT in two. At autopsy, endocardial fibrosis was the most frequent abnormality in 92 %. Thirty-eight percentage of cases with fetal LVHT survived. Fetal and postnatal echocardiographic findings challenge the âembryonic pathogeneticâ hypothesis of LVHT. Furthermore, fetal pathoanatomic findings like endocardial fibrosis might play a role in clarifying the still unsolved pathogenesis of LVHT.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030339</affiliation-url><afid>60030339</afid><affilname>Rudolfstifung Hospital</affilname><name-variant>Krankenanstalt Rudolfstiftung</name-variant><affiliation-city>Vienna</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003156</affiliation-url><afid>60003156</afid><affilname>Osterreichische Akademie Der Wissenschaften</affilname><name-variant>Austrian Academy of Sciences</name-variant><affiliation-city>Vienna</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city>Vienna</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55071525800</author-url><authid>55071525800</authid><authname>StÃ¶llberger C.</authname><surname>StÃ¶llberger</surname><given-name>Claudia</given-name><initials>C.</initials><afid>60030339</afid><afid/></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55071525800</author-url><authid>55071525800</authid><authname>StÃ¶llberger C.</authname><surname>StÃ¶llberger</surname><given-name>Claudia</given-name><initials>C.</initials><afid>60030339</afid><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35729442700</author-url><authid>35729442700</authid><authname>Wegner C.</authname><surname>Wegner</surname><given-name>Christian</given-name><initials>C.</initials><afid>60003156</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55181651300</author-url><authid>55181651300</authid><authname>Finsterer J.</authname><surname>Finsterer</surname><given-name>Josef</given-name><initials>J.</initials><afid>60030339</afid></author><authkeywords>Cardiomyopathy | Echocardiography | Fetal echocardiography | Noncompaction</authkeywords><intid>1036032716</intid><source-id>20526</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930174039"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930174039?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930174039&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930174039&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930174039</prism:url><dc:identifier>SCOPUS_ID:84930174039</dc:identifier><eid>2-s2.0-84930174039</eid><dc:title>Attitudes of Germans towards distributive issues in the German health system</dc:title><dc:creator>Ahlert M.</dc:creator><prism:publicationName>European Journal of Health Economics</prism:publicationName><prism:issn>16187598</prism:issn><prism:eIssn>16187601</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10198-015-0693-x</prism:doi><dc:description>Â© 2015 Springer-Verlag Berlin Heidelberg Social health care systems are inevitably confronted with the scarcity of resources and the resulting distributional challenges. Since prioritization implies distributional effects, decisions regarding respective rules should take citizensâ preferences into account. In this study we concentrate on two distributive issues in the German health system: firstly, we analyze the acceptance of prioritizing decisions concerning the treatment of certain patient groups, in this case patients who all need a heart operation. We focus on the patient criteria smoking behavior, age and whether the patient has or does not have young children. Secondly, we investigate Germansâ opinions towards income-dependent health services. The results reveal the strong effects of individualsâ attitudes regarding general aspects of the health system on priorities, e.g. that individuals with an unhealthy lifestyle should not be prioritized. In addition, experience of limited access to health services is found to have a strong influence on citizensâ attitudes, too. Finally, decisions on different prioritization criteria are found to be not independent.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014059</affiliation-url><afid>60014059</afid><affilname>Martin-Universitat Halle-Wittenberg</affilname><name-variant>Martin-Luther-Univ. Halle-Wittenberg</name-variant><affiliation-city>Halle</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023208</affiliation-url><afid>60023208</afid><affilname>Universitat Bayreuth</affilname><name-variant>University of Bayreuth</name-variant><affiliation-city>Bayreuth</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7801527926</author-url><authid>7801527926</authid><authname>Ahlert M.</authname><surname>Ahlert</surname><given-name>Marlies</given-name><initials>M.</initials><afid>60014059</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37028904000</author-url><authid>37028904000</authid><authname>Pfarr C.</authname><surname>Pfarr</surname><given-name>Christian</given-name><initials>C.</initials><afid>60023208</afid></author><authkeywords>Distributive preferences | Health care priority setting | Quality of health care</authkeywords><intid>1786077241</intid><source-id>13217</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930167668"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930167668?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930167668&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930167668&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930167668</prism:url><dc:identifier>SCOPUS_ID:84930167668</dc:identifier><eid>2-s2.0-84930167668</eid><dc:title>Cardioprotective Effect of Anisodamine Against Myocardial Ischemia Injury and its Influence on Cardiomyocytes Apoptosis</dc:title><dc:creator>Xing K.</dc:creator><prism:publicationName>Cell Biochemistry and Biophysics</prism:publicationName><prism:issn>10859195</prism:issn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12013-015-0642-4</prism:doi><dc:description>Â© 2015 Springer Science+Business Media New York Anisodamine is an ancient Chinese medicine derived from Tibet as a belladonna alkaloid, which is usually used for improvement of blood circulation in patients with organ phosphorus poisoning or shock. In this study, for the first time, we report its cardioprotective effects on preventing ischemia/reperfusion (I/R) injury of patients with acute myocardial infarction (AMI), and decreasing the myocardial infarction area and severity in heart of SpragueâDawley (SD) rats. Our results suggest a potential molecular mechanism of anisodamine against the I/R injury in cardiomyocytes is associated with its anti-apoptotic effect. Anisodamine treatment decreases the expression of caspase-3 and caspase-8, and increases Bcl-2/Bax ratio in cardiomyocytes. Our data suggest that anisodamine can provide significant cardioprotection against I/R injury, potentially through the suppression of cardiomyocytes apoptosis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009884</affiliation-url><afid>60009884</afid><affilname>Hebei Medical University</affilname><name-variant>Hebei Medical University</name-variant><affiliation-city>Shijiazhuang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100845379</affiliation-url><afid>100845379</afid><affilname>Second Hospital of Hebei Medical University</affilname><name-variant>Second Hospital of Hebei Medical University</name-variant><affiliation-city>Shijiazhuang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115289288</affiliation-url><afid>115289288</afid><affilname>Hebei Province Key Laboratory of Molecular Chemistry for Drug</affilname><name-variant>Hebei Province Key Laboratory of Molecular Chemistry for Drug</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113315633</affiliation-url><afid>113315633</afid><affilname>Bethune International Hospital of Chinese PLA</affilname><name-variant>Bethune International Hospital of Chinese PLA</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115288941</affiliation-url><afid>115288941</afid><affilname>The No.1 Hospital of Baoding City</affilname><name-variant>The No.1 Hospital of Baoding City</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100777480</affiliation-url><afid>100777480</afid><affilname>First Hospital of Hebei Medical University</affilname><name-variant>First Hospital of Hebei Medical University</name-variant><affiliation-city>Shijiazhuang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55780454500</author-url><authid>55780454500</authid><authname>Xing K.</authname><surname>Xing</surname><given-name>Kun</given-name><initials>K.</initials><afid>60009884</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56431753600</author-url><authid>56431753600</authid><authname>Fu X.</authname><surname>Fu</surname><given-name>Xianghua</given-name><initials>X.</initials><afid>100845379</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56661533500</author-url><authid>56661533500</authid><authname>Jiang L.</authname><surname>Jiang</surname><given-name>Lingling</given-name><initials>L.</initials><afid>60009884</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56661526800</author-url><authid>56661526800</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Yanbo</given-name><initials>Y.</initials><afid>100845379</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56661973500</author-url><authid>56661973500</authid><authname>Li W.</authname><surname>Li</surname><given-name>Wei</given-name><initials>W.</initials><afid>100845379</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56661577700</author-url><authid>56661577700</authid><authname>Gu X.</authname><surname>Gu</surname><given-name>Xinshun</given-name><initials>X.</initials><afid>100845379</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:8417516400</author-url><authid>8417516400</authid><authname>Hao G.</authname><surname>Hao</surname><given-name>Guozhen</given-name><initials>G.</initials><afid>100845379</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56661805100</author-url><authid>56661805100</authid><authname>Miao Q.</authname><surname>Miao</surname><given-name>Qing</given-name><initials>Q.</initials><afid>100845379</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56661692000</author-url><authid>56661692000</authid><authname>Ge X.</authname><surname>Ge</surname><given-name>Xiaolin</given-name><initials>X.</initials><afid>115289288</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56661527800</author-url><authid>56661527800</authid><authname>Peng Y.</authname><surname>Peng</surname><given-name>Yuhong</given-name><initials>Y.</initials><afid>113315633</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56661825000</author-url><authid>56661825000</authid><authname>Geng W.</authname><surname>Geng</surname><given-name>Wei</given-name><initials>W.</initials><afid>115288941</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56637618400</author-url><authid>56637618400</authid><authname>Bai S.</authname><surname>Bai</surname><given-name>Shiru</given-name><initials>S.</initials><afid>60009884</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56637450700</author-url><authid>56637450700</authid><authname>Wei L.</authname><surname>Wei</surname><given-name>Liye</given-name><initials>L.</initials><afid>100777480</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:56637674500</author-url><authid>56637674500</authid><authname>Bi X.</authname><surname>Bi</surname><given-name>Xile</given-name><initials>X.</initials><afid>60009884</afid></author><authkeywords>Acute myocardial infarction | Anisodamine | Apoptosis | H9c2 cells | Ischemia/reperfusion injury</authkeywords><intid>1786077029</intid><source-id>38819</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930149356"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930149356?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930149356&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930149356&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930149356</prism:url><dc:identifier>SCOPUS_ID:84930149356</dc:identifier><eid>2-s2.0-84930149356</eid><dc:title>Identification of a novel truncation mutation of EYA4 in moderate degree hearing loss by targeted exome sequencing</dc:title><dc:creator>Choi H.</dc:creator><prism:publicationName>European Archives of Oto-Rhino-Laryngology</prism:publicationName><prism:issn>09374477</prism:issn><prism:eIssn>14344726</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00405-015-3661-2</prism:doi><dc:description>Â© 2015 Springer-Verlag Berlin Heidelberg The EYA4 gene encodes a 640-amino-acid protein that serves as a transcription factor. This protein contains a highly conserved Eya domain (eya-HR) and a variable domain (eya-VR). Mutations of this gene are known to cause postlingual and progressive sensorineural hearing loss, either as non-syndromic (DFNA10) or syndromic hearing loss, depending on the location of truncation of the mutant protein. Since our previous report, we have recruited 14 families segregating autosomal dominant moderate SNHL. A thorough medical history and physical examination including evaluation of heart problems ruled out any syndromic features in these families. Screening of EYA4 was performed by targeted exome sequencing of 134 known deafness genes (TES-134) from the probands. After basic filtering of the variants, we identified one proband who carried a novel truncation mutation, c.1194delT (p.Met401TrpfsX3) of EYA4, making the frequency of DFNA10 to be 7.14 % (1/14) in Koreans. The variant co-segregated perfectly with a slightly down-sloping, moderate degree of SNHL in the family (SH117), and was not detected in any of the 592 normal control chromosomes. This variant is likely to generate protein products that are truncated just downstream of the eya-VR domain. None of the three affected family members showed any syndromic features, including cardiac problems, which was compatible with a previous genotypeâphenotype correlation. The identification of a novel EYA4 truncation mutation associated with DFNA10, rather than syndromic hearing loss, supports a previously reported genotypeâphenotype correlation in this gene. Considering its detection rate, EYA4 mutations should be suspected in hereditary moderate hearing loss with a corresponding audiologic configuration, and a cardiac examination should be included in the initial evaluation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60098516</affiliation-url><afid>60098516</afid><affilname>Seoul National University Bundang Hospital</affilname><name-variant>Seoul National University College of Medicine</name-variant><affiliation-city>Seongnam</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021119</affiliation-url><afid>60021119</afid><affilname>Seoul National University Hospital</affilname><name-variant>Seoul National University Hospital</name-variant><affiliation-city>Jongno-gu</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000656</affiliation-url><afid>60000656</afid><affilname>Seoul National University College of Medicine</affilname><name-variant>Seoul Natl. Univ. Coll. of Medicine</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56661499500</author-url><authid>56661499500</authid><authname>Choi H.</authname><surname>Choi</surname><given-name>Hyun Seok</given-name><initials>H.S.</initials><afid>60098516</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56384000700</author-url><authid>56384000700</authid><authname>Kim A.</authname><surname>Kim</surname><given-name>Ah Reum</given-name><initials>A.R.</initials><afid>60021119</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56412069400</author-url><authid>56412069400</authid><authname>Kim S.</authname><surname>Kim</surname><given-name>Shin Hye</given-name><initials>S.H.</initials><afid>60021119</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7402755409</author-url><authid>7402755409</authid><authname>Choi B.</authname><surname>Choi</surname><given-name>Byung Yoon</given-name><initials>B.Y.</initials><afid>60098516</afid><afid>60000656</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7402755409</author-url><authid>7402755409</authid><authname>Choi B.</authname><surname>Choi</surname><given-name>Byung Yoon</given-name><initials>B.Y.</initials><afid>60098516</afid><afid>60000656</afid></author><authkeywords>DFNA10 | EYA4 | Hearing loss | Targeted exome sequencing</authkeywords><intid>1786077208</intid><source-id>13682</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929893788"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929893788?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929893788&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929893788&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929893788</prism:url><dc:identifier>SCOPUS_ID:84929893788</dc:identifier><eid>2-s2.0-84929893788</eid><dc:title>Surgical Results of Anomalous Origin of One Pulmonary Artery Branch from the Ascending Aorta</dc:title><dc:creator>Cho S.</dc:creator><prism:publicationName>Pediatric Cardiology</prism:publicationName><prism:issn>01720643</prism:issn><prism:eIssn>14321971</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00246-015-1197-2</prism:doi><dc:description>Â© 2015 Springer Science+Business Media New York We reviewed our surgical experience with anomalous origin of one pulmonary artery from the ascending aorta (AOPA). From 1989 to 2012, 12 children (five neonates) aged 3â734 days (mean 152 Â± 222) with AOPA underwent operations. Eight patients had right AOPA, and four patients had left AOPA. The majority of the patients had elevated right ventricular pressure, with 58 % (7 of 12) demonstrating suprasystemic right ventricular pressure. Surgery was performed by direct anastomosis (group 1) in seven patients and by employing an autologous patch (group 2) in five patients. There were two postoperative mortalities caused by heart failure and pulmonary hypertensive crisis. The mean follow-up duration was 12.6 Â± 8 years. Catheterization showed that the right ventricle-to-systemic pressure ratio decreased following operation (preoperative vs. postoperative; 1.13 Â± 0.19 vs. 0.48 Â± 0.03, p = 0.043). There was no difference in the perfusion of the affected lung as measured by the final lung perfusion scan, between the two groups (group 1 vs. group 2; 50.0 Â± 10.3 vs. 42.7 Â± 28.7 %, p = 0.158). Two patients required reoperations for pulmonary regurgitation and pulmonary artery stenosis. There were two catheter-based interventions. At 20 years, survival by the KaplanâMeier was 91.7 Â± 8.0 %, freedom from reoperation was 80.0 Â± 17.9 %, and freedom from catheter intervention was 80.8 Â± 12.2 %. Early repair of AOPA improves right ventricular pressure and overall hemodynamics with excellent survival and low risk of reintervention. The type of surgical repair did not significantly affect the long-term outcomes (measured via lung perfusion scan).</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000656</affiliation-url><afid>60000656</afid><affilname>Seoul National University College of Medicine</affilname><name-variant>Seoul Natl. Univ. Coll. of Medicine</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:40261062800</author-url><authid>40261062800</authid><authname>Cho S.</authname><surname>Cho</surname><given-name>Sungkyu</given-name><initials>S.</initials><afid>60000656</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56576730100</author-url><authid>56576730100</authid><authname>Kim W.</authname><surname>Kim</surname><given-name>Woong Han</given-name><initials>W.H.</initials><afid>60000656</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56515964900</author-url><authid>56515964900</authid><authname>Choi E.</authname><surname>Choi</surname><given-name>Eun Seok</given-name><initials>E.S.</initials><afid>60000656</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56517031600</author-url><authid>56517031600</authid><authname>Lee J.</authname><surname>Lee</surname><given-name>Jeong Ryul</given-name><initials>J.R.</initials><afid>60000656</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56640005300</author-url><authid>56640005300</authid><authname>Kim Y.</authname><surname>Kim</surname><given-name>Yong Jin</given-name><initials>Y.J.</initials><afid>60000656</afid></author><authkeywords>Aorta | Great vessel anomalies | Hemitruncus | Pulmonary arteries</authkeywords><intid>36035445</intid><source-id>20526</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930153839"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930153839?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930153839&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930153839&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930153839</prism:url><dc:identifier>SCOPUS_ID:84930153839</dc:identifier><eid>2-s2.0-84930153839</eid><dc:title>Incompatible Sets of Gradients and Metastability</dc:title><dc:creator>Ball J.</dc:creator><prism:publicationName>Archive for Rational Mechanics and Analysis</prism:publicationName><prism:issn>00039527</prism:issn><prism:eIssn>14320673</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00205-015-0883-9</prism:doi><dc:description>Â© 2015 Springer-Verlag Berlin Heidelberg We give a mathematical analysis of a concept of metastability induced by incompatibility. The physical setting is a single parent phase, just about to undergo transformation to a product phase of lower energy density. Under certain conditions of incompatibility of the energy wells of this energy density, we show that the parent phase is metastable in a strong sense, namely it is a local minimizer of the free energy in an L&lt;sup&gt;1&lt;/sup&gt; neighbourhood of its deformation. The reason behind this result is that, due to the incompatibility of the energy wells, a small nucleus of the product phase is necessarily accompanied by a stressed transition layer whose energetic cost exceeds the energy lowering capacity of the nucleus. We define and characterize incompatible sets of matrices, in terms of which the transition layer estimate at the heart of the proof of metastability is expressed. Finally we discuss connections with experiments and place this concept of metastability in the wider context of recent theoretical and experimental research on metastability and hysteresis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026851</affiliation-url><afid>60026851</afid><affilname>University of Oxford</affilname><name-variant>Oxford University</name-variant><affiliation-city>Oxford</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005745</affiliation-url><afid>60005745</afid><affilname>University of Minnesota System</affilname><name-variant>University of Minnesota</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7401813603</author-url><authid>7401813603</authid><authname>Ball J.</authname><surname>Ball</surname><given-name>J. M.</given-name><initials>J.M.</initials><afid>60026851</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35516863500</author-url><authid>35516863500</authid><authname>James R.</authname><surname>James</surname><given-name>R. D.</given-name><initials>R.D.</initials><afid>60005745</afid></author><intid>536078182</intid><source-id>25208</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930074798"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930074798?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930074798&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930074798&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930074798</prism:url><dc:identifier>SCOPUS_ID:84930074798</dc:identifier><eid>2-s2.0-84930074798</eid><dc:title>The geography of Welsh literary production in late medieval Glamorgan</dc:title><dc:creator>Fulton H.</dc:creator><prism:publicationName>Journal of Medieval History</prism:publicationName><prism:issn>03044181</prism:issn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1080/03044181.2015.1048093</prism:doi><dc:description>Â© 2015 Taylor &amp; Francis The urban culture of medieval Swansea, which provided the political context for William Cragh and his rebellion, represents only one aspect of the Marcher lordship of Glamorgan. Within the same lordship, Welsh gentry families engaged with national politics through a literary culture shared with their English neighbours. This paper looks at some of the most significant manuscripts associated with south Wales in the fourteenth and fifteenth centuries, including the âRed Book of Hergestâ and National Library of Wales MS Peniarth 50. This latter manuscript is particularly noteworthy for its multilingual contents and for its large collection of political prophecy in Welsh, English and Latin, testifying to Welsh involvement in English politics. The paper argues that Welsh literary culture was a strong element in Glamorgan Marcher society and that an elite group of Welsh gentry were at the heart of a mobile network of scribes, poets and manuscripts.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020650</affiliation-url><afid>60020650</afid><affilname>University of Bristol</affilname><name-variant>University of Bristol</name-variant><affiliation-city>Bristol</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56660508200</author-url><authid>56660508200</authid><authname>Fulton H.</authname><surname>Fulton</surname><given-name>Helen</given-name><initials>H.</initials><afid>60020650</afid></author><authkeywords>Glamorgan | history | literature | manuscripts | medieval Wales | Red Book of Hergest</authkeywords><intid>536062324</intid><source-id>20197</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930176752"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930176752?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930176752&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930176752&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930176752</prism:url><dc:identifier>SCOPUS_ID:84930176752</dc:identifier><eid>2-s2.0-84930176752</eid><dc:title>3D Reconstruction of Chick Embryo Vascular Geometries Using Non-invasive High-Frequency Ultrasound for Computational Fluid Dynamics Studies</dc:title><dc:creator>Tan G.</dc:creator><prism:publicationName>Annals of Biomedical Engineering</prism:publicationName><prism:issn>00906964</prism:issn><prism:eIssn>15739686</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10439-015-1339-y</prism:doi><dc:description>Â© 2015 Biomedical Engineering Society Recent animal studies have provided evidence that prenatal blood flow fluid mechanics may play a role in the pathogenesis of congenital cardiovascular malformations. To further these researches, it is important to have an imaging technique for small animal embryos with sufficient resolution to support computational fluid dynamics studies, and that is also non-invasive and non-destructive to allow for subject-specific, longitudinal studies. In the current study, we developed such a technique, based on ultrasound biomicroscopy scans on chick embryos. Our technique included a motion cancelation algorithm to negate embryonic body motion, a temporal averaging algorithm to differentiate blood spaces from tissue spaces, and 3D reconstruction of blood volumes in the embryo. The accuracy of the reconstructed models was validated with direct stereoscopic measurements. A computational fluid dynamics simulation was performed to model fluid flow in the generated construct of a HamburgerâHamilton (HH) stage 27 embryo. Simulation results showed that there were divergent streamlines and a low shear region at the carotid duct, which may be linked to the carotid ductâs eventual regression and disappearance by HH stage 34. We show that our technique has sufficient resolution to produce accurate geometries for computational fluid dynamics simulations to quantify embryonic cardiovascular fluid mechanics.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017161</affiliation-url><afid>60017161</afid><affilname>National University of Singapore</affilname><name-variant>National University of Singapore</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004409</affiliation-url><afid>60004409</afid><affilname>National Heart Centre, Singapore</affilname><name-variant>National Heart Centre Singapore</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017161</affiliation-url><afid>60017161</afid><affilname>National University of Singapore</affilname><name-variant>National University of Singapore</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56661710100</author-url><authid>56661710100</authid><authname>Tan G.</authname><surname>Tan</surname><given-name>Germaine Xin Yi</given-name><initials>G.X.Y.</initials><afid>60017161</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56661844700</author-url><authid>56661844700</authid><authname>Jamil M.</authname><surname>Jamil</surname><given-name>Muhammad</given-name><initials>M.</initials><afid>60017161</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56228390100</author-url><authid>56228390100</authid><authname>Tee N.</authname><surname>Tee</surname><given-name>Nicole Gui Zhen</given-name><initials>N.G.Z.</initials><afid>60004409</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56661676100</author-url><authid>56661676100</authid><authname>Zhong L.</authname><surname>Zhong</surname><given-name>Liang</given-name><initials>L.</initials><afid>60004409</afid><afid>60017161</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56661676100</author-url><authid>56661676100</authid><authname>Zhong L.</authname><surname>Zhong</surname><given-name>Liang</given-name><initials>L.</initials><afid>60004409</afid><afid>60017161</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56487087300</author-url><authid>56487087300</authid><authname>Yap C.</authname><surname>Yap</surname><given-name>Choon Hwai</given-name><initials>C.H.</initials><afid>60017161</afid></author><authkeywords>Computational fluid dynamics | Embryonic and fetal cardiovascular fluid mechanics | High frequency ultrasound | Ultrasound image processing and segmentation</authkeywords><intid>1036071538</intid><source-id>27474</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930160483"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930160483?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930160483&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930160483&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930160483</prism:url><dc:identifier>SCOPUS_ID:84930160483</dc:identifier><eid>2-s2.0-84930160483</eid><dc:title>Hydroxysafflor yellow A attenuate lipopolysaccharide-induced endothelium inflammatory injury</dc:title><dc:creator>Jin M.</dc:creator><prism:publicationName>Chinese Journal of Integrative Medicine</prism:publicationName><prism:issn>16720415</prism:issn><prism:eIssn>19930402</prism:eIssn><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11655-015-1976-x</prism:doi><dc:description>Â© 2015 Chinese Association of the Integration of Traditional and Western Medicine and Springer-Verlag Berlin Heidelberg Objective: This study observed attenuating effect of hydroxysafflor yellow A (HSYA), an effective ingredient of aqueous extract of Carthamus tinctorius L, on lipopolysaccharide (LPS)-induced endothelium inflammatory injury. Methods: Eahy926 human endothelium cell (EC) line was used; thiazolyl blue tetrazolium bromide (MTT) test was assayed to observe the viability of EC; Luciferase reporter gene assay was applied to measure nuclear factor-ÎºB (NF-ÎºB) p65 subunit nuclear binding activity in EC; Western blot technology was used to monitor mitogen activated protein kinase (MAPKs) and NF-ÎºB activation. Reverse transcription polymerase chain reaction (RT-PCR) method was applied to observe intercellular cell adhesion molecule-1 (ICAM-1) and E-selectin mRNA level; EC surface ICAM-1 expression was measured with flow cytometry and leukocyte adhesion to EC was assayed with Rose Bengal spectrophotometry technology. Results: HSYA protected EC viability against LPS-induced injury (P&lt;0.05). LPS-induced NF-ÎºB p65 subunit DNA binding (P&lt;0.01) and nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor -Î± (I-ÎºB-Î±) phosphorylation was inhibited by HSYA. HSYA attenuated LPS triggered ICAM-1 and E-selectin mRNA levels elevation and phosphorylation of p38 MAPK or c-Jun N-terminal kinase MAPK. HSYA also inhibited LPS-induced cell surface ICAM-1 protein expressionP&lt;0.01) and leukocyte adhesion to EC (P&lt;0.05). Conclusion: HSYA is effective to protect LPS-induced high expression of endothelium adhesive molecule and inflammatory signal transduction.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026707</affiliation-url><afid>60026707</afid><affilname>Capital Medical University China</affilname><name-variant>Capital Medical University</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14421093200</author-url><authid>14421093200</authid><authname>Jin M.</authname><surname>Jin</surname><given-name>Ming</given-name><initials>M.</initials><afid>60026707</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36104742900</author-url><authid>36104742900</authid><authname>Sun C.</authname><surname>Sun</surname><given-name>Chun yan</given-name><initials>C.y.</initials><afid>60026707</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56539542600</author-url><authid>56539542600</authid><authname>Zang B.</authname><surname>Zang</surname><given-name>Bao xia</given-name><initials>B.x.</initials><afid>60026707</afid></author><authkeywords>adhesive molecule | endothelium cell | hydroxysafflor yellow A | inflammation | lipopolysaccharide</authkeywords><intid>2036071709</intid><source-id>145017</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930206961"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930206961?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930206961&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930206961&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0928493115300746"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930206961</prism:url><dc:identifier>SCOPUS_ID:84930206961</dc:identifier><eid>2-s2.0-84930206961</eid><dc:title>Analysis of the biomechanical behavior of short implants: The photo-elasticity method</dc:title><dc:creator>Pellizzer E.</dc:creator><prism:publicationName>Materials Science and Engineering C</prism:publicationName><prism:issn>09284931</prism:issn><prism:volume>55</prism:volume><prism:pageRange>187-192</prism:pageRange><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.msec.2015.05.024</prism:doi><pii>S0928493115300746</pii><dc:description>Â© 2015 Elsevier B.V. The aim of this study was to analyze the stress distribution of short implants supporting single unit or splinted crowns by the photo-elasticity method. Four photo-elastic models were produced: A (3.75 Ã 7 mm); B (3.75 Ã 7 mm, 3.75 Ã 7 mm and 3.75 Ã 7 mm); C (3.75 Ã 10 mm, 3.75 Ã 7 mm and 3.75 Ã 7 mm); D (3.75 Ã 13 mm, 3.75 Ã 7 mm and 3.75 Ã 7 mm). The prostheses were made with Ni-Cr alloy. A load of 100 N in the axial and oblique directions was applied, totaling 380 applications, individually capturing their images in each model. The data were randomized and analyzed qualitatively and quantitatively by 2 examiners. The oblique loading was significantly more damaging. The increase in length was favorable for stress distribution (p &lt; 0.05). The splinting was beneficial for the transmission of stresses mainly (p &lt; 0.05). The splinting of the crowns, as well as increasing the length of the first implant and axial loading was most beneficial in the stress distribution. Short splinted implants behaved better than single unit implants. Increasing of the length of the first implant significantly improved the stress distribution in all analyzed situations.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006028</affiliation-url><afid>60006028</afid><affilname>UNESP-Universidade Estadual Paulista</affilname><name-variant>Universidade Estadual Paulista</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115293857</affiliation-url><afid>115293857</afid><affilname>University of Sacred Heart - USC</affilname><name-variant>University of Sacred Heart - USC</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24462361800</author-url><authid>24462361800</authid><authname>Pellizzer E.</authname><surname>Pellizzer</surname><given-name>Eduardo Piza</given-name><initials>E.P.</initials><afid>60006028</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56015903900</author-url><authid>56015903900</authid><authname>De Mello C.</authname><surname>De Mello</surname><given-name>Caroline Cantieri</given-name><initials>C.C.</initials><afid>60006028</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56571045500</author-url><authid>56571045500</authid><authname>Santiago Junior J.</authname><surname>Santiago Junior</surname><given-name>Joel Ferreira</given-name><initials>J.F.</initials><afid>115293857</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56182950900</author-url><authid>56182950900</authid><authname>De Souza Batista V.</authname><surname>De Souza Batista</surname><given-name>Victor Eduardo</given-name><initials>V.E.</initials><afid>60006028</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:37080368700</author-url><authid>37080368700</authid><authname>De Faria Almeida D.</authname><surname>De Faria Almeida</surname><given-name>Daniel Augusto</given-name><initials>D.A.</initials><afid>60006028</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:21735358700</author-url><authid>21735358700</authid><authname>Verri F.</authname><surname>Verri</surname><given-name>Fellippo Ramos</given-name><initials>F.R.</initials><afid>60006028</afid></author><authkeywords>Dental implants | Dental prosthesis, implant-supported | Dental stress analysis</authkeywords><intid>536087456</intid><source-id>17813</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930196455"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930196455?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930196455&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930196455&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S153204561500054X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930196455</prism:url><dc:identifier>SCOPUS_ID:84930196455</dc:identifier><eid>2-s2.0-84930196455</eid><dc:title>Hepatic metallothioneins in molecular responses to cobalt, zinc, and their nanoscale polymeric composites in frog Rana ridibunda</dc:title><dc:creator>Falfushynska H.</dc:creator><prism:publicationName>Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology</prism:publicationName><prism:issn>15320456</prism:issn><prism:eIssn>18781659</prism:eIssn><prism:volume>172-173</prism:volume><prism:pageRange>45-56</prism:pageRange><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbpc.2015.04.006</prism:doi><pii>S153204561500054X</pii><dc:description>Â© 2015 Elsevier Inc.. All rights reserved. Despite numerous studies suggesting a dramatic decline of amphibians, the biochemical mechanisms of adaptation in these animals to polluted environment are poorly studied. The aim of this study was to elucidate the ability to release cobalt (Co) and zinc (Zn) from their nanoscale complexes (NCs) derived from the polymeric substance of N-vinylpyrrolidone (PS) in the liver of amphibian (Rana ridibunda). Frog males were subjected to 14 days exposure to waterborne Co&lt;sup&gt;2 +&lt;/sup&gt; (50 Î¼g/L), Zn&lt;sup&gt;2 +&lt;/sup&gt; (100 Î¼g/L), as well as corresponding concentrations of Co-NC, Zn-NC or PS. Main attention was paid to MT's interrelations with indices of stress and toxicity. Only Co&lt;sup&gt;2 +&lt;/sup&gt; and Zn&lt;sup&gt;2 +&lt;/sup&gt; caused elevation of the correspondent metal in MTs. Co&lt;sup&gt;2 +&lt;/sup&gt; caused down-regulation of cathepsin D activity, while Zn&lt;sup&gt;2 +&lt;/sup&gt;, Zn-NC and the PS up-regulated this activity. Zn&lt;sup&gt;2 +&lt;/sup&gt; provoked 1.6 times increase of metal-bounded form of the MT (MT-Me), while all other exposures caused the elevation of the ratio of MT total protein concentration (MT-SH) and concentrations of the MT-Me and/or immunoreactive (MTi) form (up to ~ 10 times) accompanied by a decrease in the levels of oxyradicals. The increased DNA fragmentation and down-regulation of caspase-3 activity in relation to the redox state of glutathione and/or lactate/pyruvate were shown at all exposures. These data indicate the vulnerability of the redox state of cellular thiols and inability to release Co and Zn from NCs in frog's liver.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60087521</affiliation-url><afid>60087521</afid><affilname>Ternopil V. Hnatiuk National Pedagogical University</affilname><name-variant>Ternopil National Pedagogical University</name-variant><affiliation-city>Ternopil</affiliation-city><affiliation-country>Ukraine</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070104</affiliation-url><afid>60070104</afid><affilname>Institute of Cell Biology National Academy of Sciences of Ukraine</affilname><name-variant>Institute of Cell Biology National Academy of Sciences of Ukraine</name-variant><affiliation-city>Lviv</affiliation-city><affiliation-country>Ukraine</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080765</affiliation-url><afid>60080765</afid><affilname>Lviv Polytechnic National University</affilname><name-variant>Lviv Polytechnic National University</name-variant><affiliation-city>Lviv</affiliation-city><affiliation-country>Ukraine</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068528</affiliation-url><afid>60068528</afid><affilname>Ternopil State Medical University</affilname><name-variant>Ternopol'skij Meditsinskij Institut</name-variant><affiliation-city>Ternopil</affiliation-city><affiliation-country>Ukraine</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24331602700</author-url><authid>24331602700</authid><authname>Falfushynska H.</authname><surname>Falfushynska</surname><given-name>Halina</given-name><initials>H.</initials><afid>60087521</afid><afid>60068528</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24331602700</author-url><authid>24331602700</authid><authname>Falfushynska H.</authname><surname>Falfushynska</surname><given-name>Halina</given-name><initials>H.</initials><afid>60087521</afid><afid>60068528</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36450603900</author-url><authid>36450603900</authid><authname>Gnatyshyna L.</authname><surname>Gnatyshyna</surname><given-name>Lesya</given-name><initials>L.</initials><afid>60087521</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663123800</author-url><authid>56663123800</authid><authname>Fedoruk O.</authname><surname>Fedoruk</surname><given-name>Olga</given-name><initials>O.</initials><afid>60087521</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701600534</author-url><authid>6701600534</authid><authname>Mitina N.</authname><surname>Mitina</surname><given-name>Natalia</given-name><initials>N.</initials><afid>60080765</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55399223900</author-url><authid>55399223900</authid><authname>Zaichenko A.</authname><surname>Zaichenko</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60080765</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56548785800</author-url><authid>56548785800</authid><authname>Stoliar O.</authname><surname>Stoliar</surname><given-name>Oksana</given-name><initials>O.</initials><afid>60087521</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56144795900</author-url><authid>56144795900</authid><authname>Stoika R.</authname><surname>Stoika</surname><given-name>Rostyslav</given-name><initials>R.</initials><afid>60070104</afid></author><authkeywords>Cobalt | Metallothioneins | Nanoscale composite | Rana ridibunda | Zinc</authkeywords><intid>1786088523</intid><source-id>9000153111</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930209948"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930209948?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930209948&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930209948&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1364032115003998"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930209948</prism:url><dc:identifier>SCOPUS_ID:84930209948</dc:identifier><eid>2-s2.0-84930209948</eid><dc:title>An overview of biogas production and utilization at full-scale wastewater treatment plants (WWTPs) in the United States: Challenges and opportunities towards energy-neutral WWTPs</dc:title><dc:creator>Shen Y.</dc:creator><prism:publicationName>Renewable and Sustainable Energy Reviews</prism:publicationName><prism:issn>13640321</prism:issn><prism:eIssn>18790690</prism:eIssn><prism:volume>50</prism:volume><prism:pageRange>346-362</prism:pageRange><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.rser.2015.04.129</prism:doi><pii>S1364032115003998</pii><dc:description>Â© 2015 Elsevier Ltd. Recently the United States Environmental Protection Agency qualified biogas from landfills and anaerobic digesters as a cellulosic transportation biofuel under the expanded Renewable Fuel Standard (RFS2). Biogas is a renewable fuel that can generate Renewable Identification Number credits for the producer. The wastewater industry may not be able to keep pace with this opportunity. Less than 10% of WWTPs in the US have currently produced biogas for beneficial use. Supporting growth of the biogas industry requires implementation of new practices and policies. In this review, the barriers, gaps, and challenges in deploying biogas production technology are identified. Issues are classified as economic, technical, social or regulatory issues. Some of the critical challenges to the economics of digester operations are the slow rate of biogas generation, the low energy content of the biogas, and the costs to upgrade the biogas. Currently there is little biogas utilization at US WWTPs. Most biogas is flared while some is used for onsite process heat and power production. Case studies of co-digestion of biosolids with organic wastes at field-scale show the use of co-digestion could overcome significant economic challenges including higher methane yield, more efficient digester volume utilization and reduced biosolids production. These findings could provide guidance in retrofitting existing facilities or in designing new biogas production and utilization systems. The RFS2 ruling increases market certainty, hence reduces risk. The evaluation of applications of co-digestion at WWTP scales ranging from 1 million gallons per day (MGD) to 375 MGD determined its potential feasibility for different types of digester operation, organic waste and loading rate as well as effectiveness of providing energy self-sufficiency at the WWTPs. This work could improve economics of anaerobic digestion at WWTPs, enabling viable and sustainable biogas industry and offsetting costs for wastewater management.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028609</affiliation-url><afid>60028609</afid><affilname>Argonne National Laboratory</affilname><name-variant>Argonne National Laboratory</name-variant><affiliation-city>Argonne</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662579700</author-url><authid>56662579700</authid><authname>Shen Y.</authname><surname>Shen</surname><given-name>Yanwen</given-name><initials>Y.</initials><afid>60028609</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37117362800</author-url><authid>37117362800</authid><authname>Linville J.</authname><surname>Linville</surname><given-name>Jessica L.</given-name><initials>J.L.</initials><afid>60028609</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8859384500</author-url><authid>8859384500</authid><authname>Urgun-Demirtas M.</authname><surname>Urgun-Demirtas</surname><given-name>Meltem</given-name><initials>M.</initials><afid>60028609</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7102020493</author-url><authid>7102020493</authid><authname>Mintz M.</authname><surname>Mintz</surname><given-name>Marianne M.</given-name><initials>M.M.</initials><afid>60028609</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:25224042000</author-url><authid>25224042000</authid><authname>Snyder S.</authname><surname>Snyder</surname><given-name>Seth W.</given-name><initials>S.W.</initials><afid>60028609</afid></author><authkeywords>Abbreviations AD anaerobic digestion | AG-MTM acid-methane mesophilic-thermophilic-mesophilic process | AWWTP advanced wastewater treatment plant | CHP combined heat and power | COD chemical oxygen demand | CSTR continuous stirred tank reactor | FOG fats, oil and grease | GHG greenhouse gas | GPD gallons per day | HRT hydraulic retention time | HSW high-strength waste | IC internal combustion | MBTU million British thermal unit | MGD million gallons per day (1 MGD=3785 m&lt;sup&gt;3&lt;/sup&gt;/day) | MGY million gallons per year | N/A not available | OFMSW organic fraction of municipal solid waste | PFR plug flow reactor | PS primary sludge | PSA pressure swing adsorption | RFS2 the new renewable fuel standard | RIN renewable identification numbers | scfm standard cubic feet per minute | THP thermal hydrolysis process | TS total solids | VS volatile solids | WAS waste activated sludge | WWTP wastewater treatment plant | WWTW wastewater treatment work</authkeywords><intid>1786088521</intid><source-id>27567</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930200653"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930200653?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930200653&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930200653&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0928493115300898"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930200653</prism:url><dc:identifier>SCOPUS_ID:84930200653</dc:identifier><eid>2-s2.0-84930200653</eid><dc:title>One-pot synthesis of porphyrin functionalized Î³-Fe&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;3&lt;/inf&gt; nanocomposites as peroxidase mimics for H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; and glucose detection</dc:title><dc:creator>Liu Q.</dc:creator><prism:publicationName>Materials Science and Engineering C</prism:publicationName><prism:issn>09284931</prism:issn><prism:volume>55</prism:volume><prism:pageRange>193-200</prism:pageRange><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.msec.2015.05.028</prism:doi><pii>S0928493115300898</pii><dc:description>Â© 2015 Elsevier B.V. Meso-tetrakis(4-carboxyphenyl)-porphyrin-functionalized Î³-Fe&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;3&lt;/inf&gt; nanoparticles (H&lt;inf&gt;2&lt;/inf&gt;TCPP-Î³-Fe&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;3&lt;/inf&gt;) were successfully prepared by one-pot method under hydrothermal conditions and were found to possess intrinsic peroxidase-like activity. The H&lt;inf&gt;2&lt;/inf&gt;TCPP-Î³-Fe&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;3&lt;/inf&gt; nanocomposites can catalytically oxidize peroxidase substrate 3,3â²,5,5â²-tetramethylbenzidine (TMB) in the presence of H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; to produce a blue color reaction, which can be easily observed by the naked eye. Furthermore, kinetic studies indicate that the H&lt;inf&gt;2&lt;/inf&gt;TCPP-Î³-Fe&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;3&lt;/inf&gt; nanocomposites have an even higher affinity to TMB than that of the natural enzyme, horseradish peroxidase (HRP). On the basis of the high activity, the reaction provides a simple, sensitive and selective method for colorimetric detection of H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; over a range of 10-100 Î¼M with a minimum detection limit of 1.73 Î¼M. Moreover, H&lt;inf&gt;2&lt;/inf&gt;TCPP-Î³-Fe&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;3&lt;/inf&gt;/glucose oxidase (GOx)/TMB system provides a novel colorimetric sensor for glucose and shows good response toward glucose detection over a range of 5-25 Î¼M with a minimum detection limit of 2.54 Î¼M. The results indicated that it is a simple, cheap, convenient, highly selective, sensitive and easy handling colorimetric assay. Results of a fluorescent probe suggest that the catalase-mimic activity of the H&lt;inf&gt;2&lt;/inf&gt;TCPP-Î³-Fe&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;3&lt;/inf&gt; nanocomposites effectively catalyze the decomposition of H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; into H&lt;inf&gt;2&lt;/inf&gt;O and O&lt;inf&gt;2&lt;/inf&gt;.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001429</affiliation-url><afid>60001429</afid><affilname>Shandong University of Science and Technology</affilname><name-variant>Shandong University of Science and Technology</name-variant><affiliation-city>Qingdao</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7406291808</author-url><authid>7406291808</authid><authname>Liu Q.</authname><surname>Liu</surname><given-name>Qingyun</given-name><initials>Q.</initials><afid>60001429</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56647263600</author-url><authid>56647263600</authid><authname>Zhang L.</authname><surname>Zhang</surname><given-name>Leyou</given-name><initials>L.</initials><afid>60001429</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56158234100</author-url><authid>56158234100</authid><authname>Li H.</authname><surname>Li</surname><given-name>Hui</given-name><initials>H.</initials><afid>60001429</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56060675300</author-url><authid>56060675300</authid><authname>Jia Q.</authname><surname>Jia</surname><given-name>Qingyan</given-name><initials>Q.</initials><afid>60001429</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56285234200</author-url><authid>56285234200</authid><authname>Jiang Y.</authname><surname>Jiang</surname><given-name>Yanling</given-name><initials>Y.</initials><afid>60001429</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55850182600</author-url><authid>55850182600</authid><authname>Yang Y.</authname><surname>Yang</surname><given-name>Yanting</given-name><initials>Y.</initials><afid>60001429</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56156669800</author-url><authid>56156669800</authid><authname>Zhu R.</authname><surname>Zhu</surname><given-name>Renren</given-name><initials>R.</initials><afid>60001429</afid></author><authkeywords>Colorimetric sensor | One-pot method | Peroxidase | Porphyrin | Î³-Fe&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;3&lt;/inf&gt;</authkeywords><intid>2036081501</intid><source-id>17813</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225150"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225150?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225150&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225150&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225150</prism:url><dc:identifier>SCOPUS_ID:84930225150</dc:identifier><eid>2-s2.0-84930225150</eid><dc:title>Comparison between 200mg QD and 100mg BID oral celecoxib in the treatment of knee or hip osteoarthritis</dc:title><dc:creator>Zeng C.</dc:creator><prism:publicationName>Scientific Reports</prism:publicationName><prism:eIssn>20452322</prism:eIssn><prism:volume>5</prism:volume><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1038/srep10593</prism:doi><dc:description>This network meta-analysis aimed to investigate the effectiveness and safety of 100mg BID and 200mg QD oral celecoxib in the treatment of OA of the knee or hip. PubMed, Embase and Cochrane Library were searched through from inception to August 2014. Bayesian network meta-analysis was used to combine direct and indirect evidences on treatment effectiveness and safety. A total of 24 RCTs covering 11696 patients were included. For the comparison in between the two dosage regimens, 100mg BID oral celecoxib exhibited a greater probability to be the preferred one either in terms of pain intensity or function at the last follow-up time point. For total gastrointestinal (GI) adverse effects (AEs), both of the two dosage regimens demonstrated a higher incidence compared to the placebo group. Further analyses of GI AEs revealed that only 200mg QD was associated with a significantly higher risk of abdominal pain when compared with placebo. Furthermore, 100mg BID showed a significantly lower incidence of skin AEs when compared with 200mg QD and placebo. Maybe 100mg BID should be considered as the preferred dosage regimen in the treatment of knee or hip OA.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082821</affiliation-url><afid>60082821</afid><affilname>Xiangya Hospital of Central-south University</affilname><name-variant>Central South University</name-variant><affiliation-city>Changsha</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017060</affiliation-url><afid>60017060</afid><affilname>Central South University China</affilname><name-variant>Central South University</name-variant><affiliation-city>Changsha</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55326965700</author-url><authid>55326965700</authid><authname>Zeng C.</authname><surname>Zeng</surname><given-name>Chao</given-name><initials>C.</initials><afid>60082821</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55270631700</author-url><authid>55270631700</authid><authname>Wei J.</authname><surname>Wei</surname><given-name>Jie</given-name><initials>J.</initials><afid>60017060</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56107575000</author-url><authid>56107575000</authid><authname>Li H.</authname><surname>Li</surname><given-name>Hui</given-name><initials>H.</initials><afid>60082821</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55331445500</author-url><authid>55331445500</authid><authname>Yang T.</authname><surname>Yang</surname><given-name>Tuo</given-name><initials>T.</initials><afid>60082821</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24468212700</author-url><authid>24468212700</authid><authname>Gao S.</authname><surname>Gao</surname><given-name>Shu Guang</given-name><initials>S.G.</initials><afid>60082821</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:42761502500</author-url><authid>42761502500</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yu Sheng</given-name><initials>Y.S.</initials><afid>60082821</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55433104800</author-url><authid>55433104800</authid><authname>Xiong Y.</authname><surname>Xiong</surname><given-name>Yi Lin</given-name><initials>Y.L.</initials><afid>60082821</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35744034500</author-url><authid>35744034500</authid><authname>Xiao W.</authname><surname>Xiao</surname><given-name>Wen Feng</given-name><initials>W.F.</initials><afid>60082821</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56662664300</author-url><authid>56662664300</authid><authname>Luo W.</authname><surname>Luo</surname><given-name>Wei</given-name><initials>W.</initials><afid>60082821</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56609543000</author-url><authid>56609543000</authid><authname>Yang T.</authname><surname>Yang</surname><given-name>Tu Bao</given-name><initials>T.B.</initials><afid>60017060</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7005996387</author-url><authid>7005996387</authid><authname>Lei G.</authname><surname>Lei</surname><given-name>Guang Hua</given-name><initials>G.H.</initials><afid>60082821</afid></author><intid>1786087240</intid><article-number>10593</article-number><source-id>21100200805</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225680"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225680?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225680&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225680&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1388198115001031"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225680</prism:url><dc:identifier>SCOPUS_ID:84930225680</dc:identifier><eid>2-s2.0-84930225680</eid><dc:title>5,6-Î´-DHTL, a stable metabolite of arachidonic acid, is a potential substrate for paraoxonase 1</dc:title><dc:creator>Eryanni-Levin S.</dc:creator><prism:publicationName>Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids</prism:publicationName><prism:issn>13881981</prism:issn><prism:eIssn>18792618</prism:eIssn><prism:volume>1851</prism:volume><prism:issueIdentifier>9</prism:issueIdentifier><prism:pageRange>1118-1122</prism:pageRange><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbalip.2015.04.008</prism:doi><pii>S1388198115001031</pii><dc:description>Â© 2015 Elsevier B.V. Paraoxonase 1 (PON1) is an antiatherogenic high density lipoprotein-associated lactonase. Recent findings revealed that PON1 knockout mice have low blood pressure, which is negatively correlated with the level of 5,6-epoxyeicosatrienoic acid (5,6-EET), a cytochrome P450 -derived arachidonic acid metabolite. 5,6-EET is an endothelium-derived hyperpolarizing factor that causes arterial dilation. Under physiological conditions, 5,6-EET is unstable, transforming to its Î´-lactone (5,6-Î´-DHTL) that evades the degradation by soluble epoxide hydrolase (sEH), arguing for the existence of yet another enzyme that is responsible specifically for its hydrolysis. We therefore hypothesized that PON1 degrades the 5,6-Î´-DHTL, and this specific PON1 lactonase activity thus decreases endothelial vasodilatation. The aim of the present study was to investigate the PON1-5,6-Î´-DHTL relationship. A liquid chromatography mass spectrometry based method for 5,6-EET derivatives identification was developed. Tracking the lactonization of 5,6-EET in a physiological solution revealed that 5,6-EET was fully converted into 5,6-Î´-DHTL. Incubation of 5,6-Î´-DHTL with rePON1 resulted in 85.1 Â± 3.4% degradation of the substrate to 5,6 dihydroxytrienoic acid (5,6-DHET), while only 12.0 Â± 8.7% hydrolysis was detected in the absence of PON1. Accordingly, the levels of 5,6-DHTL were found to be significantly higher in the PON1KO mice than in the wild type mice. Kinetic analysis revealed values of Vmax = 0.021 Â± 0.01 Î¼M/s and Km = 150.99 Â± 62.1 Î¼M. Calculation of the docking energy suggested possible interaction of the 5,6-Î´-DHTL in the catalytic region of PON1 with free energy of -5.57 Kcal/mol, preferentially for the (S) enantiomer. These findings demonstrate that 5,6-Î´-DHTL is a PON1 substrate and imply that the 5,6-EET vasodilation effect may be impaired by PON1.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012007</affiliation-url><afid>60012007</afid><affilname>Migal Galilee Technology Center Israel</affilname><name-variant>MIGAL</name-variant><affiliation-city>Kiryat Shmona</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012007</affiliation-url><afid>60012007</afid><affilname>Migal Galilee Technology Center Israel</affilname><name-variant>MIGAL</name-variant><affiliation-city>Kiryat Shmona</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072471</affiliation-url><afid>60072471</afid><affilname>Tel Hai Academic College</affilname><name-variant>Tel-Hai College</name-variant><affiliation-city>Upper Galilee</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663168800</author-url><authid>56663168800</authid><authname>Eryanni-Levin S.</authname><surname>Eryanni-Levin</surname><given-name>Suzy</given-name><initials>S.</initials><afid>60012007</afid><afid>60072471</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663168800</author-url><authid>56663168800</authid><authname>Eryanni-Levin S.</authname><surname>Eryanni-Levin</surname><given-name>Suzy</given-name><initials>S.</initials><afid>60012007</afid><afid>60072471</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004329612</author-url><authid>7004329612</authid><authname>Khatib S.</authname><surname>Khatib</surname><given-name>Soliman</given-name><initials>S.</initials><afid>60012007</afid><afid>60072471</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004329612</author-url><authid>7004329612</authid><authname>Khatib S.</authname><surname>Khatib</surname><given-name>Soliman</given-name><initials>S.</initials><afid>60012007</afid><afid>60072471</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663188600</author-url><authid>56663188600</authid><authname>Levy-Rosenzvig R.</authname><surname>Levy-Rosenzvig</surname><given-name>Reut</given-name><initials>R.</initials><afid>60012007</afid><afid>60072471</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663188600</author-url><authid>56663188600</authid><authname>Levy-Rosenzvig R.</authname><surname>Levy-Rosenzvig</surname><given-name>Reut</given-name><initials>R.</initials><afid>60012007</afid><afid>60072471</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004070696</author-url><authid>7004070696</authid><authname>Tamir S.</authname><surname>Tamir</surname><given-name>Snait</given-name><initials>S.</initials><afid>60012007</afid><afid>60072471</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004070696</author-url><authid>7004070696</authid><authname>Tamir S.</authname><surname>Tamir</surname><given-name>Snait</given-name><initials>S.</initials><afid>60012007</afid><afid>60072471</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24472101400</author-url><authid>24472101400</authid><authname>Szuchman-Sapir A.</authname><surname>Szuchman-Sapir</surname><given-name>Andrea</given-name><initials>A.</initials><afid>60012007</afid><afid>60072471</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24472101400</author-url><authid>24472101400</authid><authname>Szuchman-Sapir A.</authname><surname>Szuchman-Sapir</surname><given-name>Andrea</given-name><initials>A.</initials><afid>60012007</afid><afid>60072471</afid></author><authkeywords>5,6-Dihydroxylactone | 5,6-epoxyeicosatrienoic acid | Arachidonic acid metabolism | Paraoxonase 1</authkeywords><intid>1536087853</intid><source-id>16831</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930202033"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930202033?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930202033&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930202033&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930202033</prism:url><dc:identifier>SCOPUS_ID:84930202033</dc:identifier><eid>2-s2.0-84930202033</eid><dc:title>Novel expression pattern of neuropeptide Y immunoreactivity in the peripheral nervous system in a rat model of neuropathic pain</dc:title><dc:creator>Magnussen C.</dc:creator><prism:publicationName>Molecular Pain</prism:publicationName><prism:issn>17448069</prism:issn><prism:eIssn>17448069</prism:eIssn><prism:volume>11</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>May 27, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12990-015-0029-y</prism:doi><dc:description>Â© Magnussen et al. Background: Neuropeptide Y (NPY) has been implicated in the modulation of pain. Under normal conditions, NPY is found in interneurons in the dorsal horn of the spinal cord and in sympathetic postganglionic neurons but is absent from the cell bodies of sensory neurons. Following peripheral nerve injury NPY is dramatically upregulated in the sensory ganglia. How NPY expression is altered in the peripheral nervous system, distal to a site of nerve lesion, remains unknown. To address this question, NPY expression was investigated using immunohistochemistry at the level of the trigeminal ganglion, the mental nerve and in the skin of the lower lip in relation to markers of sensory and sympathetic fibers in a rat model of trigeminal neuropathic pain. Results: At 2 and 6 weeks after chronic constriction injury (CCI) of the mental nerve, de novo expression of NPY was seen in the trigeminal ganglia, in axons in the mental nerve, and in fibers in the upper dermis of the skin. In lesioned animals, NPY immunoreactivity was expressed primarily by large diameter mental nerve sensory neurons retrogradely labelled with Fluorogold. Many axons transported this de novo NPY to the periphery as NPY-immunoreactive (IR) fibers were seen in the mental nerve both proximal and distal to the CCI. Some of these NPY-IR axons co-expressed Neurofilament 200 (NF200), a marker for myelinated sensory fibers, and occasionally colocalization was seen in their terminals in the skin. Peptidergic and non-peptidergic C fibers expressing calcitonin gene-related peptide (CGRP) or binding isolectin B4 (IB4), respectively, never expressed NPY. CCI caused a significant de novo sprouting of sympathetic fibers into the upper dermis of the skin, and most, but not all of these fibers, expressed NPY. Conclusions: This is the first study to provide a comprehensive description of changes in NPY expression in the periphery after nerve injury. Novel expression of NPY in the skin comes mostly from sprouted sympathetic fibers. This information is fundamental in order to understand where endogenous NPY is expressed, and how it might be acting to modulate pain in the periphery.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002494</affiliation-url><afid>60002494</afid><affilname>McGill University</affilname><name-variant>McGill University</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002494</affiliation-url><afid>60002494</afid><affilname>McGill University</affilname><name-variant>McGill University</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002494</affiliation-url><afid>60002494</afid><affilname>McGill University</affilname><name-variant>McGill University</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><pubmed-id>25517376</pubmed-id><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55648629900</author-url><authid>55648629900</authid><authname>Magnussen C.</authname><surname>Magnussen</surname><given-name>Claire</given-name><initials>C.</initials><afid>60002494</afid><afid>60002494</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55648629900</author-url><authid>55648629900</authid><authname>Magnussen C.</authname><surname>Magnussen</surname><given-name>Claire</given-name><initials>C.</initials><afid>60002494</afid><afid>60002494</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56660293600</author-url><authid>56660293600</authid><authname>Hung S.</authname><surname>Hung</surname><given-name>Shih Ping</given-name><initials>S.P.</initials><afid>60002494</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006031642</author-url><authid>7006031642</authid><authname>Ribeiro-da-Silva A.</authname><surname>Ribeiro-da-Silva</surname><given-name>Alfredo</given-name><initials>A.</initials><afid>60002494</afid><afid>60002494</afid><afid>60002494</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006031642</author-url><authid>7006031642</authid><authname>Ribeiro-da-Silva A.</authname><surname>Ribeiro-da-Silva</surname><given-name>Alfredo</given-name><initials>A.</initials><afid>60002494</afid><afid>60002494</afid><afid>60002494</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006031642</author-url><authid>7006031642</authid><authname>Ribeiro-da-Silva A.</authname><surname>Ribeiro-da-Silva</surname><given-name>Alfredo</given-name><initials>A.</initials><afid>60002494</afid><afid>60002494</afid><afid>60002494</afid></author><authkeywords>CGRP | IB4 | Innervation | Mental nerve | Neuropeptide tyrosine | NF200 | NPY | Pain | Skin | Sympathetic nervous system | Trigeminal</authkeywords><intid>1536087721</intid><article-number>31</article-number><source-id>4400151515</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225015"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225015?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225015&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225015&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0013468615012244"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225015</prism:url><dc:identifier>SCOPUS_ID:84930225015</dc:identifier><eid>2-s2.0-84930225015</eid><dc:title>Functionalized multiwalled carbon nanotubes-nanostructured conducting polymer composite modified electrode for the sensitive determination of uricase inhibitor</dc:title><dc:creator>Rajalakshmi K.</dc:creator><prism:publicationName>Electrochimica Acta</prism:publicationName><prism:issn>00134686</prism:issn><prism:volume>173</prism:volume><prism:pageRange>506-514</prism:pageRange><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.electacta.2015.05.101</prism:doi><pii>S0013468615012244</pii><dc:description>Â© 2015 Elsevier Ltd. All rights reserved. The acid functionalized-multiwalled carbon nanotubes (FMWCNTs)-nanostructured 5-amino-2-mercapto-1,3,4-thiadiazole (AMT) composite film was fabricated on glassy carbon electrode (GCE) for the sensitive determination of rutin (Rut). The composite film was characterized by SEM, FT-IR, attenuated total reflectance (ATR)-FT-IR, XPS and cyclic voltammetry. The attachment of FMWCNTs on the electrode surface through amide bond formation was confirmed from the C1s peak at 287.3 eV in XPS and the band at 1681 cm&lt;sup&gt;-1&lt;/sup&gt; in ATR-FT-IR spectroscopy. The FMWCNTs-AMT composite film was then exploited for the determination of uricase inhibitor, rutin (Rut) in 0.2 M phosphate buffer solution (pH 3). The oxidation of Rut at composite electrode occurs with 30 mV less positive potential and 3.2-fold higher oxidation current when compared to bare GCE. The amperometric current response was increased linearly when Rut concentration was increased from 10-1000 nM and the detection limit was found to be 0.3 nM (S/N=3). Further, the composite modified electrode successfully determined the concentration of Rut in the presence of 250-fold higher concentration of one of the major interferents, ascorbic acid. The practical application of the present modified electrode was demonstrated by determining the concentration of Rut in tablets.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60102020</affiliation-url><afid>60102020</afid><affilname>Gandhigram Rural University</affilname><name-variant>Gandhigram Rural University</name-variant><affiliation-city>Dindigul</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55932716500</author-url><authid>55932716500</authid><authname>Rajalakshmi K.</authname><surname>Rajalakshmi</surname><given-name>K.</given-name><initials>K.</initials><afid>60102020</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24782902100</author-url><authid>24782902100</authid><authname>John S.</authname><surname>John</surname><given-name>S. Abraham</given-name><initials>S.A.</initials><afid>60102020</afid></author><authkeywords>carbon nanotube-polymer composite | covalent attachment of carbon nanotubes | Functionalized multiwalled carbon nanotubes | rutin | uricase inhibitor</authkeywords><intid>1036082721</intid><source-id>25181</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929957518"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929957518?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929957518&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929957518&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0959804913008940"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929957518</prism:url><dc:identifier>SCOPUS_ID:84929957518</dc:identifier><eid>2-s2.0-84929957518</eid><dc:title>Choosing the net survival method for cancer survival estimation</dc:title><dc:creator>SeppÃ¤ K.</dc:creator><prism:publicationName>European Journal of Cancer</prism:publicationName><prism:issn>09598049</prism:issn><prism:eIssn>18790852</prism:eIssn><prism:volume>51</prism:volume><prism:issueIdentifier>9</prism:issueIdentifier><prism:pageRange>1123-1129</prism:pageRange><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejca.2013.09.019</prism:doi><pii>S0959804913008940</pii><dc:description>Â© 2013 Elsevier Ltd. Abstract Background A new net survival method has been introduced by Pohar Perme et al. (2012 [4]) and recommended to substitute the relative survival methods in current use for evaluating population-based cancer survival. Methods The new method is based on the use of continuous follow-up time, and is unbiased only under non-informative censoring of the observed survival. However, the population-based cancer survival is often evaluated based on annually or monthly tabulated follow-up intervals. An empirical investigation based on data from the Finnish Cancer Registry was made into the practical importance of the censoring and the level of data tabulation. A systematic comparison was made against the earlier recommended Ederer II method of relative survival using the two currently available computer programs (Pohar Perme (2013) [10] and Dickman et al. (2013) [11]). Results With exact or monthly tabulated data, the Pohar-Perme and the Ederer II methods give, on average, results that are at five years of follow-up less than 0.5% units and at 10 and 14 years 1-2% units apart from each other. The Pohar-Perme net survival estimator is prone to random variation and may result in biased estimates when exact follow-up times are not available or follow-up is incomplete. With annually tabulated follow-up times, estimates can deviate substantially from those based on more accurate observations, if the actuarial approach is not used. Conclusion At 5 years, both the methods perform well. In longer follow-up, the Pohar-Perme estimates should be interpreted with caution using error margins. The actuarial approach should be preferred, if data are annually tabulated.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027400</affiliation-url><afid>60027400</afid><affilname>Finnish Cancer Registry</affilname><name-variant>Finnish Cancer Registry</name-variant><affiliation-city>Helsinki</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012954</affiliation-url><afid>60012954</afid><affilname>Oulun Yliopisto</affilname><name-variant>University of Oulu</name-variant><affiliation-city>Oulu</affiliation-city><affiliation-country>Finland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26032437200</author-url><authid>26032437200</authid><authname>SeppÃ¤ K.</authname><surname>SeppÃ¤</surname><given-name>Karri</given-name><initials>K.</initials><afid>60027400</afid><afid>60012954</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26032437200</author-url><authid>26032437200</authid><authname>SeppÃ¤ K.</authname><surname>SeppÃ¤</surname><given-name>Karri</given-name><initials>K.</initials><afid>60027400</afid><afid>60012954</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102060674</author-url><authid>7102060674</authid><authname>Hakulinen T.</authname><surname>Hakulinen</surname><given-name>Timo</given-name><initials>T.</initials><afid>60027400</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23482752200</author-url><authid>23482752200</authid><authname>Pokhrel A.</authname><surname>Pokhrel</surname><given-name>Arun</given-name><initials>A.</initials><afid>60027400</afid></author><authkeywords>Epidemiologic methods | Models | Neoplasms | Net survival | Prognosis | Relative survival</authkeywords><intid>2036037214</intid><article-number>8965</article-number><source-id>29761</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930205854"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930205854?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930205854&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930205854&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115003256"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930205854</prism:url><dc:identifier>SCOPUS_ID:84930205854</dc:identifier><eid>2-s2.0-84930205854</eid><dc:title>An extract of Artemisia dracunculus L. stimulates insulin secretion from Î² cells, activates AMPK and suppresses inflammation</dc:title><dc:creator>Aggarwal S.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>170</prism:volume><prism:pageRange>98-105</prism:pageRange><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.05.003</prism:doi><pii>S0378874115003256</pii><dc:description>Â© 2015 Elsevier Ireland Ltd. All rights reserved. Ethnopharmacological relevance Artemisia dracunculus L. (Russian tarragon) is a perennial herb belonging to the family Compositae and has a history of medicinal use in humans, particularly for treatment of diabetes. Aim of the study: In this study a defined plant extract from A. dracunculus L. (termed PMI-5011) is used to improve beta(Î²) cells function and maintain Î² cell number in pancreatic islets as an alternative drug approach for successful treatment of diabetes. Materials and methods Mouse and human pancreatic beta cells were treated with defined plant extract of A. dracunculus L. (PMI-5011) to understand the mechanism(s) that influence beta cell function and Î² cell number. Results We found that the PMI-5011 enhances insulin release from primary Î² cells, isolated mouse and human islets and it maintains Î² cell number. Insulin released by PMI-5011 is associated with the activation of AMP-activated protein kinase (AMPK), and protein kinase B (PKB). Furthermore, PMI-5011 suppresses LPS/INFÎ³-induced inflammation and inflammatory mediator(s) in macrophages. PMI-5011 inhibited Nitric oxide (NO) production and expression of inducible nitric oxide synthase (iNOS) at the protein level and also attenuated pro-inflammatory cytokine (IL-6) production in macrophages. Conclusion PMI-5011 has potential therapeutic value for diabetes treatment via increasing insulin release from Î² cells and decreases capacity of macrophages to combat inflammation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021235</affiliation-url><afid>60021235</afid><affilname>Pennington Biomedical Research Center</affilname><name-variant>Pennington Biomed. Research Center</name-variant><affiliation-city>Baton Rouge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021235</affiliation-url><afid>60021235</afid><affilname>Pennington Biomedical Research Center</affilname><name-variant>Pennington Biomed. Research Center</name-variant><affiliation-city>Baton Rouge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030623</affiliation-url><afid>60030623</afid><affilname>Rutgers, The State University of New Jersey</affilname><name-variant>Rutgers University</name-variant><affiliation-city>New Brunswick</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008578</affiliation-url><afid>60008578</afid><affilname>Henry Ford Hospital</affilname><name-variant>Henry Ford Hospital</name-variant><affiliation-city>Detroit</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7202808640</author-url><authid>7202808640</authid><authname>Aggarwal S.</authname><surname>Aggarwal</surname><given-name>Sita</given-name><initials>S.</initials><afid>60021235</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56663301200</author-url><authid>56663301200</authid><authname>Shailendra G.</authname><surname>Shailendra</surname><given-name>Giri</given-name><initials>G.</initials><afid>60005558</afid><afid>60008578</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56663301200</author-url><authid>56663301200</authid><authname>Shailendra G.</authname><surname>Shailendra</surname><given-name>Giri</given-name><initials>G.</initials><afid>60005558</afid><afid>60008578</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603628125</author-url><authid>6603628125</authid><authname>Ribnicky D.</authname><surname>Ribnicky</surname><given-name>David M.</given-name><initials>D.M.</initials><afid>60030623</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36954002800</author-url><authid>36954002800</authid><authname>Burk D.</authname><surname>Burk</surname><given-name>David</given-name><initials>D.</initials><afid>60021235</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55807144300</author-url><authid>55807144300</authid><authname>Karki N.</authname><surname>Karki</surname><given-name>Namrata</given-name><initials>N.</initials><afid>60021235</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56663164000</author-url><authid>56663164000</authid><authname>Qingxia Wang M.</authname><surname>Qingxia Wang</surname><given-name>M. S.</given-name><initials>M.S.</initials><afid>60021235</afid></author><authkeywords>Botanical(s) | Diabetes | Inflammation | Insulin secretion | Islets | Pancreatic beta (Î²) cells</authkeywords><intid>36085839</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930224912"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930224912?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930224912&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930224912&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930224912</prism:url><dc:identifier>SCOPUS_ID:84930224912</dc:identifier><eid>2-s2.0-84930224912</eid><dc:title>Bioaccessibility of the Bioactive Peptide Carnosine during in Vitro Digestion of Cured Beef Meat</dc:title><dc:creator>Marcolini E.</dc:creator><prism:publicationName>Journal of Agricultural and Food Chemistry</prism:publicationName><prism:issn>00218561</prism:issn><prism:eIssn>15205118</prism:eIssn><prism:volume>63</prism:volume><prism:issueIdentifier>20</prism:issueIdentifier><prism:pageRange>4973-4978</prism:pageRange><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1021/acs.jafc.5b01157</prism:doi><dc:description>Â© 2015 American Chemical Society. A bioactive compound is a food component that may have an impact on health. Its bioaccessibility, defined as the fraction released from the food matrix into the gastrointestinal tract during digestion, depends on compound stability, interactions with other food components, and supramolecular organization of food. In this study, the effect of pH on the bioaccessibility of the bioactive dipeptide carnosine was evaluated in two commercial samples of the Italian cured beef meat bresaola at two key points of digestion: before the gastric and after the duodenal phases. The digestion process was simulated using an in vitro static system, whereas capillary zone electrophoresis (CZE) and &lt;sup&gt;1&lt;/sup&gt;H nuclear magnetic resonance (NMR) were used for quantitative analysis. The gap between the total carnosine content, measured by CZE, and its free diffusible fraction observable by NMR spectroscopy, was 11 and 19% for two independent bresaola products, where such percentages represent the fraction of carnosine not accessible for intestinal absorption because it was adsorbed to the food matrix dispersed in the digestion fluid.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028218</affiliation-url><afid>60028218</afid><affilname>Alma Mater Studiorum Universita di Bologna</affilname><name-variant>University of Bologna</name-variant><affiliation-city>Bologna</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028218</affiliation-url><afid>60028218</afid><affilname>Alma Mater Studiorum Universita di Bologna</affilname><name-variant>University of Bologna</name-variant><affiliation-city>Bologna</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114402390</affiliation-url><afid>114402390</afid><affilname>National Agricultural Research and Innovation Center</affilname><name-variant>National Agricultural Research and Innovation Centre</name-variant><affiliation-city>Budapest</affiliation-city><affiliation-country>Hungary</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021859</affiliation-url><afid>60021859</afid><affilname>Universita degli Studi di Firenze</affilname><name-variant>UniversitÃ  di Firenze</name-variant><affiliation-city>Florence</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56148242100</author-url><authid>56148242100</authid><authname>Marcolini E.</authname><surname>Marcolini</surname><given-name>Elena</given-name><initials>E.</initials><afid>60028218</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56034897700</author-url><authid>56034897700</authid><authname>Babini E.</authname><surname>Babini</surname><given-name>Elena</given-name><initials>E.</initials><afid>60028218</afid><afid>60028218</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56034897700</author-url><authid>56034897700</authid><authname>Babini E.</authname><surname>Babini</surname><given-name>Elena</given-name><initials>E.</initials><afid>60028218</afid><afid>60028218</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56257117700</author-url><authid>56257117700</authid><authname>Bordoni A.</authname><surname>Bordoni</surname><given-name>Alessandra</given-name><initials>A.</initials><afid>60028218</afid><afid>60028218</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56257117700</author-url><authid>56257117700</authid><authname>Bordoni A.</authname><surname>Bordoni</surname><given-name>Alessandra</given-name><initials>A.</initials><afid>60028218</afid><afid>60028218</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:23093741900</author-url><authid>23093741900</authid><authname>Di Nunzio M.</authname><surname>Di Nunzio</surname><given-name>Mattia</given-name><initials>M.</initials><afid>60028218</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35885592100</author-url><authid>35885592100</authid><authname>Laghi L.</authname><surname>Laghi</surname><given-name>Luca</given-name><initials>L.</initials><afid>60028218</afid><afid>60028218</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35885592100</author-url><authid>35885592100</authid><authname>Laghi L.</authname><surname>Laghi</surname><given-name>Luca</given-name><initials>L.</initials><afid>60028218</afid><afid>60028218</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55241778500</author-url><authid>55241778500</authid><authname>MaczÃ³ A.</authname><surname>MaczÃ³</surname><given-name>Anita</given-name><initials>A.</initials><afid>114402390</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36991106300</author-url><authid>36991106300</authid><authname>Picone G.</authname><surname>Picone</surname><given-name>Gianfranco</given-name><initials>G.</initials><afid>60028218</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8978015900</author-url><authid>8978015900</authid><authname>Szerdahelyi E.</authname><surname>Szerdahelyi</surname><given-name>Emoke</given-name><initials>E.</initials><afid>114402390</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:37119401800</author-url><authid>37119401800</authid><authname>Valli V.</authname><surname>Valli</surname><given-name>Veronica</given-name><initials>V.</initials><afid>60028218</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:25934052700</author-url><authid>25934052700</authid><authname>Capozzi F.</authname><surname>Capozzi</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60028218</afid><afid>60028218</afid><afid>60021859</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:25934052700</author-url><authid>25934052700</authid><authname>Capozzi F.</authname><surname>Capozzi</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60028218</afid><afid>60028218</afid><afid>60021859</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:25934052700</author-url><authid>25934052700</authid><authname>Capozzi F.</authname><surname>Capozzi</surname><given-name>Francesco</given-name><initials>F.</initials><afid>60028218</afid><afid>60028218</afid><afid>60021859</afid></author><authkeywords>&lt;sup&gt;1&lt;/sup&gt;H NMR | bioaccessibility | bioactive compounds | bresaola | carnosine | CZE | in vitro digestion</authkeywords><intid>36086390</intid><source-id>33722</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930221966"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930221966?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930221966&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930221966&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930221966</prism:url><dc:identifier>SCOPUS_ID:84930221966</dc:identifier><eid>2-s2.0-84930221966</eid><dc:title>Nitrogen Oxide Atom-Transfer Redox Chemistry; Mechanism of NO&lt;inf&gt;(g)&lt;/inf&gt; to Nitrite Conversion Utilizing Î¼-oxo Heme-Fe&lt;sup&gt;III&lt;/sup&gt;-O-Cu&lt;sup&gt;II&lt;/sup&gt;(L) Constructs</dc:title><dc:creator>Hematian S.</dc:creator><prism:publicationName>Journal of the American Chemical Society</prism:publicationName><prism:issn>00027863</prism:issn><prism:eIssn>15205126</prism:eIssn><prism:volume>137</prism:volume><prism:issueIdentifier>20</prism:issueIdentifier><prism:pageRange>6602-6615</prism:pageRange><prism:coverDate>2015-05-27</prism:coverDate><prism:coverDisplayDate>27 May 2015</prism:coverDisplayDate><prism:doi>10.1021/jacs.5b02174</prism:doi><dc:description>Â© 2015 American Chemical Society. (Chemical Equation Presented) While nitric oxide (NO, nitrogen monoxide) is a critically important signaling agent, its cellular concentrations must be tightly controlled, generally through its oxidative conversion to nitrite (NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;) where it is held in reserve to be reconverted as needed. In part, this reaction is mediated by the binuclear heme a&lt;inf&gt;3&lt;/inf&gt;/Cu&lt;inf&gt;B&lt;/inf&gt; active site of cytochrome c oxidase. In this report, the oxidation of NO&lt;inf&gt;(g)&lt;/inf&gt; to nitrite is shown to occur efficiently in new synthetic Î¼-oxo heme-Fe&lt;sup&gt;III&lt;/sup&gt;-O-Cu&lt;sup&gt;II&lt;/sup&gt;(L) constructs (L being a tridentate or tetradentate pyridyl/alkylamino ligand), and spectroscopic and kinetic investigations provide detailed mechanistic insights. Two new X-ray structures of Î¼-oxo complexes have been determined and compared to literature analogs. All Î¼-oxo complexes react with 2 mol equiv NO&lt;inf&gt;(g)&lt;/inf&gt; to give 1:1 mixtures of discrete [(L)Cu&lt;sup&gt;II&lt;/sup&gt;(NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;)]&lt;sup&gt;+&lt;/sup&gt; plus ferrous heme-nitrosyl compounds; when the first NO&lt;inf&gt;(g)&lt;/inf&gt; equiv reduces the heme center and itself is oxidized to nitrite, the second equiv of NO&lt;inf&gt;(g)&lt;/inf&gt; traps the ferrous heme thus formed. For one Î¼-oxo heme-Fe&lt;sup&gt;III&lt;/sup&gt;-O-Cu&lt;sup&gt;II&lt;/sup&gt;(L) compound, the reaction with NO&lt;inf&gt;(g)&lt;/inf&gt; reveals an intermediate species ("intermediate"), formally a bis-NO adduct, [(NO)(porphyrinate)Fe&lt;sup&gt;II&lt;/sup&gt;-(NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;)-Cu&lt;sup&gt;II&lt;/sup&gt;(L)]&lt;sup&gt;+&lt;/sup&gt; (Î»&lt;inf&gt;max&lt;/inf&gt; = 433 nm), confirmed by cryo-spray ionization mass spectrometry and EPR spectroscopy, along with the observation that cooling a 1:1 mixture of [(L)Cu&lt;sup&gt;II&lt;/sup&gt;(NO&lt;inf&gt;2&lt;/inf&gt;&lt;sup&gt;-&lt;/sup&gt;)]&lt;sup&gt;+&lt;/sup&gt; and heme-Fe&lt;sup&gt;II&lt;/sup&gt;(NO) to -125Â°C leads to association and generation of the key 433 nm UV-vis feature. Kinetic-thermodynamic parameters obtained from low-temperature stopped-flow measurements are in excellent agreement with DFT calculations carried out which describe the sequential addition of NO&lt;inf&gt;(g)&lt;/inf&gt; to the Î¼-oxo complex.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005248</affiliation-url><afid>60005248</afid><affilname>Johns Hopkins University</affilname><name-variant>Johns Hopkins University</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000765</affiliation-url><afid>60000765</afid><affilname>Friedrich-Alexander-UniversitÃ¤t Erlangen-NÃ¼rnberg</affilname><name-variant>University of Erlangen-Nuremberg</name-variant><affiliation-city>Erlangen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55489495000</author-url><authid>55489495000</authid><authname>Hematian S.</authname><surname>Hematian</surname><given-name>Shabnam</given-name><initials>S.</initials><afid>60005248</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55926024500</author-url><authid>55926024500</authid><authname>Kenkel I.</authname><surname>Kenkel</surname><given-name>Isabell</given-name><initials>I.</initials><afid>60000765</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006054301</author-url><authid>7006054301</authid><authname>Shubina T.</authname><surname>Shubina</surname><given-name>Tatyana E.</given-name><initials>T.E.</initials><afid>60000765</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56205608800</author-url><authid>56205608800</authid><authname>DÃ¼rr M.</authname><surname>DÃ¼rr</surname><given-name>Maximilian</given-name><initials>M.</initials><afid>60000765</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56539047600</author-url><authid>56539047600</authid><authname>Liu J.</authname><surname>Liu</surname><given-name>Jeffrey J.</given-name><initials>J.J.</initials><afid>60005248</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:9233388500</author-url><authid>9233388500</authid><authname>Siegler M.</authname><surname>Siegler</surname><given-name>Maxime A.</given-name><initials>M.A.</initials><afid>60005248</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602629797</author-url><authid>6602629797</authid><authname>Ivanovic-Burmazovic I.</authname><surname>Ivanovic-Burmazovic</surname><given-name>Ivana</given-name><initials>I.</initials><afid>60000765</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:15921073500</author-url><authid>15921073500</authid><authname>Karlin K.</authname><surname>Karlin</surname><given-name>Kenneth D.</given-name><initials>K.D.</initials><afid>60005248</afid></author><intid>1036082776</intid><source-id>22680</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930203514"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930203514?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930203514&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930203514&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930203514</prism:url><dc:identifier>SCOPUS_ID:84930203514</dc:identifier><eid>2-s2.0-84930203514</eid><dc:title>Effect of carvedilol on serum heart-type fatty acid-binding protein, brain natriuretic peptide, and cardiac function in patients with chronic heart failure</dc:title><dc:creator>Sun Y.</dc:creator><prism:publicationName>Journal of Cardiovascular Pharmacology</prism:publicationName><prism:issn>01602446</prism:issn><prism:eIssn>15334023</prism:eIssn><prism:volume>65</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>480-484</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1097/FJC.0000000000000217</prism:doi><dc:description>Â© 2015 Wolters Kluwer Health, Inc. Objective: To observe the changes of serum heart-type fatty acid- binding protein (h-FABP) and brain natriuretic peptide (BNP) in children with chronic heart failure (CHF) and evaluate the effects of carvedilol. Methods: A total of 36 patients with CHF, including 17 of endocardial fibroelastosis and 19 of dilated cardiomyopathy, were enrolled and were randomly divided into a carvedilol treatment group (group A) and a conventional treatment group (group B). Group A (n = 16) was treated with carvedilol and conventional treatment and group B (n = 20) was managed with conventional treatment only. Thirty healthy children were enrolled as controls. The concentrations of serum h-FABP and BNP were measured by enzyme-linked immunosorbent assay, and the left ventricular end-systolic diameter, left ventricular end-diastolic diameter, left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS), and cardiac index (CI) were measured by echocardiography. Results: The concentrations of serum h-FABP and BNP in patients with CHF were significantly higher than in the control group (21.7 Â± 4.3 ng/mL vs. 6.3 Â± 1.7 ng/mL, 582.4 Â± 180.6 pg/mL vs.31.2 Â± 9.8 pg/mL, all P&lt;0.01), positively correlated with the degree of heart failure (all P&lt;0.01), and were both higher in groups endocardial fibroelastosis and dilated cardiomyopathy than in the control group (all P&lt;0.01), but there was no statistically significant difference between the 2 groups (P&gt;0.05). h-FABP concentration in patients with CHF was positively correlated with BNP (r = 0.78, P&lt;0.01) but negatively correlated with LVEF, LVFS, and CI (r = 20.65, 20.64, and 20.71, respectively; all P&lt;0.01). BNP concentration was also negatively correlated with LVEF, LVFS, and CI (r = 20.75, 20.61, and 20.79, respectively; all P,0.01). After treatment with carvedilol, the serum concentrations of h-FABP and BNP in group A were lower than in group B, and the magnitude of heart rate reduction, improvement of LVEF, LVFS, and CI, and reduction of left ventricular endsystolic diameter and left ventricular end-diastolic diameter in group A were all greater than in group B (all P&lt;0.01). Treatment with carvedilol had no adverse events. Conclusions: Serum concentrations of h-FABP and BNP can be used as biomarkers to evaluate the severity of heart failure, and carvedilol can significantly improve heart function in children with CHF.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105419243</affiliation-url><afid>105419243</afid><affilname>Women and Children's Hospital of Qingdao</affilname><name-variant>Women and Children's Hospital of Qingdao City</name-variant><affiliation-city>Qingdao</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55619295761</author-url><authid>55619295761</authid><authname>Sun Y.</authname><surname>Sun</surname><given-name>Yu Ping</given-name><initials>Y.P.</initials><afid>105419243</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662636100</author-url><authid>56662636100</authid><authname>Wei C.</authname><surname>Wei</surname><given-name>Chao Ping</given-name><initials>C.P.</initials><afid>105419243</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35933345100</author-url><authid>35933345100</authid><authname>Ma S.</authname><surname>Ma</surname><given-name>Shao Chun</given-name><initials>S.C.</initials><afid>105419243</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662803000</author-url><authid>56662803000</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yuan Feng</given-name><initials>Y.F.</initials><afid>105419243</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55655682600</author-url><authid>55655682600</authid><authname>Qiao L.</authname><surname>Qiao</surname><given-name>Ling Yan</given-name><initials>L.Y.</initials><afid>105419243</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662538800</author-url><authid>56662538800</authid><authname>Li D.</authname><surname>Li</surname><given-name>De Hua</given-name><initials>D.H.</initials><afid>105419243</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56662845500</author-url><authid>56662845500</authid><authname>Shan R.</authname><surname>Shan</surname><given-name>Ruo Bing</given-name><initials>R.B.</initials><afid>105419243</afid></author><authkeywords>brain natriuretic peptide | carvedilol | children | chronic | fatty acid-binding protein | heart failure | hearttype</authkeywords><intid>536086985</intid><source-id>22981</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930208303"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930208303?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930208303&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930208303&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930208303</prism:url><dc:identifier>SCOPUS_ID:84930208303</dc:identifier><eid>2-s2.0-84930208303</eid><dc:title>Torsemide versus furosemide in heart failure patients: Insights from duke university hospital</dc:title><dc:creator>Mentz R.</dc:creator><prism:publicationName>Journal of Cardiovascular Pharmacology</prism:publicationName><prism:issn>01602446</prism:issn><prism:eIssn>15334023</prism:eIssn><prism:volume>65</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>438-443</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1097/FJC.0000000000000212</prism:doi><dc:description>Â© 2015 Wolters Kluwer Health, Inc. Furosemide has historically been the primary loop diuretic in heart failure patients despite data suggesting potential advantages with torsemide. We used the Duke Echocardiography Lab Database to investigate patients admitted with heart failure to Duke Hospital from 2000 to 2010 who were discharged on either torsemide or furosemide. We described baseline characteristics based on discharge diuretic and assessed the relationship with all-cause mortality through 5 years. Of 4580 patients, 86% (n = 3955) received furosemide and 14% (n = 625) received torsemide. Patients receiving torsemide were more likely to be female and had more comorbidities compared with furosemide-treated patients. Survival was worse in torsemide-treated patients [5-year Kaplan-Meier estimated survival of 41.4% (95% CI: 36.7-46.0) vs. 51.5% (95% CI: 49.8-53.1)]. After risk adjustment, torsemide use was no longer associated with increased mortality (hazard ratio 1.16; 95% CI: 0.98-1.38; P = 0.0864). Prospective trials are needed to investigate the effect of torsemide versus furosemide because of the potential for residual confounding.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005200</affiliation-url><afid>60005200</afid><affilname>Duke University School of Medicine</affilname><name-variant>Duke University Medical Center</name-variant><affiliation-city>Durham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005200</affiliation-url><afid>60005200</afid><affilname>Duke University School of Medicine</affilname><name-variant>Duke University Medical Center</name-variant><affiliation-city>Durham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006564</affiliation-url><afid>60006564</afid><affilname>Rigshospitalet</affilname><name-variant>Copenhagen University Hospital</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36178231900</author-url><authid>36178231900</authid><authname>Mentz R.</authname><surname>Mentz</surname><given-name>Robert J.</given-name><initials>R.J.</initials><afid>60005200</afid><afid>60005200</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36178231900</author-url><authid>36178231900</authid><authname>Mentz R.</authname><surname>Mentz</surname><given-name>Robert J.</given-name><initials>R.J.</initials><afid>60005200</afid><afid>60005200</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36142697600</author-url><authid>36142697600</authid><authname>Buggey J.</authname><surname>Buggey</surname><given-name>Jonathan</given-name><initials>J.</initials><afid>60005200</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56553281400</author-url><authid>56553281400</authid><authname>Fiuzat M.</authname><surname>Fiuzat</surname><given-name>Mona</given-name><initials>M.</initials><afid>60005200</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:18433697400</author-url><authid>18433697400</authid><authname>ErsbÃll M.</authname><surname>ErsbÃll</surname><given-name>Mads K.</given-name><initials>M.K.</initials><afid>60006564</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56439078500</author-url><authid>56439078500</authid><authname>Schulte P.</authname><surname>Schulte</surname><given-name>Phillip J.</given-name><initials>P.J.</initials><afid>60005200</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36237400300</author-url><authid>36237400300</authid><authname>DeVore A.</authname><surname>DeVore</surname><given-name>Adam D.</given-name><initials>A.D.</initials><afid>60005200</afid><afid>60005200</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36237400300</author-url><authid>36237400300</authid><authname>DeVore A.</authname><surname>DeVore</surname><given-name>Adam D.</given-name><initials>A.D.</initials><afid>60005200</afid><afid>60005200</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005737383</author-url><authid>7005737383</authid><authname>Eisenstein E.</authname><surname>Eisenstein</surname><given-name>Eric L.</given-name><initials>E.L.</initials><afid>60005200</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603722548</author-url><authid>6603722548</authid><authname>Anstrom K.</authname><surname>Anstrom</surname><given-name>Kevin J.</given-name><initials>K.J.</initials><afid>60005200</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35371777500</author-url><authid>35371777500</authid><authname>O'Connor C.</authname><surname>O'Connor</surname><given-name>Christopher M.</given-name><initials>C.M.</initials><afid>60005200</afid><afid>60005200</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35371777500</author-url><authid>35371777500</authid><authname>O'Connor C.</authname><surname>O'Connor</surname><given-name>Christopher M.</given-name><initials>C.M.</initials><afid>60005200</afid><afid>60005200</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005945519</author-url><authid>7005945519</authid><authname>Velazquez E.</authname><surname>Velazquez</surname><given-name>Eric J.</given-name><initials>E.J.</initials><afid>60005200</afid><afid>60005200</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005945519</author-url><authid>7005945519</authid><authname>Velazquez E.</authname><surname>Velazquez</surname><given-name>Eric J.</given-name><initials>E.J.</initials><afid>60005200</afid><afid>60005200</afid></author><authkeywords>furosemide | heart failure | loop diuretics | torsemide</authkeywords><intid>1536087661</intid><source-id>22981</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225955"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225955?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225955&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225955&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225955</prism:url><dc:identifier>SCOPUS_ID:84930225955</dc:identifier><eid>2-s2.0-84930225955</eid><dc:title>Hospital readmissions of patients with heart failure: The Impact of Hospital and Primary Care Organizational Factors in Northern Italy</dc:title><dc:creator>Avaldi V.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0127796</prism:doi><dc:description>Â© 2015 Avaldi et al. Background: Primary health care is essential for an appropriate management of heart failure (HF), a disease which is a major clinical and public health issue and a leading cause of hospitalization. The aim of this study was to evaluate the impact of different organizational factors on readmissions of patients with HF. Methods: The study population included elderly resident in the Local Health Authority of Bologna (Northern Italy) and discharged with a diagnosis of HF from January to December 2010. Unplanned hospital readmissions were measured in four timeframes: 30 (short-term), 90 (medium-term), 180 (mid-long-term), and 365 days (long-term). Using multivariable multilevel Poisson regression analyses, we investigated the association between readmissions and organizational factors (discharge from a cardiology department, general practitioners' monodisciplinary organizational arrangement, and implementation of a specific HF care pathway). Results: The 1873 study patients had a median age of 83 years (interquartile range 77-87) and 55.5% were females; 52.0% were readmitted to the hospital for any reason after a year, while 20.1% were readmitted for HF. The presence of a HF care pathway was the only factor significantly associated with a lower risk of readmission for HF in the short-, medium-, mid-long- and long-term period (short-term: IRR [incidence rate ratio]=0.57, 95%CI [confidence interval]=0.35-0.92; medium-term: IRR=0.70, 95%CI=0.51-0.96; mid-long-term: IRR=0.79, 95%CI=0.64-0.98; long-term: IRR=0.82, 95%CI=0.67-0.99), and with a lower risk of all-cause readmission in the short-term period (IRR=0.73, 95%CI=0.57-0.94). Conclusion: Our study shows that the HF care specific pathway implemented at the primary care level was associated with lower readmission rate for HF in each timeframe, and also with lower readmission rate for all causes in the short-term period. Our results suggest that the engagement of primary care professionals starting from the early post-discharge period may be relevant in the management of patients with HF.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028218</affiliation-url><afid>60028218</afid><affilname>Alma Mater Studiorum Universita di Bologna</affilname><name-variant>University of Bologna</name-variant><affiliation-city>Bologna</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112952224</affiliation-url><afid>112952224</afid><affilname>Local Health Authority of Bologna</affilname><name-variant>Local Health Authority of Bologna</name-variant><affiliation-city>Bologna</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013263</affiliation-url><afid>60013263</afid><affilname>Ospedale Bellaria</affilname><name-variant>Ospedale Bellaria</name-variant><affiliation-city>Bologna</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033731</affiliation-url><afid>60033731</afid><affilname>Ospedale Maggiore</affilname><name-variant>Ospedale Maggiore</name-variant><affiliation-city>Bologna</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112952224</affiliation-url><afid>112952224</afid><affilname>Local Health Authority of Bologna</affilname><name-variant>Local Health Authority of Bologna</name-variant><affiliation-city>Bologna</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:102044915</affiliation-url><afid>102044915</afid><affilname>ANMCO Research Center</affilname><name-variant>ANMCO Research Center</name-variant><affiliation-city>Florence</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56313675200</author-url><authid>56313675200</authid><authname>Avaldi V.</authname><surname>Avaldi</surname><given-name>Vera Maria</given-name><initials>V.M.</initials><afid>60028218</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004467637</author-url><authid>7004467637</authid><authname>Lenzi J.</authname><surname>Lenzi</surname><given-name>Jacopo</given-name><initials>J.</initials><afid>60028218</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36503432900</author-url><authid>36503432900</authid><authname>Castaldini I.</authname><surname>Castaldini</surname><given-name>Ilaria</given-name><initials>I.</initials><afid>112952224</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004416217</author-url><authid>7004416217</authid><authname>Urbinati S.</authname><surname>Urbinati</surname><given-name>Stefano</given-name><initials>S.</initials><afid>60013263</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7007052574</author-url><authid>7007052574</authid><authname>Di Pasquale G.</authname><surname>Di Pasquale</surname><given-name>Giuseppe</given-name><initials>G.</initials><afid>60033731</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55757117700</author-url><authid>55757117700</authid><authname>Morini M.</authname><surname>Morini</surname><given-name>Mara</given-name><initials>M.</initials><afid>112952224</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36504911900</author-url><authid>36504911900</authid><authname>Protonotari A.</authname><surname>Protonotari</surname><given-name>Adalgisa</given-name><initials>A.</initials><afid>112952224</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:16072618900</author-url><authid>16072618900</authid><authname>Maggioni A.</authname><surname>Maggioni</surname><given-name>Aldo Pietro</given-name><initials>A.P.</initials><afid>102044915</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55255599200</author-url><authid>55255599200</authid><authname>Fantini M.</authname><surname>Fantini</surname><given-name>Maria Pia</given-name><initials>M.P.</initials><afid>60028218</afid></author><intid>2036082576</intid><article-number>e0127796</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929774160"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929774160?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929774160&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929774160&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929774160</prism:url><dc:identifier>SCOPUS_ID:84929774160</dc:identifier><eid>2-s2.0-84929774160</eid><dc:title>Dynamic and fluidâstructure interaction simulations of bioprosthetic heart valves using parametric design with T-splines and Fung-type material models</dc:title><dc:creator>Hsu M.</dc:creator><prism:publicationName>Computational Mechanics</prism:publicationName><prism:issn>01787675</prism:issn><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00466-015-1166-x</prism:doi><dc:description>Â© 2015 Springer-Verlag Berlin Heidelberg This paper builds on a recently developed immersogeometric fluidâstructure interaction (FSI) methodology for bioprosthetic heart valve (BHV) modeling and simulation. It enhances the proposed framework in the areas of geometry design and constitutive modeling. With these enhancements, BHV FSI simulations may be performed with greater levels of automation, robustness and physical realism. In addition, the paper presents a comparison between FSI analysis and standalone structural dynamics simulation driven by prescribed transvalvular pressure, the latter being a more common modeling choice for this class of problems. The FSI computation achieved better physiological realism in predicting the valve leaflet deformation than its standalone structural dynamics counterpart.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004354</affiliation-url><afid>60004354</afid><affilname>Iowa State University</affilname><name-variant>Iowa State University</name-variant><affiliation-city>Ames</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013372</affiliation-url><afid>60013372</afid><affilname>University of Texas at Austin</affilname><name-variant>University of Texas</name-variant><affiliation-city>Austin</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015197</affiliation-url><afid>60015197</afid><affilname>Universita degli Studi di Pavia</affilname><name-variant>UniversitÃ  di Pavia</name-variant><affiliation-city>Pavia</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030612</affiliation-url><afid>60030612</afid><affilname>University of California, San Diego</affilname><name-variant>University of California San Diego</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35100307700</author-url><authid>35100307700</authid><authname>Hsu M.</authname><surname>Hsu</surname><given-name>Ming Chen</given-name><initials>M.C.</initials><afid>60004354</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54884405300</author-url><authid>54884405300</authid><authname>Kamensky D.</authname><surname>Kamensky</surname><given-name>David</given-name><initials>D.</initials><afid>60013372</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56654632000</author-url><authid>56654632000</authid><authname>Xu F.</authname><surname>Xu</surname><given-name>Fei</given-name><initials>F.</initials><afid>60004354</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35098985900</author-url><authid>35098985900</authid><authname>Kiendl J.</authname><surname>Kiendl</surname><given-name>Josef</given-name><initials>J.</initials><afid>60015197</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56621887500</author-url><authid>56621887500</authid><authname>Wang C.</authname><surname>Wang</surname><given-name>Chenglong</given-name><initials>C.</initials><afid>60004354</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56610968800</author-url><authid>56610968800</authid><authname>Wu M.</authname><surname>Wu</surname><given-name>Michael C H</given-name><initials>M.C.H.</initials><afid>60004354</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:53866947300</author-url><authid>53866947300</authid><authname>Mineroff J.</authname><surname>Mineroff</surname><given-name>Joshua</given-name><initials>J.</initials><afid>60004354</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8398321500</author-url><authid>8398321500</authid><authname>Reali A.</authname><surname>Reali</surname><given-name>Alessandro</given-name><initials>A.</initials><afid>60015197</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:8582816900</author-url><authid>8582816900</authid><authname>Bazilevs Y.</authname><surname>Bazilevs</surname><given-name>Yuri</given-name><initials>Y.</initials><afid>60030612</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56603341000</author-url><authid>56603341000</authid><authname>Sacks M.</authname><surname>Sacks</surname><given-name>Michael S.</given-name><initials>M.S.</initials><afid>60013372</afid></author><authkeywords>Arbitrary LagrangianâEulerian | Bioprosthetic heart valve | Fluidâstructure interaction | Fung-type hyperelastic model | Immersogeometric analysis | Isogeometric analysis | KirchhoffâLove shell | NURBS and T-splines</authkeywords><intid>1536020166</intid><source-id>28457</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929172468"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929172468?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929172468&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929172468&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929172468</prism:url><dc:identifier>SCOPUS_ID:84929172468</dc:identifier><eid>2-s2.0-84929172468</eid><dc:title>Effects of prolonged head-down bed rest on working memory</dc:title><dc:creator>Liu Q.</dc:creator><prism:publicationName>Neuropsychiatric Disease and Treatment</prism:publicationName><prism:issn>11766328</prism:issn><prism:eIssn>11782021</prism:eIssn><prism:volume>11</prism:volume><prism:pageRange>835-842</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.2147/NDT.S76292</prism:doi><dc:description>Â© 2015 Liu et al. Background: The weightlessness caused by prolonged bed rest results in changes in cerebral circulation and thus, brain functions, which is of interest. Methods: We investigated the effects of 45-day, -6Â° head-down bed rest, which stimulated microgravity, on working memory in 16 healthy male participants. The 2-back task was used to test the working memory variations on the 2nd day before bed rest (R-2); on the 11th (R11), 20th (R20), 32nd (R32), and 40th (R40) days of bed rest; and on the eighth day after bed rest (R+8). The cognitive response and the physiological reactivity (such as galvanic skin response, heart rate, and heart rate variability) under the 2-back task were recorded simultaneously. Results: The results showed that compared with R-2, on the R+8, the participantsâ galvanic skin response increased significantly, and the high frequency of heart rate variability (HF), low frequency of heart rate variability (LF), and reaction time in the 2-back task decreased significantly. There were positive correlations between the participantsâ reaction time of working memory and the LF/HF under head-down bed rest (at R11, R20, and R32). Conclusion: The results suggested that the prolonged head-down bed rest may have a detrimental effect on individual physiology and working memory. Physiology indices, such as galvanic skin response and heart rate variability, were sensitive to the prolonged bed rest.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100466965</affiliation-url><afid>100466965</afid><affilname>School of Psychology</affilname><name-variant>School of Psychology</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115234596</affiliation-url><afid>115234596</afid><affilname>Research Center of Emotion Regulation</affilname><name-variant>Research Center of Emotion Regulation</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023237</affiliation-url><afid>60023237</afid><affilname>Beijing Normal University</affilname><name-variant>Beijing Normal University</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033100</affiliation-url><afid>60033100</afid><affilname>Nanjing University</affilname><name-variant>Nanjing University</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003640</affiliation-url><afid>60003640</afid><affilname>Northwest Normal University</affilname><name-variant>Northwest Normal University</name-variant><affiliation-city>Lanzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031004</affiliation-url><afid>60031004</afid><affilname>University of Queensland</affilname><name-variant>The University of Queensland</name-variant><affiliation-city>Brisbane</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56640069200</author-url><authid>56640069200</authid><authname>Liu Q.</authname><surname>Liu</surname><given-name>Qing</given-name><initials>Q.</initials><afid>100466965</afid><afid>115234596</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56640069200</author-url><authid>56640069200</authid><authname>Liu Q.</authname><surname>Liu</surname><given-name>Qing</given-name><initials>Q.</initials><afid>100466965</afid><afid>115234596</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56403850900</author-url><authid>56403850900</authid><authname>Zhou R.</authname><surname>Zhou</surname><given-name>Renlai</given-name><initials>R.</initials><afid>100466965</afid><afid>115234596</afid><afid>60023237</afid><afid>60033100</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56403850900</author-url><authid>56403850900</authid><authname>Zhou R.</authname><surname>Zhou</surname><given-name>Renlai</given-name><initials>R.</initials><afid>100466965</afid><afid>115234596</afid><afid>60023237</afid><afid>60033100</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56403850900</author-url><authid>56403850900</authid><authname>Zhou R.</authname><surname>Zhou</surname><given-name>Renlai</given-name><initials>R.</initials><afid>100466965</afid><afid>115234596</afid><afid>60023237</afid><afid>60033100</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56403850900</author-url><authid>56403850900</authid><authname>Zhou R.</authname><surname>Zhou</surname><given-name>Renlai</given-name><initials>R.</initials><afid>100466965</afid><afid>115234596</afid><afid>60023237</afid><afid>60033100</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55839372300</author-url><authid>55839372300</authid><authname>Zhao X.</authname><surname>Zhao</surname><given-name>Xin</given-name><initials>X.</initials><afid>60003640</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56641899300</author-url><authid>56641899300</authid><authname>Soei T.</authname><surname>Soei</surname><given-name>Tian Po S</given-name><initials>T.P.S.</initials><afid>60031004</afid></author><authkeywords>Galvanic skin response | Heart rate | Heart rate variability</authkeywords><intid>535918590</intid><source-id>4100151703</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225517"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225517?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225517&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225517&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225517</prism:url><dc:identifier>SCOPUS_ID:84930225517</dc:identifier><eid>2-s2.0-84930225517</eid><dc:title>Characterization of regional left ventricular function in nonhuman primates using magnetic resonance imaging biomarkers: A test-retest repeatability and inter-subject variability study</dc:title><dc:creator>Sampath S.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0127947</prism:doi><dc:description>Â© 2015 Sampath et al. Pre-clinical animal models are important to study the fundamental biological and functional mechanisms involved in the longitudinal evolution of heart failure (HF). Particularly, large animal models, like nonhuman primates (NHPs), that possess greater physiological, biochemical, and phylogenetic similarity to humans are gaining interest. To assess the translatability of these models into human diseases, imaging biomarkers play a significant role in non-invasive phenotyping, prediction of downstream remodeling, and evaluation of novel experimental therapeutics. This paper sheds insight into NHP cardiac function through the quantification of magnetic resonance (MR) imaging biomarkers that comprehensively characterize the spatiotemporal dynamics of left ventricular (LV) systolic pumping and LV diastolic relaxation. MR tagging and phase contrast (PC) imaging were used to quantify NHP cardiac strain and flow. Temporal inter-relationships between rotational mechanics, myocardial strain and LV chamber flow are presented, and functional biomarkers are evaluated through test-retest repeatability and inter subject variability analyses. The temporal trends observed in strain and flow was similar to published data in humans. Our results indicate a dominant dimension based pumping during early systole, followed by a torsion dominant pumping action during late systole. Early diastole is characterized by close to 65% of untwist, the remainder of which likely contributes to efficient filling during atrial kick. Our data reveal that moderate to good intra-subject repeatability was observed for peak strain, strain-rates, E/circumferential strain-rate (CSR) ratio, E/longitudinal strain-rate (LSR) ratio, and deceleration time. The inter-subject variability was high for strain dyssynchrony, diastolic strain-rates, peak torsion and peak untwist rate. We have successfully characterized cardiac function in NHPs using MR imaging. Peak strain, average systolic strain-rate, diastolic E/CSR and E/LSR ratios, and deceleration time were identified as robust biomarkers that could potentially be applied to future pre-clinical drug studies.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103484</affiliation-url><afid>60103484</afid><affilname>Merck Research Laboratories</affilname><name-variant>Merck Research Laboratories</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103484</affiliation-url><afid>60103484</afid><affilname>Merck Research Laboratories</affilname><name-variant>Merck Research Laboratories</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103484</affiliation-url><afid>60103484</afid><affilname>Merck Research Laboratories</affilname><name-variant>Merck Research Laboratories</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101315665</affiliation-url><afid>101315665</afid><affilname>Maccine Pte Ltd</affilname><name-variant>Maccine Pte Ltd</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017161</affiliation-url><afid>60017161</afid><affilname>National University of Singapore</affilname><name-variant>National University of Singapore</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7103194876</author-url><authid>7103194876</authid><authname>Sampath S.</authname><surname>Sampath</surname><given-name>Smita</given-name><initials>S.</initials><afid>60103484</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54894029100</author-url><authid>54894029100</authid><authname>Klimas M.</authname><surname>Klimas</surname><given-name>Michael</given-name><initials>M.</initials><afid>60103484</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56403870900</author-url><authid>56403870900</authid><authname>Feng D.</authname><surname>Feng</surname><given-name>Dai</given-name><initials>D.</initials><afid>60103484</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202309937</author-url><authid>7202309937</authid><authname>Baumgartner R.</authname><surname>Baumgartner</surname><given-name>Richard</given-name><initials>R.</initials><afid>60103484</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56404637600</author-url><authid>56404637600</authid><authname>Manigbas E.</authname><surname>Manigbas</surname><given-name>Elaine</given-name><initials>E.</initials><afid>101315665</afid><afid>60017161</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56404637600</author-url><authid>56404637600</authid><authname>Manigbas E.</authname><surname>Manigbas</surname><given-name>Elaine</given-name><initials>E.</initials><afid>101315665</afid><afid>60017161</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662769400</author-url><authid>56662769400</authid><authname>Liang A.</authname><surname>Liang</surname><given-name>Ai Leng</given-name><initials>A.L.</initials><afid>60103484</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35858165400</author-url><authid>35858165400</authid><authname>Evelhoch J.</authname><surname>Evelhoch</surname><given-name>Jeffrey L.</given-name><initials>J.L.</initials><afid>60103484</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56404034700</author-url><authid>56404034700</authid><authname>Chin C.</authname><surname>Chin</surname><given-name>Chih Liang</given-name><initials>C.L.</initials><afid>60103484</afid></author><intid>536087668</intid><article-number>e0127947</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929703373"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929703373?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929703373&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929703373&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0168927414001858"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929703373</prism:url><dc:identifier>SCOPUS_ID:84929703373</dc:identifier><eid>2-s2.0-84929703373</eid><dc:title>Parallel multilevel solvers for the cardiac electro-mechanical coupling</dc:title><dc:creator>Colli Franzone P.</dc:creator><prism:publicationName>Applied Numerical Mathematics</prism:publicationName><prism:issn>01689274</prism:issn><prism:volume>95</prism:volume><prism:pageRange>140-153</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.apnum.2014.11.002</prism:doi><pii>S0168927414001858</pii><dc:description>Â© 2014 IMACS. We develop a parallel solver for the cardiac electro-mechanical coupling. The electric model consists of two non-linear parabolic partial differential equations (PDEs), the so-called Bidomain model, which describes the spread of the electric impulse in the heart muscle. The two PDEs are coupled with a non-linear elastic model, where the myocardium is considered as a nearly-incompressible transversely isotropic hyperelastic material. The discretization of the whole electro-mechanical model is performed by Q1 finite elements in space and a semi-implicit finite difference scheme in time. This approximation strategy yields at each time step the solution of a large scale ill-conditioned linear system deriving from the discretization of the Bidomain model and a non-linear system deriving from the discretization of the finite elasticity model. The parallel solver developed consists of solving the linear system with the Conjugate Gradient method, preconditioned by a Multilevel Schwarz preconditioner, and the non-linear system with a Newton-Krylov-Algebraic Multigrid solver. Three-dimensional parallel numerical tests on a Linux cluster show that the parallel solver proposed is scalable and robust with respect to the domain deformations induced by the cardiac contraction.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015197</affiliation-url><afid>60015197</afid><affilname>Universita degli Studi di Pavia</affilname><name-variant>UniversitÃ  di Pavia</name-variant><affiliation-city>Pavia</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030318</affiliation-url><afid>60030318</afid><affilname>Universita degli Studi di Milano</affilname><name-variant>University of Milan</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7004416974</author-url><authid>7004416974</authid><authname>Colli Franzone P.</authname><surname>Colli Franzone</surname><given-name>P.</given-name><initials>P.</initials><afid>60015197</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56154224500</author-url><authid>56154224500</authid><authname>Pavarino L.</authname><surname>Pavarino</surname><given-name>L. F.</given-name><initials>L.F.</initials><afid>60030318</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:19639288300</author-url><authid>19639288300</authid><authname>Scacchi S.</authname><surname>Scacchi</surname><given-name>S.</given-name><initials>S.</initials><afid>60030318</afid></author><authkeywords>Algebraic Multigrid | Bidomain model | Cardiac electromechanics | Finite elasticity | Multilevel Schwarz preconditioners</authkeywords><intid>2035994928</intid><source-id>28067</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930210756"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930210756?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930210756&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930210756&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930210756</prism:url><dc:identifier>SCOPUS_ID:84930210756</dc:identifier><eid>2-s2.0-84930210756</eid><dc:title>Cardiac nitric oxide synthases and Na&lt;sup&gt;+&lt;/sup&gt;/K&lt;sup&gt;+&lt;/sup&gt;-ATPase in the rat model of polycystic ovary syndrome induced by dihydrotestosterone</dc:title><dc:creator>TepavÄeviÄ S.</dc:creator><prism:publicationName>Experimental and Clinical Endocrinology and Diabetes</prism:publicationName><prism:issn>09477349</prism:issn><prism:eIssn>14393646</prism:eIssn><prism:volume>123</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>303-307</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0035-1548929</prism:doi><dc:description>Â© Georg Thieme Verlag KG. Abstract Nitric oxide synthases (NOSs) and Na&lt;sup&gt;+&lt;/sup&gt;/K&lt;sup&gt;+&lt;/sup&gt;-ATPase are enzymes essential for regular functioning of the heart. Since both enzymes are under insulin and androgen regulation and since insulin action and androgen level were disturbed in polycystic ovary syndrome (PCOS), we hypothesized that cardiac nitric oxide (NO) production and sodium/potassium transport would be deteriorated in PCOS. To test our hypothesis we introduced animal model of PCOS based on dihydrotestosterone (DHT) treatment of female Wistar rats and analyzed protein expression, phosphorylation or subcellular localization of endothelial NOS (eNOS), inducible NOS (iNOS) and alpha subunits of Na&lt;sup&gt;+&lt;/sup&gt;/K&lt;sup&gt;+&lt;/sup&gt;-ATPase in the heart. Obtained results indicate that DHT treatment significantly decreased cardiac eNOS protein level and activating phosphorylation at serine 1177, while inhibitory phosphorylation at threonine 495 was increased. In contrast to expression of eNOS, iNOS protein level in the heart of DHT-treated rats was significantly elevated. Furthermore, cardiac protein level of alpha 1 subunit of the ATPase, as well as its plasma membrane content, were decreased in rats with PCOS. In line with this, alpha 2 subunit protein level in fraction of plasma membranes was also significantly below control level. In conclusion, DHT treatment impaired effectiveness of NOSs and Na&lt;sup&gt;+&lt;/sup&gt;/K&lt;sup&gt;+&lt;/sup&gt;-ATPase in the female rat heart. Regarding the importance of NO production and sodium/potassium transport in the cardiac contraction and blood flow regulation, it implicates strong consequences of PCOS for heart functioning.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068815</affiliation-url><afid>60068815</afid><affilname>University of Belgrade</affilname><name-variant>University of Belgrade</name-variant><affiliation-city>Belgrade</affiliation-city><affiliation-country>Serbia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068815</affiliation-url><afid>60068815</afid><affilname>University of Belgrade</affilname><name-variant>University of Belgrade</name-variant><affiliation-city>Belgrade</affiliation-city><affiliation-country>Serbia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068815</affiliation-url><afid>60068815</afid><affilname>University of Belgrade</affilname><name-variant>University of Belgrade</name-variant><affiliation-city>Belgrade</affiliation-city><affiliation-country>Serbia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115293787</affiliation-url><afid>115293787</afid><affilname>CHC BeÅ½anijska kosa</affilname><name-variant>CHC BeÅ½anijska kosa</name-variant><affiliation-city>Belgrade</affiliation-city><affiliation-country>Serbia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23568812800</author-url><authid>23568812800</authid><authname>TepavÄeviÄ S.</authname><surname>TepavÄeviÄ</surname><given-name>S.</given-name><initials>S.</initials><afid>60068815</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603782935</author-url><authid>6603782935</authid><authname>MilutinoviÄ D.</authname><surname>MilutinoviÄ</surname><given-name>D. V.</given-name><initials>D.V.</initials><afid>60068815</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35557111400</author-url><authid>35557111400</authid><authname>Macut D.</authname><surname>Macut</surname><given-name>D.</given-name><initials>D.</initials><afid>60068815</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56663071300</author-url><authid>56663071300</authid><authname>StaniÅ¡iÄ J.</authname><surname>StaniÅ¡iÄ</surname><given-name>J.</given-name><initials>J.</initials><afid>60068815</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55934742100</author-url><authid>55934742100</authid><authname>NikoliÄ M.</authname><surname>NikoliÄ</surname><given-name>M.</given-name><initials>M.</initials><afid>60068815</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56016978300</author-url><authid>56016978300</authid><authname>BoÅ¾iÄ-AntiÄ I.</authname><surname>BoÅ¾iÄ-AntiÄ</surname><given-name>I.</given-name><initials>I.</initials><afid>60068815</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56663156100</author-url><authid>56663156100</authid><authname>RodaljeviÄ S.</authname><surname>RodaljeviÄ</surname><given-name>S.</given-name><initials>S.</initials><afid>60068815</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:54400683700</author-url><authid>54400683700</authid><authname>BjekiÄ-Macut J.</authname><surname>BjekiÄ-Macut</surname><given-name>J.</given-name><initials>J.</initials><afid>115293787</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004010397</author-url><authid>7004010397</authid><authname>MatiÄ G.</authname><surname>MatiÄ</surname><given-name>G.</given-name><initials>G.</initials><afid>60068815</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:14040352900</author-url><authid>14040352900</authid><authname>KoriÄanac G.</authname><surname>KoriÄanac</surname><given-name>G.</given-name><initials>G.</initials><afid>60068815</afid></author><authkeywords>dihydrotestosterone | heart | Na&lt;sup&gt;+&lt;/sup&gt;/K&lt;sup&gt;+&lt;/sup&gt;-ATPase | nitric oxide synthase | polycystic ovary syndrome</authkeywords><intid>1536088038</intid><article-number>eced12-2014-0467-endo</article-number><source-id>26086</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226897"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226897?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226897&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226897&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226897</prism:url><dc:identifier>SCOPUS_ID:84930226897</dc:identifier><eid>2-s2.0-84930226897</eid><dc:title>Identification of 4-trimethylaminobutyraldehyde dehydrogenase (TMABA-DH) as a candidate serum autoantibody target for Kawasaki disease</dc:title><dc:creator>Matsunaga A.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0128189</prism:doi><dc:description>Â© 2015 Matsunaga et al. Kawasaki disease (KD), an acute vasculitis that preferentially affects coronary arteries, is still the leading cause of acquired heart disease in children. Although the involvement of immune system malfunction in the onset of KD is suggested, its etiology still remains to be clarified. We investigated autoantibodies in KD patients, which are frequently found in sera from patients with autoimmune diseases, vasculitides and arteritides. We performed two-dimensional western blotting and LC-MS/MS to analyze the antigens of autoantibodies, detected two protein spots with 4 out of 24 sera from KD patients but not with 6 control sera, and identified the antigens as 4-trimethylaminobutyraldehyde dehydrogenase (TMABA-DH). A slot blot analysis with TMABA-DH as an antigen also revealed higher reactivities of patients' sera than control sera (positive rates: 18/43 vs 3/41). Using an enzyme-linked immunosorbent assay (ELISA), we found that the reactivity of anti-TMABA-DH antibodies in sera from KD patients was significantly higher than that in sera from age-matched controls. The optimal cut-off value of 0.043 had a sensitivity of 83.7% and a specificity of 80.0% in detecting KD patients (positive rates: 37/43 for KD patients, 9/41 for controls). Immunohistochemistry performed on thin sections of rat heart revealed that TMABA-DH colocalized with myosin light chains in cardiac myocytes. Patient sera with high reactivity gave similar immunostaining pattern. These results suggest that the detection of anti-TMABA-DH auto-antibody could be a potential strategy for a diagnosis of KD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103898</affiliation-url><afid>60103898</afid><affilname>Institute of Medical Science The University of Tokyo</affilname><name-variant>University of Tokyo</name-variant><affiliation-city/><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006321</affiliation-url><afid>60006321</afid><affilname>Kitasato University</affilname><name-variant>Kitasato University</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002354</affiliation-url><afid>60002354</afid><affilname>University of Tokyo Faculty of Medicine</affilname><name-variant>University of Tokyo</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112766708</affiliation-url><afid>112766708</afid><affilname>Tokyo Metropolitan Children's Medical Center</affilname><name-variant>Tokyo Metropolitan Children's Medical Center</name-variant><affiliation-city>Fuchu</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104703</affiliation-url><afid>60104703</afid><affilname>National Center for Child Health and Development</affilname><name-variant>National Center for Child Health and Development</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008461</affiliation-url><afid>60008461</afid><affilname>Toho University School of Medicine</affilname><name-variant>Toho University School of Medicine</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">16</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662812500</author-url><authid>56662812500</authid><authname>Matsunaga A.</authname><surname>Matsunaga</surname><given-name>Atsuko</given-name><initials>A.</initials><afid>60103898</afid><afid>60006321</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662812500</author-url><authid>56662812500</authid><authname>Matsunaga A.</authname><surname>Matsunaga</surname><given-name>Atsuko</given-name><initials>A.</initials><afid>60103898</afid><afid>60006321</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35603589600</author-url><authid>35603589600</authid><authname>Harita Y.</authname><surname>Harita</surname><given-name>Yutaka</given-name><initials>Y.</initials><afid>60103898</afid><afid>60002354</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35603589600</author-url><authid>35603589600</authid><authname>Harita Y.</authname><surname>Harita</surname><given-name>Yutaka</given-name><initials>Y.</initials><afid>60103898</afid><afid>60002354</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003803911</author-url><authid>7003803911</authid><authname>Shibagaki Y.</authname><surname>Shibagaki</surname><given-name>Yoshio</given-name><initials>Y.</initials><afid>60006321</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662692900</author-url><authid>56662692900</authid><authname>Shimizu N.</authname><surname>Shimizu</surname><given-name>Nobutaka</given-name><initials>N.</initials><afid>60002354</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662749900</author-url><authid>56662749900</authid><authname>Shibuya K.</authname><surname>Shibuya</surname><given-name>Kazuhiko</given-name><initials>K.</initials><afid>112766708</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662703900</author-url><authid>56662703900</authid><authname>Ono H.</authname><surname>Ono</surname><given-name>Hiroshi</given-name><initials>H.</initials><afid>60104703</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56662625500</author-url><authid>56662625500</authid><authname>Kato H.</authname><surname>Kato</surname><given-name>Hitoshi</given-name><initials>H.</initials><afid>60104703</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56662748200</author-url><authid>56662748200</authid><authname>Sekine T.</authname><surname>Sekine</surname><given-name>Takashi</given-name><initials>T.</initials><afid>60002354</afid><afid>60008461</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56662748200</author-url><authid>56662748200</authid><authname>Sekine T.</authname><surname>Sekine</surname><given-name>Takashi</given-name><initials>T.</initials><afid>60002354</afid><afid>60008461</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56662721000</author-url><authid>56662721000</authid><authname>Sakamoto N.</authname><surname>Sakamoto</surname><given-name>Naoko</given-name><initials>N.</initials><afid>60104703</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56662717200</author-url><authid>56662717200</authid><authname>Igarashi T.</authname><surname>Igarashi</surname><given-name>Takashi</given-name><initials>T.</initials><afid>60002354</afid><afid>60104703</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56662717200</author-url><authid>56662717200</authid><authname>Igarashi T.</authname><surname>Igarashi</surname><given-name>Takashi</given-name><initials>T.</initials><afid>60002354</afid><afid>60104703</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7201924244</author-url><authid>7201924244</authid><authname>Hattori S.</authname><surname>Hattori</surname><given-name>Seisuke</given-name><initials>S.</initials><afid>60103898</afid><afid>60006321</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7201924244</author-url><authid>7201924244</authid><authname>Hattori S.</authname><surname>Hattori</surname><given-name>Seisuke</given-name><initials>S.</initials><afid>60103898</afid><afid>60006321</afid></author><intid>1536087594</intid><article-number>e0128189</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929783421"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929783421?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929783421&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929783421&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929783421</prism:url><dc:identifier>SCOPUS_ID:84929783421</dc:identifier><eid>2-s2.0-84929783421</eid><dc:title>Depression, anxiety and major adverse cardiovascular and cerebrovascular events in patients following coronary artery bypass graft surgery: A five year longitudinal cohort study</dc:title><dc:creator>Tully P.</dc:creator><prism:publicationName>BioPsychoSocial Medicine</prism:publicationName><prism:eIssn>17510759</prism:eIssn><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>May 26, 2015</prism:coverDisplayDate><prism:doi>10.1186/s13030-015-0041-5</prism:doi><dc:description>Â© 2015 Tully et al.; licensee BioMed Central. Background: Although depression and anxiety have been implicated in risk for major adverse cardiovascular and cerebrovascular events (MACCE), a theoretical approach to identifying such putative links is lacking. The objective of this study was to examine the association between theoretical conceptualisations of depression and anxiety with MACCE at the diagnostic and symptom dimension level. Methods: Before coronary artery bypass graft (CABG) surgery, patients (N = 158; 20.9 % female) underwent a structured clinical interview to determine caseness for depression and anxiety disorders. Depression and anxiety disorders were arranged into the distress cluster (major depression, dysthymia, generalized anxiety disorder, post-traumatic stress disorder) and fear cluster (panic disorder, agoraphobia, social phobia). Patients also completed the self-report Mood and Anxiety Symptom Questionnaire, measuring anhedonia, anxious arousal and general distress/negative affect symptom dimensions. Incident MACCE was defined as fatal or non-fatal; myocardial infarction, unstable angina pectoris, repeat revascularization, heart failure, sustained arrhythmia, stroke or cerebrovascular accident, left ventricular failure and mortality due to cardiac causes. Time-to-MACCE was determined by hazard modelling after adjustment for EuroSCORE, smoking, body mass index, hypertension, heart failure and peripheral vascular disease. Results: In the total sample, there were 698 cumulative person years of survival for analysis with a median follow-up of 4.6 years (interquartile range 4.2 to 5.2 years) and 37 MACCE (23.4 % of total). After covariate adjustment, generalized anxiety disorder was associated with MACCE (hazard ratio [HR] = 2.79, 95 % confidence interval [CI] 1.00-7.80, p = 0.049). The distress disorders were not significantly associated with MACCE risk (HR = 2.14; 95 % CI .92-4.95, p = 0.077) and neither were the fear-disorders (HR = 0.24, 95 % CI .05-1.20, p = 0.083). None of the symptom dimensions were significantly associated with MACCE. Conclusions: Generalized anxiety disorder was significantly associated with MACCE at follow-up after CABG surgery. The findings encourage further research pertaining to generalized anxiety disorder, and theoretical conceptualizations of depression, general distress and anxiety in persons undergoing CABG surgery.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025641</affiliation-url><afid>60025641</afid><affilname>Universitat Freiburg im Breisgau</affilname><name-variant>UniversitÃ¤t Freiburg</name-variant><affiliation-city>Freiburg im Breisgau</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009512</affiliation-url><afid>60009512</afid><affilname>University of Adelaide</affilname><name-variant>University of Adelaide</name-variant><affiliation-city>Adelaide</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020828</affiliation-url><afid>60020828</afid><affilname>Flinders University of South Australia</affilname><name-variant>Flinders University of South Australia</name-variant><affiliation-city>Adelaide</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009512</affiliation-url><afid>60009512</afid><affilname>University of Adelaide</affilname><name-variant>University of Adelaide</name-variant><affiliation-city>Adelaide</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017145</affiliation-url><afid>60017145</afid><affilname>Tilburg University</affilname><name-variant>Tilburg University</name-variant><affiliation-city>Tilburg</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019160</affiliation-url><afid>60019160</afid><affilname>Syddansk Universitet</affilname><name-variant>University of Southern Denmark</name-variant><affiliation-city>Odense</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015591</affiliation-url><afid>60015591</afid><affilname>Odense Universitetshospital</affilname><name-variant>Odense University Hospital</name-variant><affiliation-city>Odense</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032114</affiliation-url><afid>60032114</afid><affilname>Erasmus University Medical Center</affilname><name-variant>Erasmus Medical Center</name-variant><affiliation-city>Rotterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23493887200</author-url><authid>23493887200</authid><authname>Tully P.</authname><surname>Tully</surname><given-name>Phillip J.</given-name><initials>P.J.</initials><afid>60025641</afid><afid>60009512</afid><afid>60020828</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23493887200</author-url><authid>23493887200</authid><authname>Tully P.</authname><surname>Tully</surname><given-name>Phillip J.</given-name><initials>P.J.</initials><afid>60025641</afid><afid>60009512</afid><afid>60020828</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23493887200</author-url><authid>23493887200</authid><authname>Tully P.</authname><surname>Tully</surname><given-name>Phillip J.</given-name><initials>P.J.</initials><afid>60025641</afid><afid>60009512</afid><afid>60020828</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006437284</author-url><authid>7006437284</authid><authname>Winefield H.</authname><surname>Winefield</surname><given-name>Helen R.</given-name><initials>H.R.</initials><afid>60009512</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7404219718</author-url><authid>7404219718</authid><authname>Baker R.</authname><surname>Baker</surname><given-name>Robert A.</given-name><initials>R.A.</initials><afid>60020828</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004068881</author-url><authid>7004068881</authid><authname>Denollet J.</authname><surname>Denollet</surname><given-name>Johan</given-name><initials>J.</initials><afid>60017145</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7401501694</author-url><authid>7401501694</authid><authname>Pedersen S.</authname><surname>Pedersen</surname><given-name>Susanne S.</given-name><initials>S.S.</initials><afid>60019160</afid><afid>60015591</afid><afid>60032114</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7401501694</author-url><authid>7401501694</authid><authname>Pedersen S.</authname><surname>Pedersen</surname><given-name>Susanne S.</given-name><initials>S.S.</initials><afid>60019160</afid><afid>60015591</afid><afid>60032114</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7401501694</author-url><authid>7401501694</authid><authname>Pedersen S.</authname><surname>Pedersen</surname><given-name>Susanne S.</given-name><initials>S.S.</initials><afid>60019160</afid><afid>60015591</afid><afid>60032114</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7003817969</author-url><authid>7003817969</authid><authname>Wittert G.</authname><surname>Wittert</surname><given-name>Gary A.</given-name><initials>G.A.</initials><afid>60009512</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7201359601</author-url><authid>7201359601</authid><authname>Turnbull D.</authname><surname>Turnbull</surname><given-name>Deborah A.</given-name><initials>D.A.</initials><afid>60009512</afid><afid>60009512</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7201359601</author-url><authid>7201359601</authid><authname>Turnbull D.</authname><surname>Turnbull</surname><given-name>Deborah A.</given-name><initials>D.A.</initials><afid>60009512</afid><afid>60009512</afid></author><authkeywords>Cardiovascular disease | Coronary artery bypass grafts | Coronary heart disease | Depression | Generalized anxiety disorder | Prognosis | Survival analysis</authkeywords><intid>1036014564</intid><source-id>6400153136</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930205695"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930205695?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930205695&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930205695&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930205695</prism:url><dc:identifier>SCOPUS_ID:84930205695</dc:identifier><eid>2-s2.0-84930205695</eid><dc:title>Hyperpigmentation, to get to the heart of it | Hyperpigmentierungen auf den punkt gebracht</dc:title><dc:creator>Bayerl C.</dc:creator><prism:publicationName>Aktuelle Dermatologie</prism:publicationName><prism:issn>03402541</prism:issn><prism:eIssn>1438938X</prism:eIssn><prism:volume>41</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>167</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0035-1547090</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073790</affiliation-url><afid>60073790</afid><affilname>Dr. Horst Schmidt Klinik GmbH</affilname><name-variant>Dr. Horst Schmidt Klinik</name-variant><affiliation-city>Wiesbaden</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ed</subtype><subtypeDescription>Editorial</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36766384500</author-url><authid>36766384500</authid><authname>Bayerl C.</authname><surname>Bayerl</surname><given-name>C.</given-name><initials>C.</initials><afid>60073790</afid></author><intid>36085903</intid><source-id>24225</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930221722"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930221722?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930221722&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930221722&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930221722</prism:url><dc:identifier>SCOPUS_ID:84930221722</dc:identifier><eid>2-s2.0-84930221722</eid><dc:title>Translational regulation shapes the molecular landscape of complex disease phenotypes</dc:title><dc:creator>Schafer S.</dc:creator><prism:publicationName>Nature Communications</prism:publicationName><prism:eIssn>20411723</prism:eIssn><prism:volume>6</prism:volume><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1038/ncomms8200</prism:doi><pii>ncomms8200</pii><dc:description>Â© 2015 Macmillan Publishers Limited. The extent of translational control of gene expression in mammalian tissues remains largely unknown. Here we perform genome-wide RNA sequencing and ribosome profiling in heart and liver tissues to investigate strain-specific translational regulation in the spontaneously hypertensive rat (SHR/Ola). For the most part, transcriptional variation is equally apparent at the translational level and there is limited evidence of translational buffering. Remarkably, we observe hundreds of strain-specific differences in translation, almost doubling the number of differentially expressed genes. The integration of genetic, transcriptional and translational data sets reveals distinct signatures in 3â²UTR variation, RNA-binding protein motifs and miRNA expression associated with translational regulation of gene expression. We show that a large number of genes associated with heart and liver traits in human genome-wide association studies are primarily translationally regulated. Capturing interindividual differences in the translated genome will lead to new insights into the genes and regulatory pathways underlying disease phenotypes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024629</affiliation-url><afid>60024629</afid><affilname>Max Delbruck Center for Molecular Medicine</affilname><name-variant>Max Delbruck Center for Molecular Medicine</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004409</affiliation-url><afid>60004409</afid><affilname>National Heart Centre, Singapore</affilname><name-variant>National Heart Centre Singapore</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030619</affiliation-url><afid>60030619</afid><affilname>Max Planck Institute for Molecular Genetics</affilname><name-variant>Max Planck Institute for Molecular Genetics</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088737</affiliation-url><afid>60088737</afid><affilname>Institute of Physiology of the Academy of Sciences of the Czech Republic</affilname><name-variant>Institute of Physiology, Czech Academy of Sciences</name-variant><affiliation-city>Prague</affiliation-city><affiliation-country>Czech Republic</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024629</affiliation-url><afid>60024629</afid><affilname>Max Delbruck Center for Molecular Medicine</affilname><name-variant>Max Delbruck Center for Molecular Medicine</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113741391</affiliation-url><afid>113741391</afid><affilname>DZHK (German Centre for Cardiovascular Research), Partner Site Berlin</affilname><name-variant>DZHK (German Centre for Cardiovascular Research), Partner Site Berlin</name-variant><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032724</affiliation-url><afid>60032724</afid><affilname>University Medical Center Utrecht</affilname><name-variant>University Medical Center Utrecht</name-variant><affiliation-city>Utrecht</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010719</affiliation-url><afid>60010719</afid><affilname>National Heart and Lung Institute</affilname><name-variant>National Heart and Lung Institute</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017161</affiliation-url><afid>60017161</afid><affilname>National University of Singapore</affilname><name-variant>National University of Singapore</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026245</affiliation-url><afid>60026245</afid><affilname>Charite - Universitatsmedizin Berlin</affilname><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">21</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55139195500</author-url><authid>55139195500</authid><authname>Schafer S.</authname><surname>Schafer</surname><given-name>Sebastian</given-name><initials>S.</initials><afid>60024629</afid><afid>60004409</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55139195500</author-url><authid>55139195500</authid><authname>Schafer S.</authname><surname>Schafer</surname><given-name>Sebastian</given-name><initials>S.</initials><afid>60024629</afid><afid>60004409</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56310197300</author-url><authid>56310197300</authid><authname>Adami E.</authname><surname>Adami</surname><given-name>Eleonora</given-name><initials>E.</initials><afid>60024629</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24166551900</author-url><authid>24166551900</authid><authname>Heinig M.</authname><surname>Heinig</surname><given-name>Matthias</given-name><initials>M.</initials><afid>60024629</afid><afid>60030619</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24166551900</author-url><authid>24166551900</authid><authname>Heinig M.</authname><surname>Heinig</surname><given-name>Matthias</given-name><initials>M.</initials><afid>60024629</afid><afid>60030619</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662853100</author-url><authid>56662853100</authid><authname>Rodrigues K.</authname><surname>Rodrigues</surname><given-name>Katharina E Costa</given-name><initials>K.E.C.</initials><afid>60024629</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:37074906400</author-url><authid>37074906400</authid><authname>Kreuchwig F.</authname><surname>Kreuchwig</surname><given-name>Franziska</given-name><initials>F.</initials><afid>60024629</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:37095945800</author-url><authid>37095945800</authid><authname>Silhavy J.</authname><surname>Silhavy</surname><given-name>Jan</given-name><initials>J.</initials><afid>60088737</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:24167489500</author-url><authid>24167489500</authid><authname>Van Heesch S.</authname><surname>Van Heesch</surname><given-name>Sebastiaan</given-name><initials>S.</initials><afid>60024629</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55668078800</author-url><authid>55668078800</authid><authname>Simaite D.</authname><surname>Simaite</surname><given-name>Deimante</given-name><initials>D.</initials><afid>60024629</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6701538795</author-url><authid>6701538795</authid><authname>Rajewsky N.</authname><surname>Rajewsky</surname><given-name>Nikolaus</given-name><initials>N.</initials><afid>60024629</afid><afid>113741391</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6701538795</author-url><authid>6701538795</authid><authname>Rajewsky N.</authname><surname>Rajewsky</surname><given-name>Nikolaus</given-name><initials>N.</initials><afid>60024629</afid><afid>113741391</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6602072918</author-url><authid>6602072918</authid><authname>Cuppen E.</authname><surname>Cuppen</surname><given-name>Edwin</given-name><initials>E.</initials><afid>60032724</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7007016265</author-url><authid>7007016265</authid><authname>Pravenec M.</authname><surname>Pravenec</surname><given-name>Michal</given-name><initials>M.</initials><afid>60088737</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:55251970500</author-url><authid>55251970500</authid><authname>Vingron M.</authname><surname>Vingron</surname><given-name>Martin</given-name><initials>M.</initials><afid>60030619</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56662704100</author-url><authid>56662704100</authid><authname>Cook S.</authname><surname>Cook</surname><given-name>Stuart A.</given-name><initials>S.A.</initials><afid>60004409</afid><afid>60010719</afid><afid>60017161</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56662704100</author-url><authid>56662704100</authid><authname>Cook S.</authname><surname>Cook</surname><given-name>Stuart A.</given-name><initials>S.A.</initials><afid>60004409</afid><afid>60010719</afid><afid>60017161</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56662704100</author-url><authid>56662704100</authid><authname>Cook S.</authname><surname>Cook</surname><given-name>Stuart A.</given-name><initials>S.A.</initials><afid>60004409</afid><afid>60010719</afid><afid>60017161</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7003749232</author-url><authid>7003749232</authid><authname>Hubner N.</authname><surname>Hubner</surname><given-name>Norbert</given-name><initials>N.</initials><afid>60024629</afid><afid>113741391</afid><afid>60026245</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7003749232</author-url><authid>7003749232</authid><authname>Hubner N.</authname><surname>Hubner</surname><given-name>Norbert</given-name><initials>N.</initials><afid>60024629</afid><afid>113741391</afid><afid>60026245</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7003749232</author-url><authid>7003749232</authid><authname>Hubner N.</authname><surname>Hubner</surname><given-name>Norbert</given-name><initials>N.</initials><afid>60024629</afid><afid>113741391</afid><afid>60026245</afid></author><intid>1536087514</intid><article-number>7200</article-number><source-id>19700182758</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930077162"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930077162?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930077162&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930077162&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930077162</prism:url><dc:identifier>SCOPUS_ID:84930077162</dc:identifier><eid>2-s2.0-84930077162</eid><dc:title>Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy</dc:title><dc:creator>Dean J.</dc:creator><prism:publicationName>Nature Reviews Cardiology</prism:publicationName><prism:issn>17595002</prism:issn><prism:eIssn>17595010</prism:eIssn><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1038/nrcardio.2015.72</prism:doi><pii>nrcardio.2015.72</pii><dc:description>Â© 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. Cardiovascular disease is the leading cause of death worldwide. In the presence of signs and symptoms of myocardial ischaemia, women are more likely than men to have no obstructive coronary artery disease (CAD). Women have a greater burden of symptoms than men, and are often falsely reassured despite the presence of ischaemic heart disease because of a lack of obstructive CAD. Coronary microvascular dysfunction should be considered as an aetiology for ischaemic heart disease with signs and symptoms of myocardial ischaemia, but no obstructive CAD. Coronary microvascular dysfunction is defined as impaired coronary flow reserve owing to functional and/or structural abnormalities of the microcirculation, and is associated with an adverse cardiovascular prognosis. Therapeutic lifestyle changes as well as antiatherosclerotic and antianginal medications might be beneficial, but clinical outcome trials are needed to guide treatment. In this Review, we discuss the prevalence, presentation, diagnosis, and treatment of coronary microvascular dysfunction, with a particular emphasis on ischaemic heart disease in women.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112591008</affiliation-url><afid>112591008</afid><affilname>Sinai Medical Center</affilname><name-variant>Cedats-Sinai Medical Center</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56660297300</author-url><authid>56660297300</authid><authname>Dean J.</authname><surname>Dean</surname><given-name>Jenna</given-name><initials>J.</initials><afid>112591008</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56660390700</author-url><authid>56660390700</authid><authname>Cruz S.</authname><surname>Cruz</surname><given-name>Sherwin Dela</given-name><initials>S.D.</initials><afid>112591008</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56660295800</author-url><authid>56660295800</authid><authname>Mehta P.</authname><surname>Mehta</surname><given-name>Puja K.</given-name><initials>P.K.</initials><afid>112591008</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56660437200</author-url><authid>56660437200</authid><authname>Merz C.</authname><surname>Merz</surname><given-name>C. Noel Bairey</given-name><initials>C.N.B.</initials><afid>112591008</afid></author><intid>1786062089</intid><source-id>17700156509</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930227316"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930227316?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930227316&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930227316&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930227316</prism:url><dc:identifier>SCOPUS_ID:84930227316</dc:identifier><eid>2-s2.0-84930227316</eid><dc:title>Critical appraisal of bivalirudin versus heparin for percutaneous coronary intervention: A meta-analysis of randomized trials</dc:title><dc:creator>Bavry A.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0127832</prism:doi><dc:description>Â© 2015, Public Library of Science. All rights reserved. Percutaneous coronary intervention with bivalirudin plus bail-out glycoprotein IIb/IIIa inhibitors has been shown to be as effective as unfractionated heparin plus routine glycoprotein IIb/IIIa inhibitors in preventing cardiac ischemic events, but with a lower bleeding risk. It is unknown whether bivalirudin would have the same beneficial effects if compared with heparin when the use of glycoprotein IIb/IIIa inhibitors was similar between treatment arms. We searched the MEDLINE, Web of Science, and Cochrane databases from inception until March 2015 for randomized trials that compared bivalirudin to heparin in patients undergoing percutaneous coronary intervention. We required that the intended use of glycoprotein IIb/IIIa inhibitors was similar between the study groups. Summary estimates were principally constructed by the Peto method. Fifteen trials met our inclusion criteria, which yielded 25,824 patients. Bivalirudin versus heparin was associated with an increased hazard of stent thrombosis (odds ratio [OR] 1.49, 95% confidence interval [CI] 1.15-1.92, P = .002, I&lt;sup&gt;2&lt;/sup&gt; = 16.9%), with a similar hazard of myocardial infarction (OR 1.09, 95% CI 0.98-1.22, P = .11, I&lt;sup&gt;2&lt;/sup&gt; = 35.8%), all-cause mortality (OR 0.88, 95% CI 0.72-1.08, P = .21, I&lt;sup&gt;2&lt;/sup&gt; = 31.5%) and major adverse cardiac events (OR 1.04, 95% CI 0.94-1.14, P = .46, I&lt;sup&gt;2&lt;/sup&gt; = 53.9%). Bivalirudin was associated with a reduced hazard of major bleeding (OR 0.80, 95% CI 0.70-0.92, P = .001, I&lt;sup&gt;2&lt;/sup&gt; = 63.5%). The dose of heparin in the control arm modified this association; when the dose of unfractionated heparin in the control arm was â¥ 100 units/kg, bivalirudin was associated with a reduction in major bleeding (OR 0.55, 95% CI 0.45-0.68, P &lt; .0001), but when the dose of unfractionated heparin was â¤ 75 units/kg, bivalirudin was not associated with reduction in bleeding (OR 1.09, 95% CI 0.91-1.31, P = .36). Among patients undergoing PCI, bivalirudin was associated with an increased hazard of stent thrombosis. Bivalirudin may be associated with a reduced hazard of major bleeding; however, this benefit was no longer apparent when compared with a dose of unfractionated heparin â¤ 75 units/kg.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014232</affiliation-url><afid>60014232</afid><affilname>VA Medical Center</affilname><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013959</affiliation-url><afid>60013959</afid><affilname>University of Florida</affilname><name-variant>University of Florida</name-variant><affiliation-city>Gainesville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603002274</author-url><authid>6603002274</authid><authname>Bavry A.</authname><surname>Bavry</surname><given-name>Anthony A.</given-name><initials>A.A.</initials><afid>60014232</afid><afid>60013959</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6603002274</author-url><authid>6603002274</authid><authname>Bavry A.</authname><surname>Bavry</surname><given-name>Anthony A.</given-name><initials>A.A.</initials><afid>60014232</afid><afid>60013959</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56022050500</author-url><authid>56022050500</authid><authname>Elgendy I.</authname><surname>Elgendy</surname><given-name>Islam Y.</given-name><initials>I.Y.</initials><afid>60013959</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56089937700</author-url><authid>56089937700</authid><authname>Mahmoud A.</authname><surname>Mahmoud</surname><given-name>Ahmed</given-name><initials>A.</initials><afid>60013959</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56336982300</author-url><authid>56336982300</authid><authname>Jadhav M.</authname><surname>Jadhav</surname><given-name>Manoj P.</given-name><initials>M.P.</initials><afid>60013959</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56579890300</author-url><authid>56579890300</authid><authname>Huo T.</authname><surname>Huo</surname><given-name>Tianyao</given-name><initials>T.</initials><afid>60013959</afid></author><intid>1786087253</intid><article-number>e0127832</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930224849"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930224849?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930224849&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930224849&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930224849</prism:url><dc:identifier>SCOPUS_ID:84930224849</dc:identifier><eid>2-s2.0-84930224849</eid><dc:title>Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes</dc:title><dc:creator>Kuppusamy K.</dc:creator><prism:publicationName>Proceedings of the National Academy of Sciences of the United States of America</prism:publicationName><prism:issn>00278424</prism:issn><prism:eIssn>10916490</prism:eIssn><prism:volume>112</prism:volume><prism:issueIdentifier>21</prism:issueIdentifier><prism:pageRange>E2785-E2794</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1073/pnas.1424042112</prism:doi><dc:description>Â© 2015, National Academy of Sciences. All rights reserved. In metazoans, transition from fetal to adult heart is accompanied by a switch in energy metabolism-glycolysis to fatty acid oxidation. The molecular factors regulating this metabolic switch remain largely unexplored. We first demonstrate that the molecular signatures in 1-year (y) matured human embryonic stem cell-derived cardiomyocytes (hESC-CMs) are similar to those seen in in vivo-derived mature cardiac tissues, thus making them an excellent model to study human cardiac maturation. We further show that let-7 is the most highly up-regulated microRNA (miRNA) family during in vitro human cardiac maturation. Gain- and loss-of-function analyses of let-7g in hESC-CMs demonstrate it is both required and sufficient for maturation, but not for early differentiation of CMs. Overexpression of let-7 family members in hESC-CMs enhances cell size, sarcomere length, force of contraction, and respiratory capacity. Interestingly, large-scale expression data, target analysis, and metabolic flux assays suggest this let-7-driven CM maturation could be a result of down-regulation of the phosphoinositide 3 kinase (PI3K)/AKT protein kinase/insulin pathway and an up-regulation of fatty acid metabolism. These results indicate let-7 is an important mediator in augmenting metabolic energetics in maturing CMs. Promoting maturation of hESC-CMs with let-7 overexpression will be highly significant for basic and applied research.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109288063</affiliation-url><afid>109288063</afid><affilname>Institute for Stem Cell and Regenerative Medicine</affilname><name-variant>Institute of Stem Cell and Regenerative Medicine</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015481</affiliation-url><afid>60015481</afid><affilname>University of Washington Seattle</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015481</affiliation-url><afid>60015481</afid><affilname>University of Washington Seattle</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015481</affiliation-url><afid>60015481</afid><affilname>University of Washington Seattle</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115293541</affiliation-url><afid>115293541</afid><affilname>LabCorp Genomic Services</affilname><name-variant>LabCorp Genomic Services</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015481</affiliation-url><afid>60015481</afid><affilname>University of Washington Seattle</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015481</affiliation-url><afid>60015481</afid><affilname>University of Washington Seattle</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015481</affiliation-url><afid>60015481</afid><affilname>University of Washington Seattle</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015481</affiliation-url><afid>60015481</afid><affilname>University of Washington Seattle</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015481</affiliation-url><afid>60015481</afid><affilname>University of Washington Seattle</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003625</affiliation-url><afid>60003625</afid><affilname>Fred Hutchinson Cancer Research Center</affilname><name-variant>Fred Hutchinson Cancer Research Center</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015481</affiliation-url><afid>60015481</afid><affilname>University of Washington Seattle</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015481</affiliation-url><afid>60015481</afid><affilname>University of Washington Seattle</affilname><name-variant>University of Washington</name-variant><affiliation-city>Seattle</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">40</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8553714100</author-url><authid>8553714100</authid><authname>Kuppusamy K.</authname><surname>Kuppusamy</surname><given-name>Kavitha T.</given-name><initials>K.T.</initials><afid>109288063</afid><afid>60015481</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8553714100</author-url><authid>8553714100</authid><authname>Kuppusamy K.</authname><surname>Kuppusamy</surname><given-name>Kavitha T.</given-name><initials>K.T.</initials><afid>109288063</afid><afid>60015481</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662589000</author-url><authid>56662589000</authid><authname>Jones D.</authname><surname>Jones</surname><given-name>Daniel C.</given-name><initials>D.C.</initials><afid>60015481</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55818448600</author-url><authid>55818448600</authid><authname>Sperber H.</authname><surname>Sperber</surname><given-name>Henrik</given-name><initials>H.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55818448600</author-url><authid>55818448600</authid><authname>Sperber H.</authname><surname>Sperber</surname><given-name>Henrik</given-name><initials>H.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55818448600</author-url><authid>55818448600</authid><authname>Sperber H.</authname><surname>Sperber</surname><given-name>Henrik</given-name><initials>H.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662785300</author-url><authid>56662785300</authid><authname>Madan A.</authname><surname>Madan</surname><given-name>Anup</given-name><initials>A.</initials><afid>115293541</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56214963300</author-url><authid>56214963300</authid><authname>Fischer K.</authname><surname>Fischer</surname><given-name>Karin A.</given-name><initials>K.A.</initials><afid>109288063</afid><afid>60015481</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56214963300</author-url><authid>56214963300</authid><authname>Fischer K.</authname><surname>Fischer</surname><given-name>Karin A.</given-name><initials>K.A.</initials><afid>109288063</afid><afid>60015481</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7404259382</author-url><authid>7404259382</authid><authname>Rodriguez M.</authname><surname>Rodriguez</surname><given-name>Marita L.</given-name><initials>M.L.</initials><afid>60015481</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:13105276800</author-url><authid>13105276800</authid><authname>Pabon L.</authname><surname>Pabon</surname><given-name>Lil</given-name><initials>L.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:13105276800</author-url><authid>13105276800</authid><authname>Pabon L.</authname><surname>Pabon</surname><given-name>Lil</given-name><initials>L.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:13105276800</author-url><authid>13105276800</authid><authname>Pabon L.</authname><surname>Pabon</surname><given-name>Lil</given-name><initials>L.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:14069349700</author-url><authid>14069349700</authid><authname>Zhu W.</authname><surname>Zhu</surname><given-name>Wei Zhong</given-name><initials>W.Z.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:14069349700</author-url><authid>14069349700</authid><authname>Zhu W.</authname><surname>Zhu</surname><given-name>Wei Zhong</given-name><initials>W.Z.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:14069349700</author-url><authid>14069349700</authid><authname>Zhu W.</authname><surname>Zhu</surname><given-name>Wei Zhong</given-name><initials>W.Z.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:24577882500</author-url><authid>24577882500</authid><authname>Tulloch N.</authname><surname>Tulloch</surname><given-name>Nathaniel L.</given-name><initials>N.L.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:24577882500</author-url><authid>24577882500</authid><authname>Tulloch N.</authname><surname>Tulloch</surname><given-name>Nathaniel L.</given-name><initials>N.L.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:24577882500</author-url><authid>24577882500</authid><authname>Tulloch N.</authname><surname>Tulloch</surname><given-name>Nathaniel L.</given-name><initials>N.L.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56040320600</author-url><authid>56040320600</authid><authname>Yang X.</authname><surname>Yang</surname><given-name>Xiulan</given-name><initials>X.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56040320600</author-url><authid>56040320600</authid><authname>Yang X.</authname><surname>Yang</surname><given-name>Xiulan</given-name><initials>X.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56040320600</author-url><authid>56040320600</authid><authname>Yang X.</authname><surname>Yang</surname><given-name>Xiulan</given-name><initials>X.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:8623695500</author-url><authid>8623695500</authid><authname>Sniadecki N.</authname><surname>Sniadecki</surname><given-name>Nathan J.</given-name><initials>N.J.</initials><afid>60015481</afid><afid>60015481</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:8623695500</author-url><authid>8623695500</authid><authname>Sniadecki N.</authname><surname>Sniadecki</surname><given-name>Nathan J.</given-name><initials>N.J.</initials><afid>60015481</afid><afid>60015481</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004526895</author-url><authid>7004526895</authid><authname>Laflamme M.</authname><surname>Laflamme</surname><given-name>Michael A.</given-name><initials>M.A.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004526895</author-url><authid>7004526895</authid><authname>Laflamme M.</authname><surname>Laflamme</surname><given-name>Michael A.</given-name><initials>M.A.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004526895</author-url><authid>7004526895</authid><authname>Laflamme M.</authname><surname>Laflamme</surname><given-name>Michael A.</given-name><initials>M.A.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7003704899</author-url><authid>7003704899</authid><authname>Ruzzo W.</authname><surname>Ruzzo</surname><given-name>Walter L.</given-name><initials>W.L.</initials><afid>60015481</afid><afid>60015481</afid><afid>60003625</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7003704899</author-url><authid>7003704899</authid><authname>Ruzzo W.</authname><surname>Ruzzo</surname><given-name>Walter L.</given-name><initials>W.L.</initials><afid>60015481</afid><afid>60015481</afid><afid>60003625</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7003704899</author-url><authid>7003704899</authid><authname>Ruzzo W.</authname><surname>Ruzzo</surname><given-name>Walter L.</given-name><initials>W.L.</initials><afid>60015481</afid><afid>60015481</afid><afid>60003625</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7006341337</author-url><authid>7006341337</authid><authname>Murry C.</authname><surname>Murry</surname><given-name>Charles E.</given-name><initials>C.E.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7006341337</author-url><authid>7006341337</authid><authname>Murry C.</authname><surname>Murry</surname><given-name>Charles E.</given-name><initials>C.E.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7006341337</author-url><authid>7006341337</authid><authname>Murry C.</authname><surname>Murry</surname><given-name>Charles E.</given-name><initials>C.E.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7006341337</author-url><authid>7006341337</authid><authname>Murry C.</authname><surname>Murry</surname><given-name>Charles E.</given-name><initials>C.E.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7006341337</author-url><authid>7006341337</authid><authname>Murry C.</authname><surname>Murry</surname><given-name>Charles E.</given-name><initials>C.E.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:6603939302</author-url><authid>6603939302</authid><authname>Ruohola-Baker H.</authname><surname>Ruohola-Baker</surname><given-name>Hannele</given-name><initials>H.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:6603939302</author-url><authid>6603939302</authid><authname>Ruohola-Baker H.</authname><surname>Ruohola-Baker</surname><given-name>Hannele</given-name><initials>H.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:6603939302</author-url><authid>6603939302</authid><authname>Ruohola-Baker H.</authname><surname>Ruohola-Baker</surname><given-name>Hannele</given-name><initials>H.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:6603939302</author-url><authid>6603939302</authid><authname>Ruohola-Baker H.</authname><surname>Ruohola-Baker</surname><given-name>Hannele</given-name><initials>H.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:6603939302</author-url><authid>6603939302</authid><authname>Ruohola-Baker H.</authname><surname>Ruohola-Baker</surname><given-name>Hannele</given-name><initials>H.</initials><afid>109288063</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid><afid>60015481</afid></author><authkeywords>Cardiac maturation | HESC-cardiomyocyte | Let-7 | Metabolism | MicroRNA</authkeywords><intid>1036081722</intid><source-id>21121</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930221872"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930221872?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930221872&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930221872&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930221872</prism:url><dc:identifier>SCOPUS_ID:84930221872</dc:identifier><eid>2-s2.0-84930221872</eid><dc:title>Association of leisure-time physical activity to cardiovascular disease prevalence in relation to smoking among adult Nevadans</dc:title><dc:creator>Teramoto M.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0128424</prism:doi><dc:description>Â© 2015 Teramoto et al. It is well known that cigarette smoking and physical activity have significant impacts on cardiovascular disease (CVD) mortality and morbidity. Meanwhile, it is of interest to understand whether physical activity protects against CVD for smokers in a similar manner as it does for non-smokers. The present study examined how leisure-time physical activity (LTPA) is associated with the prevalence of CVD in relation to smoking status among adult Nevadans, using data from the 2010 Nevada Behavioral Risk Factor Surveillance System. Of the 3,913 survey respondents, 8.5% self-reported that they had ever been diagnosed with CVD. People with a history of CVD were significantly less likely to engage in LTPA than those with no history of CVD (p &lt; 0.05). After adjusting for common sociodemographic variables, it was revealed that people with CVD were twice more likely to not engage in LTPA than their counterparts independent of smoking status. Without taking LTPA into account, the odds of having CVD for current and former smokers was 1.87-2.25 times higher than the odds for non-smokers. Interestingly, however, if LTPA was accounted for, there was no significant difference in the odds of having CVD between current and non-smokers. These results indicate that LTPA is inversely associated with the prevalence of CVD independent of smoking status, and that regular physical activity may protect against CVD for smokers as well as for non-smokers. Physical activity, along with smoking cessation, should be promoted to better prevent and control CVD among smokers.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025488</affiliation-url><afid>60025488</afid><affilname>University of Utah</affilname><name-variant>University of Utah</name-variant><affiliation-city>Salt Lake City</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031892</affiliation-url><afid>60031892</afid><affilname>University of Nevada, Las Vegas</affilname><name-variant>University of Nevada</name-variant><affiliation-city>Las Vegas</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008165</affiliation-url><afid>60008165</afid><affilname>Nevada State College</affilname><name-variant>Nevada State College</name-variant><affiliation-city>Henderson</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031892</affiliation-url><afid>60031892</afid><affilname>University of Nevada, Las Vegas</affilname><name-variant>University of Nevada</name-variant><affiliation-city>Las Vegas</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24377067900</author-url><authid>24377067900</authid><authname>Teramoto M.</authname><surname>Teramoto</surname><given-name>Masaru</given-name><initials>M.</initials><afid>60025488</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8433936500</author-url><authid>8433936500</authid><authname>Moonie S.</authname><surname>Moonie</surname><given-name>Sheniz</given-name><initials>S.</initials><afid>60031892</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662785500</author-url><authid>56662785500</authid><authname>Cross C.</authname><surname>Cross</surname><given-name>Chad L.</given-name><initials>C.L.</initials><afid>60008165</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662841400</author-url><authid>56662841400</authid><authname>Chino M.</authname><surname>Chino</surname><given-name>Michelle</given-name><initials>M.</initials><afid>60031892</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005395293</author-url><authid>7005395293</authid><authname>Alpert P.</authname><surname>Alpert</surname><given-name>Patricia T.</given-name><initials>P.T.</initials><afid>60031892</afid></author><intid>2036081611</intid><article-number>e0128424</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226410"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226410?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226410&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226410&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226410</prism:url><dc:identifier>SCOPUS_ID:84930226410</dc:identifier><eid>2-s2.0-84930226410</eid><dc:title>Cardiac-specific SOCS3 deletion prevents in vivo myocardial ischemia reperfusion injury through sustained activation of cardioprotective signaling molecules</dc:title><dc:creator>Nagata T.</dc:creator><prism:publicationName>PLoS ONE</prism:publicationName><prism:eIssn>19326203</prism:eIssn><prism:volume>10</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1371/journal.pone.0127942</prism:doi><dc:description>Â© 2015 Nagata et al. Myocardial ischemia reperfusion injury (IRI) adversely affects cardiac performance and the prognosis of patients with acute myocardial infarction. Although myocardial signal transducer and activator of transcription (STAT) 3 is potently cardioprotective during IRI, the inhibitory mechanism responsible for its activation is largely unknown. The present study aimed to investigate the role of the myocardial suppressor of cytokine signaling (SOCS)-3, an intrinsic negative feedback regulator of the Janus kinase (JAK)-STAT signaling pathway, in the development of myocardial IRI. Myocardial IRI was induced in mice by ligating the left anterior descending coronary artery for 1 h, followed by different reperfusion times. One hour after reperfusion, the rapid expression of JAK-STAT-activating cytokines was observed. We precisely evaluated the phosphorylation of cardioprotective signaling molecules and the expression of SOCS3 during IRI and then induced myocardial IRI in wild-type and cardiac-specific SOCS3 knockout mice (SOCS3-CKO). The activation of STAT3, AKT, and ERK1/2 rapidly peaked and promptly decreased during IRI. This decrease correlated with the induction of SOCS3 expression up to 24 h after IRI in wild-type mice. The infarct size 24 h after reperfusion was significantly reduced in SOCS3-CKO compared with wild-type mice. In SOCS3-CKO mice, STAT3, AKT, and ERK1/2 phosphorylation was sustained, myocardial apoptosis was prevented, and the expression of anti-apoptotic Bcl-2 family member myeloid cell leukemia-1 (Mcl-1) was augmented. Cardiac-specific SOCS3 deletion led to the sustained activation of cardioprotective signaling molecules including and prevented myocardial apoptosis and injury during IRI. Our findings suggest that SOCS3 may represent a key factor that exacerbates the development of myocardial IRI.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001377</affiliation-url><afid>60001377</afid><affilname>Kurume University School of Medicine</affilname><name-variant>Kurume Univ. Sch. Med.</name-variant><affiliation-city>Kurume</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022116</affiliation-url><afid>60022116</afid><affilname>Kurume University</affilname><name-variant>Kurume University</name-variant><affiliation-city>Kurume</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000239</affiliation-url><afid>60000239</afid><affilname>Universitat Lausanne Schweiz</affilname><name-variant>University of Lausanne</name-variant><affiliation-city>Lausanne</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030612</affiliation-url><afid>60030612</afid><affilname>University of California, San Diego</affilname><name-variant>University of California San Diego</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024740</affiliation-url><afid>60024740</afid><affilname>International University of Health and Welfare</affilname><name-variant>International University of Health and Welfare</name-variant><affiliation-city>Otawara</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">17</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55013432100</author-url><authid>55013432100</authid><authname>Nagata T.</authname><surname>Nagata</surname><given-name>Takanobu</given-name><initials>T.</initials><afid>60001377</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004370193</author-url><authid>7004370193</authid><authname>Yasukawa H.</authname><surname>Yasukawa</surname><given-name>Hideo</given-name><initials>H.</initials><afid>60001377</afid><afid>60022116</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004370193</author-url><authid>7004370193</authid><authname>Yasukawa H.</authname><surname>Yasukawa</surname><given-name>Hideo</given-name><initials>H.</initials><afid>60001377</afid><afid>60022116</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55319190800</author-url><authid>55319190800</authid><authname>Kyogoku S.</authname><surname>Kyogoku</surname><given-name>Sachiko</given-name><initials>S.</initials><afid>60001377</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:37038320300</author-url><authid>37038320300</authid><authname>Oba T.</authname><surname>Oba</surname><given-name>Toyoharu</given-name><initials>T.</initials><afid>60001377</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662716700</author-url><authid>56662716700</authid><authname>Takahashi J.</authname><surname>Takahashi</surname><given-name>Jinya</given-name><initials>J.</initials><afid>60001377</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662853400</author-url><authid>56662853400</authid><authname>Nohara S.</authname><surname>Nohara</surname><given-name>Shoichiro</given-name><initials>S.</initials><afid>60001377</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55011853700</author-url><authid>55011853700</authid><authname>Minami T.</authname><surname>Minami</surname><given-name>Tomoko</given-name><initials>T.</initials><afid>60001377</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56268192100</author-url><authid>56268192100</authid><authname>Mawatari K.</authname><surname>Mawatari</surname><given-name>Kazutoshi</given-name><initials>K.</initials><afid>60001377</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7005318502</author-url><authid>7005318502</authid><authname>Sugi Y.</authname><surname>Sugi</surname><given-name>Yusuke</given-name><initials>Y.</initials><afid>60001377</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56663059100</author-url><authid>56663059100</authid><authname>Shimozono K.</authname><surname>Shimozono</surname><given-name>Koutatsu</given-name><initials>K.</initials><afid>60001377</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6507337197</author-url><authid>6507337197</authid><authname>Pradervand S.</authname><surname>Pradervand</surname><given-name>Sylvain</given-name><initials>S.</initials><afid>60000239</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004618176</author-url><authid>7004618176</authid><authname>Hoshijima M.</authname><surname>Hoshijima</surname><given-name>Masahiko</given-name><initials>M.</initials><afid>60030612</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:56463448000</author-url><authid>56463448000</authid><authname>Aoki H.</authname><surname>Aoki</surname><given-name>Hiroki</given-name><initials>H.</initials><afid>60022116</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:56662776100</author-url><authid>56662776100</authid><authname>Fukumoto Y.</authname><surname>Fukumoto</surname><given-name>Yoshihiro</given-name><initials>Y.</initials><afid>60001377</afid><afid>60022116</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:56662776100</author-url><authid>56662776100</authid><authname>Fukumoto Y.</authname><surname>Fukumoto</surname><given-name>Yoshihiro</given-name><initials>Y.</initials><afid>60001377</afid><afid>60022116</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:56662758500</author-url><authid>56662758500</authid><authname>Imaizumi T.</authname><surname>Imaizumi</surname><given-name>Tsutomu</given-name><initials>T.</initials><afid>60024740</afid></author><intid>1536088030</intid><article-number>e0127942</article-number><source-id>10600153309</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930210239"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930210239?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930210239&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930210239&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930210239</prism:url><dc:identifier>SCOPUS_ID:84930210239</dc:identifier><eid>2-s2.0-84930210239</eid><dc:title>Light and dark of reactive oxygen species for vascular function: 2014 ASVB (Asian Society of Vascular Biology)</dc:title><dc:creator>Shimokawa H.</dc:creator><prism:publicationName>Journal of Cardiovascular Pharmacology</prism:publicationName><prism:issn>01602446</prism:issn><prism:eIssn>15334023</prism:eIssn><prism:volume>65</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>412-418</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1097/FJC.0000000000000159</prism:doi><dc:description>Â© 2014 Wolters Kluwer Health, Inc. Vascular-derived hydrogen peroxide (H2O2) serves as an important signaling molecule in the cardiovascular system and contributes to vascular homeostasis. H2O2 is a second messenger, transducing the oxidative signal into biological responses through posttranslational protein modification. The balance between oxidant and antioxidant systems regulates intracellular redox status, and their imbalance causes oxidative or reductive stress, leading to cellular damage in cardiovascular systems. Excessive H2O2 deteriorates vascular functions and promotes vascular disease through multiple pathways. The RhoA/Rho-kinase pathway plays an important role in various fundamental cellular functions, including production of excessive reactive oxygen species, leading to the development of cardiovascular diseases. Rho-kinase (ROCK1 and ROCK2) belongs to the family of serine/threonine kinases and is an important downstream effector of the small GTP-binding protein RhoA. Rho-kinase plays a crucial role in the pathogenesis of vasospasm, arteriosclerosis, ischemia/reperfusion injury, hypertension, pulmonary hypertension, stroke, and heart failure. Thus, Rho-kinase inhibitors may be useful for the treatment of cardiovascular diseases in humans. In this review, we will briefly discuss the roles of vascular-derived H2O2 and review the recent progress in the translational research on the therapeutic importance of the Rho-kinase pathway in cardiovascular medicine.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016416</affiliation-url><afid>60016416</afid><affilname>Tohoku University School of Medicine</affilname><name-variant>Tohoku University Graduate School of Medicine</name-variant><affiliation-city>Sendai</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16684837100</author-url><authid>16684837100</authid><authname>Shimokawa H.</authname><surname>Shimokawa</surname><given-name>Hiroaki</given-name><initials>H.</initials><afid>60016416</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55808642000</author-url><authid>55808642000</authid><authname>Satoh K.</authname><surname>Satoh</surname><given-name>Kimio</given-name><initials>K.</initials><afid>60016416</afid></author><authkeywords>reactive oxygen species | Rho-kinase | vascular diseases | vascular homeostasis</authkeywords><intid>1786088221</intid><source-id>22981</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930013704"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930013704?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930013704&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930013704&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930013704</prism:url><dc:identifier>SCOPUS_ID:84930013704</dc:identifier><eid>2-s2.0-84930013704</eid><dc:title>Treating Others Merely as Means: A Reply to Kerstein</dc:title><dc:creator>PAPADAKI L.</dc:creator><prism:publicationName>Utilitas</prism:publicationName><prism:issn>09538208</prism:issn><prism:eIssn>17416183</prism:eIssn><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1017/S0953820815000138</prism:doi><pii>S0953820815000138</pii><dc:description>Copyright Â© Cambridge University Press 2015 At the heart of Kantian theory lies the prohibition against treating humanity merely as a means. Two of the most influential interpretations of what this means are Wood's and O'Neill's. Drawing on these thinkers' ideas, Kerstein formulates two accounts of what is involved in the idea of treating a person merely as a means: the âend-sharingâ and âpossible consentâ accounts. Kerstein's attempt is to show that they are problematic. He introduces his âreinforced hybrid accountâ to alleviate the problems they face. I argue that the end-sharing and possible consent accounts are not vulnerable to Kerstein's criticism. However, they both face a shortcoming: they fail to support the Kantian conclusion that the prostitute and the servile person are treated merely as means. Through reconstructing these accounts, I surmount this difficulty. Moreover, my proposal helps Kerstein's own account overcome a problem he admits it has, without the need to resort to consequentialism.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001524</affiliation-url><afid>60001524</afid><affilname>Panepistimio Kritis</affilname><name-variant>University of Crete</name-variant><affiliation-city>Rethymnon</affiliation-city><affiliation-country>Greece</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56659332900</author-url><authid>56659332900</authid><authname>PAPADAKI L.</authname><surname>PAPADAKI</surname><given-name>LINA</given-name><initials>L.</initials><afid>60001524</afid></author><intid>1786055130</intid><source-id>19900191624</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930038436"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930038436?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930038436&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930038436&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930038436</prism:url><dc:identifier>SCOPUS_ID:84930038436</dc:identifier><eid>2-s2.0-84930038436</eid><dc:title>Boosting in Elite Athletes with Spinal Cord Injury: A Critical Review of Physiology and Testing Procedures</dc:title><dc:creator>Gee C.</dc:creator><prism:publicationName>Sports Medicine</prism:publicationName><prism:issn>01121642</prism:issn><prism:eIssn>11792035</prism:eIssn><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s40279-015-0340-9</prism:doi><dc:description>Â© 2015 Springer International Publishing Switzerland Many individuals with spinal cord injury (SCI) experience autonomic dysfunction, which can have major implications on heart rate and blood pressure responses to exercise, and consequently athletic performance. Athletic performance may be improved by the induction of autonomic dysreflexia (âboostingâ), a dangerous and sometimes life-threatening condition. Here, we review the autonomic response to exercise in individuals with SCI and the current testing methods for boosting, and examine the potential for autonomic testing to be used in the classification of SCI athletes. Given the difficulties associated with researching the effects of boosting, only three studies have compared the physiological performance of elite athletes in the boosted and unboosted state. These studies found athletes had an improved performance of ~7 to 10 % in the boosted state. Blood pressure, heart rate, oxygen consumption, and circulating catecholamines were also higher in the boosted state. Although 27.1 % of athletes believe that boosting was common in their sport, no athlete has ever tested positive for boosting at an event sanctioned by the International Paralympic Committee. Athletes with SCI competing in sports that have a high cardiovascular demand/aerobic component may experience the greatest benefit of boosting. Boosting improves athletic performance even at blood pressure levels well below the current threshold for disqualification set by the International Paralympic Committee, a level at which individuals with SCI are putting their health and lives at serious risk.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010365</affiliation-url><afid>60010365</afid><affilname>The University of British Columbia</affilname><name-variant>University of British Columbia</name-variant><affiliation-city>Vancouver</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010365</affiliation-url><afid>60010365</afid><affilname>The University of British Columbia</affilname><name-variant>University of British Columbia</name-variant><affiliation-city>Vancouver</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010365</affiliation-url><afid>60010365</afid><affilname>The University of British Columbia</affilname><name-variant>University of British Columbia</name-variant><affiliation-city>Vancouver</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60098909</affiliation-url><afid>60098909</afid><affilname>GF Strong Rehabilitation Centre, British Columbia</affilname><name-variant>GF Strong Rehabilitation Centre</name-variant><affiliation-city>Vancouver</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56339817900</author-url><authid>56339817900</authid><authname>Gee C.</authname><surname>Gee</surname><given-name>Cameron M.</given-name><initials>C.M.</initials><afid>60010365</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56232410100</author-url><authid>56232410100</authid><authname>West C.</authname><surname>West</surname><given-name>Christopher R.</given-name><initials>C.R.</initials><afid>60010365</afid><afid>60010365</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56232410100</author-url><authid>56232410100</authid><authname>West C.</authname><surname>West</surname><given-name>Christopher R.</given-name><initials>C.R.</initials><afid>60010365</afid><afid>60010365</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003542604</author-url><authid>7003542604</authid><authname>Krassioukov A.</authname><surname>Krassioukov</surname><given-name>Andrei V.</given-name><initials>A.V.</initials><afid>60010365</afid><afid>60010365</afid><afid>60098909</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003542604</author-url><authid>7003542604</authid><authname>Krassioukov A.</authname><surname>Krassioukov</surname><given-name>Andrei V.</given-name><initials>A.V.</initials><afid>60010365</afid><afid>60010365</afid><afid>60098909</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003542604</author-url><authid>7003542604</authid><authname>Krassioukov A.</authname><surname>Krassioukov</surname><given-name>Andrei V.</given-name><initials>A.V.</initials><afid>60010365</afid><afid>60010365</afid><afid>60098909</afid></author><intid>2036048588</intid><source-id>20373</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929850821"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929850821?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929850821&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929850821&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929850821</prism:url><dc:identifier>SCOPUS_ID:84929850821</dc:identifier><eid>2-s2.0-84929850821</eid><dc:title>Inhibitory Effects and Sympathetic Mechanisms of Distension in the Distal Organs on Small Bowel Motility and Slow Waves in Canine</dc:title><dc:creator>Song J.</dc:creator><prism:publicationName>Cell Biochemistry and Biophysics</prism:publicationName><prism:issn>10859195</prism:issn><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12013-015-0679-4</prism:doi><dc:description>Â© 2015 Springer Science+Business Media New York Rectal distension (RD) is known to induce intestinal dysmotility. Few studies were performed to compare effects of RD, colon distension (CD) and duodenal distension (DD) on small bowel motility. This study aimed to investigate effects and underlying mechanisms of distensions in these regions on intestinal motility and slow waves. Eight dogs chronically implanted with a duodenal fistula, a proximal colon fistula, and intestinal serosal electrodes were studied in six sessions: control, RD, CD, DD, RD + guanethidine, and CD + guanethidine. Postprandial intestinal contractions and slow waves were recorded for the assessment of intestinal motility. The electrocardiogram was recorded for the assessment of autonomic functions. (1) Isobaric RD and CD suppressed intestinal contractions (contractile index: 6.0 Â± 0.4 with RD vs. 9.9 Â± 0.9 at baseline, P = 0.001, 5.3 Â± 0.2 with CD vs. 7.7 Â± 0.8 at baseline, P = 0.008). Guanethidine at 3 mg/kg iv was able to partially block the effects. (2) RD and CD reduced the percentage of normal intestinal slow waves from 92.1 Â± 2.8 to 64.2 Â± 3.4 % (P &lt; 0.001) and from 90 Â± 2.7 to 69.2 Â± 3.7 % (P = 0.01), respectively. Guanethidine could eliminate these inhibitory effects. (3) DD did not induce any changes in small intestinal contractions and slow waves (P &gt; 0.05). (4) The spectral analysis of the heart rate variability showed that both RD and CD increased sympathetic activity (LF) and reduced vagal activity (HF) (P &lt; 0.05). Isobaric RD and CD could inhibit postprandial intestinal motility and impair intestinal slow waves, which were mediated via the sympathetic pathway. However, DD at a site proximal to the measurement site did not seem to impair small intestinal contractions or slow waves.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014569</affiliation-url><afid>60014569</afid><affilname>UT Medical Branch at Galveston</affilname><name-variant>University of Texas Medical Branch</name-variant><affiliation-city>Galveston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113552456</affiliation-url><afid>113552456</afid><affilname>Ningbo Pace Translational Medical Research Center</affilname><name-variant>Ningbo Pace Translational Medical Research Center</name-variant><affiliation-city>Ningbo</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005248</affiliation-url><afid>60005248</afid><affilname>Johns Hopkins University</affilname><name-variant>Johns Hopkins University</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025761</affiliation-url><afid>60025761</afid><affilname>Huazhong University of Science and Technology</affilname><name-variant>Huazhong Univ. of Sci. and Technol.</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56226572400</author-url><authid>56226572400</authid><authname>Song J.</authname><surname>Song</surname><given-name>Jun</given-name><initials>J.</initials><afid>60014569</afid><afid>60025761</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56226572400</author-url><authid>56226572400</authid><authname>Song J.</authname><surname>Song</surname><given-name>Jun</given-name><initials>J.</initials><afid>60014569</afid><afid>60025761</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56655802900</author-url><authid>56655802900</authid><authname>Yin J.</authname><surname>Yin</surname><given-name>Jieyun</given-name><initials>J.</initials><afid>60014569</afid><afid>113552456</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56655802900</author-url><authid>56655802900</authid><authname>Yin J.</authname><surname>Yin</surname><given-name>Jieyun</given-name><initials>J.</initials><afid>60014569</afid><afid>113552456</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56421771300</author-url><authid>56421771300</authid><authname>Chen J.</authname><surname>Chen</surname><given-name>Jiande D Z</given-name><initials>J.D.Z.</initials><afid>60014569</afid><afid>113552456</afid><afid>60005248</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56421771300</author-url><authid>56421771300</authid><authname>Chen J.</authname><surname>Chen</surname><given-name>Jiande D Z</given-name><initials>J.D.Z.</initials><afid>60014569</afid><afid>113552456</afid><afid>60005248</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56421771300</author-url><authid>56421771300</authid><authname>Chen J.</authname><surname>Chen</surname><given-name>Jiande D Z</given-name><initials>J.D.Z.</initials><afid>60014569</afid><afid>113552456</afid><afid>60005248</afid></author><authkeywords>Colon distension | Heart rate variability | Intestinal motility | Intestinal slow waves | Rectal distension</authkeywords><intid>36036178</intid><source-id>38819</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930216566"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930216566?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930216566&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930216566&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930216566</prism:url><dc:identifier>SCOPUS_ID:84930216566</dc:identifier><eid>2-s2.0-84930216566</eid><dc:title>An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)</dc:title><dc:creator>DeWire M.</dc:creator><prism:publicationName>Journal of Neuro-Oncology</prism:publicationName><prism:issn>0167594X</prism:issn><prism:eIssn>15737373</prism:eIssn><prism:volume>123</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>85-91</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11060-015-1764-7</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Co-expression of ERBB2 and ERBB4, reported in 75Â % of pediatric ependymomas, correlates with worse overall survival. Lapatinib, a selective ERBB1 and ERBB2 inhibitor has produced prolonged disease stabilization in patients with ependymoma in a phase I study. Bevacizumab exposure in ependymoma xenografts leads to ablation of tumor self-renewing cells, arresting growth. Thus, we conducted an open-label, phase II study of bevacizumab and lapatinib in children with recurrent ependymomas. Patients â¤21Â years of age with recurrent ependymoma received lapatinib orally twice daily (900Â mg/m&lt;sup&gt;2&lt;/sup&gt;/dose to the first 10 patients, and then 700Â mg/m&lt;sup&gt;2&lt;/sup&gt;/dose) and bevacizumab 10Â mg/kg intravenously on days 1 and 15 of a 28-day course. Lapatinib serum trough levels were analyzed prior to each course. Total and phosphorylated VEGFR2 expression was measured in peripheral blood mononuclear cells (PBMCs) before doses 1 and 2 of bevacizumab and 24â48Â h following dose 2 of bevacizumab. Twenty-four patients with a median age of 10Â years (range 2â21Â years) were enrolled; 22 were eligible and 20 evaluable for response. Thirteen had anaplastic ependymoma. There were no objective responses;Â 4 patients had stable disease for â¥4 courses (range 4â14). Grade 3 toxicities included rash, elevated ALT, and diarrhea. Grade 4 toxicities included peri-tracheostomy hemorrhage (nÂ =Â 1) and elevated creatinine phosphokinase (nÂ =Â 1). The median lapatinib pre-dose trough concentration was 3.72Â ÂµM. Although the combination of bevacizumab and lapatinib was well tolerated in children with recurrent ependymoma, it proved ineffective.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030440</affiliation-url><afid>60030440</afid><affilname>Cincinnati Children's Hospital Medical Center</affilname><name-variant>Children's Hospital Medical Center</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101968213</affiliation-url><afid>101968213</afid><affilname>St. Jude Children's Research Hospital</affilname><name-variant>St. Jude Childrenâs Research Hospital</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:101968213</affiliation-url><afid>101968213</afid><affilname>St. Jude Children's Research Hospital</affilname><name-variant>St. Jude Childrenâs Research Hospital</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030319</affiliation-url><afid>60030319</afid><affilname>Hospital for Sick Children University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015023</affiliation-url><afid>60015023</afid><affilname>University of Texas M. D. Anderson Cancer Center</affilname><name-variant>University of Texas</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015023</affiliation-url><afid>60015023</afid><affilname>University of Texas M. D. Anderson Cancer Center</affilname><name-variant>University of Texas</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015023</affiliation-url><afid>60015023</afid><affilname>University of Texas M. D. Anderson Cancer Center</affilname><name-variant>University of Texas</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112940595</affiliation-url><afid>112940595</afid><affilname>Ann and Robert H. Lurie Children's Hospital of Chicago</affilname><name-variant>Ann and Robert H. Lurie Children's Hospital of Chicago</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032063</affiliation-url><afid>60032063</afid><affilname>Lucille Packard Children's Hospital</affilname><name-variant>Lucile Packard Children's Hospital</name-variant><affiliation-city>Palo Alto</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015023</affiliation-url><afid>60015023</afid><affilname>University of Texas M. D. Anderson Cancer Center</affilname><name-variant>University of Texas</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030319</affiliation-url><afid>60030319</afid><affilname>Hospital for Sick Children University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009343</affiliation-url><afid>60009343</afid><affilname>Memorial Sloan-Kettering Cancer Center</affilname><name-variant>Memorial Sloan-Kettering Cancer Center</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005723</affiliation-url><afid>60005723</afid><affilname>Children's National Medical Center</affilname><name-variant>Children's National Medical Center</name-variant><affiliation-city>Washington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115293635</affiliation-url><afid>115293635</afid><affilname>Childrenâs Hospital of Colorado</affilname><name-variant>Childrenâs Hospital of Colorado</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015023</affiliation-url><afid>60015023</afid><affilname>University of Texas M. D. Anderson Cancer Center</affilname><name-variant>University of Texas</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">19</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6504828096</author-url><authid>6504828096</authid><authname>DeWire M.</authname><surname>DeWire</surname><given-name>Mariko</given-name><initials>M.</initials><afid>60030440</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701769411</author-url><authid>6701769411</authid><authname>Fouladi M.</authname><surname>Fouladi</surname><given-name>Maryam</given-name><initials>M.</initials><afid>60030440</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662408300</author-url><authid>56662408300</authid><authname>Turner D.</authname><surname>Turner</surname><given-name>David C.</given-name><initials>D.C.</initials><afid>101968213</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004472397</author-url><authid>7004472397</authid><authname>Wetmore C.</authname><surname>Wetmore</surname><given-name>Cynthia</given-name><initials>C.</initials><afid>101968213</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7202254005</author-url><authid>7202254005</authid><authname>Hawkins C.</authname><surname>Hawkins</surname><given-name>Cynthia</given-name><initials>C.</initials><afid>60030319</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:24830462600</author-url><authid>24830462600</authid><authname>Jacobs C.</authname><surname>Jacobs</surname><given-name>Carmen</given-name><initials>C.</initials><afid>60015023</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56542154600</author-url><authid>56542154600</authid><authname>Yuan Y.</authname><surname>Yuan</surname><given-name>Ying</given-name><initials>Y.</initials><afid>60015023</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56467479900</author-url><authid>56467479900</authid><authname>Liu D.</authname><surname>Liu</surname><given-name>Diane</given-name><initials>D.</initials><afid>60015023</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:35268606400</author-url><authid>35268606400</authid><authname>Goldman S.</authname><surname>Goldman</surname><given-name>Stewart</given-name><initials>S.</initials><afid>112940595</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7402666880</author-url><authid>7402666880</authid><authname>Fisher P.</authname><surname>Fisher</surname><given-name>Paul</given-name><initials>P.</initials><afid>60032063</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6603013382</author-url><authid>6603013382</authid><authname>Rytting M.</authname><surname>Rytting</surname><given-name>Michael</given-name><initials>M.</initials><afid>60015023</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:55371757900</author-url><authid>55371757900</authid><authname>Bouffet E.</authname><surname>Bouffet</surname><given-name>Eric</given-name><initials>E.</initials><afid>60030319</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:6603130954</author-url><authid>6603130954</authid><authname>Khakoo Y.</authname><surname>Khakoo</surname><given-name>Yasmin</given-name><initials>Y.</initials><afid>60009343</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:55622944300</author-url><authid>55622944300</authid><authname>Hwang E.</authname><surname>Hwang</surname><given-name>Eugene I.</given-name><initials>E.I.</initials><afid>60005723</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7005236296</author-url><authid>7005236296</authid><authname>Foreman N.</authname><surname>Foreman</surname><given-name>Nicholas</given-name><initials>N.</initials><afid>115293635</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:55628581551</author-url><authid>55628581551</authid><authname>Stewart C.</authname><surname>Stewart</surname><given-name>Clinton F.</given-name><initials>C.F.</initials><afid>101968213</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:7202762344</author-url><authid>7202762344</authid><authname>Gilbert M.</authname><surname>Gilbert</surname><given-name>Mark R.</given-name><initials>M.R.</initials><afid>60015023</afid></author><author seq="18"><author-url>http://api.elsevier.com/content/author/author_id:24738692300</author-url><authid>24738692300</authid><authname>Gilbertson R.</authname><surname>Gilbertson</surname><given-name>Richard</given-name><initials>R.</initials><afid>101968213</afid></author><author seq="19"><author-url>http://api.elsevier.com/content/author/author_id:8403778400</author-url><authid>8403778400</authid><authname>Gajjar A.</authname><surname>Gajjar</surname><given-name>Amar</given-name><initials>A.</initials><afid>101968213</afid></author><authkeywords>Bevacizumab | Children | Lapatinib | Recurrent ependymoma</authkeywords><intid>1536086957</intid><source-id>29954</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929832460"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929832460?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929832460&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929832460&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929832460</prism:url><dc:identifier>SCOPUS_ID:84929832460</dc:identifier><eid>2-s2.0-84929832460</eid><dc:title>Unique Aspects of Coronary Artery Disease in Indian Women</dc:title><dc:creator>Bhatt P.</dc:creator><prism:publicationName>Cardiovascular Drugs and Therapy</prism:publicationName><prism:issn>09203206</prism:issn><prism:eIssn>15737241</prism:eIssn><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10557-015-6594-5</prism:doi><dc:description>Â© 2015 Springer Science+Business Media New York Purpose: Epidemiologic and clinical research suggests important gender-related differences in the prevalence, presentation, associated conventional and non-conventional risk factors, management and outcomes of coronary heart disease (CHD) patients. Adequate data is not available for Indian population where prevalence of CHD and depression is high. Method: We conducted an observational, single-center, study from January 2010 to December 2011 on 10450 consecutive patients visiting a tertiary care center, Ahmedabad, Gujarat, India who presented with complaints related to CHD. Results: Of these, 6867 patients had coronary artery disease (CAD) as confirmed by angiographic investigation; 5678 were males, and 1189 were females with similar mean age. As compared to males, females had higher prevalence of hypertension, diabetes and obesity while males had higher prevalence of smoking. Invasive treatment options like Coronary Artery Bypass Grafting (p &lt; 0.001) and Percutaneous Coronary Intervention (p = 0.001) were used less often to treat females, and medical therapy (p &lt; 0.001) was the preferred treatment option irrespective of the contributing risk factors/extent of CAD. Depression was observed in 39.8 % of acute coronary syndrome patients (n = 1648) as assessed by MARDS scale. It was higher in female patients and in low socioeconomic strata (p &lt; 0.001).At 12 and 36 months, rates of revascularization (p &lt; 0.001) and mortality (p &lt; 0.005) were higher with poor quality of life (QoL) (P &lt; 0.001) in depressed CAD patients. Conclusion: In India, women appear to have a higher prevalence of hypertension, diabetes, obesity, and family history of CHD. Yet women get invasive treatments less often than men. Depression is also more common in women and is associated with poor QoL and early mortality than men.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017891</affiliation-url><afid>60017891</afid><affilname>L.M. College of Pharmacy India</affilname><name-variant>L.M. College of Pharmacy</name-variant><affiliation-city>Ahmedabad</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112679702</affiliation-url><afid>112679702</afid><affilname>Care Institute of Medical Sciences (CIMS)</affilname><name-variant>Care Institute of Medical Sciences (CIMS)</name-variant><affiliation-city>Ahmedabad</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021160</affiliation-url><afid>60021160</afid><affilname>Cleveland Clinic Foundation</affilname><name-variant>Cleveland Clinic Foundation</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024885</affiliation-url><afid>60024885</afid><affilname>University of Arkansas for Medical Sciences</affilname><name-variant>Univ. of Arkansas for Med. Sciences</name-variant><affiliation-city>Little Rock</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:19933648200</author-url><authid>19933648200</authid><authname>Bhatt P.</authname><surname>Bhatt</surname><given-name>Parloop</given-name><initials>P.</initials><afid>60017891</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56108981000</author-url><authid>56108981000</authid><authname>Parikh P.</authname><surname>Parikh</surname><given-name>Parth</given-name><initials>P.</initials><afid>112679702</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56654661000</author-url><authid>56654661000</authid><authname>Patel A.</authname><surname>Patel</surname><given-name>Aditi</given-name><initials>A.</initials><afid>112679702</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56108961200</author-url><authid>56108961200</authid><authname>Parikh R.</authname><surname>Parikh</surname><given-name>Roosha</given-name><initials>R.</initials><afid>60021160</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56557236800</author-url><authid>56557236800</authid><authname>Patel A.</authname><surname>Patel</surname><given-name>Apurva</given-name><initials>A.</initials><afid>60021160</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56653043900</author-url><authid>56653043900</authid><authname>Mehta J.</authname><surname>Mehta</surname><given-name>Jawahar L.</given-name><initials>J.L.</initials><afid>60024885</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:15843943000</author-url><authid>15843943000</authid><authname>Parikh K.</authname><surname>Parikh</surname><given-name>Keyur</given-name><initials>K.</initials><afid>112679702</afid></author><authkeywords>Clinical outcomes | Coronary artery disease | Depression | Gender difference | Quality of life</authkeywords><intid>1036015457</intid><source-id>22552</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929416029"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929416029?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929416029&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929416029&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929416029</prism:url><dc:identifier>SCOPUS_ID:84929416029</dc:identifier><eid>2-s2.0-84929416029</eid><dc:title>Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease</dc:title><dc:creator>Jones P.</dc:creator><prism:publicationName>International Journal of COPD</prism:publicationName><prism:issn>11769106</prism:issn><prism:eIssn>11782005</prism:eIssn><prism:volume>10</prism:volume><prism:pageRange>677-687</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.2147/COPD.S76520</prism:doi><dc:description>Â© 2015 Jones. Three long-acting muscarinic antagonists (LAMAs) are now available in Europe, providing clinicians and patients with a choice of interventions, which is important in COPD, which is clinically a heterogeneous disease. The first LAMA, tiotropium, has been widely used over the last decade as a once-daily maintenance therapy in stable COPD to improve patientsâ health-related quality of life and to reduce the risk of exacerbations. Administered via the HandiHaler&lt;sup&gt;Â®&lt;/sup&gt; device, it is safe and well tolerated. Another new once-daily LAMA, glycopyrronium, has also been shown to improve health status and reduce exacerbations, and is well tolerated. The subject of this review is a third LAMA, aclidinium bromide, which was approved as a twice-daily maintenance bronchodilator treatment. In the pivotal Phase III clinical trials, patients receiving aclidinium achieved significantly greater improvements in lung function, reductions in breathlessness, and improvements in health status compared with placebo, for up to 24 weeks. In continuation studies, these improvements were sustained for up to 52 weeks. Pooled data showed exacerbation frequency was significantly reduced with aclidinium versus placebo. Preclinical and pharmacological studies demonstrating low systemic bioavailability and a low propensity to induce cardiac arrhythmias were translated into a favorable tolerability profile in the clinical trial program â the adverse event profile of aclidinium was similar to placebo, with a low incidence of anticholinergic and cardiac adverse events. While additional studies are needed to evaluate its full clinical potential, aclidinium is an important part of this recent expansion of LAMA therapeutic options, providing clinicians and patients with an effective and well-tolerated COPD treatment.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033387</affiliation-url><afid>60033387</afid><affilname>University of London</affilname><name-variant>University of London</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26121204500</author-url><authid>26121204500</authid><authname>Jones P.</authname><surname>Jones</surname><given-name>Paul W.</given-name><initials>P.W.</initials><afid>60033387</afid></author><authkeywords>Aclidinium bromide | Anticholinergic | Chronic obstructive pulmonary disease | Long-acting muscarinic antagonist | Multidose dry powder inhaler</authkeywords><intid>35955255</intid><source-id>6200180178</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929865520"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929865520?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929865520&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929865520&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929865520</prism:url><dc:identifier>SCOPUS_ID:84929865520</dc:identifier><eid>2-s2.0-84929865520</eid><dc:title>Tourism along the geopolitical barrier: implications of the Holy Land fence</dc:title><dc:creator>Gelbman A.</dc:creator><prism:publicationName>GeoJournal</prism:publicationName><prism:issn>03432521</prism:issn><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10708-015-9644-4</prism:doi><dc:description>Â© 2015 Springer Science+Business Media Dordrecht Geopolitical borders in the form of physical barriers greatly influence tourism, mainly as an obstacle to free transborder movement of tourists but can constitute a tourist attraction. The main aims of this article are to describe, analyze and propose a typology of consequences on tourism as a geopolitical barrier through a case study of the fence in the Holy Land. The security fence dividing Israel and the Palestinian Authority is also called a separation fence or wall and it is located in the heart of a tourism region of global interest. The methodology is based on a review of literature that deals with the ramifications of such a fence in general and specifically with reference to tourism. The study provides an understanding of the new reality created by the fence, its varied influences on tourism planning and its ramifications on physical, environmental, administrative and image-related aspects of reality in the area.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60093513</affiliation-url><afid>60093513</afid><affilname>Kinneret College on the Sea of Galilee</affilname><name-variant>Kinneret College</name-variant><affiliation-city>Lake Kinneret</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24166509700</author-url><authid>24166509700</authid><authname>Gelbman A.</authname><surname>Gelbman</surname><given-name>Alon</given-name><initials>A.</initials><afid>60093513</afid></author><authkeywords>Geopolitical borders | Israel | Security fence/wall | The Palestinian Authority</authkeywords><intid>536037199</intid><source-id>28772</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926289485"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926289485?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926289485&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926289485&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115001944"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926289485</prism:url><dc:identifier>SCOPUS_ID:84926289485</dc:identifier><eid>2-s2.0-84926289485</eid><dc:title>Ethnobotanical survey of medicinally important shrubs and trees of Himalayan region of Azad Jammu and Kashmir, Pakistan</dc:title><dc:creator>Rashid S.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>166</prism:volume><prism:pageRange>340-351</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.03.042</prism:doi><pii>S0378874115001944</pii><dc:description>Â© 2015 Elsevier Ireland Ltd. All rights reserved. Abstract Ethnopharmacological relevance Present study was commenced with an aim to document the indigenous knowledge of medicinally important shrubs and trees of Himalayan region of Azad Jammu and Kashmir, Pakistan. This is the first contribution to the quantitative ethnobotany of this region, as no reported data focusing on shrubs and trees from the area have been published. Study reported the ethnobotanical significance of medicinal plants for the treatment of various diseases. Method Study was conducted during 2012-2014 following standard ethnobotanical methods. The ethnomedicinal data was collected through informed consent semi- structured interviews of 160 key informants. Documented data was analyzed by using quantitative indices of informant consensus factor (ICF), fidelity level (FL), use value (UV) and relative frequency citation (RFC). Results A total of 73 shrub and tree species belonging to 56 genera and 37 families were reported to be used ethnomedicinally for the treatment of various ailments. Medicinal plant diversity showed that Rosaceae was dominating family with (9 spp.) followed by Moraceae (7 spp.), Euphorbiaceae, Mimosaceae, Pinaceae, Rhamnaceae (4 spp. each), Oleaceae (3 spp.), Apocynaceae, Caesalpinaceae, Ebenaceae, Fagaceae, Lythraceae, Papilionaceae, Acanthaceae, Verbenaceae (2 spp. each) while remaining 22 families were represented by one species each. Leaves (23%) were highly utilized plant parts, followed by fruits (22%), bark (18%), seeds (10%), roots (9%), flowers (8%), whole plant and aerial parts (4% each) and stem (2%). Modes of preparation fall into 14 categories including powder (33 reports) followed by decoction (29 reports), paste (22 reports), juice (18 reports), infusion (12 reports), raw (8 reports), extract and latex (5 reports each), gum and oil (4 reports each), fresh part and pulp (2 reports each), chewed and cooked (1 report each). The highest FIC was recorded for Gastro-intestinal disorders (0.58) followed by nail, skin and hair disorders (0.44). Maximum fidelity level (FL=100%) was expressed by Abies pindrow, Adhatoda vasica, Bauhinia variegata and Cedrela serrata. Based on use value Juglans regia (0.88) was found most significant species followed by Acacia nilotica (0.83), Phyllanthus emblica (0.81), Pinus roxburghii (0.75) and Punica granatum (0.71). Conclusion The area has a rich diversity of medicinally important shrub and tree species. The tradition of using plants for medicinal purposes is still alive in the local community but recently this tradition is gradually declining in new generation. Therefore awareness is needed to be raised among the local people on sustainable use and conservation of local flora.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60064058</affiliation-url><afid>60064058</afid><affilname>Quaid-i-Azam University</affilname><name-variant>Quaid-i-Azam University</name-variant><affiliation-city>Islamabad</affiliation-city><affiliation-country>Pakistan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26030611900</author-url><authid>26030611900</authid><authname>Rashid S.</authname><surname>Rashid</surname><given-name>Sofia</given-name><initials>S.</initials><afid>60064058</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35221248900</author-url><authid>35221248900</authid><authname>Ahmad M.</authname><surname>Ahmad</surname><given-name>Mushtaq</given-name><initials>M.</initials><afid>60064058</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004661383</author-url><authid>7004661383</authid><authname>Zafar M.</authname><surname>Zafar</surname><given-name>Muhammad</given-name><initials>M.</initials><afid>60064058</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:24077714300</author-url><authid>24077714300</authid><authname>Sultana S.</authname><surname>Sultana</surname><given-name>Shazia</given-name><initials>S.</initials><afid>60064058</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8850595700</author-url><authid>8850595700</authid><authname>Ayub M.</authname><surname>Ayub</surname><given-name>Muhammad</given-name><initials>M.</initials><afid>60064058</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56262166700</author-url><authid>56262166700</authid><authname>Khan M.</authname><surname>Khan</surname><given-name>Mir Ajab</given-name><initials>M.A.</initials><afid>60064058</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56125349000</author-url><authid>56125349000</authid><authname>Yaseen G.</authname><surname>Yaseen</surname><given-name>Ghulam</given-name><initials>G.</initials><afid>60064058</afid></author><authkeywords>Azad Jammu and Kashmir Pakistan | Ethnobotany | Himalayan region | Medicinal plants</authkeywords><intid>1035424936</intid><article-number>9402</article-number><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926139839"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926139839?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926139839&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926139839&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378874115001683"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926139839</prism:url><dc:identifier>SCOPUS_ID:84926139839</dc:identifier><eid>2-s2.0-84926139839</eid><dc:title>Comparative pharmacokinetics and tissue distribution profiles of lignan components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe</dc:title><dc:creator>Yang T.</dc:creator><prism:publicationName>Journal of Ethnopharmacology</prism:publicationName><prism:issn>03788741</prism:issn><prism:eIssn>18727573</prism:eIssn><prism:volume>166</prism:volume><prism:pageRange>305-312</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jep.2015.03.024</prism:doi><pii>S0378874115001683</pii><dc:description>Â© 2015 Elsevier Ireland Ltd All rights reserved. Ethnopharmacological relevance Fuzheng Huayu recipe (FZHY) is formulated on the basis of Chinese medicine theory in treating liver fibrosis. Aim of the study To illuminate the influence of the pathological state of liver fibrosis on the pharmacokinetics and tissue distribution profiles of lignan components from FZHY. Materials and methods Male Wistar rats were randomly divided into normal group and Hepatic fibrosis group (induced by dimethylnitrosamine). Six lignan components were detected and quantified by ultrahigh performance liquid chromatography-tandem mass spectrometry(UHPLC-MS/MS)in the plasma and tissue of normal and hepatic fibrosis rats. Results A rapid, sensitive and convenient UHPLC-MS/MS method has been developed for the simultaneous determination of six lignan components in different rat biological samples successfully. After oral administration of FZHY at a dose of 15 g/kg, the pharmacokinetic behaviors of schizandrin A (SIA), schizandrin B (SIB), schizandrin C (SIC), schisandrol A (SOA), Schisandrol B (SOB) and schisantherin A (STA) have been significantly changed in hepatic fibrosis rats compared with the normal rats, and their AUC&lt;inf&gt;(0-t)&lt;/inf&gt; values were increased by 235.09%, 388.44%, 223.30%, 669.30%, 295.08% and 267.63% orderly (P&lt;0.05). Tissue distribution results showed the amount of SIA, SIB, SOA and SOB were significant increased in heart, lung, spleen and kidney of hepatic fibrosis rats compared with normal rats at most of the time point (P&lt;0.05). Meanwhile, the result also reveals that the hepatic fibrosis could delay the peak time of lignans in liver. Conclusion The results proved that the established UHPLC-MS/MS method could be applied to the comparative study on pharmacokinetics and tissue distribution of lignan components in normal and hepatic fibrosis rats. The hepatic fibrosis could alter the pharmacokinetics and tissue distribution properties of lignan components in rats after administration of FZHY. The results might be helpful for guide the clinical application of this medicine.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010170</affiliation-url><afid>60010170</afid><affilname>Shanghai University of Traditional Chinese Medicine</affilname><name-variant>Shanghai University of Traditional Chinese Medicine</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011069</affiliation-url><afid>60011069</afid><affilname>East China University of Science and Technology</affilname><name-variant>East China University of Science and Technology</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112603956</affiliation-url><afid>112603956</afid><affilname>Shanghai Key Laboratory of Traditional Chinese Clinical Medicine</affilname><name-variant>Shanghai Key Laboratory of Traditional Chinese Clinical Medicine</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100856373</affiliation-url><afid>100856373</afid><affilname>Shanghai Municipal Education Commission</affilname><name-variant>Shanghai Municipal Education Commission</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56397422700</author-url><authid>56397422700</authid><authname>Yang T.</authname><surname>Yang</surname><given-name>Tao</given-name><initials>T.</initials><afid>60010170</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:34880398600</author-url><authid>34880398600</authid><authname>Liu S.</authname><surname>Liu</surname><given-name>Shan</given-name><initials>S.</initials><afid>60010170</afid><afid>60011069</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:34880398600</author-url><authid>34880398600</authid><authname>Liu S.</authname><surname>Liu</surname><given-name>Shan</given-name><initials>S.</initials><afid>60010170</afid><afid>60011069</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56579668000</author-url><authid>56579668000</authid><authname>Zheng T.</authname><surname>Zheng</surname><given-name>Tian Hui</given-name><initials>T.H.</initials><afid>60010170</afid><afid>60011069</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56579668000</author-url><authid>56579668000</authid><authname>Zheng T.</authname><surname>Zheng</surname><given-name>Tian Hui</given-name><initials>T.H.</initials><afid>60010170</afid><afid>60011069</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56579578500</author-url><authid>56579578500</authid><authname>Tao Y.</authname><surname>Tao</surname><given-name>Yan Yan</given-name><initials>Y.Y.</initials><afid>60010170</afid><afid>112603956</afid><afid>100856373</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56579578500</author-url><authid>56579578500</authid><authname>Tao Y.</authname><surname>Tao</surname><given-name>Yan Yan</given-name><initials>Y.Y.</initials><afid>60010170</afid><afid>112603956</afid><afid>100856373</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56579578500</author-url><authid>56579578500</authid><authname>Tao Y.</authname><surname>Tao</surname><given-name>Yan Yan</given-name><initials>Y.Y.</initials><afid>60010170</afid><afid>112603956</afid><afid>100856373</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23982831300</author-url><authid>23982831300</authid><authname>Liu C.</authname><surname>Liu</surname><given-name>Cheng Hai</given-name><initials>C.H.</initials><afid>60010170</afid><afid>60011069</afid><afid>112603956</afid><afid>100856373</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23982831300</author-url><authid>23982831300</authid><authname>Liu C.</authname><surname>Liu</surname><given-name>Cheng Hai</given-name><initials>C.H.</initials><afid>60010170</afid><afid>60011069</afid><afid>112603956</afid><afid>100856373</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23982831300</author-url><authid>23982831300</authid><authname>Liu C.</authname><surname>Liu</surname><given-name>Cheng Hai</given-name><initials>C.H.</initials><afid>60010170</afid><afid>60011069</afid><afid>112603956</afid><afid>100856373</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23982831300</author-url><authid>23982831300</authid><authname>Liu C.</authname><surname>Liu</surname><given-name>Cheng Hai</given-name><initials>C.H.</initials><afid>60010170</afid><afid>60011069</afid><afid>112603956</afid><afid>100856373</afid></author><authkeywords>Fuzheng Huayu recipe | Hepatic fibrosis | Lignan | Pharmacokinetics | Tissue distribution | UHPLC-MS/MS</authkeywords><intid>35405903</intid><source-id>23015</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930079202"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930079202?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930079202&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930079202&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930079202</prism:url><dc:identifier>SCOPUS_ID:84930079202</dc:identifier><eid>2-s2.0-84930079202</eid><dc:title>Continuous evolution of risk assessment methods for cardiac surgery and intervention</dc:title><dc:creator>Javadikasgari H.</dc:creator><prism:publicationName>Nature Reviews Cardiology</prism:publicationName><prism:issn>17595002</prism:issn><prism:eIssn>17595010</prism:eIssn><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1038/nrcardio.2014.136-c1</prism:doi><pii>nrcardio.2014.136-c1</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021160</affiliation-url><afid>60021160</afid><affilname>Cleveland Clinic Foundation</affilname><name-variant>Cleveland Clinic Foundation</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:48761287800</author-url><authid>48761287800</authid><authname>Javadikasgari H.</authname><surname>Javadikasgari</surname><given-name>Hoda</given-name><initials>H.</initials><afid>60021160</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005597400</author-url><authid>7005597400</authid><authname>Gillinov A.</authname><surname>Gillinov</surname><given-name>A. Marc</given-name><initials>A.M.</initials><afid>60021160</afid></author><intid>2036056286</intid><source-id>17700156509</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927160460"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927160460?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927160460&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927160460&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0223523415002615"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927160460</prism:url><dc:identifier>SCOPUS_ID:84927160460</dc:identifier><eid>2-s2.0-84927160460</eid><dc:title>Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors</dc:title><dc:creator>Li M.</dc:creator><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationName><prism:issn>02235234</prism:issn><prism:eIssn>17683254</prism:eIssn><prism:volume>96</prism:volume><prism:pageRange>122-138</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejmech.2015.04.012</prism:doi><pii>S0223523415002615</pii><dc:description>Â© 2015 Elsevier Masson SAS. Twenty-one fluorinated dabigatran derivatives were designed based on the bioisosteric principle. All derivatives were synthesised and evaluated for their thrombin inhibitory activity in vitro. Among these compounds, 14h, 14m, 14s and 14t were potent and the activity was in the range of reference drug, dabigatran. Three structural changes were introduced in these 21 compounds to elucidate the structure-activity relationship of the drugs. In addition, prodrugs of compounds 14h and 14s were developed to investigate their anticoagulant activities in vivo. In these experiments, compound 16 showed a fairly strong inhibitory effect on thrombin-induced platelet aggregation, and demonstrated potent activity for inhibiting arteriovenous thrombosis with an inhibition rate of (73 Â± 6) %, which was comparable to that of dabigatran etexilate (76 Â± 2) %. Moreover, molecular docking studies were performed to understand the binding interactions of active compounds 14h, 14s and 14t with thrombin protein (PDB ID:1KTS). Contour maps obtained from the 3D-QSAR model are meaningful in designing more active molecules to act as direct inhibitors of thrombin.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009246</affiliation-url><afid>60009246</afid><affilname>Shanghai Institute of Technology</affilname><name-variant>Shanghai Institute of Technology</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56587009300</author-url><authid>56587009300</authid><authname>Li M.</authname><surname>Li</surname><given-name>Mei Lin</given-name><initials>M.L.</initials><afid>60009246</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54279410200</author-url><authid>54279410200</authid><authname>Ren Y.</authname><surname>Ren</surname><given-name>Yu Jie</given-name><initials>Y.J.</initials><afid>60009246</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56510989200</author-url><authid>56510989200</authid><authname>Dong M.</authname><surname>Dong</surname><given-name>Ming Hui</given-name><initials>M.H.</initials><afid>60009246</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56587353000</author-url><authid>56587353000</authid><authname>Ren W.</authname><surname>Ren</surname><given-name>Wei Xin</given-name><initials>W.X.</initials><afid>60009246</afid></author><authkeywords>Anticoagulant activity | Computer-aided simulation | Fluorinated dabigatran derivatives | Synthesis</authkeywords><intid>1035565396</intid><source-id>17464</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930028373"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930028373?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930028373&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930028373&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930028373</prism:url><dc:identifier>SCOPUS_ID:84930028373</dc:identifier><eid>2-s2.0-84930028373</eid><dc:title>A recessive homozygous p.Asp92Gly SDHD mutation causes prenatal cardiomyopathy and a severe mitochondrial complex II deficiency</dc:title><dc:creator>Alston C.</dc:creator><prism:publicationName>Human Genetics</prism:publicationName><prism:issn>03406717</prism:issn><prism:eIssn>14321203</prism:eIssn><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00439-015-1568-z</prism:doi><dc:description>Â© 2015 The Author(s) Succinate dehydrogenase (SDH) is a crucial metabolic enzyme complex that is involved in ATP production, playing roles in both the tricarboxylic cycle and the mitochondrial respiratory chain (complex II). Isolated complex II deficiency is one of the rarest oxidative phosphorylation disorders with mutations described in three structural subunits and one of the assembly factors; just one case is attributed to recessively inherited SDHD mutations. We report the pathological, biochemical, histochemical and molecular genetic investigations of a male neonate who had left ventricular hypertrophy detected on antenatal scan and died on day one of life. Subsequent postmortem examination confirmed hypertrophic cardiomyopathy with left ventricular non-compaction. Biochemical analysis of his skeletal muscle biopsy revealed evidence of a severe isolated complex II deficiency and candidate gene sequencing revealed a novel homozygous c.275A&gt;G, p.(Asp92Gly) SDHD mutation which was shown to be recessively inherited through segregation studies. The affected amino acid has been reported as a Dutch founder mutation p.(Asp92Tyr) in families with hereditary head and neck paraganglioma. By introducing both mutations into Saccharomyces cerevisiae, we were able to confirm that the p.(Asp92Gly) mutation causes a more severe oxidative growth phenotype than the p.(Asp92Tyr) mutant, and provides functional evidence to support the pathogenicity of the patientâs SDHD mutation. This is only the second case of mitochondrial complex II deficiency due to inherited SDHD mutations and highlights the importance of sequencing all SDH genes in patients with biochemical and histochemical evidence of isolated mitochondrial complex II deficiency.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026712</affiliation-url><afid>60026712</afid><affilname>University of Newcastle upon Tyne, Faculty of Medicine</affilname><name-variant>The University</name-variant><affiliation-city>Newcastle</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004969</affiliation-url><afid>60004969</afid><affilname>Universita degli Studi di Parma</affilname><name-variant>UniversitÃ  di Parma</name-variant><affiliation-city>Parma</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020035</affiliation-url><afid>60020035</afid><affilname>Our Lady's Hospital for Sick Children</affilname><name-variant>Our Lady's Hospital for Sick Children</name-variant><affiliation-city>Dublin</affiliation-city><affiliation-country>Ireland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002869</affiliation-url><afid>60002869</afid><affilname>Sheffield Children's Hospital</affilname><name-variant>Child. Hosp.</name-variant><affiliation-city>Sheffield</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022148</affiliation-url><afid>60022148</afid><affilname>UCL</affilname><name-variant>University College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020035</affiliation-url><afid>60020035</afid><affilname>Our Lady's Hospital for Sick Children</affilname><name-variant>Our Lady's Hospital for Sick Children</name-variant><affiliation-city>Dublin</affiliation-city><affiliation-country>Ireland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24605137800</author-url><authid>24605137800</authid><authname>Alston C.</authname><surname>Alston</surname><given-name>Charlotte L.</given-name><initials>C.L.</initials><afid>60026712</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56659238100</author-url><authid>56659238100</authid><authname>Berti C.</authname><surname>Berti</surname><given-name>Camilla Ceccatelli</given-name><initials>C.C.</initials><afid>60004969</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7007016174</author-url><authid>7007016174</authid><authname>Blakely E.</authname><surname>Blakely</surname><given-name>Emma L.</given-name><initials>E.L.</initials><afid>60026712</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:25951612600</author-url><authid>25951612600</authid><authname>OlÃ¡hovÃ¡ M.</authname><surname>OlÃ¡hovÃ¡</surname><given-name>Monika</given-name><initials>M.</initials><afid>60026712</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56523746400</author-url><authid>56523746400</authid><authname>He L.</authname><surname>He</surname><given-name>Langping</given-name><initials>L.</initials><afid>60026712</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56594407100</author-url><authid>56594407100</authid><authname>McMahon C.</authname><surname>McMahon</surname><given-name>Colin J.</given-name><initials>C.J.</initials><afid>60020035</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7003917298</author-url><authid>7003917298</authid><authname>Olpin S.</authname><surname>Olpin</surname><given-name>Simon E.</given-name><initials>S.E.</initials><afid>60002869</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7003781174</author-url><authid>7003781174</authid><authname>Hargreaves I.</authname><surname>Hargreaves</surname><given-name>Iain P.</given-name><initials>I.P.</initials><afid>60022148</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56589980100</author-url><authid>56589980100</authid><authname>Nolli C.</authname><surname>Nolli</surname><given-name>Cecilia</given-name><initials>C.</initials><afid>60004969</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:36817580300</author-url><authid>36817580300</authid><authname>McFarland R.</authname><surname>McFarland</surname><given-name>Robert</given-name><initials>R.</initials><afid>60026712</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7004087302</author-url><authid>7004087302</authid><authname>Goffrini P.</authname><surname>Goffrini</surname><given-name>Paola</given-name><initials>P.</initials><afid>60004969</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56659432600</author-url><authid>56659432600</authid><authname>OâSullivan M.</authname><surname>OâSullivan</surname><given-name>Maureen J.</given-name><initials>M.J.</initials><afid>60020035</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7405758539</author-url><authid>7405758539</authid><authname>Taylor R.</authname><surname>Taylor</surname><given-name>Robert W.</given-name><initials>R.W.</initials><afid>60026712</afid></author><intid>36053142</intid><source-id>22245</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929773615"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929773615?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929773615&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929773615&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929773615</prism:url><dc:identifier>SCOPUS_ID:84929773615</dc:identifier><eid>2-s2.0-84929773615</eid><dc:title>Phosphorylation of Ser-204 and Tyr-405 in human malonyl-CoA decarboxylase expressed in silkworm Bombyx mori regulates catalytic decarboxylase activity</dc:title><dc:creator>Hwang I.</dc:creator><prism:publicationName>Applied Microbiology and Biotechnology</prism:publicationName><prism:issn>01757598</prism:issn><prism:eIssn>14320614</prism:eIssn><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00253-015-6687-x</prism:doi><dc:description>Â© 2015 Springer-Verlag Berlin Heidelberg Decarboxylation of malonyl-CoA to acetyl-CoA by malonyl-CoA decarboxylase (MCD; EC 4.1.1.9) is a vital catalytic reaction of lipid metabolism. While it is established that phosphorylation of MCD modulates the enzymatic activity, the specific phosphorylation sites associated with the catalytic function have not been documented due to lack of sufficient production of MCD with proper post-translational modifications. Here, we used the silkworm-based Bombyx mori nucleopolyhedrovirus (BmNPV) bacmid system to express human MCD (hMCD) and mapped phosphorylation effects on enzymatic function. Purified MCD from silkworm displayed post-translational phosphorylation and demonstrated coherent enzymatic activity with high yield (â200 Î¼g/silkworm). Point mutations in putative phosphorylation sites, Ser-204 or Tyr-405 of hMCD, identified by bioinformatics and proteomics analyses reduced the catalytic activity, underscoring the functional significance of phosphorylation in modulating decarboxylase-based catalysis. Identified phosphorylated residues are distinct from the decarboxylation catalytic site, implicating a phosphorylation-induced global conformational change of MCD as responsible in altering catalytic function. We conclude that phosphorylation of Ser-204 and Tyr-405 regulates the decarboxylase function of hMCD leveraging the silkworm-based BmNPV bacmid expression system that offers a fail-safe eukaryotic production platform implementing proper post-translational modification such as phosphorylation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103680</affiliation-url><afid>60103680</afid><affilname>National University Corporation Shizuoka University</affilname><name-variant>Shizuoka Univ</name-variant><affiliation-city>Shizuoka</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103680</affiliation-url><afid>60103680</afid><affilname>National University Corporation Shizuoka University</affilname><name-variant>Shizuoka Univ</name-variant><affiliation-city>Shizuoka</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103680</affiliation-url><afid>60103680</afid><affilname>National University Corporation Shizuoka University</affilname><name-variant>Shizuoka Univ</name-variant><affiliation-city>Shizuoka</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103680</affiliation-url><afid>60103680</afid><affilname>National University Corporation Shizuoka University</affilname><name-variant>Shizuoka Univ</name-variant><affiliation-city>Shizuoka</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005558</affiliation-url><afid>60005558</afid><affilname>Mayo Clinic</affilname><name-variant>Mayo Clinic</name-variant><affiliation-city>Rochester</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012704</affiliation-url><afid>60012704</afid><affilname>Kyungpook National University</affilname><name-variant>Kyungpook National University</name-variant><affiliation-city>Daegu</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55943230900</author-url><authid>55943230900</authid><authname>Hwang I.</authname><surname>Hwang</surname><given-name>In Wook</given-name><initials>I.W.</initials><afid>60103680</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55943429900</author-url><authid>55943429900</authid><authname>Makishima Y.</authname><surname>Makishima</surname><given-name>Yu</given-name><initials>Y.</initials><afid>60103680</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56336678700</author-url><authid>56336678700</authid><authname>Suzuki T.</authname><surname>Suzuki</surname><given-name>Tomohiro</given-name><initials>T.</initials><afid>60103680</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55270209300</author-url><authid>55270209300</authid><authname>Kato T.</authname><surname>Kato</surname><given-name>Tatsuya</given-name><initials>T.</initials><afid>60103680</afid><afid>60103680</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55270209300</author-url><authid>55270209300</authid><authname>Kato T.</authname><surname>Kato</surname><given-name>Tatsuya</given-name><initials>T.</initials><afid>60103680</afid><afid>60103680</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56184011400</author-url><authid>56184011400</authid><authname>Park S.</authname><surname>Park</surname><given-name>Sungjo</given-name><initials>S.</initials><afid>60005558</afid><afid>60005558</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56184011400</author-url><authid>56184011400</authid><authname>Park S.</authname><surname>Park</surname><given-name>Sungjo</given-name><initials>S.</initials><afid>60005558</afid><afid>60005558</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004939597</author-url><authid>7004939597</authid><authname>Terzic A.</authname><surname>Terzic</surname><given-name>Andre</given-name><initials>A.</initials><afid>60005558</afid><afid>60005558</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004939597</author-url><authid>7004939597</authid><authname>Terzic A.</authname><surname>Terzic</surname><given-name>Andre</given-name><initials>A.</initials><afid>60005558</afid><afid>60005558</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7404292790</author-url><authid>7404292790</authid><authname>Chung S.</authname><surname>Chung</surname><given-name>Shin kyo</given-name><initials>S.k.</initials><afid>60012704</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7402224773</author-url><authid>7402224773</authid><authname>Park E.</authname><surname>Park</surname><given-name>Enoch Y.</given-name><initials>E.Y.</initials><afid>60103680</afid><afid>60103680</afid><afid>60103680</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7402224773</author-url><authid>7402224773</authid><authname>Park E.</authname><surname>Park</surname><given-name>Enoch Y.</given-name><initials>E.Y.</initials><afid>60103680</afid><afid>60103680</afid><afid>60103680</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7402224773</author-url><authid>7402224773</authid><authname>Park E.</authname><surname>Park</surname><given-name>Enoch Y.</given-name><initials>E.Y.</initials><afid>60103680</afid><afid>60103680</afid><afid>60103680</afid></author><authkeywords>Bombyx mori nucleopolyhedrovirus | Human malonyl-CoA decarboxylase (hMCD) | Lipid metabolism | Phosphorylation/dephosphorylation | Silkworm | Site-directed mutagenesis</authkeywords><intid>36019079</intid><source-id>14957</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929991229"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929991229?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929991229&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929991229&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0041010115001154"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929991229</prism:url><dc:identifier>SCOPUS_ID:84929991229</dc:identifier><eid>2-s2.0-84929991229</eid><dc:title>Solid phase synthesis, NMR structure determination of Î±-KTx3.8, its in silico docking to Kv1.x potassium channels, and electrophysiological analysis provide insights into toxin-channel selectivity</dc:title><dc:creator>Kohl B.</dc:creator><prism:publicationName>Toxicon</prism:publicationName><prism:issn>00410101</prism:issn><prism:eIssn>18793150</prism:eIssn><prism:volume>101</prism:volume><prism:pageRange>70-78</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.toxicon.2015.04.018</prism:doi><pii>S0041010115001154</pii><dc:description>Â© 2015 Elsevier Ltd. All rights reserved. Animal venoms, such as those from scorpions, are a potent source for new pharmacological substances. In this study we have determined the structure of the Î±-KTx3.8 (named as Bs6) scorpion toxin by multidimensional &lt;sup&gt;1&lt;/sup&gt;H homonuclear NMR spectroscopy and investigated its function by molecular dynamics (MD) simulations and electrophysiological measurements. Bs6 is a potent inhibitor of the Kv1.3 channel which plays an important role during the activation and proliferation of memory T-cells (T&lt;inf&gt;EM&lt;/inf&gt;), which play an important role in autoimmune diseases. Therefore, it could be an interesting target for treatment of autoimmune diseases. In this study, Bs6 was synthesised by solid phase synthesis and its three-dimensional (3D) structure has been determined. To gain a deeper insight into the interaction of Bs6 with different potassium channels like hKv1.1 and hKv1.3, the protein-protein complex was modelled based on known toxin-channel structures and tested for stability in MD simulations using GROMACS. The toxin-channel interaction was further analysed by electrophysiological measurements of different potassium channels like hKv1.3 and hKv7.1. As potassium channel inhibitors could play an important role to overcome autoimmune diseases like multiple sclerosis and type-1 diabetes mellitus, our data contributes to the understanding of the molecular mechanism of action and will ultimately help to develop new potent inhibitors in future.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005322</affiliation-url><afid>60005322</afid><affilname>Universitat Bochum</affilname><name-variant>Ruhr-UniversitÃ¤t Bochum</name-variant><affiliation-city>Bochum</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006490</affiliation-url><afid>60006490</afid><affilname>Universitatsklinikum Munster</affilname><name-variant>UniversitÃ¤tsklinikum MÃ¼nster</name-variant><affiliation-city>Munster</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017246</affiliation-url><afid>60017246</afid><affilname>Universitat Tubingen</affilname><name-variant>University of TÃ¼bingen</name-variant><affiliation-city>Tubingen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60061893</affiliation-url><afid>60061893</afid><affilname>University of Karachi</affilname><name-variant>University of Karachi</name-variant><affiliation-city>Karachi</affiliation-city><affiliation-country>Pakistan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033717</affiliation-url><afid>60033717</afid><affilname>Dow University of Health Sciences Pakistan</affilname><name-variant>Dow University of Health Sciences</name-variant><affiliation-city>Karachi</affiliation-city><affiliation-country>Pakistan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55440098700</author-url><authid>55440098700</authid><authname>Kohl B.</authname><surname>Kohl</surname><given-name>Bastian</given-name><initials>B.</initials><afid>60005322</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55980294800</author-url><authid>55980294800</authid><authname>Rothenberg I.</authname><surname>Rothenberg</surname><given-name>Ina</given-name><initials>I.</initials><afid>60006490</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36122450700</author-url><authid>36122450700</authid><authname>Ali S.</authname><surname>Ali</surname><given-name>Syed Abid</given-name><initials>S.A.</initials><afid>60017246</afid><afid>60061893</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36122450700</author-url><authid>36122450700</authid><authname>Ali S.</authname><surname>Ali</surname><given-name>Syed Abid</given-name><initials>S.A.</initials><afid>60017246</afid><afid>60061893</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:24498541100</author-url><authid>24498541100</authid><authname>Alam M.</authname><surname>Alam</surname><given-name>Mehtab</given-name><initials>M.</initials><afid>60033717</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602980105</author-url><authid>6602980105</authid><authname>Seebohm G.</authname><surname>Seebohm</surname><given-name>Guiscard</given-name><initials>G.</initials><afid>60006490</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:26643483100</author-url><authid>26643483100</authid><authname>Kalbacher H.</authname><surname>Kalbacher</surname><given-name>Hubert</given-name><initials>H.</initials><afid>60017246</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36049285600</author-url><authid>36049285600</authid><authname>Voelter W.</authname><surname>Voelter</surname><given-name>Wolfgang</given-name><initials>W.</initials><afid>60017246</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7103058461</author-url><authid>7103058461</authid><authname>Stoll R.</authname><surname>Stoll</surname><given-name>Raphael</given-name><initials>R.</initials><afid>60005322</afid></author><authkeywords>Docking | NMR | Potassium channel inhibitor | Scorpion toxin | Solid phase synthesis | TEVC method</authkeywords><intid>2036044967</intid><source-id>22319</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930024037"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930024037?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930024037&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930024037&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930024037</prism:url><dc:identifier>SCOPUS_ID:84930024037</dc:identifier><eid>2-s2.0-84930024037</eid><dc:title>Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation</dc:title><dc:creator>DÃ¶rr O.</dc:creator><prism:publicationName>Clinical Research in Cardiology</prism:publicationName><prism:issn>18610684</prism:issn><prism:eIssn>18610692</prism:eIssn><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00392-015-0874-8</prism:doi><dc:description>Â© 2015 Springer-Verlag Berlin Heidelberg Background: Renal sympathetic denervation (RSD) represents a safe and effective treatment option for certain patients with resistant hypertension and has been shown to decrease sympathetic activity. Neuropeptide Y (NPY) is a neurotransmitter that is co-released with norepinephrine and is up-regulated during increased sympathetic activity. The aim of the present study was to examine the effect of RSD on NPY and to analyze the association between changes in NPY levels and blood pressure reduction after RSD. Methods: A total of 150 consecutive patients (age 64.9 Â± 10.2 years) from three clinical centers undergoing RSD were included in this study. Response to RSD was defined as an office systolic blood pressure (SBP) reduction of &gt;10 mmHg 6 months after RSD. Venous blood samples for measurement of NPY were collected prior to and 6 months after RSD. Results: BP and NPY levels were significantly reduced by 23/9 mmHg (p = 0.001/0.001) and 0.24 mg/dL (p &lt; 0.01) 6 months after RSD. There was a significant correlation between baseline SBP- and RSD-related systolic BP reduction (r = â0.43; p &lt; 0.001) and between serum NPY baseline values and NPY level changes (r = â0.52; p &lt; 0.001) at the 6-month follow-up. The BP response to RSD (&gt;10 mmHg) was associated with a significantly greater reduction in NPY level when compared with BP non-responders (p = 0.001). Conclusion: This study demonstrates an effect of RSD on serum NPY levels, a specific marker for sympathetic activity. The association between RSD-related changes in SBP and NPY levels provides further evidence of the effect of RSD on the sympathetic nervous system.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017134</affiliation-url><afid>60017134</afid><affilname>Justus Liebig University Giessen</affilname><affiliation-city>Giessen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023686</affiliation-url><afid>60023686</afid><affilname>Universitatsklinikum des Saarlandes Medizinische Fakultat der Universitat des Saarlandes</affilname><name-variant>University of Saarland</name-variant><affiliation-city>Homburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Kerckhoff Heart and Thorax Center</affilname><name-variant>Department of Cardiology</name-variant><affiliation-city>Bad Nauheim</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113854148</affiliation-url><afid>113854148</afid><affilname>DZHK (German Centre for Cardiovascular Research)</affilname><name-variant>DZHK (German Centre for Cardiovascular Research)</name-variant><affiliation-city>Bad Nauheim</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022195</affiliation-url><afid>60022195</afid><affilname>Massachusetts Institute of Technology</affilname><name-variant>Massachusetts Inst. of Technology</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">19</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37051895900</author-url><authid>37051895900</authid><authname>DÃ¶rr O.</authname><surname>DÃ¶rr</surname><given-name>Oliver</given-name><initials>O.</initials><afid>60017134</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55576025600</author-url><authid>55576025600</authid><authname>Ewen S.</authname><surname>Ewen</surname><given-name>Sebastian</given-name><initials>S.</initials><afid>60023686</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35738660400</author-url><authid>35738660400</authid><authname>Liebetrau C.</authname><surname>Liebetrau</surname><given-name>Christoph</given-name><initials>C.</initials><afid/><afid>113854148</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35738660400</author-url><authid>35738660400</authid><authname>Liebetrau C.</authname><surname>Liebetrau</surname><given-name>Christoph</given-name><initials>C.</initials><afid/><afid>113854148</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55599039700</author-url><authid>55599039700</authid><authname>MÃ¶llmann H.</authname><surname>MÃ¶llmann</surname><given-name>Helge</given-name><initials>H.</initials><afid/><afid>113854148</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55599039700</author-url><authid>55599039700</authid><authname>MÃ¶llmann H.</authname><surname>MÃ¶llmann</surname><given-name>Helge</given-name><initials>H.</initials><afid/><afid>113854148</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35388197500</author-url><authid>35388197500</authid><authname>Gaede L.</authname><surname>Gaede</surname><given-name>Luise</given-name><initials>L.</initials><afid/><afid>113854148</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35388197500</author-url><authid>35388197500</authid><authname>Gaede L.</authname><surname>Gaede</surname><given-name>Luise</given-name><initials>L.</initials><afid/><afid>113854148</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:16233517500</author-url><authid>16233517500</authid><authname>Linz D.</authname><surname>Linz</surname><given-name>Dominik</given-name><initials>D.</initials><afid>60023686</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004621257</author-url><authid>7004621257</authid><authname>Hohl M.</authname><surname>Hohl</surname><given-name>Mathias</given-name><initials>M.</initials><afid>60023686</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:22936486200</author-url><authid>22936486200</authid><authname>Troidl C.</authname><surname>Troidl</surname><given-name>Christian</given-name><initials>C.</initials><afid/><afid>113854148</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:22936486200</author-url><authid>22936486200</authid><authname>Troidl C.</authname><surname>Troidl</surname><given-name>Christian</given-name><initials>C.</initials><afid/><afid>113854148</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:15060093200</author-url><authid>15060093200</authid><authname>Bauer T.</authname><surname>Bauer</surname><given-name>Timm</given-name><initials>T.</initials><afid>60017134</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:35392235500</author-url><authid>35392235500</authid><authname>BÃ¶hm M.</authname><surname>BÃ¶hm</surname><given-name>Michael</given-name><initials>M.</initials><afid>60023686</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56659137800</author-url><authid>56659137800</authid><authname>Hamm C.</authname><surname>Hamm</surname><given-name>Christian</given-name><initials>C.</initials><afid>60017134</afid><afid/></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56659137800</author-url><authid>56659137800</authid><authname>Hamm C.</authname><surname>Hamm</surname><given-name>Christian</given-name><initials>C.</initials><afid>60017134</afid><afid/></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:26428326200</author-url><authid>26428326200</authid><authname>Mahfoud F.</authname><surname>Mahfoud</surname><given-name>Felix</given-name><initials>F.</initials><afid>60023686</afid><afid>60022195</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:26428326200</author-url><authid>26428326200</authid><authname>Mahfoud F.</authname><surname>Mahfoud</surname><given-name>Felix</given-name><initials>F.</initials><afid>60023686</afid><afid>60022195</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:8641511400</author-url><authid>8641511400</authid><authname>Nef H.</authname><surname>Nef</surname><given-name>Holger</given-name><initials>H.</initials><afid>60017134</afid></author><authkeywords>Hypertension | Procedural success | Renal sympathetic denervation</authkeywords><intid>1536053997</intid><source-id>3100147501</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927124861"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927124861?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927124861&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927124861&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0223523415002317"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927124861</prism:url><dc:identifier>SCOPUS_ID:84927124861</dc:identifier><eid>2-s2.0-84927124861</eid><dc:title>Regioselective chemical and rapid enzymatic synthesis of a novel redox-Antiproliferative molecular hybrid</dc:title><dc:creator>Geromichalou E.</dc:creator><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationName><prism:issn>02235234</prism:issn><prism:eIssn>17683254</prism:eIssn><prism:volume>96</prism:volume><prism:pageRange>47-57</prism:pageRange><prism:coverDate>2015-05-26</prism:coverDate><prism:coverDisplayDate>26 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejmech.2015.03.064</prism:doi><pii>S0223523415002317</pii><dc:description>Â© 2015 Elsevier Masson SAS. Recent science evidenced the interlinkage of oxidative stress and cancer. Due to the inherent complexity of cancer and its accompanying effect of oxidative stress, novel molecules, containing combinatorial functionalities should be targeted. Herein, we synthesized gemcitabine-5'2-O-lipoate derived from a regioselective coupling of the chemotherapeutic drug gemcitabine (GEM), a first-line agent for cancer therapy and Â±-lipoic acid (LA), a potent antioxidant. gemcitabine-5'2-O-lipoate was obtained in 4 chemical steps. To avoid the tedious and laborious chemical steps we also utilized biocatalysis using immobilized Candida antarctica lipase B (CALB), and the optimum conditions for the regioselective and one-pot synthesis of gemcitabine-5'2-O-lipoate were established by exploiting different solvents (organic solvents and ionic liquids) and enzyme immobilization (acrylic resin and carbon nanotubes). Cytotoxic activity of co-administrating GEM and LA was proven to be synergistic against non-small cell lung cancer cells whereas antagonistic for bladder cancer cells. In contrast, the gemcitabine-5'2-O-lipoate hybrid was found to be superior to the parent compounds against both non-small cell lung cancer and bladder cancer cells as also was found to preserve the redox activity of the parent compound LA. The regioselective biotransformation mediated synthesis of the anticancer-antioxidant hybrid illustrates the capacity of biocatalysis to act as an asset in molecular hybridization techniques.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004716</affiliation-url><afid>60004716</afid><affilname>Panepistimion Ioanninon</affilname><name-variant>University of Ioannina</name-variant><affiliation-city>Ioannina</affiliation-city><affiliation-country>Greece</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60048838</affiliation-url><afid>60048838</afid><affilname>Theagenion Cancer Hospital</affilname><name-variant>Theagenion Cancer Hospital</name-variant><affiliation-city>Thessaloniki</affiliation-city><affiliation-country>Greece</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031155</affiliation-url><afid>60031155</afid><affilname>Panepistimion Patron</affilname><name-variant>University of Patras</name-variant><affiliation-city>Patra</affiliation-city><affiliation-country>Greece</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010330</affiliation-url><afid>60010330</afid><affilname>Slovak Academy of Sciences</affilname><name-variant>Slovak Academy of Sciences</name-variant><affiliation-city>Bratislava</affiliation-city><affiliation-country>Slovakia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004716</affiliation-url><afid>60004716</afid><affilname>Panepistimion Ioanninon</affilname><name-variant>University of Ioannina</name-variant><affiliation-city>Ioannina</affiliation-city><affiliation-country>Greece</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004716</affiliation-url><afid>60004716</afid><affilname>Panepistimion Ioanninon</affilname><name-variant>University of Ioannina</name-variant><affiliation-city>Ioannina</affiliation-city><affiliation-country>Greece</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37025946600</author-url><authid>37025946600</authid><authname>Geromichalou E.</authname><surname>Geromichalou</surname><given-name>Elena</given-name><initials>E.</initials><afid>60004716</afid><afid>60048838</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37025946600</author-url><authid>37025946600</authid><authname>Geromichalou E.</authname><surname>Geromichalou</surname><given-name>Elena</given-name><initials>E.</initials><afid>60004716</afid><afid>60048838</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55343265900</author-url><authid>55343265900</authid><authname>Sayyad N.</authname><surname>Sayyad</surname><given-name>Nisar</given-name><initials>N.</initials><afid>60004716</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55003121900</author-url><authid>55003121900</authid><authname>Kyriakou E.</authname><surname>Kyriakou</surname><given-name>Eleni</given-name><initials>E.</initials><afid>60004716</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55654088500</author-url><authid>55654088500</authid><authname>Chatzikonstantinou A.</authname><surname>Chatzikonstantinou</surname><given-name>Alexandra V.</given-name><initials>A.V.</initials><afid>60004716</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602650394</author-url><authid>6602650394</authid><authname>Giannopoulou E.</authname><surname>Giannopoulou</surname><given-name>Efstathia</given-name><initials>E.</initials><afid>60031155</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004158025</author-url><authid>7004158025</authid><authname>Vrbjar N.</authname><surname>Vrbjar</surname><given-name>Norbert</given-name><initials>N.</initials><afid>60010330</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7006725218</author-url><authid>7006725218</authid><authname>Kalofonos H.</authname><surname>Kalofonos</surname><given-name>Haralabos P.</given-name><initials>H.P.</initials><afid>60031155</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7004211187</author-url><authid>7004211187</authid><authname>Stamatis H.</authname><surname>Stamatis</surname><given-name>Haralambos</given-name><initials>H.</initials><afid>60004716</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6507951437</author-url><authid>6507951437</authid><authname>Tzakos A.</authname><surname>Tzakos</surname><given-name>Andreas G.</given-name><initials>A.G.</initials><afid>60004716</afid><afid>60004716</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6507951437</author-url><authid>6507951437</authid><authname>Tzakos A.</authname><surname>Tzakos</surname><given-name>Andreas G.</given-name><initials>A.G.</initials><afid>60004716</afid><afid>60004716</afid></author><authkeywords>Antiproliferative activity | Biotransformation | Bladder cancer | Gemcitabine | Molecular hybrid | Non-small cell lung cancer | Synergism | Î±-lipoic acid</authkeywords><intid>1785570718</intid><source-id>17464</source-id></entry></search-results>
